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Abstract
The release and clearance of von Willebrand Factor (VWF) in a group of patients with 
the quantitative deficiency type 1 von Willebrand Disease (VWD) was investigated.
This was done by analysis of circulating VWF and VWF released from the endothelial 
pool on infusion of a vasopressin analogue. A variety of parameters were investigated 
pre-and post infusion in order to identify VWF gene linked and non-linked variables that 
could affect VWF clearance. Increased clearance of plasma VWF in a significant 
proportion of type 1 VWD patients was shown but this was not consistently associated 
with steady-state levels of VWF, indicating that circulating plasma VWF levels are not a 
consistent reflection of the VWF life-cycle in this patient group. An association between 
galactose exposure and reduced levels of VWF was demonstrated by the increased 
binding of the lectins Ricinus communis and Erythina crystagalli, this was unrelated to 
clearance. In addition, no significant ABO blood group effect on VWF clearance was 
demonstrated. The absolute level of ADAMTS-13, and the susceptibility of VWF to 
cleavage by ADAMTS-13 were not associated with the clearance rate of VWF in 
patients with type 1 VWD. Three novel candidate mutations were identified in 
association with significantly accelerated VWF clearance. Notably, candidate mutations 
were generally identified in patients with steady-state VWF levels reduced to 
<20 IUdL'1 and family analysis suggests absolute linkage with the VWF gene.
Despite demonstrating an increased rate of clearance in the majority of patients with 
type 1 VWD, no single underlying common characteristic or variable was predominant 
within this study group.
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Chapter 1 
INTRODUCTION
i
1n 1926, Erik von Willebrand, a physician based in Helskinki, first reported a novel 
inherited bleeding disorder in a large family who presented with a variety of bleeding 
symptoms ranging from mild to life threatening. (Von Willebrand 1926) The 
underlying cause of the bleeding diatheses could not be determined at the time. It is 
now known that the bleeding disorder was associated with abnormalities of a 
glycoprotein now known as von Willebrand factor (VWF). VWF plays an important 
role in platelet adhesion, thrombus formation and coagulation. The functional 
deficiency of VWF, known as von Willebrand disease (VWD) is the most common 
inherited bleeding disorder in humans. While many details regarding the 
biosynthesis, secretion and function of VWF are well established, aspects of the 
mechanisms of clearance of VWF remain unclear.
1.1 HISTORICAL PERSPECTIVE
Von Willebrand described the bleeding symptoms of a large family who lived on 
Foglo, an island of the Aland archipelago in the Gulf of Bothnia between Sweden 
and Finland. (Von Willebrand 1926) The propositus, a five year old girl, had suffered 
from severe spontaneous bleeding since birth. Numerous family members including 
the parents exhibited severe and fatal bleeding patterns. Four of the proband’s five 
sisters had died in infancy from intestinal, nasal and wound bleeding. The propositus 
herself died during her fourth menstrual period at the age of 13 years. Von 
Willebrand studied a further 58 family members and found 22 to have similar 
symptoms to the propositus, reporting consistent prolongation of the bleeding time 
and a predominantly mucocutaneous bleeding pattern in affected members. He 
distinguished this bleeding disorder from haemophilia, calling it hereditary 
pseudohaemophilia and concluded that the inheritance was of an X-linked dominant 
pattern. Von Willebrand proposed that the bleeding diathesis resulted from the 
combined effect of a platelet function disorder and systemic vessel wall lesion. 
Collaboration with a German physician, Dr Rudolf Jurgens also led to the suggestion 
that there was an abnormality in platelet function and for some time the condition 
was termed von Willebrand- Jurgens thrombopathy.(von Willebrand 1933)
The distinction between ‘pseudohaemophilia’ and haemophilias A and B remained 
purely theoretical until the early 1950s by which time improved methods for 
measuring factor VIII (FVIII) had been devised. In 1953 two cases of a combined 
haemostatic defect were described, namely prolonged bleeding time and decreased 
FVIII activity.(Alexander 1953) Although the bleeding symptoms were similar to 
those reported by von Willebrand, in these cases platelet function appeared to be
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normal. The idea that haemophilia and VWD could result from deficiencies of distinct 
proteins arose following observations by a Swedish group studying transfusional 
therapy. This group reported a number of patients with a severe bleeding disorder 
characterised by factor VIII deficiency and prolonged bleeding time.(Blomback, et al 
1956, Nilsson, et al 1957b) At around the same time, FVIII activity was successfully 
recovered during the purification of fibrinogen from Cohn’s fraction I; this was 
designated fraction l-O. (Nilsson, et al 1957b) Treatment with fraction l-O, but not 
fibrinogen was shown to swiftly control bleeding symptoms as well as correct the 
bleeding time in the aforementioned patients.(Nilsson, etal 1957a) Following 
treatment with fraction l-O, the half-life of FVIII (then known as antihaemophilic 
factor, AHF) was shown to differ between these patients and those with haemophilia 
A. In addition, infusion of Fraction l-O was shown to result in a secondary rise in 
FVIII activity in these patients. Finally, the prolonged bleeding time was found to be 
corrected following infusion of fraction l-O prepared from haemophilia A 
plasma.(Nilsson, et al 1957b) Together, these findings suggested that the prolonged 
bleeding time in this group of patients was due to a lack of a plasma factor (VWF) 
and not to a primary platelet dysfunction or capillary wall defect. The subsequent 
finding of decreased platelet adhesiveness in these patients suggested this as a 
pathogenic mechanism for the deficiency of VWF,(Salzman 1963) and provided an 
explanation for the improvement in both primary haemostasis and bleeding time 
observed following infusion of fraction l-O.
The next milestone in the history of VWD was the isolation and characterisation of 
VWF in the early 1970s. A cross-reactive protein demonstrated in haemophilia A 
patients was shown to be reduced or absent in patients with VWD.(Zimmerman, et 
al 1971) Meanwhile, an antibody been raised that, as well as inhibiting AHF activity 
in normal plasma, was shown to reduce the platelet retention of normal blood in 
glass bead columns and block the capacity of purified AHF to correct the decreased 
platelet retention of VWD.(Bouma, et al 1972) It was concluded that either normal 
plasma contained a bifunctional molecule with both FVIII and VWD correcting 
activity, or that the two activities were located on different molecules with antigenic 
determinants that could not be differentiated in the available serum. Similar studies 
were subsequently published and although definitive evidence that the correcting 
factor of VWD was identical to VWF was yet to come, it had become customary to 
refer to the correcting factor as VWF. The antigen detected by the precipitating 
antibodies against FVIII had become known as ‘FVIII-related antigen’. Concurrently, 
Howard and Firkin demonstrated that while the antibiotic ristocetin caused 
aggregation of platelets derived from both normal individuals and haemophilia
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patients resulted from, this was not found in platelets from patients with 
VWD.(Howard and Firkin 1971) These studies led to a clearer understanding of the 
functions of VWF and the beginning of a classification of VWD. Assays for the 
quantification of FVIII-related antigen were developed with most laboratories at this 
time employing the rocket immunoelectrophoresis technique of Laurell.(Laurell 
1966)
Further laboratory investigation of the family originally described by von Willebrand 
showed concordant reductions in VWF antigen levels (VWF:Ag) and ristocetin 
cofactor activity (VWF:RCo), consistent with a partial quantitative deficiency of VWF. 
Following cloning of the VWF gene in 1985, genotypic analysis identified 
heterozgosity for a nucleotide deletion in exon 18 in five surviving siblings of the 
original propositus.(Zhang, et al 1992a) The five girls, including the propositus, who 
died from uncontrolled bleeding, are likely to have been homozygous for the 
deletion.
1.2 VON WILLEBRAND FACTOR GENE AND PROTEIN
Von Willebrand factor (VWF) is a plasma glycoprotein(Legaz, et al 1973, Shapiro, et 
al 1973) that plays a central role in the critical initial phases of haemostasis. VWF 
has two main haemostatic functions: firstly, it binds to platelet membrane receptors 
(glycoprotein Iba and the integrin am,^) and to the subendothelial matrix. In doing 
so, VWF mediates both the adhesion and aggregation of platelets. Secondly, VWF 
is a specific carrier of FVIII in plasma, protecting FVIII from proteolytic degradation 
and thus prolonging its half-life in the circulation,(Morfini, et al 1993) and localising 
FVIII at sites of vascular injury. The complex structure of VWF facilitates these 
varied interactions, as well as its binding to many ligands.
1.2.1 VWF gene
The gene that encodes VWF (VWF) is located on chromosome 12p13.3 and was 
cloned and characterised by four independent groups in 1985.(Ginsburg, et al 1985, 
Lynch, et al 1985, Sadler, et al 1985, Verweij, et al 1986) VWF spans 178 kb, is 
composed of 52 exons and is transcribed into an 8.7-kb mRNA. The pseudogene is 
located on chromosome 22q11.2 and corresponds to exons 23 to 34 of VWF, 
demonstrating 97% homology (Mancuso, et al 1991) Exon 1 of VWF encodes the 5’ 
untranslated sequence and the initiation codon is located in exon 2. Exons 2 to 18 
encode the signal peptide and propeptide and the remainder of the exons encode 
the mature VWF peptide.
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1.2.2 Structure of the VWF monomer
VWF is synthesised in endothelial cells and megakaryocytes as a precursor 
molecule of 2813 amino acids, known as pre-pro-VWF.(Bonthron, et al 1986) Pre- 
pro-VWF is composed of a 22-residue signal peptide, a 741 propeptide and a 2050- 
residue mature VWF subunit.(Sadler 1998) The molecular weight of the pre-pro 
VWF is approximately 270 kDa. (Shapiro, et al 1973) The molecular weight of the 
mature sub-unit is 220 kDa and circulates as multimers of up to 20 MDa.(Counts, et 
al 1978, Hoyer and Shainoff 1980). The complete amino acid sequence of VWF was 
elucidated from the cDNA sequence for pre-pro-VWF,(Appendix 1) and the 
recommended nomenclature for its numbering is to start from the first amino acid of 
the signal peptide (the initiator methionine), thus 764 is the first amino acid of 
mature VWF (Fig.1.1).(Goodeve and Peake 2001) The domain structure of pre-pro 
VWF is D1 -D2-D’-D3-A1 -A2-A3-D4-B1-B2-B3-C1-C2-CK: the four repetitive 
domains are shown in Fig. 1.1 and the extents of the domains are given in Table 1.1. 
VWF is heavily glycosylated with the carbohydrate component constituting around 
20% of its molecular weight. The carbohydrate component is distributed amongst 22 
oligosaccharide chains, 12 of which are asparagine- (N-) linked and 10 serine or 
threonine- (O-) linked glycosylation sites.(Matsui, et al 1992, Titani, et al 1986) 
Approximately 12% of the N-linked oligosaccharides bear ABH antigens.(Sodetz, et 
al 1979) The structure and function of the oligosaccharide structures of VWF is 
discussed in Section 1.4.
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Table 1.1 Domain structure of pre-pro VWF.
Residues are numbered from the initiator methionine (+1) of pre-pro-VWF
VWF Domain Amino acid residues Exon(s)
D1 34 -  386 3 - 1 0
D2 387 -  745 11 -1 7
D’ 769 -  866 18-20
D3 867-1241 2 0 -2 8
A1 1242-1479 28
A2 1480-1672 28
A3 1673-1875 2 8 -3 2
D4 1947 -  2295 3 5 -3 9
B1-B3 2296 -  2399 4 0 -4 2
C1 2400 -  2516 44
02 2544 -  2663 4 5 -4 8
CK 2724-2813 52
Figure 1.1 Schematic structure of pre-pro-VWF. Showing internal homologies 
(A-D) and functional regions. The locations of binding sites for several ligands, 
and the regions involved in dimerisation and multimerisation are shown. The 
locations of the protein disulphide isomerise activity of the propeptide are shown. 
Amino acid residues are indicated for the beginning and end of the signal peptide 
(SP), propeptide (VWFpp) and mature VWF. Amino acid residues are numbered 
from the initiator methionine (+1).
Heparin « • * »
| |  Dl |  D2 | n |  D3 | Al A2 A3 D4
RCD
Cl C2 CK
Protein disulphide isotnerase 
activity
r
Multimerisation Collagen 
botrocetin 
heparin 
r sulphatides
Collagen Dimerisatioi
1 23 763 2813
S P  VWFpp Mature von Willebrand Factor
6
1.2.3 VWF biosynthesis and multimeric structure
VWF is synthesised in endothelial cells and megakaryocytes giving rise to distinct 
pools of platelet, plasma and subendothelial VWF.(Jaffe, et al 1973, Nachman, et al 
1977) Prior to its secretion VWF undergoes a number of intracellular modifications. 
(Fig. 1.2) Firstly, the VWF signal peptide is cleaved in the rough endoplasmic 
reticulum and 12 N-linked oligosaccharide chains are added to each VWF 
monomer.(Wagner and Marder 1984) Following this initial glycosylation, dimers of 
pro-VWF are formed through disulphide bonding of the carboxyl terminal 151 
residues of the VWF subunit, which incorporates the CK domain.(Katsumi, et al
2000) The dimers of pro-VWF then translocate to the Golgi bodies and trans-Golgi 
network where they undergo multimerisation, sulphation and further glycosylation, 
including modification of the N-linked oligosaccharide chains and the addition of 10 
O-linked oligosaccharide chains. The propeptide is cleaved and remains 
noncovalently associated with VWF while in the cell. The mechanisms that 
determine whether newly synthesised VWF is secreted into the circulation or stored 
within endothelial cell-specific storage organelles, the Weibel-Palade bodies(Weibel 
1964) or a granules of platelets remain unclear. Multimerisation may continue while 
VWF is stored and the extent of multimerisation may differ between VWF molecules, 
resulting in a range in the size of circulating VWF multimers. A detailed discussion of 
the structures and possible functions of the oligosaccharide side chains is presented 
in Section 1.4.
1.2.4 VWF propeptide
The VWF propeptide (VWFpp) was identified as a 741 amino acid residue 
containing the D1 and D2 domains during the characterisation of full-length VWF 
cDNA.(Ginsburg, et al 1985) This was shown to be identical to a previously known 
VWF-associated protein (VWF antigen ll).(Fay, etal 1986, Montgomery and 
Zimmerman 1978) Propeptides are frequently referred to as ‘intramolecular 
chaperones’ in view of their functional roles in the processing and folding of their 
mature proteins and.(Shinde, et al 1999) The main functions of VWFpp appear to be 
its facilitation of VWF multimerisation and its trafficking into storage 
organelles.(Haberichter, et al 2003, van Mourik and Romani de Wit 2001, Wise, et al 
1988) and several mutations within VWFpp have been shown to interfere with VWF 
multimerisation.(Allen, e ta l2000, Gaucher, et al 1998, Schneppenheim, et al 1995) 
VWFpp forms a disulphide-linked intermediate with the D’D3 domain of VWF in the 
endoplasmic reticulum that rearranges to form multimers in the Golgi.(Purvis and 
Sadler 2004, Voorberg, et al 1990, Wagner, et al 1986) Following assembly of the 
VWF multimers in the trans-Golgi network, VWFpp is cleaved from the amino-
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terminal region of VWF by a paired amino acid cleaving enzyme (PACE), also 
known as furin.(Wagner, et al 1987) Like mature VWF, VWFpp is either secreted 
into the circulation or stored in the platelet a granules or Weibel-Palade bodies.
Upon stimulation, both the cleaved VWFpp and mature VWF have been shown to 
be released in equimolar amounts.(Sadler 1998, Wagner, et al 1987) Although some 
plasma VWFpp may derive from platelets, this is not thought to be of major 
significance except in situations of massive platelet activation.(Vischer, et al 1997) 
The function of VWFpp in the circulation remains unclear.
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Figure 1.2 Biosynthesis of VWF: (Ruggeri 1999)The signal peptide is cleaved and 
initial glycosylation takes place as the polypeptide is transported into the rough 
endoplasmic reticulum (RER). Once in the RER, dimers of pro-VWF are formed 
which are transported to the Golgi apparatus where they undergo post-translational 
glycosylation and sulphation. Finally, the propeptide is cleaved from the dimers in 
the trans-golgi network (TGN) and fully functional VWF multimers are stored in 
Weibel-Palade bodies (WPB).
C-carboxy terminal; N-amino terminal
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1.2.5 Storage and secretion of VWF 
Plasma VWF
Plasma VWF is derived almost entirely from endothelial cells,(Nichols, et al 1995a) 
and two distinct pathways of secretion have been identified.(Ruggeri and 
Zimmerman 1987) (Fig. 1.3) Approximately 95% of endothelial-derived VWF is 
secreted via the constitutive pathway in which VWF (composed of dimers and small 
multimers) is continuously released from the endothelial cell. The remainder is 
stored within Weibel-Palade bodies and secreted via the regulated pathway on 
stimulation by secretagogues (Table 1.2): this VWF is composed of the largest 
multimeric species.(Spom, et al 1986, Sporn, et al 1989) Many of the 
secretagogues, including thrombin, histamine, complement and fibrin induce 
intracellular influx of calcium ions. Other secretagogues (notably adrenaline, 
adenosine triphosphate and adenosine diphosphate) induce release of VWF by an 
increase in intracellular levels of cyclic adenosine monophosphate (cAMP). Both 
adrenaline and adenosine potentiate the effect of thrombin induced VWF release. 
Possible mechanisms of release of 1-deamino-8-d-arginine vasopressin 
(desmopressin or DDAVP) are discussed in Section 1.5.
Platelet VWF
Platelet VWF is stored within a granules and its secretion occurs only by a regulated 
pathway following platelet activation at a site of injury. While platelet-derived VWF 
has not been shown to contribute significantly towards the circulating pool of plasma 
VWF, up to 20% of the total VWF present in blood is found in platelets.
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Figure 1.3 Pathways of VWF secretion. 95% of endothelial cell-derived VWF is 
secreted via the constitutive pathway whereby VWF is continuously released from 
the endothelial cell. The remaining 5% is stored within Weibel-Palade (WP) bodies 
and secreted via the regulated pathway on stimulation by secretagogues.
ER endoplasmic reticulum
Constitutive
Release
AGONIST
Regulated Secretion
nucleus
Table 1.2 Agonists that induce VWF release from endothelial cells
Intracellular response to agonist is given as mechanism of exocytosis: [C an  for 
intracellular calcium flux; cAMP for increase in intracellular levels of cyclic adenosine 
monophosphate. PMA - phorbol myristate acetate. DDAVP - desmopressin. PAF - 
platelet activating factor. VWGF - vascular endothelial growth factor. ATP -  
adenosine triphosphate. ADP -  adenosine diphosphate.
Agonist Mechanism Reference
Thrombin [Ca+1 (Levine, et al 1982)
Histamine [CO. (Hamilton and Sims 1987)
Fibrin [Can (Ribes, et al 1987)
Calcium ionophore [Can. (Spom, et al 1986)
PAF [Can (Hashemi, et al 1993)
VEGF [Can, (Brock, et al 1991)
Leukotrienes [Can (Datta, et al 1995)
Endothelin [Can. (Pruis and Emeis 1990)
Complement C5b-9 [Can, (Hattori, et al 1989)
Trypsin [Can (Collins, et al 1993)
Bradykinin [Can (Tranquille and Emeis 1991)
Endotoxin ? (Schorer, et al 1987)
PMA Protein kinase C (Giddings and Shall 1987)
ATP & ADP cAMP & [Ca++]i (Vischer and Wollheim 1998)
Vasopressin/DDAVP cAMP (Kaufmann, et al 2000)
Adrenaline cAMP (Vischer and Wollheim 1997)
Prostacyclin cAMP (Hegeman, et al 1998)
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1.2.6 Relationship between structure and function of VWF
Endothelial damage and exposure of the subendothelium promotes a highly 
regulated and integrated series of events that result in the formation of a platelet 
plug, stabilisation by fibrin deposition and clot retraction. VWF supports thrombus 
formation by maintaining platelet adhesion to sites of injury and promoting platelet- 
platelet aggregation. Platelets respond rapidly to alterations of endothelial cells by 
firmly attaching to the site of lesion where exposure of subendothelial components 
may have occurred. The first layer of platelets is in contact with the thrombogenic 
surface (adhesion), whereas subsequent growth of the haemostatic plug depends 
on platelet-platelet interactions (aggregation). Both aspects of platelet function are 
influenced by the interaction of VWF with specific platelet membrane glycoprotein 
(GP) receptors. The biological function of VWF is dependent on the distinct domains 
in the constitutive sub-unit, each one containing the structural elements responsible 
for the specificity and affinity of different interactions. The association between VWF 
region and function is shown in Fig. 1.1.
VWF interaction with platelets
VWF interacts with platelets via two platelet receptor complexes: GPIba and the 
integrin anbf^ 3 . composed of the glycoproteins lib and Ilia. The primary binding 
domain for the platelet receptor GPIba has been mapped to the VWF-A1 domain, 
although the exact residues are not known.(Celikel, et al 1998, Emsley, et al 1998) 
This binding, which is reversible, is modulated by high shear conditions in vivo 
(around 1000 s'1) and can be simulated in vitro using the negatively charged 
antibiotic ristocetin.(Scott, et al 1991) On this first layer of adherent platelets, further 
VWF binds and uncoils, thus presenting the next attachment layer for the attraction 
of more platelets. Activation of anbfJ3 mainly occurs via signalling initiated by 
membrane receptors that bind collagen or by stimulation by agonists released (e.g. 
ADP) or locally generated (e.g. thrombin) Adhesive ligands, mainly fibrinogen and 
VWF, bind via activated an^on the membrane of the adherent platelets and 
become the substrate for the additional recruitment and attachment of incoming 
platelets. The interaction of VWF with anbfi3 occurs via the peptide sequence RGDS, 
residues 1744 -  1747, located in the carboxy-region of the VWF-C1 
domain.(Beacham, et al 1992, Plow, et al 1985) Recent studies have shown that 
under conditions of extreme shear stress, the interaction between GPIba and VWF 
can result in activation-independent platelet aggregation: at shear rates above 10 
000 s'1, exposed active VWF-A1 domains are able to bind GPIba, promoting 
additional platelet recruitment that results in an exponential rise in shear rate. 
(Ruggeri, et al 2006) Up to shear rates of 20,000 s'1, the aggregates have been
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shown to be reversible; above this threshold the adhered platelets appear to be 
capable of persisting as the core of aggregates for several minutes.(Ruggeri, et al 
2006)
VWF interaction with collagen
VWF constitutively present in the subendothelial matrix is sufficient to stimulate 
initial platelet adhesion, the exact mechanism of which is unclear. VWF can bind to 
the fibrillar collagens types I and III and the non-fibrillar collagen type VI. Collagen 
type VI, found in most connective tissues, is abundant in the subendothelial matrix. 
VWF binding to type VI collagen is primarily via the A1 domain,(Hoylaerts, et al 
1997) and to the fibrillar collagens, types I and III via the A3 domain.(Cruz, et al 
1995, Lankhof, et al 1996)
VWF interaction with FVIII
Each VWF monomer has one binding domain, located in the amino terminus in the 
D’ domain (amino acid residues 764 to 1035) that is able to bind one FVIII molecule 
in vivo. However, only 1-2% of available VWF monomers are occupied by FVIII, 
resulting in the plasma molar ratio of FVIII monomer to VWF monomer of 1:50.(Vlot, 
et al 1998)
VWF interaction with heparin
The interaction of VWF with the subendothelial matrix may also involve the heparin 
and sulphatide binding sites of VWF via an interaction with sulphated sugars on 
proteoglycans. There are two heparin binding sites: two clusters of amino acids 
within the VWF-A1 domain,(Rastegar-Lari, et al 2002) and a lower affinity heparin 
binding site within the D’ and D3 domains.
1.2.7 VWF in the circulation
VWF circulates in plasma as a tight, non-covalently linked complex with FVIII. 
Several mechanisms may explain the necessity for this complex formation:
• VWF stabilises the heterodimeric structure of VWF.
• VWF protects FVIII from proteolytic degradation by phospholipid-binding 
proteases such as activated protein C (APC) and activated factor X (FXa).
• VWF interferes with the binding of FVIII to negatively-charged phospholipid 
surfaces.
• VWF inhibits the binding of FVIII to activated factor IX (FIXa).
• VWF prevents the cellular uptake of FVIII.
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VWF is released into the circulation uncleaved, and the physiological reduction in 
multimer size occurs mainly through a process of controlled cleavage thatresults in 
rapid proteolysis of the highly thrombotic unusually/ultra large (UL) multimers to 
smaller, less adhesive forms. This cleavage is the function of a plasma 
metalloprotease that was first identified in 1996,(Furlan, et al 1996, Tsai 1996) 
although the suggestion of a VWF ‘splitting enzyme’ were first made by Bloom and 
colleagues as long ago as 1973.(Bloom 1973) The metalloprotease has 
subsequently been purified and cloned and found to be a member of the ADAMTS 
family (a disintegrin and metalloprotease with thrombospondin motifs), designated 
ADAMTS-13, a multidomain protease that is highly specific for VWF.(Fujikawa, et al 
2001, Gerritsen, et al 2001, Zheng, et al 2001) ADAMTS-13-mediated proteolysis of 
VWF occurs at a single peptide bond Tyr 1605 -  Met 1606 in the A2 domain,(Dent, et al 
1990) generating two fragments of molecular mass 176 kDa (residues 843 to 2050) 
and 140 kDa (residues 1 to 842) that are responsible for the ‘satellite bands’ 
observed flanking the major bands on VWF multimer gels.(Dent, et al 1991, Furlan, 
et al 1993) It has recently been shown that ADAMTS-13 is synthesised in human 
endothelial cells, and released constitutively.(Tumer, et al 2006) Although both the 
A1 and A3 domains of VWF may contain binding sites for ADAMTS-13, the A3 
domain appears to be the preferred binding site for the metalloprotease under 
conditions of flow.(Dong, et al 2003) It has been suggested that the fragments of 
VWF released into the circulation following ADAMTS-13 proteolysis may no longer 
be subject to shear stress and therefore do not bind to platelets and rather it is the 
VWF-platelet string remaining at the cell surface that participates in the subsequent 
stages of clot formation.(Dong 2005) Although platelet VWF was previously believed 
to be segregated from ADAMTS-13 activity, a recent study has demonstrated 
platelets to contain functionally active ADAMTS-13.(Liu, et al 2005) In addition to 
modifying the release of UL-VWF from platelets, this second pool of ADAMTS-13 
may also encounter the UL-VWF released from endothelial cells.
The glycoprotein thrombospondin-1 (TSP-1) has also been shown to regulate the 
size of VWF multimers. TSP-1 is stored in platelet a granules and is released 
following platelet activation and like ADAMTS-13, binds to the VWF A3 domain.TSP- 
1 cleaves disulphide bonds between VWF multimers,(Xie, et al 2001) and in wild 
type mice the multimer size of platelet- but not endothelial-derived VWF has been 
shown to reduce more rapidly than TSP-1 null mice, suggesting TSP-1 may be more 
relevant for the control of platelet VWF multimers.(Pimanda, et al 2004)
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1.2.8 Modifiers of VWF level
VWF levels vary considerably within the general population with 95% of values 
occurring between 50 and 200% of the mean. This variation is due to several 
genetic and environmental determinants.(Levy and Ginsburg 2001) Twin studies 
have shown that around 60% of the variation in VWF levels is genetically 
determined, of which approximately one third is due to the influence of ABO blood 
group.(Gill, et al 1987, Orstavik, et al 1985) Linkage analysis has confirmed a direct 
functional effect of the ABO locus on plasma VWF levels,(Souto, et al 2000) and a 
detailed discussion of possible mechanisms for the ABO effect is presented in 
Section 1.4. The remainder of the genetic variability is yet to be determined although 
ethnic influences on VWF levels have been suggested.(Miller, et al 2001) Other 
factors shown to influence VWF levels include age, oestrogen, exercise, stress, 
pregnancy, acute phase reaction, diurnal variation, thyroid status and menstrual 
cycle.(Bennett and Ratnoff 1972, Gill, et al 1987, Hansen, et al 1990, Jem, et al 
1989, Kadir, etal 1999)
1.2.9 VWF clearance
While the biosynthesis and function of VWF has been well defined, relatively little is 
understood about the mechanism(s) by which VWF is cleared from the circulation. 
The intricate linkage between VWF and FVIII complicates the assessment of how 
the VWF-FVIII complex or its individual components are removed from the 
circulation and wheras VWF is a determinant of the survival of FVIII, clearance of 
VWF is independent of FVIII.
The half-life of exogenous VWF in patients with type 3 VWD is approximately 15 
hours with some inter-individual variation.(Dobrkovska A 1998, Goudemand, et al 
2005) The survival of endogenous VWF has also been shown to differ between 
individuals, as evidenced from studies using DDAVP.(Brown, et al 2003, Michiels, et 
al 2002, van Genderen P. J. J 1997) Survival of VWFpp has been shown to be 3-4 
fold shorter than for the mature VWF protein, at approximately 2 -3 
hours.(Borchiellini, et al 1996)
Possible mechanisms by which VWF is cleared from the circulation include 
mediation by endocytic receptors, proteolysis, renal excretion and extravasation. In 
view of the molecular size of VWF, the latter two seem unlikely. At the time of this 
study, it was not known whether VWF clearance was dependent on the distribution 
of its multimers and therefore related to its proteolysis. Discordance between the 
half-lives of VWF level and functional activity had been reported following DDAVP,
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reflecting a possible effect of rapid proteolysis of VWF and loss of HMW multimers 
on VWF clearance.(Batlle, et al 1987, Casonato, et al 2001a, van Genderen P. J. J 
1997) Furthermore, the rate of ADAMTS-13 mediated proteolysis had been shown 
to vary according to ABO blood group,(Bowen 2003)and a founder haplotype in type 
1 VWD, the Y1584C mutation,(O'Brien, et al 2003) was reported to segregate with 
increased susceptibility of VWF to ADAMTS-13 proteolysis.(Bowen 2004) While the 
significance of this increased in vitro VWF proteolysis on the in vivo clearance of 
VWF had not been established, the absence of proteolytic fragments in a rat model 
lacking O-linked VWF carbohydrates and demonstrating increased VWF clearance 
favoured a receptor-based, rather than a proteolytic-based clearance 
mechanism.(Stoddart, et al 1996) However, in contrast to FVIII, little information was 
available on the identity of cells and receptors that may mediate the clearance of 
VWF in humans. It seemed likely that the structural diversity of VWF would facilitate 
its interaction with a number of endocytic receptors. The liver had been identified as 
the principal site of VWF clearance in animal models using radiolabelled 
VWF.(Lenting, et al 2004, Roussi, et al 1998, Stoddart, et al 1996) A detailed 
discussion of the effect of glycosylation on VWF clearance is presented in Section 
1.5: the only known receptor at the time of the study was the asialoglycoprotein 
receptor (ASGPR), which had been shown mediate the hepatic clearance of hypo- 
sialylated VWF (Ellies, et al 2002, Sodetz, et al 1977)or VWF with an altered 
glycosylation profile in animal studies.(Mohlke, etal 1999b)
In addition to the carbohydrate moiety, it is also likely that polypeptide regions of 
VWF contribute towards its interaction with clearance receptors. Evidence 
supporting this was accumulating around the time of this study following the 
observation of increased clearance of VWF released after DDAVP treatment in type 
2M Vicenza patients with the R1205H mutation.(Casonato, e ta l2002) Subsequent 
in vivo clearance studies of recombinant VWF/R1205H in VWF-deficient mice 
demonstrated the direct causative effect of this mutation.(Lenting, et al 2004) This 
has been followed by reports of other VWF mutations in association with increased 
VWF clearance and a type 1 VWD phenotype.(Haberichter, et al 2006a, Schooten, 
et al 2005) Furthermore, several regions within the VWF molecule have now been 
shown to be contribute towards the recognition and clearance of VWF.(Lenting, et al
2004)
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1.3 VON WILLEBRAND DISEASE
1.3.1 Prevalence of VWD
VWD is recognised as the most common inherited bleeding disorder in humans. The 
frequently quoted population prevalence of VWD of 1% derives from two 
epidemiologic studies (Rodeghiero, et al 1987, Werner, et al 1993) In contrast, the 
prevalence of symptomatic VWD presenting to haematologists has been estimated 
to be approximately 1 in 10 000.(Bloom 1991) In 2001, there were approximately 
6000 patients registered in the UK with VWD.(Laffan, et al 2004)
1.3.2 Clinical features of VWD
The predominant clinical symptoms of VWD are nosebleeds, bleeding from lesions 
in the skin, mucosa or gastrointestinal tract, menorrhagia and excessive bleeding 
following trauma, surgical interventions or childbirth. Patients with severe disease 
may also bleed into joints or muscles.
1.3.3 Classification of VWD
VWD is a highly heterogeneous disorder resulting from the deficiency and/or 
dysfunction of VWF, rendering a standardised approach to its diagnosis and 
subsequent management as particularly problematic. In 1994 a revised classification 
of VWD was recommended by the VWF Scientific Subcommittee of the International 
Society on Thrombosis and Haemostasis Scientific and Standardisation Committee 
on VWF (ISTH) (Table 1.3).(Sadler 1994) This classification is a simplified 
modification of an earlier classification,(Ruggeri and Zimmerman 1987) and 
assumes that all cases of VWD arise from mutations within the VWF gene.(Sadler 
1994) VWD is divided into two broad types based on whether the VWF defect is 
quantitative, whereby there is a decrease in structurally normal VWF or qualitative, 
whereby the VWF molecule is abnormal. Type 1 VWD, a partial quantitative 
deficiency of VWF, is the most common variant and represents around 70% of all 
cases of VWD. Type 2 variants (subtypes A, B, M and N) are characterised by 
qualitative defects that correspond with a loss or gain of function. Type 3 VWD is 
characterised by a severe quantitative deficiency of VWF. Quantitative and 
qualitative defects are differentiated by means of quantitative and functional 
laboratory parameters and by analysis of the electrophoretic pattern of VWF 
multimers.
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Table 1.3 Classification of VWD subtypes according to the 1994ISTH 
guidelines.(Sadler 1994)
Subtype
Frequency 
(% of VWD 
cases)
(Colvin 1986)
Clinical Features Diagnosis Molecular Basis
Type 3 ~6% Severe bleeding 
disorder:
Autosomal
recessive
inheritance
Markedly 
decreased or 
undetectable 
VWF:Ag, 
functional activity 
and VIII:C
VWF gene deletions, 
nonsense, missense 
and frameshift 
mutations
Type 1
-70%
Mild to moderate
bleeding,
autosomal
dominant;
incomplete
penetrance
VWF:Ag, 
functional activity 
and VIII:C all 
proportionately 
decreased 
Normal multimeric 
distribution
A few missense 
mutations reported, 
some cases 
represent
heterozygous form of 
type 3
Type 2A -10-15% Mild to moderate 
bleeding; usually 
autosomal 
dominant, more 
complete 
penetrance than
type 1
Variably 
decreased 
VWF:Ag, platelet- 
dependent 
function and FVIII; 
relative decrease 
in intermediate 
and high 
molecular weight 
multimers
Missense mutations 
clustered within 
VWF- A2 repeat.
Two subgroups:
a.defect in
intracellular transport
b. increased 
proteolysis post­
secretion
Type 2B <5% Mild to moderate 
bleeding; 
autosomal 
dominant
Variably 
decreased 
VWF:Ag and 
functional activity 
and VIII:C; loss of 
large multimers; 
enhanced RIPA, 
thrombocytopenia
Missense mutations 
clustered in VWF-A1 
repeat result in 
increased affinity of 
VWF for GPIba, 
leading to
spontaneous platelet 
binding
Type 2M rare Variable bleeding;
autosomal
dominant
Variably 
decreased 
VWF:Ag and 
platelet-dependent 
function despite 
normal multimeric 
pattern.
Missense mutations 
and small in frame 
deletions in VWF-A1 
repeat
Type 2N Uncommon: 
heterozygotes 
may be 
prevalent in 
some
populations
Variable bleeding. 
Homozygotes (or 
compound 
heterozygotes) may 
resemble 
autosomal 
haemophilia A. 
Coinheritance may 
modify severity of 
type 1.
Variable VWF:Ag 
and activity. 
Disproportionately 
low FVIII:C. 
Generally normal 
multimers. 
Decreased or 
absent VWF 
binding to FVIII.
Missense mutations 
in VWF-D* or D3 
domains in the N- 
terminus of mature 
VWF that interfere 
with FVIII binding
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1.3.4 Testing
The following screening and specific tests used to diagnose and subtype VWD are
available:
1) Screening tests
(a) Bleeding time or PFA-100™. Both tests assess primary haemostasis 
and are not specific for VWD.
(b) Activated partial thromboplastin time (APTT).
(c) Platelet count.
2) Specific tests
(a) FVIII:C: This can be assayed by a one-stage(Simone, et al 1967) or 
two-stage clotting assay and by a chromogenic assay.
(b) VWF:Ag: Immunological methods are used to measure the quantity
of VWF:Ag in plasma.(Short, et al 1982)
(c) VWF functional assays:
i. VWF ristocetin cofactor activity (VWF:RCo) remains the 
standard functional assay for VWF.(Macfariane, et al 1975) This 
test is a measurement of the interaction of VWF with the 
platelet receptor GPIba. However, there are several drawbacks 
associated with VWF:RCo, which include considerable inter- 
and intra-assay variation.
ii. VWF collagen binding activity (VWF.CB) is measured using 
ELISA and is sensitive to functional variants associated with the 
loss of high molecular weight (HMW) multimers of VWF.(Brown 
and Bosak 1986)
iii. VWF activity immunoassay (VWF:Ac) uses monoclonal 
antibodies that recognise an epitope on VWF involved in its 
interaction with GPIba.(Murdock, et al 1997)
iv. Ristocetin induced platelet aggregation (RIPA). In this assay a 
range of concentrations of ristocetin (0.2 -1 .5  mg/mL) are 
added to platelet rich plasma. The amount of platelet 
aggregation is dependent on the VWF level and the integrity of 
the VWF -  GPIba interaction.
v. VWF multimer analysis. The multimer composition of VWF can 
be determined by agarose gel electrophoresis in the presence 
of sodium dodecyl sulphate (SDS).(Ruggeri and Zimmerman
1981) Despite this being the most useful method for the typing
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and subtyping of VWD, it is the least suitable for 
standardisation.(Schneppenheim, et al 2001)
vi. FVIII binding assay. This assay measures the ability of VWF to 
bind FVIII by immobilising the VWF/FVIII complex prior to 
dissociation of the FVIII using a high concentration calcium 
chloride. Exogenous FVIII is added to the immobilised VWF and 
the amount of exogenous FVIII bound by the VWF is measured, 
utilising either a chromogenic substrate or anti-FVIII antibody.
There has been much debate as to whether the VWF:CB assay should replace 
VWF:RCo as the measurement of functional activity of VWF. However, limitations in 
the differentiation of some variants of type 2 from type 1 VWD have been 
demonstrated,(Riddell, et al 2002) and results have been shown to vary according to 
the type of collagen used.(Penas, et al 2005) The increasing use of VWF:CB to 
measure VWF function has led to the detection of subtypes of VWD with isolated 
collagen-binding defects, which are not classifiable using the 1994 ISTH 
recommendations. (Ribba, et al 2001) At present VWF:RCo remains the gold 
standard for diagnostic purposes,(Rodeghiero, et al 1990) although recommended 
practice in the UK is to use both VWF:RCo and VWF:CB.(Laffan, et al 2004)
1.3.5 Diagnosis of VWD
The diagnosis of VWD is based upon three clinical and laboratory components 
(Table 1.3). These comprise:
1. a personal history of excessive mucocutaneous bleeding
2. laboratory evaluation consistent with a quantitative and/or qualitiative defect 
in VWF
3. a family history of excessive bleeding or appropriate VWF gene mutation
1.3.6 Molecular genetics of VWD 
Types 2 and 3 VWD
There is a significant body of evidence to indicate that types 2A and 2B VWD are 
almost always autosomal dominant traits due to missense mutations within 
VWF,(Fressinaud, et al 2002, Mohlke, et al 1999a) and that type 2N and type 3 
VWD variants are recessive VWF gene traits.(Baronciani, et al 2003, Mazurier 1992, 
Meyer, et al 1997, Zhang, et al 1992b)
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• The majority of type 2A VWD mutations are located within the VWF-A2 
domain. The characteristic type 2A phenotype can arise via two distinct 
mechanisms:
1. Group 1: Intracellular processing defects
The responsible mutation results in an incorrectly folded protein that is 
retained in the endoplasmic reticulum (ER). The larger VWF multimers 
are more likely to contain at least one mutant subunit and are therefore 
retained in the ER while the smaller multimers are secreted 
normally.(Lyons, et al 1992)
2. Group 2: Increased extracellular proteolysis
VWF is normally secreted from the cell but has an increased 
susceptibility to ADAMTS-13 cleavage within the A2 domain resulting in 
loss of the largest VWF multimers.(Dent, et al 1990)
Other reported causes of HMW deficiency include intracellular 
proteolysis,(Englender, et al 1996) and defective post-translational 
processing, including defects of dimerisation or 
multimerisation.(Schneppenheim, et al 2001)
• Type 2B VWD is caused by mutations within the VWF-A1 domain that result 
in increased affinity of VWF for the platelet GPIba receptor. This leads to 
spontaneous binding of the platelets to the largest VWF multimers and the 
removal of these complexes from the plasma.
• Type 2M mutations have been described in the VWF-A1 domain that 
contains the Gplba binding site. The Vicenza subtype, resulting from 
R1205H in the VWF-D3 domain was classified as a type 2M variant at the 
time of this study.(Sadler 1994)
• Type 2N VWD is associated with mutations in the D’ or D3 domains of VWF 
that affect VWF binding to FVIII. Co-inheritance of a type 2N mutation with a 
type 1 VWD allele has been shown to contribute towards the variable 
expressivity of type 1 VWD.(Mazurier, et al 2001)
• Most cases of type 3 VWD are compound heterozygotes, with inheritance of 
an affected allele from each parent. True homozygotes are also found, 
usually where consanguinity is common and notably in the family originally 
described by von Willebrand.(Von Willebrand 1926) The most common 
mutations in type 3 VWD are total or partial deletions, nonsense, splicing and 
frameshift mutations found throughout all 52 exons of VWF.(Baronciani, et al 
2003, Mohlke, et al 1999a, Zhang, et al 1992b)
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Type 1 VWD
Despite being the most common subtype of VWD, relatively few mutations causing 
type 1 VWD had been characterised until very recently. Prior to 2000 a total of 14 
mutations had been reported, comprising 11 missense mutations in exons 26, 28 
and 52, as well as one nonsense and two frameshift mutations. Furthermore, the 
mechanism by which a single allele mutation could result in a bleeding disorder was 
not clear. Two cysteine mutations in the D3 domain, 3445T>C (C1149R) and 3389 
G>T (C1130F), were reported as causing an autosomal dominant type 1 phenotype 
due to a dominant negative effect of the intracellular degradation and impaired 
secretion of VWF.(Bodo, et al 2001, Eikenboom, et al 1996) The molecular basis for 
recessive inheritance has been shown to result from the co-inheritance of a null 
allele and a mutation on the other allele, commonly one found in type 2N VWD as 
described above.(Eikenboom, etal 1993)
In an attempt to address the molecular and clinical features of type 1 VWD, three 
multicentre studies were initiated in 2000:
1. European Union (EU) study: Molecular and Clinical Markers for the Diagnosis
and Management of Type 1 von Willebrand disease (MCMDM-1VWD)
2. Canadian type 1 VWD study
3. United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) type
1 VWD molecular study
The common aim of these studies was to examine the genetic basis of type 1 VWD 
by analysis of VWF in clinically affected patients and to relate the findings to the 
patient's clinical and laboratory phenotype and response to treatment. The protocols 
included extensive bleeding histories, comprehensive testing for VWF level and 
function, linkage analysis to VWF, and sequencing of the VWF coding region in 
affected patients.
1.3.7 Difficulties associated with the diagnosis of type 1 VWD
A diagnosis of type 1 VWD is based upon a history of significant mucocutaneous 
bleeding, laboratory tests compatible with a partial quantitative deficiency of VWF 
and either a positive family history of type 1 VWD or appropriate VWF mutation 
(Table 1.3).(Sadler 1994) Although strict definitions of VWD subtype are required for 
the interpretation and aggregation of data and are therefore appropriate for research 
purposes, the clinical priority is to determine the risk of bleeding in an individual 
patient and initiate appropriate treatment if indicated, irrespective of whether the 
patient fulfils a centrally agreed definition. Acknowledgement of the differences in
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perspective between the clinician and the scientist may alleviate the frequent 
problems imposed by strict definitions of VWD in the clinical setting, particularly in 
the diagnosis of type 1 VWD.
Whether to define type 1 VWD as a disease or a deficiency can pose a challenge to 
clinicians. It has been proposed that while low VWF levels may identify a risk factor 
for bleeding, they do not mandate a diagnosis of type 1 VWD.(Sadler 2002) The 
designation of a cut-off VWF value for the diagnosis of type 1 VWD is arbitrary and 
considerable overlap is observed between VWF levels in patients and healthy 
controls.(Sadler 2005) With the exception of severe cases, no strong relationship is 
generally observed between plasma VWF levels and bleeding 
manifestations.(Sadler 2003) Furthermore, many factors are known to influence 
VWF levels, as previously discussed. Other factors that may result in difficulties in 
the diagnosis of type 1 VWD include the frequent finding of non-linkage between the 
VWF gene and the type 1 phenotype,(Casana, et al 2001, Castaman, et al 1999) the 
incomplete penetrance and variable expressivity of mutant VWF alleles,(Abildgaard, 
et al 1980, Miller, et al 1979a, Miller, et al 1979b)and the objective evaluation of a 
bleeding history or demonstration of a positive family history, such that excessive 
numbers of healthy individuals are possibly being misdiagnosed with an inherited 
haemorrhagic disorder.(Rodeghiero and Castaman 2001, Sadler 2002, Sadler 2004) 
Previous attempts to address these difficulties by classifying some patients as 
having ‘possible’ or ‘probable’ type 1 VWD,(Nitu-Whalley, et al 2000, Sadler 2004) 
have only further added to the confusion. Increasing emphasis has been placed on 
the utility of the bleeding history in recent years and the usefulness of a quantitative 
bleeding score in the diagnosis of type 1 VWD has been demonstrated.(Rodeghiero, 
etal 2005)
1.3.8 Type 1 VWD as a complex genetic trait
Although mutation analysis in type 1 VWD had rarely been reported at the outset of 
this study, the finding of non-linkage between disease phenotype and VWF gene as 
well as the inconsistent correlation between genotype and phenotype in the few 
identified VWF mutations in type 1 VWD, were suggestive of co-existent pathogenic 
mechanisms in type 1 VWD that may or may not relate to the VWF gene. VWF 
levels were shown to be higher in recombinant variants of VWF/C1149R and 
VWF/C1130F compared to those observed in the plasma of heterozygous 
patients,(Bodo, et al 2001, Tjemberg, et al 2004) a discrepancy that may be 
explained by the subsequent demonstration of increased clearance of VWF in these 
VWF mutants.(Schooten, et al 2005) In addition to the ABO effect on VWF levels,
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other as yet unidentified genetic influences account for 40% of the variation in VWF 
levels in humans.(Levy and Ginsburg 2001) A murine model has been identified in 
which VWF concentrations have been shown to be significantly altered in response 
to an aberrantly expressed glycosyltransferase gene that is distinct from the murine 
VWF gene (Mohlke, et al 1999b): this model is discussed in detail in Section 1.4.3.
In addition, the ST3Gal-IV sialyltransferase has been identified as a possible VWF 
modifier gene in humans.(Ellies, et al 2002) Other studies demonstrate the influence 
of single nucleotide polymorphisms (SNP) in the promoter region of VWF on plasma 
VWF levels.(Harvey, et al 2000) Genome-wide linkage analysis has shown that in 
addition to the ABO locus on chromosome 9, VWF levels are influenced by regions 
of chromosomes 1, 2, 5, 6, and 22.(Souto, et al 2003)
Therefore, at the time of this study, type 1 VWD was beginning to emerge as a 
complex genetic trait,(Sadler 2002) with heterogeneity in pathophysiological 
mechanisms. The likely involvement of a number of modifiers of VWF level, both 
within and outwith the VWF gene was becoming increasingly recognised. These 
modifiers may have little effect in isolation, but in combination could account for the 
wide variation in clinical severity and incomplete penetrance of type 1 VWD.
1.4 OLIGOSACCHARIDE STRUCTURES OF VON WILLEBRAND FACTOR
In this section possible pathogenic mechanisms by which the oligosaccharide side 
chains of VWF may contribute towards a partial quantitative deficiency of the protein 
are reviewed. The structures of these oligosaccharides and how understanding of 
their possible functional roles has evolved over the past four decades is also 
discussed.
1.4.1 Oligosaccharide side chains of VWF 
Structure
Oligosaccharides make up approximately 20% of the mass of VWF. N-linked 
glycosylation occurs co-translationally and the sites of the 12 N-linked and 10 O- 
linked oligosaccharide side chains have been identified and are distributed 
throughout the VWF molecule (Appendix 1, Fig.1.4).(Titani, et al 1986)
Sialic acids are possibly the most biologically important monosaccharide units of 
glycoconjugates and are commonly linked to the penultimate galactose (Gal) or N- 
acetylgalactosamine (GalNAc) on N- and O-glycan branches. The majority of sialic
24
acids attached to plasma components are a2-3 linked and are produced by up to six 
of the 18 sialyltransferase enzymes encoded by a2-3 ST3Gal genes.
The primary structure of the major N-linked oligosaccharide chain is a 
monosialylated biantennary complex glycan in which the basic pentasaccharide core 
has two N-acetyllactosamine residues (Gaip(1->4)GlcNac) added, one of these 
terminating in sialic acid (Fig.1.5A).(Debeire, et al 1983, Samor, et al 1982) This 
structure is identical to that of human lacto-transferrin glycopeptide D,(Spik, et al
1982) and also to that of glycopeptide fraction B, derived from secretory 
immunoglobulin A from human milk.(Pierce-Cretel, et al 1982) The primary structure 
of a tetraantennary glycan has subsequently been described whereby four N- 
acetyllactosamine residues are added to the basic core in addition to sialic 
acid.(Samor, et al 1986) At present, the structures of 94% of the N-linked 
oligosaccharides of bi-, tri- and tetra-antennary types are known.(Matsui, et al 1992) 
These include a proportion (-12%) of oligosaccharides containing blood group A, B 
and H antigenic structures.(Matsui, et al 1999, Sodetz, et al 1979) Analysis of the CD- 
linked oligosaccharide side chains has shown them to be comprised of mucin-type 
structures in which GalNAc is linked (a1-3) to either serine or threonine residues 
(Fig. 1.5B).(Samor, et al 1989) Blood group antigens have not been demonstrated on 
these glycans.
Figure 1.4 Positions of the N- and O-linked oligosaccharide side chains on 
the VWF molecule (amino acid: aa)
O-l inked N-linkedaa763
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Figure 1.5 Primary structures of the major N-linked (A) and O-linked (B) 
glycans on VWF
Man - mannose; GlcNAc - N-acetylglucosamine; Gal -  galactose;
GalNAc - N-acetylgalactosamine; NeuAc - N-acetylneuraminic (sialic) acid; 
Gal(ft1 -4)GlcNAc-N-acetyllactosamine
A. N-linked
NeuAc(a2-6)Gal(fc1 -4)GlcNAc(fi1 -2)Man(a 1 -3)
Man(fi1 -4)GlcNAc((i1 -4)GlcNAc((l1 -N)Asn
Fuc
Gal(R1 -4)GlcNAc((i1 -2)Man(a 1 -6)
B. O-linked
NeuAc(a2-3)Gal(li1 -3)
»alNAc(a1-3) Ser or Thr
NeuAc(a2-6)
Possible functional roles
In the 1970s, although the structure of the carbohydrate moiety had not yet been 
elucidated, there was much interest in studying the function of the VWF 
oligosaccharide chains, especially the sialic acid and galactose residues, with 
respect to the biological activity of the protein. Structurally altered carbohydrate 
moieties as demonstrated by absent Periodic Acid Schiff (PAS) reactions were 
reported, suggestive of glycosylation defects, in qualitative variants of 
VWD.(Gralnick, et al 1976, Gralnick, et al 1977) However, the absence or decrease 
of PAS-reactive VWF carbohydrate was not found to be a consistent abnormality in 
VWD.(Zimmerman, et al 1979) These results should be interpreted in light of the 
knowledge that PAS is sensitive, but not specific for sialic acid residues. The 
possible functional roles of the oligosaccharide side chains, in particular, the sialic 
acid and galactose residues, discussed in this section are summarised in Table 1.4.
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Platelet aggregation
The in vitro removal of sialic acid from VWF using neuraminidase exposes the 
penultimate Gal molecule. It is now well established that this in vitro removal does 
not affect the VWF:Ag concentration, however, its effect on platelet aggregation is 
disputed in the literature. Some investigators have demonstrated desialylated VWF 
to be capable of inducing spontaneous platelet aggregation independent of 
ristocetin, an effect that was abolished by recruitment of GPIba-defective 
platelets.(De Marco and Shapiro 1981, Vermylen, et al 1974, Vermylen, et al 1973) 
Others report a resultant incremental loss of VWF:RCo,(Kao, et al 1980, Levy- 
Toledano, et al 1973, Rosenfeld and Kirby 1979, Sodetz, et al 1978, Sodetz, et al 
1977) with further studies reporting no effect on VWF:RCo,(Fukui, et al 1977, 
Gralnick 1978, Morisato and Gralnick 1980) or platelet aggregation in the 
presence,(Goudemand, et al 1985, Morisato and Gralnick 1980) or 
absence,(Rosenfeld and Kirby 1979) of ristocetin. Few studies have tested the direct 
effects of p-galactosidase or galactose oxidase on intact VWF: these enzymes 
respectively remove or oxidise only the terminal Gal residues. Treatment of VWF 
with p-D-galactosidase was shown in one study to result in reduction in 
RIPA.(Goudemand, et al 1985) Another showed treatment with galactose oxidase, 
but not p-galactosidase, to result in significant loss of VWF:RCo.(Fukui, et al 1977)
In a further study neither galactose oxidase nor p-galactosidase-treated VWF was 
shown to have any effect on VWF:RCo.(Gralnick, et al 1983) The majority of studies 
have tested the effects of p-galactosidase or galactose oxidase on desialylated 
VWF, which results in both the terminal and penultimate Gal residues being 
released or oxidised. In this state, platelet aggregation was shown to be reduced in 
both the presence and absence of ristocetin.(Goudemand, et al 1985, Gralnick 
1978, Kao, et al 1980, Vermylen, et al 1973) The VWF:RCo was also shown to be 
reduced.(Gralnick 1978, Gralnick, et al 1983, Morisato and Gralnick 1980, Sodetz, 
et al 1978)
These in vitro studies report discrepant results following the removal of either sialic 
acid or the terminal Gal residue. However, the studies are in agreement that 
removal of the penultimate Gal residue results in a loss of VWF:RCo activity. This 
suggests that intact penultimate Gal moieties on VWF are necessary for its effect on 
platelet aggregation.
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Adsorption to Collagen
Desialylation of intact VWF has been shown not to interfere with the adsorption of 
VWF to type I collagen.(Kessler, et al 1990) However, treatment of desialylated 
VWF with p-galactosidase or galactose oxidase markedly reduces collagen 
adsorption suggesting that penultimate galactose moieties are also required for the 
adsorption of VWF to collagen.(Kessler, et al 1990)
Multimeric Structure
It is not clear whether the effect of modified carbohydrates on VWF-platelet and 
collagen interactions is direct, via altered binding sites, or indirect, via degradation of 
VWF multimers. Removal or oxidation of the penultimate Gal moiety from 
desialylated VWF has been shown to significantly affect its multimeric structure with 
loss of HMW and increase in low molecular weight (LMW) multimers.(Goudemand, 
et al 1985, Gralnick, et al 1983, Kessler, et al 1990) One of these studies reported a 
similar loss of HMW multimers upon removal of only the terminal Gal,(Goudemand, 
et al 1985) a finding not confirmed by others.(Gralnick, et al 1983) These results 
suggest that the penultimate and possibly the terminal Gal residues are essential for 
the maintenance of normal multimeric structure. The effects of inhibiting N- 
glycosylation in VWF have been studied by treating human umbilical vein 
endothelial cells (HUVEC) with tunicamycin. The resulting pro-VWF monomers 
failed to dimerise and accumulated in the endoplasmic reticulum.(Wagner, et al 
1986) This suggests that initial glycosylation is necessary for VWF multimerisation 
with carbohydrates providing the VWF monomer with a conformation that favours 
dimerisation.
Protection from proteolytic degradation
Following the extensive work outlined above, it was shown that rather than being 
necessary for maintaining multimeric structure and platelet aggregation directly, the 
carbohydrate moiety protected VWF from proteolytic degradation.(Federici, et al 
1984) Although a fall in VWF:RCo following treatment with neuraminidase and p- 
galactosidase was reported in this study, this was to levels which were considerably 
higher than those previously reported.(Gralnick 1978, Sodetz, et al 1978) When 
VWF was treated with neuraminidase and p-galactosidase in the presence of 
protease inhibitors, removal of carbohydrate was comparable to that seen in 
previous studies but there was no associated change in VWF:RCo. Moreover, the 
multimeric structure remained intact. This would suggest that the oligosaccharide 
side chains have a role in protecting VWF multimers against traces of one or more 
plasma proteases. Since traces of one or more proteases may contaminate even
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highly purified VWF, removal of the carbohydrate moiety may appear to be directly 
responsible for causing loss of HMW multimers when it is simply making the protein 
susceptible to proteolysis by these proteases. Loss of HMW multimers causes a 
reduction in VWF:RCo and in the absence of protease inhibitors there may have 
been proteolysis of the HMW multimers resulting in the observed reduction in 
VWF:RCo. It has subsequently been shown that sialic acid protects VWF by 
preventing its cleavage in the N-terminal region and thus inhibits the loss of HMW 
multimers.(Berkowitz and Federici 1988) Studies in other glycoproteins demonstrate 
similar protective effects by the carbohydrate moiety from both intracellular and 
extracellular degradation.(Bemard, et al 1982)
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Table 1.4 Summary of in vitro studies of functional roles of VWF in which the sialic acid (asialo-), terminal galactose (agalacto-) and sial­
ic acid and terminal and penultimate galactose residues (asialo-, agalacto-) have been removed. References denoted by number. 
VWF:RCo=ristocetin cofactor activity; VWF:CB=collagen binding activity; HMW=high molecular weight; LMW=low molecular weight; T= increased; 
i=decreased; <-»=unchanged.
Treated
VWF
Platelet aggregation
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1.4.2 VWF glycosylation and clearance
Clearance of glycoproteins
A primary purpose of glycosylation is to encode the half-life of a glycoprotein. One of 
the possible reasons for this is the diversity in sugar structures, which results from 
variety in both constituent oligosaccharides and the linkages that connect them. The 
carbohydrate moiety of many plasma glycoproteins including erythropoietin, 
interferon, sex hormone-binding globulin and caeruloplasmin is known to play a key 
role in their plasma clearance.(Ashwell and Harford 1982, Cousin, et al 1999) 
Desialylation and the subsequent exposure of the penultimate Gal residue has been 
shown to increase the rate of removal of several glycoproteins from the 
circulation.(Ain, eta! 1987, Durocher, etal 1975, Morell, etal 1971, Nelsestuen and 
Suttie 1971) This reduction of intravascular half-life has been found when as little as 
25% of the sialic acid has been removed. The asialoglycoprotein receptor (ASGPR), 
a lectin on hepatocytes has been shown to mediate the cellular uptake of a number 
of desialylated proteins in vitro by recognising exposed Gal and GalNAc 
residues.(Ashwell and Harford 1982, Morell, et al 1971, Spivak 1989) The affinity of 
ASGPR has been shown to be up to 60-fold greater for structures containing 
GalNAc than for Gal.(Kolatkar, et al 1998) However a study using ASGPR-defective 
mice failed to detect any substantial accumulation of desialylated 
glycoproteins,(Ishibashi, et al 1994) and the role of the ASGPR in vivo remains to be 
determined.
In vitro modification of the carbohydrate moiety of VWF
Asialo-VWF has been shown to bind to the ASGPR and is rapidly removed from the 
circulation in animal studies.(Sodetz, et al 1978, Sodetz, et al 1977) In contrast, both 
intact VWF and asialo-VWF which has been treated with galactosidase exhibit 
minimal affinity for this receptor.(Sodetz, et al 1978) This suggests that exposed 
penultimate Gal residues may be required for the recognition and subsequent 
binding of VWF to the hepatic ASGPR in these animal models. As a result of these 
findings, it was postulated that the increased desialylation and subsequent rapid 
plasma clearance of VWF may result in a partial quantitative deficiency of the 
protein in v/Vo.(Sodetz, et al 1977)
Although these studies focus on terminal sialic deletion, it is not proposed that this is 
the only defect; rather that a spectrum of carbohydrate structural modifications could 
explain the heterogeneity seen in plasma VWF levels. There may be more extensive 
deletions extending into the structural core of the carbohydrate moiety.
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1.4.3 Animal models of a partial quantitative deficiency of VWF
The RIIIS/J mouse was described in 1990 as a model for a partial quantitative 
deficiency of VWF.(Sweeney, et al 1990) The gene responsible, Mvwf, is on 
chromosome 11 .(Mohlke, et al 1998) distinct from the murine VWF locus on 
chromosome 6.(Nichols, et al 1995b) Mvwf is the allele of a previously known 
glycosyltransferase gene, N-acetylgalactosaminyltransferase (Galgt2),(Mohlke, etal 
1999b) the murine expression of which is usually restricted to the kidney and 
intestine. In RIIIS/J mice, a regulatory mutation causes a switch of this Galgt2 gene 
expression to the vascular endothelial cells where plasma VWF is synthesised. Here 
the VWF undergoes aberrant post-translational modification, with the addition of 
GalNAc onto the glycans. This abnormal carbohydrate expression in VWF results in 
a plasma half-life of 25 min as compared with 300 min for unmodified VWF thus 
reducing the steady state plasma levels of VWF.(Mohlke, et al 1999b) Similar 
phenotypes are observed in homozygous and heterozygous RIIIS/J models, 
consistent with this gain-of-function hypothesis. The high affinity of the hepatic 
ASGPR for structures containing subterminal GalNAc suggests that Ga/gf2-modified 
VWF may be cleared via this receptor. This is supported by the correction of the 
rapid clearance of the modified VWF following saturation of this receptor with the 
competitive ligand asialofetuin, although is yet to be definitively shown. Increased 
VWF clearance has also been demonstrated in other animal models including 
recombinant VWF defective in O-linked carbohydrates in a rat model,(Stoddart, et al 
1996) and endogenous VWF in the absence of the sialyltransferase enzyme 
ST3GallV in a murine model.(Ellies, et al 2002)
1.4.4 ABO blood group
ABH blood group expression on VWF and ABO effect on plasma VWF levels
The relationship between plasma VWF concentration and ABO blood group is well 
established. Levels of VWF vary by 20 -  30% according to individual ABO blood 
group with the plasma VWF levels increasing in the order 0<A<B<AB.(Gill, et al 
1987, Orstavik, et al 1985) The ABH blood group antigens consist of terminal 
carbohydrate molecules which are synthesised by the sequential action of 
glycosyltransferases.(Lowe 1993) These catalyse the addition of specific 
monosaccharides to a common core precursor antigen (H antigen) to form distinct A 
and B antigens. A and B antigens differ only by their terminal sugar structure: A 
antigens terminate in GalNAc, B antigens terminate in Gal, and H in a fucose 
residue. Individuals with blood group O lack these glycosyltransferases and express 
only the basic H antigen.
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VWF is one of only three glycoproteins shown to express ABH antigens, which are 
present on 13% of the N-linked oligosaccharide chains of plasma VWF according to 
the blood group of the individual.(Sodetz, et al 1979) ABH antigens are also 
expressed by FVIII and a2 macroglobulin. Platelet VWF, in contrast, appears to 
express significantly less ABH antigens,(Brown, et al 2002, Matsui, et al 1999) and 
this is consistent with the absence of variation of platelet VWF levels between blood 
groups.(Sweeney and Hoemig 1992) A possible explanation for this is that intra­
platelet VWF is compartmentalised away from the ABO-encoded 
glycosyltransferases. Alternatively, the carbohydrate side chains of platelet VWF 
may differ from that of other intra-platelet proteins such that AB antigen addition 
cannot occur.Although the mechanism for the ABO effect on plasma VWF levels is 
not known, it seems likely that it is mediated by the presence of the ABH antigenic 
structures on VWF.
ABH determinants and VWF synthesis and secretion
While it is possible that ABO blood group alters the synthesis or secretion of VWF 
within endothelial cells, several lines of evidence suggest that this is not the case. 
Firstly, ABO blood group has not been shown to influence the rate of VWF secretion 
by the regulated secretory pathway in in vivo studies using DDAVP.(Brown, et al 
2003, O'Donnell and Laffan 2001) Secondly, ABO blood group has not been shown 
to influence plasma levels of VWFpp or platelet VWF levels. (O'Donnell and Laffan
2001) Finally, transfection of A transferase in a phenotypically group-O endothelial 
cell line has not been shown to affect the rate of VWF synthesis.(0'Donnell and 
Laffan 2003) These data suggest that it is unlikely that the ABO effect on VWF 
levels is mediated by alterations in the biosynthesis and secretion of VWF, and 
alternative explanations should therefore be sought.
ABH determinants and ADAMTS-13 mediated proteoiysis of VWF
It is now a well established view that the one of the functions of the carbohydrate 
moiety of VWF is to protect the protein from proteolytic degradation, as discussed in 
Section 1.4.1(Federici, et al 1984) Recent studies have demonstrated that the ABO 
blood group determinants may influence the susceptibility of plasma VWF to 
ADAMTS-13 proteolysis. The rate of proteolysis was shown to be greater for HMW 
plasma VWF of group O VWF compared with non-0 (in the order O = B > A =
AB),(Bowen 2003) and proteolysis of HMW plasma VWF from individuals of the 
Bombay phenotype was shown to be greater than that for group 0.(0'Donnell, et al
2005) In addition, measurement of ADAMTS-13 levels has shown these to be higher 
in blood group O than in non-O individuals.(Mannucci, et al 2004) The mechanism
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by which ABO blood group may influence the rate of ADAMTS-13 proteolysis of 
plasma VWF remains unknown. The cleavage site in VWF for the metalloprotease 
ADAMTS13 is flanked by two N-linked and five O-linked glycosylation sites. In the 
primary VWF structure, these represent the nearest glycosylation sites, although 
there may be other nearby glycosylation sites in the tertiary structure. These 
observations suggest that the presence of ABH antigens on one or more of the 
glycosylation moieties that flank the VWF cleavage site for ADAMTS-13 may 
influence proteolysis and through this mechanism influence plasma VWF level. 
Alternatively, VWF proteolysis and VWF level may not be directly related although 
both may be influenced by ABO blood group.
ABH determinants and VWF clearance
The hypothesis that terminal carbohydrate moiety expression may determine the 
rate of VWF clearance is supported by studies of the RIIIS/J mouse,(Mohlke, et al 
1999b), as described above. Data from other studies has shown infused Factor VIII 
has a shorter half-life in blood group O compared to group A haemophilia A 
patients, suggesting the importance of ABH antigens on VWF in determining the 
rate of clearance.(Vlot, et al 2000)
Other blood group antigens
In addition to the ABH blood group antigens, the effect of two other 
glycosyltransferases on VWF levels has been studied. The Secretor (Se) and Lewis 
b blood group antigens encode an a(1,2)-fucosyltransferase that generates the H 
blood group antigen in tissues other than red blood cells. An association was found 
between Se, but not Lewis genotype, and VWF:Ag level with the highest VWF levels 
found in Se homozygotes.(0’Donnell, et al 2002b)
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1.5 MANAGEMENT OF VWD
The primary aim of treatment of VWD is to correct the dual defect of haemostasis, 
namely the platelet adhesive defect and the low level of FVIII. There are currently 
two main therapeutic options: administration of DDAVP or replacement therapy with 
plasma-derived concentrates.(Mannucci 2004)
1.5.1 DDAVP
Historical background
In 1772, it was reported by William Hewson that blood clotted rapidly when collected 
under conditions of stress.(Hewson 1846) Over two centuries later, rapid blood 
clotting associated with stress was shown to result from the release of 
adrenaline,(Cannon 1914) which was subsequently explained by the finding of a 
transient increase in FVIII in rabbits following the administration of 
adrenaline.(Marcianiak 1957) Reports of raised FVIII following adrenaline infusion in 
humans soon followed with around two fold increases of FVIII being demonstrated in 
both haemophilic patients and normal subjects, with no measurable change in other 
known clotting factors.(lngram 1961) Investigation of other hormones led to the 
observation that the antidiuretic hormone vasopressin also led to increased FVIII 
levels(Mannucci 1972) and the similar effect of its analogue 1-deamino-8-D-arginine 
vasopressin (DDAVP) was subsequently described.(Cash, et al 1974) DDAVP had 
less vasoactive properties than vasopressin and was used for the first time to treat 
patients with haemophilia A and VWD in 1977.(Mannucci, et al 1977)
Mechanisms of action
DDAVP results in a two to three fold rise in FVIII and VWF levels, with the release of 
UL VWF multimers that potentiate haemostasis by enhancing the platelet-vessel 
wall interaction.(Ruggeri, et al 1982) DDAVP induces the release of stores of both 
mature VWF and VWFpp from the Weibel-Palade bodies of endothelial cells via the 
regulated pathway as discussed in Section 1.2 .2.(Borchiellini, et al 1996, Mannucci, 
et al 1976, Tsakiris, et al 1995, van Mourik, et al 1999) DDAVP is a specific agonist 
for the vasopressin V2 receptor (V2R) and is known to exert its antidiuretic effect via 
a rise in cAMP in kidney collecting ducts. However, the cellular mechanism of the 
haemostatic effects of DDAVP is not clear. Injection of DDAVP into rats has been 
shown to elicit biological responses that are clearly related to the activation of 
endothelial cells, including the surface expression of P selectin and subsequent 
marginalisation of leukocytes.(Kanwar, etal 1995) Immunohistochemical
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examination of endothelial cells in vivo following DDAVP shows a reduction and 
altered localisation of VWF, with a tendency for the protein to move abluminally 
towards the cellular basement membrane.(Takeuchi, et al 1988) DDAVP has been 
shown to stimulate VWF secretion in a cAMP-dependent manner in cultured human 
umbilical vein endothelial cells (HUVEC) following transfection by the 
V2R.(Kaufmann, et al 2000, Moffat, et al 1984) Furthermore, V2R mRNA has been 
demonstrated in human lung microvascular endothelial cells 
vasopressin.(Kaufmann, et al 2000)
Although it was previously hypothesised that the rise in FVIII following DDAVP 
resulted from its stabilisation in plasma secondary to the release of VWF,(Mannucci 
and Cattaneo 1992) the finding of comparable FVIII release following DDAVP in 
type 2N VWD,(Mazurier, et al 1994) is suggestive of release of FVIII from as yet 
unidentified cellular stores. Neither FVIII nor VWF have been shown to be released 
following chronic administration of exogenous VWF to patients with type 3 VWD, 
confirming that endogenous synthesis of both VWF and FVIII is required for 
DDAVP-induced release of FVIII. Furthermore, patients with haemophilia who have 
undergone liver transplantation for end-stage liver disease have been shown to 
demonstrate a response in VWF, but not FVIII to DDAVP. (Lamont and Ragni 2005) 
In contrast, there was a response in both VWF and FVIII in a non-haemophilic 
transplant recipient. These findings suggest that intracellular co-localisation of FVIII 
and VWF is necessary for in vivo FVIII secretion after DDAVP. Although the storage 
site(s) of FVIII is not well established, at least some is likely to be released from 
sinusoidal endothelial cells. In addition, FVIII has been shown to be synthesised in 
the lung microvascular endothelium(Jacquemin, et al 2006)and the co-expression of 
FVIII and VWF in microvascular endothelial cells has been demonstrated in lung 
tissue, the significance of which is not yet clear
Use in treatment of VWD
Despite the widely held view that the majority of type 1 VWD patients are responsive 
to DDAVP, with reported response rates as high as 90%,(Nolan, et al 2000) recent 
results from a multicentre study have suggested that response rates may be much 
lower, with only 27% of type 1 VWD patients being shown to respond.(Federici, et al 
2004) The rate of response to DDAVP partly depends upon how response is 
defined: in the former study, the correction of VWF:Ag, VWF:Ac and FVIII:C into the 
normal range 30 min following DDAVP infusion constituted a response.(Nolan, et al 
2000) However, for response to be achieved in the latter study, the attainment of a 
minimum three fold increase of FVIII:C and VWF:RCo to levels of at least 30 lU/dL 
and a bleeding time (BT) of less than 12 min was required 2 h after DDAVP
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infusion.(Federici, et al 2004) The different time intervals used in these studies is 
likely to account for some of the discrepancy in response rates: as expected, FVIII 
and VWF:RCo were found to peak at 30 min in the second study and response rates 
would therefore have been higher had this timepoint been employed. The low 
proportion of responsive type 1 patients in the latter study may also reflect the 
severe phenotype of the recruited patients as well as the misclassification of around 
one third of this patient cohort who showed low VWF:RCo/Ag ratios and normal 
multimer patterns consistent with type 2M disease.
The heterogeneity of type 2 VWD necessitates consideration of the specific VWF 
functional defect to determine appropriate treatment: although it has been reported 
that patients with the subtype 2A show a variable response to DDAVP,(Gralnick, et 
al 1986) none of the type 2A patients in the aforementioned multicentre study were 
found to be responsive, regardless of the underlying mutation and mechanism of 
VWF dysfunction.(Federici, et al 2004) Other studies have shown no increase in 
circulating HMW multimers following DDAVP in type 2A disease despite satisfactory 
increases in VWF and FVIII.(Ruggeri, et al 1982) Opinion on the use of DDAVP in 
type 2B VWD is divided: some clinicians avoid it due to the risk of transient 
thrombocytopenia and potential adverse events associated with the formation of 
platelet aggregates,(Federici 2006, Holmberg, et al 1983) while others report 
successful treatment with DDAVP in these patients.(Casonato, et al 1990, Fowler, et 
al 1989) Although good responses to DDAVP have been demonstrated in patients 
with type 2N VWD irrespective of their causative mutation,(Mazurier, et al
1994)other data suggest response is limited to patients with the most common 
mutation, 2561 G>A (R854Q).(Federici, et al 2004) Because type 3 VWD patients 
lack releasable stores of VWF, they do not respond to DDAVP,(Ruggeri, et al 1982) 
although DDAVP can be used as an adjunct in these patients.
The obvious advantages of DDAVP include cost and the elimination of risk of blood- 
boume pathogen transmission. DDAVP can be administered by intravenous, 
subcutaneous or intranasal routes at a dose of 0.3 pg kg'1. Respective peak values 
occur at 30-60 min following intravenous and 90-120 min after subcutaneous and 
intranasal treatment,(Mannucci 1997)and this response has been shown to be 
sustained for several hours.(Mannucci 1982) Despite consistency in the response of 
a given patient on different occasions,(Rodeghiero, et al 1989) the therapeutic effect 
in not predictable in an individual patient and it is recommended that the response to 
DDAVP is measured in all patients at diagnosis and/or two weeks prior to surgery. 
The current UK guidelines recommend a trial of DDAVP be performed in patients 
with types 1 (where baseline VWF levels > 10 IU dL'1), 2A and 2M VWD, and
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considered in 2N and 2B disease.(Pasi, et al 2004) DDAVP infusions can be 
repeated every 12 - 24 h depending on the type and severity of the 
bleeding.(Mannucci, et al 1977) However, tachyphylaxis can develop in some 
patients,(Mannucci, et al 1992) and in general, treatment with DDAVP can be 
usefully repeated between two and four times. The commonest side-effects of 
DDAVP are facial flushing, headache and tachycardia. Hyponatraemia due to the 
antidiuretic effect of DDAVP is unusual if excess fluid intake is avoided. In view of 
the release of UL-VWF multimers, DDAVP is contra-indicated in ischaemic heart 
disease, although substantiated evidence is lacking.
There are currently no clear objective criteria that define a response to DDAVP. The 
recommendations in the UK guidelines state that the definition of an adequate 
response will depend, in part, upon the indication for treatment.(Pasi, et al 2004) 
Although FVIII:C is commonly used as a surrogate marker of the clinical efficacy of 
DDAVP, it has been shown to be an unreliable guide in VWD patients.(Michiels, et 
al 2002, Nolan, et al 2000) The UK guidelines recommend the measurement of both 
VWF and FVIII levels and in addition to measuring response to DDAVP suggest that 
levels are repeated at 3 -  6 h post DDAVP to ensure that there is not a rapid fall off 
in levels.(Pasi, et al 2004) Prospective studies on the biological response versus 
clinical efficacy of DDAVP in VWD types 1 and 2 are in currently in progress.
1.5.2 Plasma concentrates
The second treatment option for VWD relies on the administration of blood products 
containing concentrated VWF and FVIII and is used in patients unresponsive to 
DDAVP or in whom DDAVP is contra-indicated. For many years, cryoprecipitate was 
the mainstay of VWD treatment. Several intermediate-purity and high-purity 
VWF/FVIII concentrates are now available and have been shown to be effective in 
both bleeding and surgical settings.(Mannucci 2004) The relative concentrations of 
VWF and FVIII vary between preparations,(Lethagen, et al 2004) and as with any 
plasma-derived concentrate, there is a risk of transmission of blood-bourne 
pathogens. Although thrombotic events are rare in VWD patients receiving repeated 
infusions of concentrates, there is concern that sustained high FVIII levels may 
increase risk of postoperative venous thromboembolism.(Federici 2006) New VWF 
products almost devoid of FVIII, as well as recombinant VWF are currently under 
evaluation.
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1.5.3 Other therapies
Other treatments that can be used either alone or adjunctively in VWD include 
antifibrinolytic agents (mainly tranexamic acid), platelet concentrations and oral 
oestrogen-progestogen preparations. During recent years initial steps in the 
development of a gene-based therapy for severe VWD have been taken.(De Meyer 
2007, Pergolizzi, et al 2006)
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INITIAL AIMS
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2.1 OVERVIEW OF PREVIOUS STUDIES OF VWF CLEARANCE
Despite the 1994 classification of VWD being based upon the assumption that all 
VWD arose from mutations of the VWF gene,(Sadler 1994) by the time of this study 
it was becoming increasingly accepted that a partial quantitative deficiency of VWF 
may represent a complex genetic trait.(Sadler 2002) In contrast to other VWD types, 
very few mutations in VWF had been linked to type 1 VWD.(Allen, et al 2000, Bodo, 
et al 2001, Eikenboom, et al 1996) Although some type 1 VWD phenotypes had 
been linked to defects within VWF, others were not shown to cosegregate with 
genetic markers at the VWF locus.(Casana, et al 2001, Castaman, et al 1999) 
Furthermore, variation in resting VWF levels in obligate heterozygous carriers of 
VWD type 3 alleles had been demonstrated.(Sadler 2002) Other than ABO blood 
group, factors contributing towards the genetic variability in VWF levels were largely 
unknown. The increasing recognition of modifiers of plasma levels of VWF that were 
independent of VWF supported the view that while some case of type 1 VWD may 
result from mutations within VWF, the remainder could result from the mutation of a 
gene separate from VWF or the interaction of several genes. Type 1 VWD was 
therefore becoming more widely viewed as a continuum, with low levels of VWF 
associated with a bleeding phenotype resulting from heterogeneous pathogenic 
mechanisms.
The half-life of VWF following the administration of the vasopressin analogue 
DDAVP was studied during the early development of DDAVP as a therapeutic 
agent.(Mannucci, et al 1977) Initial observations suggested that there was no 
significant difference in the half-lives of VWF released following DDAVP infusion 
between patients with ‘classical’ VWD and either a normal control group or 
individuals with mild haemophilia A.(Mannucci 1982) However, the rapid return to 
baseline of plasma FVIII:C, VWF:Ag and VWF:RCo following DDAVP infusion in 
type 1 VWD patients was subsequently observed,(de la Fuente, et al 1985) and half- 
life values for these parameters were found to be reduced in type 1 VWD 
subjects.(Rodeghiero, etal 1988) Latterly, the half-life of VWF released following 
DDAVP was determined in patients with type 1 VWD as well as mild haemophilia A 
patients and normal controls.(Brown, et al 2003, Michiels, et al 2002, van Genderen 
P. J. J 1997) These studies showed significant reductions in VWF half-life in a 
proportion of patients with type 1 VWD and it was proposed that increased plasma 
clearance of VWF may contribute towards the pathogenesis of type 1 VWD in some 
patients.(Brown, et al 2003)
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Increased steady-state plasma ratios of VWF propeptide (VWFpp) to the mature 
VWF protein were reported in some patients with VWD, in particular in patients with 
type 2A VWD in whom increased sensitivity to proteolysis had been 
demonstrated.(de Romeuf and Mazurier 1998) However this ratio was not found to 
reliably discriminate between types 1 and 2 VWD, consistent with the theory that 
increased VWF clearance may also underlie some cases of type 1 VWD. Few 
studies had examined VWFpp in type 1 VWD.
No common mechanism had been identified that could account for the increased 
clearance of VWF observed in some patients with type 1 VWD following DDAVP. 
Clearance mechanism(s) of VWF were poorly defined, although data supportive of 
both receptor mediated and proteolytic-based mechanisms had been 
published.(Batlle, etal 1987, Bowen 2003, Casonato, e ta l2001a, Stoddart, etal 
1996, van Genderen P. J. J 1997) Defective proteolysis by the metalloprotease 
ADAMTS-13 had been characterised as the pathogenic mechanism in thrombotic 
thrombocytopenic purpura.(Moake, et al 1982) However, little was known about the 
possible effects of increased ADAMTS-13 proteolysis on circulating VWF levels, and 
no studies had been published examining the relationship between proteolysis of 
VWF by ADAMTS-13 and VWF plasma clearance.
It was not known whether increased VWF clearance in humans could result from 
either alteration in the primary structure of VWF or its post-translational 
modifications, including glycosylation as demonstrated in the RIIIS/J murine model. 
There was a paucity of mutational data in type 1 VWD and no studies had been 
published examining the molecular basis of VWF clearance. Data from the 1970s 
had demonstrated binding of asialo-VWF to the hepatic ASGPR and its subsequent 
rapid removal from the circulation in animal studies,(Sodetz, et al 1978, Sodetz, et al 
1977) suggesting that exposed galactose residues may be required for the binding 
of VWF to the ASGPR. This was supported by the demonstration of increased 
clearance of endogenous VWF in a murine model in the absence of the 
sialyltransferase ST3GallV, an enzyme that mediates attachment of sialyl groups to 
terminal galactose residues. The finding that VWF released from endothelial storage 
organelles following DDAVP infusion differed from circulating VWF in terms of 
multimer composition and expression of A antigen (Brown, et al 2002, Ruggeri, et al 
1982) suggested that there may be other structural differences between stored and 
circulating VWF, which could include other variations in glycosylation pattern. While 
it had been proposed that the ABH glycans may influence the rate of VWF 
clearance,(Mohlke, et al 1999b, O'Donnell, et al 2002a, Vlot, et al 2000) no direct
42
examination of the effect of ABO blood group on VWF clearance had been 
performed. Furthermore, no studies had investigated the influence of exposure of 
galactose residues of VWF on VWF clearance in humans.
2.2 INITIAL AIMS AND APPROACH
The aim of this study was to investigate whether increased VWF clearance is a 
possible pathogenic mechanism in type 1 VWD, and to identify determinants that 
may affect it. The plan of investigation was to recruit patients with type 1 VWD, to 
measure steady-state levels of VWF and related parameters, and to stimulate VWF 
release from the endothelial pool by infusion with DDAVP. The half-life of the 
released VWF would be determined, structural features, such as VWF glycosylation 
and collagen binding ability investigated and susceptibility to cleavage and 
ADAMTS-13 levels determined. Thus criteria that reflect and may directly affect 
VWF life-cycle and clearance would be monitored. Discrete areas of the VWF gene 
were to be sequenced in order to identify causative mutations underlying the VWD. 
A control group of patients with haemophilia A was chosen, as by definition these 
patients would have normal VWF synthesis and structure.
This approach has the limitation that VWF clearance being examined in both patient 
and control groups is not VWF released by constitutive secretion, but rather the 
stored pool in Weibel Palade bodies of endothelial cells. However, this approach 
was safe and involved the study of human clearance systems, including proteolysis 
and clearance receptors. In addition, valuable information for individual patient 
treatment would be gathered.
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STANDARD MATERIALS AND METHODS
44
3.1 PATIENT MATERIAL
Patients and controls studied were registered at the Katharine Dormandy 
Haemophilia Centre, Royal Free Hospital. All patients had been previously 
diagnosed with VWD and controls with mild Haemophilia A. Patient material was 
collected with informed patient consent and the study was conducted with ethical 
committee approval.
The diagnosis of type 1 VWD was based upon a personal and family history of 
bleeding, and a concordant reduction in VWF:Ag level and VWF:RCo activity in 
accordance with the 1994 ISTH recommendations.(Sadler 1994) Genotypic analysis 
had not been performed previously. Phenotypic data of the 43 type 1 VWD and 17 
Haemophilia A patients investigated are shown in Appendix 2. Three of the recruited 
VWD patients were subsequently excluded from the study (Patients 3, 20 and 43) 
based on the finding of abnormal ratios of VWF:CB to VWF:Ag (< 0.7), which is not 
consistent with ‘a normal VWF which is quantitatively decreased’.(Sadler 1994) 
These patients are further investigated in Chapter 8.
The diagnosis of type 2M VWD was based on a personal and family bleeding 
history, reduced VWF:Ag and VWF:RCo with a discordant VWF:RCoA/WF:Ag ratio 
of <0.7 in the presence of HMW VWF multimers.(Federici 1998) Data for these 
patients is presented in Chapter 9.
Whole blood samples were collected by venepuncture into 1 mL trisodium citrate,
0.106 molL'1 (Sarstedt Monovette, Germany) in a ratio of 1 part anticoagulant to 9 
parts blood for phenotypic analysis. Plasma samples were double centrifuged at 
2000g, separated and stored at -80°C until assayed.
3.2 COAGULATION INVESTIGATIONS
Initial investigations and resulting diagnoses were in general performed by 
laboratory staff at the Haemophilia Centre, Royal Free Hospital. Further coagulation 
tests prior to and over 6 h following infusion of DDAVP were performed by myself 
and Ms.Anne Riddell, Senior Research and Development Scientist.
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3.2.1 Chemicals and Reagents
Common chemicals were supplied by BDH Chemical Ltd, and Sigma-Aldrich 
Chemical Company, Dorset, UK unless otherwise stated.
3.2.2 von Willebrand factor antigen (VWF:Ag) ELISA
Chemicals and Reagents
1. Rabbit anti-human VWF antibody (Dako, Cambridgeshire, UK).
2. Horseradish peroxidise (HRP)-conjugated rabbit anti-human VWF antibody 
(Dako, Cambridgeshire, UK).
3. Pooled normal plasma: Cryocheck (Precision Biologic, Canada) calibrated 
against 9th British Standard reference plasma with known [VWF] (NIBSC, 
Potters Bar, UK)
4. Abnormal reference plasma: Trol-P (Dade Behring. Germany)
5. Bicarbonate coating buffer 0.05 M, pH 9.6
a. Na2C 03 0.79 g
b. NaHC03 1.47 g
c. Distilled H20  500 mL
6. Wash buffer: Phosphate Buffered Saline (PBS) with Tween 20 (Tw 20),
0.2%, 0.155M, pH 7.0 (10 x working strength)
a. NaH2P04.2H20  1.95 g
b. Na2HP04.12H20  13.4 g
c. NaCI 141.1g
d. 10 mL Tween 20
e. Distilled H20  5 L
7. Dilution buffer: 15 g Polyethylene glycol (PEG) 8000 in 500 mL working 
strength PBS-Tw20
8. Substrate buffer. 0.1 M, pH 5.0
a. Citric acid 3.65 g
b. Na2HP04.12H20  11.94g
c. Distilled H20  500 mL
9. O-Phenylenediamine (OPD) tablet: 10 mg
10.1.5 M H2S04
11. Patient platelet poor plasma 
12.30% Hydrogen Peroxide (BD, UK)
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Equipment
1. Maxisorb 96 well microtitre plates (NUNC; Life Technologies, Paisley, UK)
2. Sealing film
3. Plate washer (Dynex MRW, West Sussex, UK)
4. Plate reader (Dynex MRX, West Sussex, UK)
5. Gilson 401 dilutor
6. Plate shaker (Amersham International pic, Bucks, UK)
7. Pipettes and tips
8. Waterbath 37°C
Method
The 96 well plate was coated with the rabbit anti-human VWF antibody, diluted 
1/1000 in 0.05 molL'1 carbonate/bicarbonate buffer (pH 9.6) and 100 pL of the 
diluted coating antibody was added to each well of the plate. The plate was then 
sealed and incubated at 4°C overnight. The plate was washed five times with the 
wash buffer, then inverted and gently blotted on absorbent paper.
The standard curve consisted of dilutions of pooled normal plasma (Cryocheck) from 
1/80 to 1/1600. The patient plasma samples and reference samples were diluted 
1:100 and 1:200 in dilution buffer. Each dilution was dispensed in duplicate, with 100 
pL of sample per well. The plate was sealed and incubated on a plate shaker (400- 
500 oscillations per minute) at room temperature for one hour, and then washed five 
times with the wash buffer. The HRP-conjugated rabbit anti-human VWF antibody 
was diluted 1/8000 in dilution buffer, and 100 pL was added to each well. The plate 
was again sealed and incubated for one hour at room temperature on the plate 
shaker. Prior to the end of incubation the substrate solution was prepared by 
dissolving one OPD tablet in 15 mL of substrate buffer. This was brought to room 
temperature in a waterbath during which time the plate was washed for a final five 
times. Immediately prior to use, 7 pL of 30% Hydrogen Peroxide was added to the 
substrate solution. 100 pL of substrate was added to each well and the plate was 
incubated on the bench for 8-10 min to allow optimal colour development. The 
reaction was terminated by adding 100 pL of 1.5 M H2S04to each well at the same 
time interval as the substrate was added and gently shaking the plate to mix.
The plate optical density (OD) at 490 nm was then read on a spectrophotometric 
plate reader. The standard curve was derived from a plot of the OD49onm against 
VWF concentration on a semi-log plot. The 1/100 dilution of the reference plasma
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was taken as 100%. The VWF:Ag levels of the samples were extrapolated from the 
standard curve and the mean values were calculated. The coefficient of variation 
(CV) was < 5%.
3.2.3 Ristocetin Co-factor activity (VWF'.RCo)
Chemicals and Reagents
1. Lyophilised platelets (Alpha Laboratories, UK) reconstituted with 4.0 mL Tris 
Buffered Saline (TBS)
2. Ristocetin A S04 (Lundbeck, Germany)
3. Distilled H20
4. Citrate saline diluent: 2 mL 33.3 gL'1 sodium citrate solution made up to 20 
mL with sodium chloride 0.9% (Baxter, UK)
5. Pooled normal plasma: Cryocheck (Precision Biologic, Canada) calibrated 
against 9th British Standard reference plasma with known [VWF] (NIBSC, 
Potters Bar, UK)
6. Abnormal reference plasma (Dade Behring. Germany)/ SYSMEX Trol-P
7. 9th British Standard reference plasma (NIBSC, Potters Bar, UK) with known 
VWF:RCo: reconstituted with 1mL distilled water
8. Patient platelet-poor plasma
Equipment
1. PAP-4 Aggregometer (Alpha Laboratories, UK)
2. Pipettes
3. Plastic coated stir bars (Alpha Laboratories, UK)
4. Glass tubes (Alpha Laboratories, UK)
Method
Doubling dilutions of standard (Cryocheck) were prepared from 1/2 to 1/32 for use 
as the standard curve. Normal and abnormal controls were prepared using 
reconstituted British standard and SYSMEX Trol-P respectively and prepared at 
dilutions of 1/2 and 1/4 in citrate saline. Patient samples were thawed and initial 
dilutions of 1/4 in citrate saline were prepared. The assay was performed on a PAP- 
4 platelet aggregometer connected to a pen recorder. The 100% baseline was 
calibrated as 125 pL lyophilised platelets + 125 pL TBS. Cuvettes containing 200 pL 
lyophilised platelets and 25 pL ristocetin were prepared and inserted into the test 
well and the test baseline (0%) set for each of the four channels. 25 pL plasma
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dilutions of standard or test was added to each tube. Following completion of 
agglutination, the reading was stopped (180 secs). The standard curve was plotted 
on log-linear paper (2 cycles) with agglutination in divisions on the linear scale and 
U/dL co-factor on the log scale. The patient VWF:RCo was read off the standard 
curve.
3.2.4 Factor VIII:C (One stage clotting assay: Semi-automated)
Chemicals and Reagents
1. Owren’s buffered saline (OBSL pH 7.35:
Owren’s Barbiturate Buffer 200 mL
NaCI (0.9%) 800 mL
Owren’s Barbiturate Buffer:
2. Lyophilised FVIII deficient plasma (Technoclone, UK) reconstituted with 1 mL 
distilled H20
3. Patient platelet-poor plasma
4. Pooled normal plasma: Cryocheck (Precision Biologic, Canada) calibrated 
against 9th British Standard reference plasma with known [FVIII] (NIBSC, 
Potters Bar, UK)
5. APTT Lyophilised silica (Instrumentation laboratories, Warrington, UK): 1 L 
reconstituted with 9 mL distilled H20.
6. 25 mM CaCI2
Equipment
1. ACL 3000 (Instrumentation Laboratories, Warrington, UK)
2. Gilson 401 dilutor
3. ACL cuvettes
4. Pipettes and tips
5. Waterbath 37°C
Method
The samples and standard were prepared in OBS: samples were diluted 1/10 -
1/40 and the standard 1/10. The reconstituted FVIIl-deficient plasma, APTT
reagent and CaCI2 were placed in the ACL 3000 and one cuvette per sample
a. Sodium Diethylbarbiturate (Barbitone Sodium) 5.88 g
b. Sodium Chloride
c. 1 M Hydrochloric Acid
d. Distilled H20
7.34 g 
21.5 mL
1 L
49
dilution were placed consecutively from position 1. In addition, one sample 
cuvette was placed in ‘pool’ and ‘dir positions: diluted (1/10) standard was 
added to the cuvette in ‘pool’ position and OBS to the ‘dil’ position. The diluted 
patient samples were added to each cuvette in turn (minimum 250 pL). The 
Single Factor option was selected for FVIII followed by High Curve and the value 
of the standard was entered. A fresh rotor was place in the ACL Rotor 
compartment, the sample numbers entered onto a loadlist and the run 
commenced. The results were calculated automatically.
3.3 VON WILLEBRAND FACTOR MULTIMER ANALYSIS
Chemicals & Reagents
1. Electrode Buffer. pH = 8.45
a. lOOmMTris 60.55 g
b. 15 mM Glycine 22.52 g
c. 1 g/LSDS 50 mL @ 10%
d. Distilled H20  4950 mL 
NB Dilute 1:2 for anode
2. Sample Buffer. pH 6.7
a. 70 mM Tris 0.085 g
b. 4 mM EDTA 0.015 g
c. 24g/L SDS 0.24 g
d. Urea 0.54 g
e. Distilled H20  10 mL
3. Separating gel buffer. pH 9.6
a. 200 mM Tris 6.05 g
b. 100 mM Glycine 1.88 g
c. 4 g/LSDS 10mL@10)%
d. Distilled H20  250 mL
4. Stacking gel buffer. pH 6.7
a. 70 mM Tris 2.118 g
b. 4 mM EDTA 0.373 g
c. 4 g/LSDS 10mL@10%
d. Distilled H20  250 mL
5. Transfer Buffer: PBS (3.2.2)
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6. Tween Tris Buffered Saline (TTBS), pH= 7.5
a. Tris Base
b. NaCI
c. Distilled H20  
Adjust pH with HCL
d. Tween 20
60.55 g 
45 g
5000 mL
10 mL
7. 0.1 M Tris HCL (Ph = 9.5)
a. Tris base
b. Distilled H20
1.21 g 
100 mL
Adjust pH with 0.1 M HCL
8. Rabbit anti-human VWF antibody (Dako, Cambridgeshire, UK).
9. Vectastain Kit - Alkaline phosphatase Rabbit IgG (Vector Laboratories, UK) 
AK5001
10. Alkaline phosphatase substrate kit IV BCIP/NBT (Vector Laboratories, UK) 
SK 5400
11. Skimmed Milk Powder (MARVEL) Chivers, Ireland Ltd, Dublin, Ireland
Equipment
1. Gel Tray
2. Glasswear
3. BIORAD Electrophoresis Tank
4. Power Pack
5. 2 x 3  MM wick (Whatman Gel Blot Paper, Fisher Scientific, UK)
6. Cotton Lint
7. Cling Film
8. Whatman 3MM chromatography paper
9. Tissues
10. Nitrocellulose Paper (Hybond C)
11. Perspex Tray for Blotting
12. Thick glass plate
13. Orbital Mixer
14. Weight
15. ImageStore 7500
Method (Ruggeri, et al 1982)
1. Prepare gel tray and pre-warm in incubator at 55°C.
2. Preparation of Separating Gel
Dissolve 0.60 g agarose in 40 mL Separating Gel Buffer (1.4%) by bringing 
to boil, allow to cool to 55°C and set in tray at 4°C for a minimum of 1 h.
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3. Preparation of Stacking Gel:
Remove a 18 mm strip of agarose from the top edge of the separating gel. 
Dissolve 0.16 g agarose in 20 mL Stacking Gel Buffer (0.8%). Allow stacking 
gel to cool to 55°C then, using the 10 mL syringe, add 7.5-8.0 mL into the 
separating gel. Insert the comb allowing a 1.5mm gap between the bottom 
of the comb teeth and the gel tray. Leave to set for minimum 20 min.
4. Fill the electrophoresis tank, reservoirs with electrode buffer, dilute buffer 1:2 
or anode
5. Gently remove the comb and tape from the gel and place the gel into the 
electrophoresis tank.
6. Position 3 x3 MM wicks on each end of the gel, ensuring full contact across 
the width of the gel.
7. Prepare the controls and samples by adding 10 pL sample to 90 pL sample 
buffer. Vortex briefly to ensure mixing
8. Add 20 pL of appropriate sample to each well. Switch unit to voltage and run 
at 280V to run the samples out of the wells. Switch to Amps and reduce to
0.02A
9. Preparation of Blot:
1 tray
1 Gel tray
2x3MM 3 sided wick 
exclusion frame 
Nitrocellulose paper 
2x3MM wick
10 cm stack of blue towelling 
glass plate
10. After electrophoresis remove the gel and briefly wash in transfer buffer 
before inverting onto capillary blotting unit.
11. Leave the blotting unit overnight, take down blot carefully, remove 
nitrocellulose paper and block with 100 mL milk solution (minimum 15 min)
12. Decant the milk solution and wash in 100 mL TBS (10 min)
13. Decant the PBS and carefully roll nitrocellulose paper, insert into wide 
necked 500 mL bottle, Carefully unroll the paper ensuring there are no air 
bubbles between the paper and bottle
14. Wash again with 50 mL TBS for 5 min
15. Decant TBS and add first antibody to the front of the membrane: 80 pL anti- 
VWF in 100 mL PBS; incubate for 3 h.
16. Decant and wash with 50 mL TBS for 5 min X 3
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17. From Vectastain kit, for each gel dilute 66 fiL of biotinylated anti-rabbit 
antibody in 20 mL of TTBS.
18. Add to 500 mL bottle containing blot and incubate for 2 h.
19. Decant and wash with 50 mL TBS for 5 min X 3.
20. From the Vectastain kit, add 3 drops of reagent A to 15 mL of TTBS, then add 
3 drops of reagent B. Incubate the membrane in reagent A+B for 30 minutes on 
the orbital mixer at room temperature.
21. Wash3Xs in TTBS
22. Carefully re-roll nitrocellulose paper and remove from bottle, unroll into tray
23. Prepare colour reagents: Vectastain Kit.
24. Visualisation: Using the alkaline phosphatase substrate kit, for each 
membrane make up the substrate solution as shown.
25. 5 mL 0.1 mL 0.1 M Tris HCI. Add 3 drops of solution reagent 1, 2 & 3. Mix well
and then pour onto the nitrocellulose blot.
26. Allow to develop so that multimeric pattern can be seen.
27. Wash with distilled water
28. When developed dry flat on absorbent paper.
29. Make a permanent record by photographing using the photocopier (Fig. 8.1)
3.4 GENOTYPIC ANALYSIS
3.4.1 Preparation of deoxyribonucleic acid (DNA)
Chemicals and Reagents
1. Cell Ivsis buffer (CLB):
Sucrose 110g
Triton x 100 10 mL
1MMgCI2 5 mL
Tris-HCMM 10 mL
Deionised H20: to 1000 mL
2. TE Buffer. pH 8.0 
10mM Tris pH 7.6 
1mM EDTA pH 8.0
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3. Nuclear Ivsis buffer (NLB):
Lithium acetate 3.5 g
Lithium dodecylsulphate 2 g 
Disodium EDTA 0.1M pH 8.0 1 mL 
Tris-HCMM 1 mL
Distilled H20: tolOOmL
4. Phenol:Chloroform:lsoamylalcohol (25:24:1)
5. Chloroform
6. Ice cold ethanol
Equipment
1. Standard pastettes
2. 10 mL capped polypropylene tubes
3. 50 mL Falcon tubes
4. Sealed glass Pasteur pipettes
5. 1 mL Sarsted screw top tubes and caps
6. Benchtop centrifuge
7. Rotary mixer
Method
Buffy coats from 10 mL whole blood were thawed at room temperature and 
decanted into a 50 mL Falcon tube. 50mL CLB (stored at 4°C) was added and the 
tube that contained the buffy coat was rinsed with CLB to remove adherent cells.
The Falcon tube containing buffy coat and CLB was mixed and placed on ice for 20 
min. It was then centrifuged at 2400 rpm for 20 min. The supernatant, containing the 
lysed red blood cells was discarded. The white blood cell pellet was re-suspended in 
1 mL TE pH 8.0 and to this, 2 mL NLB was added and mixed on an orbital shaker 
for 5 min. The sample was then transferred into 10 mL polypropylene tube and 1 mL 
phenol:chloroform:isoamylalcohol was added. Following ten inversions of the tube to 
mix, the sample was spun at 2400 rpm for 5 min. The aqueous layer was removed
to a fresh tube and 1 mL chloroform was added. This was again mixed and
centrifuged. The aqueous layer was removed and the DNA precipitated by adding
2.5 volumes of absolute ethanol (stored at -20 °C) and slowly inverting the tube. The 
DNA was collected onto a sealed Pasteur pipette and resuspended in a Sarsted 
tube for 24 h in 250-500 pL TE buffer. Genomic DNA was then ready to use.
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3.4.2 Quantification of DNA
Equipment
1. Glass microcapillary tubules
2. GeneQuant pro spectrophotometer
Method
The spectrophotometer was zeroed using a microcapillary with TE buffer prior to 
drawing up the DNA sample. The absorbance of the DNA sample was read at 260 
nm and 280 nm. The ratio of the absorbance at 260 nm to that at 280 nm was used 
to give an indication of the purity of the DNA.
3.4.3 Poiymerase chain reaction (PCR)
(For amplification of exon 28 (28B) encoding A2 domain)
Chemicals and Reagents
1. 10 x NH4 reaction buffer*
2. 1.25 mM dNTPs (Helena Biosciences, Sunderland, UK)
3. 50 mM MgCI2*
4. 20 mM primer mix**
5. Bio Tag polymerase buffer (Bioline, London, UK)
6. Sterile H20
*supplied with Taq
** PRIMERS FOR AMPLIFICATION OF 682 bp product of EXON 28: primers K2A 
and K1B
forward: 5TGGTTCTGGATGTGGCGTTC3’ 
reverse: 5TCTTGGCAGATGCATGTAGC3’
Equipment
GeneAmp PCR system 9700 (Applied Biosystems, Warrington, UK)
Eppendorf tubes
Genomic DNA was amplified in a 50 pL mixture containing: 5 pL 10 x NH4 reaction 
buffer, 5 pL 1.25 mM dNTPs, 1.5 pL 50 mM MgCI2, 1 pL primer mix, 0.25 pL Bio Taq 
polymerase buffer and 35.25 pL sterile H20. A megamix was prepared with the 
primers, dNTPs, polymerase buffer and water to a volume calculated on the total 
number of PCR reactions. Finally the Bio Taq polymerase was added to the 
megamix (from ice), which was aliquotted into 48 pL samples in 0.5 mL Eppendorf 
tubes, to which 2 pL of DNA was added and mixed/centrifuged.
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40 cycles of PCR (94 °C/30 sec; 58 °C/30 sec; 72 °C/30 sec) were performed in 
GeneAmp PCR system 9700 thermal cycler. These were preceded by 5 min 
incubation at 94°C and followed by 10 min incubation at 72°C. Each PCR 
experiment included a ‘no template control’. PCR products (5 pL) were 
electrophoresed with gel-loading buffer (2 pL) at 100V for 1 h through the agarose 
gel (1.5% w/v) and visualised under UV light using ethidium bromide staining 
(Fig.3.1).
Figure 3.1 Products obtained following PCR amplification of exon 28B of VWF 
gene using primers K2A and K1B. PCR products were electrophoresed at 100 V 
for 1 h through a 1.5% w/v agarose gel and visualised under UV light with ethidium 
bromide staining.
Lane 1 of each row: marker (MXIV, Roche Diagnostics, Mannheim, Germany), 
Lanes 2 -1 5 :  genomic DNA, lane 10 of lower row: negative control (blank).
«
Lane: 1 2  3 4 5 6 7 8 9 10 11 12 13 14 15
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3.5 MEASUREMENT OF PLASMA CLEARANCE OF VWF FOLLOWING 
ADMINISTRATION OF DDAVP
3.5.1 Principle of method used to determine VWF:Ag half-life (Somosgyi 1999) 
VWF:Ag levels are measured at baseline and and at hourly time intervals over 6 h 
following DDAVP. The baseline VWF:Ag level is subtracted from the subsequent 
VWF:Ag levels and linear regression analysis is used to determine the slope of the 
semi-logarithmic plot of VWF:Ag against time. From this slope, the first-order rate 
constant for the elimination of released VWF (k) is derived, based on the formula Ct 
ssCo©-*1, which describes the changes in concentration of a substance with a 
clearance demonstrating first-order kinetics. Ct = plasma concentration of VWF:Ag 
at time point t after DDAVP infusion, C0 = concentration of VWF at time O, e = base 
for natural logarithms.The apparent half-life of VWF:Ag (VWF:Ag ti/2) is then 
calculated from the equation: ti/2= In 2/k.
Calculation of the VWF:Ag t1/2 by this method assumes the following:
1. VWF clearance demonstrates first order kinetics.(Mannucci 1982)
2. The lack of an extravascular compartment for VWF.(Meriane, et al 1993)
3. A distribution phase of VWF of one hour and therefore the VWF:Ag level 1 h 
following DDAVP represents the beginning of the elimination phase.
This method was selected to determine VWF:Ag ti/2 for two reasons. Firstly, it is an 
accepted and published method of calculating the VWF:Ag ti/2, which enables 
comparison of the results from this study to be made with previously published 
data.(Brown, et a /2003, Mannucci 1982, Michiels, ef a/2002, van Genderen P. J. J 
1997) Secondly, unlike pharmacokinetic data in severe factor deficiencies, the 
determination of the baseline VWF:Ag level is problematic due to variability in the 
steady-state VWF level over a protracted time period. In a pharmacokinetic study of 
a Factor VIII concentrate in patients with severe haemophilia A, the standard 
practice would be to take regular samples over a time period that is equivalent to at 
least two or three times the half-life. The derivation of the first-order rate constant for 
the elimination of VWF from the slope of the semi-logarithmic plot of VWF 
concentration against time surmounts problems of both a fluctuating basal VWF 
level and quantity of VWF released by DDAVP.
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3.5.2 Validation of method
The method used to determine VWF:Ag t^  in this thesis has previously been 
compared to the pharmacokinetic evaluation of VWF:Ag data up to 48 h post 
DDAVP.(Brown 2003) As expected, significant variability was found amongst 
VWF:Ag values following return to steady-state levels, illustrating the difficulty in 
determining the correct cut off for a return to the baseline VWF:Ag level. However, 
no significant difference was found between VWF:Ag t1/2 values calculated using a 
pharmacokinetic software programme (PK Analyst) for the 48 h data with those 
derived over 6 h by the method used in this study.(Brown 2003).
3.5.3 Validation of control group
Performing DDAVP studies in normal volunteers is not possible on an ethical basis. 
The selection of a control group of haemophila A patients in this study was based on 
data from previously published studies: the method used to estimate VWF:Ag ti/2 
has previously been used in DDAVP studies of normal individuals and patients with 
mild haemophilia A, as well as VWD patients.(Brown, et al 2003, Mannucci 1982, 
Michiels, et al 2002, van Genderen P. J. J 1997) These studies show that calculated 
VWF:Ag t1/2 values obtained in haemophilia A patients are comparable to normal 
controls with respective median values and 95% confidence intervals of 9.4 h (8.2 -
10.5 h, n = 7, (Mannucci 1982) and 11.8 h (10.5- 14.3 h, n = 9,(van Genderen P. J. 
J 1997) in normal controls and 9.9 h (8.5 -  11.2 h, n = 9,(Mannucci 1982) and 9.5 h 
(4.3 -  17.4 h, n = 7, (Brown, et al 2003) in patients with mild haemophilia A.
3.5.4 Subjects
Inclusion criteria: Type 1 VWD study group
Forty three patients (23 males, 20 females) from 40 kindred with a historical 
diagnosis of type 1 VWD were re-evaluated and recruited into the study on 
satisfaction of the following criteria, based on the 1994 ISTH recommendations: 
(Sadler 1994)
1. Personal/family history of bleeding
2. Age > 18 years and < 60 years
3. VWF:Ag level < 50 IUdL’1
4. VWF:RCo activity < 50 IUdL'1
5. VWF:RCoA/WG:Ag ratio > 0.7
6. Normal VWF multimer profile
Phenotypic data for the patient cohort are shown in Appendix 2. Genotypic analysis 
had not previously been performed in these patients.
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Inclusion criteria: Haemophilia A control group
VWF clearance was measured in a control group of 17 male patients:
1. Age >18 years and < 60 years
2. FVIII:C levels between 5 and 50 IUdL'1.
Phenotypic data for the control group are shown in Appendix 2.
Exclusion criteria (study and control groups)
1. Known arterial disease, hypertension or history of thrombosis
2. Impaired renal or liver function
3. FVIII or VWF inhibitor, past or present
4. Regular medication
5. Previous vasovagal syncope due to venesection or DDAVP
3.5.5 Method 
6 h DDAVP study
DDAVP was infused intravenously over 15 min at a dose of 0.3 pgkg'1. Venous 
blood samples were taken prior to the start of the DDAVP infusion (time 0, T0) and 
hourly for 6 h from the start of the infusion (T, -T 6). Whole blood samples were 
collected into 3.8% trisodium citrate (109 mmolL'1, 10% v/v). Platelet poor plasma 
was prepared and stored at -80°C until assayed. The VWF:Ag was assayed using 
ELISA.
Calculation of VWF:Ag half-life
Concentration of VWF:Ag (T0) was subtracted from VWF:Ag concentrations aXT^-  
T6. Values obtained from the logarithmic transformation of the change in VWF:Ag at 
each timepoint were plotted against time and and the slope of the best-fit line was 
determined by regression analysis. The k value was calculated by multiplying the 
slope by -2.303 and VWF:Ag t^  calculated by dividing the natural logarithmic value 
of 2 by the k value (In 2/k).(Somosgyi 1999).
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Chapter 4
CLEARANCE OF VWF IN TYPE 1 VWD
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4.1 INTRODUCTION
The quantitative decrease in VWF levels characteristic of type 1 VWD may result 
from defects in VWF synthesis or secretion and/or increased clearance of VWF. 
Indeed a shortened half-life of VWF has been reported in some patients with a 
partial quantitative VWF deficiency.(Brown, et al 2003, Michiels, et al 2002, van 
Genderen P. J. J 1997) DDAVP induces the release of intracellular stores of VWF, 
and the measurement of VWF half-life in previous studies was based on the time 
taken for VWF released following DDAVP to return to steady-state concentrations.
Levels of VWF vary by 20 - 30% according to individual ABO blood group, with 
plasma VWF levels increasing in the order 0<A<B<AB.(Gill, et al 1987, Shima, et al
1995) Although the mechanism for the ABO effect on plasma VWF levels is not 
known, it appears likely that it is mediated by the ABH antigenic structures present 
on the N-linked chains of VWF.(Matsui, et al 1992, Sodetz, et al 1979) Data from 
previous studies do not suggest an effect of ABO determinants on the synthesis 
and/or secretion of VWF.(Brown, et al 2003, O'Donnell and Laffan 2001, O'Donnell 
and Laffan 2003) The hypothesis that ABH antigen expression may influence the 
rate of VWF clearance is supported by studies of the RIIIS/J mouse.(Mohlke, et al 
1999b). Indirect evidence is provided by the observation that infused FVIII 
disappears more rapidly in blood group O than in non-O haemophilia patients.(Vlot, 
et al 2000) Furthermore, recent in-vitro studies have shown a variation in 
susceptibility of VWF cleavage by the metalloprotease ADAMTS-13 according to 
blood group, with VWF associated with blood group O being the most susceptible to 
cleavage.(Bowen 2003)
The ratio of FVIII to VWF:Ag has been shown to provide useful information on the 
steady state kinetics of VWF. While defects in VWF synthesis or secretion have 
been shown to result in increased ratios of greater than one, this ratio has not 
shown to be affected by increased VWF clearance in some patients with type 2 
VWD.(Eikenboom, et al 2002)
4.2 AIMS
The objectives of this study were to investigate the release and clearance of 
endothelial derived VWF in a group of type 1 VWD patients and haemophilia A 
controls following infusion of DDAVP. The possibility that expression of ABH 
antigens on VWF may influence the rate of plasma clearance of VWF was examined 
in these subjects. Finally, the relationship between VWF clearance and the ratio of 
FVIILC to VWF:Ag was investigated in this cohort of type 1 VWD patients.
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4.3. MATERIALS AND METHODS
4.3.1 Patient and controls
The patients recruited into the study and control groups are described in Chapter 3, 
Section 3.1 (Appendix 2).
4.3.2 Phenotypic data
VWF:Ag and FVIII levels were measured as described in Chapter 3, Section 3.2.
4.3.3 Measurement of plasma clearance of VWF
The method used to calculate VWF:Ag half-life (VWF:Ag t 1/2) is described in 
Chapter 3, Section 3.5.
4.3.4 Data and statistical analysis
Analyses of data were performed using GraphPad Prism (GraphPad Prism version
4.0, GraphPad Software, San Diego, USA). Results are expressed as median 
values with range. Data was analysed using Spearman’s rank correlation and the 
Mann-Whitney-Wilcoxon and Kruskal-Wallis tests.
Table 4.1. Phenotypic data for type 1 VWD patients and haemophilia A 
controls at diagnosis
Data is presented as median with range.
Values are based on the mean of 3 separate measurements 
number of subjects (n)
*P < 0.001
FVIII:C
(IUdL*1)
50-150
VWF:Ag
(IUdL*1)
50-150
VWF:RCo
(IUdL*1)
50-150
VWF:RCo/ 
VWF:Ag
Type 1 VWD 
(n = 40)
60 (7-131) 36* (9 - 50) 36* (9 - 50) 0.97 (0.72 - 2.29)
Haemophilia A 
(n = 17)
17(4-38) 105 (45-238) 106 (48-300) 1.00 (0.71 - 1.78)
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4.4 RESULTS
4.4.1 Phenotypic data
Diagnostic phenotypic data for the 40 patients with type 1 VWD (study group) and 
17 patients with mild haemophilia A (control group) are shown in Appendices 1 and 
2 and summarised in Table 4.1. As expected, the respective median concentrations 
of VWF:Ag were significantly lower in the type 1 VWD patients than haemophilia 
controls (P < 0.001). The median age of the VWD patients was 39 years (21 -  60) 
compared to 41 years (19-58) in the haemophilia A controls. No significant 
difference was found in VWF:Ag concentration between type 1 VWD patients of 
blood group O (median 36 IUdL'1, P = 0.4, n = 22) and blood group A (30 IUdL'1, n = 
15)
4.4.2 One hour response to DDA VP
The increase in VWF:Ag from pre-DDAVP (T0) to 1 h post DDAVP (Ti) in individual 
study patients and controls are shown in Appendix 3. VWF:Ag levels at T0 were 
found to be greater than 50 IUdL'1 in a proportion of patients who, on previous 
repeated testing, including recruitment samples, had fulfilled the criteria for type 1 
VWD.(Sadler 1994)
The absolute 1 h VWF:Ag response was greater in the controls than the study 
group, P < 0.01 with respective median increases of 138 IUdL'1 (30 -  202, n = 17) 
and 103 IUdL'1 (14 -  234, n = 40, Table 4.2). However, the relative 1 h response 
was found to be less in the controls than the VWD patients, P < 0.001, with 
respective median increases of 2.5 fold (1.2 -  4.4, n = 17) and 3.6 fold (2.3 -  12.5, n 
= 40, Table 4.2). The absolute and relative 1 h responses plotted against VWF:Ag 
levels at T0are shown in Fig. 4.1 and Fig. 4.2. The absolute increase in VWF:Ag 
was shown to correlate with VWF:Ag level at T0 in the whole group (r = 0.47, P < 
0.001, n = 57, Fig.4.1). Although this correlation was shown to be significant in the 
VWD patients (r = 0.57, P < 0.001, n = 40), this was not found in the haemophilia A 
controls (r = -0.02, P = 0.9, n = 17). Within the VWD study group, no significant 
difference in absolute 1 h increase in VWF:Ag was found between patients of blood 
group O and A, P = 0.35 with respective median increases of 119 IUdL'1 (28 -  188, 
n = 22) and 100 IUdL'1 (14 -  234, n = 15).
The inverse correlation demonstrated between VWF:Ag level at T0 and the relative 
increase in VWF:Ag in the whole group (r = -0.6, P < 0.001, n = 57, Fig.4.2), was 
largely attributable to the haemophilia A controls (r = -0.9, P < 0.001, n = 17); as
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expected, such inverse correlation was not seen in the type 1 VWD patients (r = - 
0.28, P = 0.08, n = 40)
Table 4.2.1 h DDAVP response and calculated half-life values of VWF:Ag in 
type 1 VWD patients and haemophilia A controls.
Data is presented as median with range; * P < 0.0001; ** P < 0.02 
Response is defined as the difference between plasma concentration of VWF:Ag at 
baseline (T0 ) and 1 h following DDAVP (Ti).
1 h absolute 
increase inVWF'.Ag 
(IUdL1)
1 h relative
increase
in VWF:Ag (fold)
VWF:Ag t 1/2 
(h)
Type 1 VWD 103* 3.6* 4.2**
(n = 40) (14-234) (2 .3-12.5 (1 .3-11.4)
Haemophilia A 138 2.5 10.1
(n = 17) (30 -  202) (1 .2 -4 .4 ) (4.1 to greater 
than 30)
Figure 4.1. Relationship between baseline VWF: Ag levels and absolute 
increase in VWF:Ag 1 h following DDAVP. VWF:Ag prior to the administration of 
DDAVP (T0) and increase in VWF:Ag 1 h post DDAVP are shown for patients with 
type 1 VWD ( ^ , n = 40) and haemophilia A controls ( A  n = 17). Correlation was 
found between baseline VWF:Ag levels and absolute 1 h increase in VWF:Ag in the 
study and control groups, r = 0.47, P < 0.001, n = 57 and the study group alone, r = 
0.57, P < 0.001, n = 40 but not in the controls, r= -0.02, P = 0.9, n = 17.
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Figure 4.2. Relationship between baseline VWF: Ag levels and relative 
increase in VWF:Ag 1 h following DDAVP. VWF:Ag prior to the administration of 
DDAVP and relative rise in VWF:Ag 1 h post DDAVP are shown for patients with 
type 1 VWD ( ♦.n  = 40) and haemophilia A controls (A , n = 17). Inverse 
correlation was found between baseline VWF:Ag levels and relative 1 h increase in 
VWF:Ag in the study and control groups, r = -0.6, P < 0.001, n = 57 and the control 
group alone, r = -0.9, P < 0.001, n = 17 but not in the study group, r = -0.28, P = 
0.08, n = 40.
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4.4.3 VWF:Ag levels pre- and over 6 hours post-DDAVP
VWF:Ag levels at T0 - T6 in the type 1 VWD study patients and haemophilia A 
controls are shown in Fig. 4.3. Despite the greater 1 h increase in VWF:Ag in the 
control group, the rate of return of VWF:Ag to steady-state levels was greater in the 
study patients. Furthermore, the interquartile range was found to be wider in the 
control group than VWD patients.
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Figure 4.3. VWF:Ag values prior to and over 6 h following DDAVP 
administration in type 1 VWD patients (n = 40) and haemophilia A controls (n = 
17).
Data is presented as 25th and 75th centiles with range. Normal range 5 0 -1 5 0  IUdL'1
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4.4.4 Plasma clearance of VWF:Ag post DDAVP infusion
Individual VWF:Ag t 1/2 values are shown in Appendix 3. The VWF:Ag t 1/2 values in 
the type 1 VWD patients were significantly shorter (median 4.2 h, 1.9 -  11.4, n = 40) 
P < 0.001 than the controls (10.1 h, 4.1 - >30, n = 17, Fig. 4.4). In two of the control 
subjects, the 1 h rise in VWF:Ag concentration was sustained over the 6 h time 
course and a first-order rate constant for the elimination phase of released VWF (k 
value) was not obtainable. The VWF:Ag t1/2 values for these subjects is shown as 
greater than 30 h. Significant correlation was found between the VWF:Ag level at T0 
and the VWF:Ag tm when the study and control groups were analysed together (r = 
0.58, P < 0.001, n = 57, Fig.4.5). However, when the study and controls groups 
were analysed separately, this correlation was shown to be weak (r = 0.26, P = 0.08, 
n = 40 and r = 0.46, P -  0.06, n = 17, respectively). The VWF:Ag values for 
family members within the two families recruited with type 1 VWD are shown in 
Table 4.3.
Figure 4.4. Calculated half-life values VWF:Ag in type 1 VWD patients and 
haemophilia A controls. VWF:Ag was measured in plasma samples taken prior to 
and at hourly intervals over 6 h following intravenous administration of DDAVP. The 
plasma clearance of VWF:Ag was increased in the type 1 VWD patients (median 4.2 
h, P<  0.001, n = 40) compared to the controls (10.1 h, n = 17). In two of the control 
subjects, the 1 h rise in VWF:Ag concentration was sustained over the 6 h time 
course and a k value was not obtainable. The VWF:Ag t1/2 values for these subjects 
is shown as being greater than 30 h.
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Figure 4.5. Relationship between baseline VWF:Ag concentration and half-life 
of released VWF. VWF:Ag concentration prior to the administration of DDAVP (T0) 
and calculated VWF:Ag t1/2 values are shown for patients with type 1 VWD ( ^  n = 
40, and haemophilia A controls ( ^ , n  = 17). Correlation was found between 
baseline VWF:Ag and VWF:Ag t1/2 in the study and control groups (r = 0.58, P < 
0.001, n = 57) but not in the study or control groups alone (r = 0.26, P = 0.08, n =
40; r = 0.46, P = 0.06, n = 17 respectively).
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Table 4.3. VWF:Ag half-life values within type 1 VWD kindred.
Generation is indicated in superscript.
Kindred Patient No. ABO blood 
group
Age VWF:Ag
(IUdL1)
VWF:Ag t 1/2 
(h)
8Z 8 A 36 29 3.0
81 11 A 60 36 6.8
8Z 13 A 31 36 3.2
102 10 A 21 21 3.2
10' 25 A 45 13 5.6
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4.4.5 Clearance of VWF:Ag and ABO blood group
The VWF:Ag t^  values for the study and control groups according to ABO blood 
group are shown in Fig.4.6. Although the median VWF:Ag ti/2 was shorter in 
subjects of blood group A (5.2 h, n = 18 ) compared to blood group O (4.5 h, n = 34), 
no significant difference in VWF:Ag t1/2 values was found between ABO blood 
groups, P = 0.3. Similarly, no significant difference in VWF.Ag t1/2 values was found 
between ABO blood groups when the study and control groups were analysed 
separately (P = 0.7, n = 37; P = 0.4, n = 17 respectively, data not shown).
Figure 4.6. Calculated VWF:Ag half-life values for study and control groups 
according to ABO blood group. Median values are shown: blood group O: 4.5 h (n 
= 34); blood group A: 5.2 h (n = 18); blood group B: 9.8 h (n = 2). No significant 
difference in VWF:Ag ti/2 values between ABO blood groups was found, P = 0.3.
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4.4.6 Clearance of VWF:Ag and ratio of FVIII to VWF:Ag
The median FVIII:VWF ratio in the type 1 VWD patients was 1.68 (0.43 - 3.14), n = 
40. No correlation was shown between VWF:Ag ti/2 and the ratio of FVIII to VWF:Ag 
in the type 1 VWD patients (r = 0.08, P = 0.6, n = 40, Fig. 4.7). Inverse correlation 
was found between the FVIII:VWF ratio and the absolute 1 h increase in VWF:Ag , r 
= -0.36, P< 0.02, n = 40, Fig. 4.8.
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Figure 4.7. Relationship between half-life values of VWF and circulating 
plasma ratio of FVIII:C to VWF:Ag in patients with type 1 VWD. No correlation 
was found between the FVIII/VWF ratio and VWF:Ag t1/2l r = 0.08, P = 0.6, n = 40.
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Figure 4.8. Relationship between ratio of FVIII:C to VWF:Ag and 1h increase in 
VWF:Ag in type 1 VWD patients. Inverse correlation was found between 
FVIII/VWF:Ag ratio and 1 h increase in VWF:Ag following DDAVP , r = -0.36, P < 
0.02, n = 40.
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4.4.7 Analysis of type 1 VWD patients according to disease phenotype
It has been demonstrated that type 1 VWD patients with more severe phenotypes, 
as defined by VWF:Ag < 20 IUdL"1 are more likely to demonstrate causative 
mutations within the VWF gene.(Eikenboom, et al 2006) Therefore a partial 
quantitative deficiency of VWF resulting from composite factors distinct from 
deleterious mutations within VWF is more likely to be of relevance in milder type 1 
VWD phenotypes. In view of the likely heterogeneity in pathogenic mechanisms 
within this study cohort, type 1 VWD patients were subclassified into categories of 
‘severe’ or ‘mild’ phenotype, defined using a cut-off VWF:Ag level of 20 IUdL'1. 
Patients were analysed according to whether VWF:Ag level was greater (n = 30) or 
less (n = 10, Table 4.4) than 20 IUdL’1. ABO blood groups were found to be more 
evenly distributed within the severe patients (five blood group A and four blood 
group O). This differed from the group with milder phenotype in whom a greater 
number of patients were blood group O than A (22 and 15 respectively). The 1 h 
increase in VWF:Ag level following DDAVP was variable within both subgroups, with 
neither demonstrating significant correlation between VWF:Ag level at T0 and 
absolute 1 h increase in VWF:Ag (r = 0.19, P=  0.6, n = 10; r = 0.19, P = 0.3, n = 30 
respectively). VWF:Ag ti/2 values in patients with VWF:Ag levels < 20 IUdL'1 were 
found to be shortened (median 2.9 h, P < 0.005, n = 10) as compared to patients 
with VWF:Ag levels > 20 IUdL'1(4.7 h, n = 30, Fig. 4.9, Table 4.4) although both 
subgroups demonstrated significantly shorter VWF.Ag h/2 values than the 
haemophilia A controls, P < 0.001. No significant correlation between VWF:Ag level 
at T0 and VWF:Ag t1/2 was found in either subgroup (r = 0.4, P -  0.24, n = 10; r = - 
0.3, P = 0.09, n = 30). While the circulating ratio of FVIII to VWF:Ag was found to be 
higher in the more severe patients (median 2.07, n = 10) than the milder patients 
with type 1 VWD (1.6, n = 30) this was not shown to be statistically significant (P =
0.08).
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Table 4.4.1 h DDAVP response and half-life values of VWF:Ag in type 1 VWD 
patients with steady-state VWF:Ag levels of less than 20 IUdL'1 (n = 10)
Patient
No.
ABO
Blood
group
VWF:Ag
To
(IUdL'1)
VWF:Ag
Ti
(IUdL'1)
VWF:Ag t1/2 
(h)
Ratio of 
FVIILC to 
VWF:Ag
7 A 17 117 2.3 2.6
14 O 13 41 3.3 1.5
22 A 18 54 6.2 3.1
27 A 10 24 2.6 2.8
28 O 17 46 2.9 2.1
31 O 18 93 3.5 1.5
32 NT 9 113 1.5 2.3
38 O 13 48 3.6 2.1
40 A 14 85 1.3 1.3
43 A 14 56 3.0 1.6
Figure 4.9. Calculated VWFiAg half-life values for type 1 VWD patients 
according to disease phenotype. VWF:Ag t1/2 values for patients with VWF:Ag 
levels < 20 IUdL'1 are shorter (median 2.9 h, P < 0.005, n = 10) than for patients with 
VWF:Ag levels > 20 IUdL'1 (4.7 h, n = 30). The VWF:Ag t1/2 values in both groups 
were shorter than the haemophilia A controls, P < 0.001.
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4.5 DISCUSSION
In this study, the release and clearance of VWF released following treatment with 
DDAVP has been examined in patients with type 1 VWD and haemophilia A 
controls. In keeping with previous reports, DDAVP resulted in the correction of the 
VWF levels into the normal range in most of the type 1 VWD study patients,(Nolan, 
et al 2000) and all of the controls, with approximately two to three fold increases in 
FVIII and VWF levels observed.(Ruggeri, et al 1982) A partial quantitative deficiency 
of VWF can result from reduced or impaired intracellular transport or secretion of 
VWF, or increased plasma clearance or a combination of both mechanisms. This 
study demonstrates increased plasma clearance of VWF in a significant proportion 
of patients with type 1 VWD, a finding that is consistent with previous 
reports.(Brown, eta !2003, Michiels, ef a/2002, van Genderen P. J. J 1997) 
Together, these observations suggest that decreased survival of VWF in plasma 
may be a mechanism underlying low levels in some patients with type 1 VWD.
The half-life of VWF:Ag showed only a weak correlation with circulating plasma 
levels |n the patients with type 1 VWD suggesting that reduced steady state VWF 
levels are either not, or only in part, due to increased clearance of VWF; a defect in 
intracellular transport and secretion by endothelial cells may also contribute towards 
the deficiency of VWF in these patients. Another possible explanation for these 
observations is that because of structural differences between VWF released by the 
regulated pathway following DDAVP administration and plasma VWF, the clearance 
kinetics of plasma and newly released VWF may differ. Indeed, in terms of multimer 
composition and expression of A antigen VWF released following DDAVP infusion 
differs from circulating VWF.(Brown, et al 2002, Ruggeri, et al 1982) A third 
explanation for the apparent discrepancy between plasma VWF levels and 
increased VWF clearance could be that the clearance rate is dependent on the 
plasma VWF concentration. However as VWF clearance has been shown to 
demonstrate first order kinetics, (Mannucci 1982) higher steady state levels of 
VWF:Ag can be interpreted as a consequence, rather than a cause, of longer VWF 
half-life values in this study. This is supported by the previous finding of normal VWF 
half-lives of infused cryoprecipitate and high purity VWF concentrates in patients 
with type 3 VWD.(Meriane, et al 1993, Over, et al 1978, Sultan, et al 1976) It 
therefore appears unlikely that the relationship between VWF:Ag half-life and 
VWF:Ag level can be explained by saturation of the clearance pathway.
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In view of these findings, caution should be exercised in extrapolating post-DDAVP 
clearance kinetics to steady state plasma VWF levels.
The co-existence of impaired VWF synthesis or secretion and increased VWF 
clearance resulting in the reduced VWF levels in some type 1 VWD patients in this 
study is supported by several further findings. Firstly, a restricted VWF response to 
DDAVP was found in a significant proportion of type 1 VWD patients, in particular 
those with a more severe phenotype. As synthesis and secretion of VWF is normal 
in patients with haemophilia A, the observation that plasma VWF levels appear to be 
independent of the amount of VWF released is expected in this group.
Secondly, the ratio of circulating FVIII to VWF:Ag was found to be increased (a 
suggested indicator of impaired VWF synthesis/secretion) in the majority of type 1 
VWD patients, irrespective of VWF:Ag half-life, a finding that was also more 
pronounced within the more severe VWD patients. This ratio was shown to inversely 
correlate with the response in VWF:Ag to DDAVP in the type 1 VWD cohort, with 
greater restriction in VWF response resulting in higher ratios of FVIII to VWF:Ag. 
VWF and FVIII circulate in plasma as a non-covalent complex, with only 1-2% of 
available VWF monomers being occupied by FVIII.(Vlot, et al 1998) Although the 
plasma molar ratio of 1:1 refers to the respective measurement of levels of FVIII and 
VWF in plasma in standardised units based on assumed levels of normality (100 
IUdL'1), the circulating molecular weight ratio of FVIII to VWF is around 1:50. It has 
been demonstrated that the molar ratio of FVIII to VWF:Ag can vary in VWD 
according to the underlying pathogenic mechanism: while defects in VWF synthesis 
or secretion have been shown to be associated with an increase in this ratio, 
FVIIIA/WF:Ag ratios appear unchanged in cases of type 2 VWD with increased VWF 
clearance.(Eikenboom, et al 2002) A ratio of FVIII to VWF:Ag of less than one was 
found in a type 1 VWD patient known to have a FVIII binding defect as well as a 
known carrier of haemophilia A with type 1 VWD (Appendix 2). These patients are 
further discussed in Chapter 8.
Higher heritability of VWD has previously been reported in patients with lower VWF 
levels.(Eikenboom, et al 2006) In this study, patients with steady-state VWF levels 
reduced to < 20 IUdL'1 were found to be less likely to achieve satisfactory responses 
to DDAVP and more likely to display higher ratios of FVIII to VWF:Ag. While both of 
these findings are suggestive of defective synthesis or secretion of VWF, no 
correlation was found between the concentrations of circulating and released VWF 
in this subgroup.
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Furthermore, many of the patients with more severe phenotype displayed shortened 
VWF t1/2 values, which appeared to contribute significantly towards the relationship 
between half-life of VWF:Ag and circulating plasma levels observed in the whole 
type 1 VWD group. These findings suggest that some cases of a partial quantitative 
deficiency of VWF may result from mutations within VWF that could, at least in part, 
be causative of increased VWF clearance. Indeed, recent studies have 
demonstrated VWF mutations that cause both increased clearance of VWF and 
impaired VWF synthesis or secretion. (Bodo, et al 2001, Schooten, et al 2005, 
Tjemberg, et al 2004) Molecular analysis of the patients in this study, including the 
limited family data is discussed in Chapter 8.
On the other hand, deleterious mutations within the VWF gene are less likely to be 
found in patients with higher VWF levels.(Eikenboom, et al 2006) Milder phenotypes 
are therefore more likely to result from the interplay of multiple factors, which include 
ABO blood group and polymorphisms. Indeed, around 60% of the type 1 VWD 
patients in this study were of blood group O as compared to 45% in the normal 
population, a finding that is well established.(Gill, et al 1987) Such enrichment of 
blood group O in this study was limited to the patients displaying a milder 
phenotype. To date, ABO blood group is the only genetic factor that has been 
clearly linked to VWF plasma concentration, accounting for around one third of the 
genetic variability of plasma VWF levels,(Orstavik, et al 1985) although the 
mechanism of ABO effect has not been established. ABH antigens are present 
within the oligosaccharide component of VWF according to the blood group of the 
individual,(Matsui, et al 1992) although detection of the antigens on VWF varies 
between plasma and intracellular VWF in humans.(Brown, et al 2002) .In view of 
possible confounding influences on VWF level in the type 1 VWD study patients, it is 
likely that any ABO effect would be more apparent in the control patients in this 
study and for this reason the study and control groups were analysed together. No 
significant difference in VWF response was found between blood group O and non- 
O individuals in this study (data not shown) consistent with previous observations 
that ABO group does not affect the rate of secretion by the regulated 
pathway.(0'Donnell and Laffan 2001, O'Donnell, et al 2000) Despite the finding that 
VWF half-lives were shorter in blood group O than blood group A subjects, this was 
not found to be statistically significant. Although these findings do not suggest a 
direct relationship between ABO blood group and the plasma clearance of VWF, this 
could be due to insufficient numbers of study and control patients and therefore this 
study may be under-powered and limited in its ability to demonstrate a significant 
difference in VWF clearance between blood groups. Furthermore, the effect of ABO
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type may be modest because a difference in clearance rate of only 25 -  35% would 
account for the average difference in VWF level between blood groups.
The indirect evidence supporting increased clearance of VWF with respect to ABO 
blood group derives from the effect of aberrant glycosylation of murine VWF with 
resultant increased clearance,(Mohlke, et al 1999b) as well as the observation that 
infused FVIII disappears more rapidly in blood group O than in non-0 haemophilia 
patients.(Vlot, et al 2000) More recently, the ratio of VWFpp to VWF:Ag, a 
suggested marker of increased clearance, has been shown to be higher in blood 
group O subjects than their non-0 counterparts.(Haberichter, et al 2006b, Nossent, 
et al 2006) This is further addressed in Chapter 5. As discussed in Chapter 1, a 
receptor-based basis formed the favoured mechanism of VWF clearance at the time 
of this study although no receptors had yet been identified. The ASGPR has a high 
affinity for GalNAc and Gal, which are the respective terminal sugar residues on the 
A and B blood group antigenic structures, in contrast to the O antigenic structures, 
which terminate in a fucose residue. Therefore the lowest clearance rates (and 
resultant highest VWF plasma levels) would be expected in individuals of blood 
group O were the ASGPR to significantly contribute towards uptake of VWF in 
humans. Although the effect of ADAMTS-13 mediated proteolysis on VWF 
clearance is not known, ABO blood group determinants have been shown to 
influence the susceptibility of plasma VWF to ADAMTS-13 proteolysis.(Bowen 2003, 
O'Donnell, et al 2005) The relationship between ADAMTS-13 mediated proteolysis 
and the clearance of VWF within this patient cohort, including that in relation to ABO 
blood group, is examined in Chapter 6.
The rationale for the use of patients with mild haemophilia A as controls in this study 
has been discussed in Chapter 3. The distribution of the pre- and post-DDAVP 
VWF:Ag values was found to be wider in the controls compared to the type 1 VWD 
patients, a finding most likely to reflect normal biological variation. Similarly, there 
was more variation in the half-life values in the controls than the type 1 VWD 
patients, although significant differences between the respective medians/means 
has consistently been shown in both this and previous studies.(Brown, et al 2003)
Finally, the findings in this study illustrate the potential limitations of judging the 
effectiveness of DDAVP treatment by the initial rise of VWF alone and support the 
recommendation of measuring VWF levels at several time points following 
DDAVP.(Pasi, et al 2004) Few studies have addressed the clinical efficacy of 
DDAVP, in particular as the sole therapeutic agent.(Rodeghiero, et al 1996) The
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data in this study suggest that if normal VWF levels are required to prevent or stop 
bleeding, treatment with DDAVP at intervals of 12 hours, as is the current standard 
practice, may be insufficient in some type 1 VWD patients. However, the rapid fall in 
VWF levels post-DDAVP in some type 1 VWD patients may be compensated by the 
other haemostatic effects of DDAVP.(Cattaneo, et al 1989) To address this, studies 
of the efficacy of DDAVP are required that analyse clinical response in relation to 
the VWF half-life.
In summary, increased clearance of VWF released following DDAVP is a frequent 
finding in type 1 VWD patients in this study, the largest of its kind to date. This 
increased clearance does not appear to consistently reflect the lowered steady state 
plasma VWF levels in these patients and possible limitations in the use of this 
method to study clearance of VWF following its constitutive secretion have been 
discussed. The findings in this study illustrate the need for a better understanding of 
the in vivo mechanisms of VWF clearance both intrinsic and extrinsic to VWF. 
Further studies in this thesis attempt to identify a common mechanism as a cause of 
the increased VWF clearance found in these patients.
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Chapter 5 
VWF PROPEPTIDE
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5.1 INTRODUCTION
The propeptide of VWF (VWFpp) was first reported in 1978,(Montgomery and 
Zimmerman 1978) when it was found to be absent from the platelets and plasma 
from individuals with severe VWD. Although the VWF gene encodes both VWFpp 
and the mature VWF protein,(Ginsburg, et al 1985) VWFpp is cleaved prior to 
secretion of VWF.(Wagner, et al 1987) Secretion of both VWFpp and mature VWF is 
via the constitutive and regulated pathways and the two proteins circulate 
independently in plasma. VWFpp has been shown to be important for the 
intracellular trafficking and processing of VWF.(Borchiellini, etal 1996, Haberichter, 
et al 2003, Haberichter, et al 2002, Rosenberg, et al 2002, van Mourik and Romani 
de Wit 2001, Wise, et al 1988)
In normal individuals VWFpp is found to circulate at around one tenth of the molar 
concentration of mature VWF.(Borchiellini, et al 1996) Despite the demonstration of 
near-equimolar release of VWFpp and VWF,(Borchiellini, et al 1996, Wagner, et al 
1987) the respective half-lives have been shown to differ by 3 -  4 fold,(Borchiellini, 
et al 1996) thus accounting for the difference in steady-state concentrations. 
Measurement of the plasma concentration of VWFpp and VWF:Ag in patients with a 
partial quantitative deficiency of VWF may therefore provide insight into the 
underlying pathogenic mechanism. Indeed, it has been proposed that an increased 
ratio of VWFpp to VWF:Ag may be a useful marker of plasma VWF clearance.(de 
Romeuf and Mazurier 1998)
5.2 AIMS
The aims of this study were to investigate the release and clearance of endothelial 
derived VWFpp following administration of DDAVP in patients with type 1 VWD and 
to compare these findings with the data previously obtained from studies of the 
mature VWF protein. To examine whether measurement of the relative plasma 
concentrations of VWFpp and VWF:Ag is predictive of increased plasma clearance 
of VWF, the relationship between the half-life of VWF released following DDAVP 
and the steadi-state ratio of VWFpp to VWF:Ag was investigated. Finally, to further 
investigate the mechanism of ABO effect on plasma VWF levels, the ratios of 
VWFpp to VWF:Ag were examined for ABO-related differences.
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5.3 MATERIALS AND METHODS
5.3.1 Patients and controls
Subgroups of type 1 VWD patients (n = 26) and haemophilia A controls (n = 10) 
from the cohorts recruited to the VWF clearance study in Chapter 4 were 
investigated (Appendix 3). Baseline plasma samples of 20 normal controls were 
used to derive a reference range for the plasma concentration of VWFpp. Five of the 
type 1 VWD patients had steady-state VWF:Ag levels reduced to < 20 IUdL'1. 
Diagnostic phenotypic data for patient and control groups is summarised in Table 
5.1.
5.3.2 Measurement of VWFpp by ELISA 
Principle
The method employed in this study is based on a previously described 
method.(Borchiellini, et al 1996) A monoclonal antibody directed to human VWFpp, 
coupled to a polystyrene microtitre plate, is incubated with the plasma sample to be 
analysed. The immune complex formed is then incubated with a second anti- 
propeptide antibody covalently coupled to horse radish peroxidise (HRP). The 
amount of bound HRP relates to the concentration of propeptide antigen in the 
sample.
Chemicals, reagents, controls, equipment and method were as described for the 
VWF:Ag ELISA (Chapter 3, Section 3.2.2) using the following modifications:
1. The standard curve consisted of doubling dilutions of pooled normal 
plasma from 1/10 to 1/1280.
2. Coating antibody: CLB -  pproIgG (Sanquin Research, University of 
Amsterdam, Netherlands) stored at 30°C, diluted to 5 pgrnL’1 in 
bicarbonate coating buffer. Incubation was at 4°C.
3. All subsequent incubations were performed at 37°C (incubator).
4. Dilution buffer: PBS/Tw-20/1% BSA (Sigma-Aldrich, Dorset, UK)
5. Following overnight incubation with coat buffer, free binding sites were 
blocked with dilution buffer for 2 h, 200 pL per well. This was then 
washed x 5 before addition of plasma patient and reference samples.
6. Plasma samples were incubated for 2 h.
7. Capture antibody: HRP-CLB -  pro 14.3, stored at 30°C, diluted 1/4000 
(Sanquin Research, University of Amsterdam, Netherlands)
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8. Measurements were determined against a plasma pool standard 
containing 6.3 nmolL*1 propeptide and 50 nmolL '1 VWF (monomer 
concentration) and results were expressed in molar concentrations.
9. CV for the assay was 6.8%.
5.3.3 Measurement of molar concentration of VWF:Ag
Because endothelial cell release reactions link VWF and its propeptide relative to 
their molar concentrations, the use of relative unitage concentrations has the 
potential to cause confusion when comparing different data. VWF:Ag data were 
therefore also expressed as molar concentrations in these studies. Molar 
concentrations of VWF:Ag were derived from the VWF:Ag levels measured in 
Chapter 4 (IU dL'1) as previously described.(Borchiellini, et al 1996)
5.3.4 Measurement of release and clearance of VWFpp and VWF:Ag 
following DDAVP
Platelet poor plasma samples were analysed prior to (T0) and over 6 h following 
DDAVP administration (T, - T6). The decay curves of VWFpp and VWF:Ag were 
extrapolated to the time point T = 30 min (linear regression of semi-log plot), the 
calculated values were corrected for baseline values and the respective 30 min 
responses of VWF and propeptide were plotted, and the slope determined. The 
method used to calculate VWF:Ag 11/2 and VWFpp t V2 is described in Chapter 3, 
Section 3.5.
5.3.5 Data and statistical analysis
Analyses of data were performed using GraphPad Prism (GraphPad Prism version
4.0, GraphPad Software, San Diego, USA). Data was analysed using the Mann- 
Whitney-Wilcoxon, Kruskall-Wallis tests and paired t- test and correlation analysis 
was performed using Spearman’s rank. Data are presented as median values with 
range.
81
Table 5.1. Phenotypic data of patients with type 1 VWD and haemophilia A and 
normal controls.
FVIII:C 
(IU dL'1) 
50-150
VWF:Ag 
(IU dL'1) 
50-150
VWFrRCo 
(IU dL'1) 
50-150
VWFrRCo / 
VWF:Ag
Type 1 VWD 
(n = 26)
60
(1 3 -8 0 )
36
(1 3 -5 0 )
36
(11 -5 2 )
0.97
(0 .7 - 1.4)
Haemophilia A 
(n = 10)
18
(5 -  38)
94
(45-193)
100
(50-158)
0.94
(0 .7 -1 .3 )
Normal controls 
(n = 20) -
115
(66-194) - -
Data are shown as median (range).
5.4 RESULTS
5.4.1 Pre-DDAVP
Molar concentrations of VWFpp and VWF:Ag at T0 in the type 1 VWD patients (n = 
26) and the haemophilia A controls (n = 10) are given in Appendix 3 and circulating 
VWF:Ag levels in 20 normal controls are given in Appendix 4. Data is shown in 
Fig.5.1 and summarised in Table 5.2. The respective median concentrations of 
VWF:Ag and VWFpp were lower in the type 1 VWD patients than both the 
haemophilia A and normal control groups, P < 0.001. The VWFppA/WF:Ag ratio was 
found to be increased in five patients with type 1 VWD (Fig. 5.1C). However, 
VWFppA/WF:Ag ratios did not differ between the VWD patients and haemophilia A 
and normal control groups, P = 0.4 (Fig. 5.1C).
5.4.2 Relationship between baseline VWF:Ag concentration and ratio of 
VWFpp to VWF.Ag
Significant inverse correlation was found between circulating VWF:Ag levels at T0 
and VWFppA/WF:Ag ratio in the type 1 VWD study and haemophilia A control 
groups (r = -0.38, P < 0.02, n = 36, Fig.5.2) and VWD patients alone (r = -0.58, P < 
0.01, n = 26) but was not observed in the haemophilia A controls (r = -0.45, P = 0.2, 
n = 10) Four of the patients with increased VWFppA/WF:Ag ratios had T0 VWF:Ag 
levels < 20 IUdL‘1 (<10 nmol L'1, Fig. 5.2).
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5.4.3 One hour response to DDA VP
One hour responses in VWFpp and VWF:Ag did not differ between the VWD 
patients and haemophilia A controls, P>  0.2. Median increases in VWFpp from T0 to 
Ti were 28.4 and 40.0 nmolL'1 respectively (Table 5.3). However, in both the VWD 
and control groups, the increase in VWF:Ag from T0 to was significantly higher 
than the VWFpp increase, P < 0.005 (Table 5.3). In addition, the comparative 
release of VWFpp and VWF:Ag 30 min following DDAVP was examined in the type 
1 VWD patients: VWFpp and VWF:Ag responses were derived at time point T = 30 
min. The slope of the VWFpp vs VWF:Ag response was 0.48 (Fig. 5.3), representing 
the molar ratio of released VWFpp to VWF:Ag. The VWFppA/WF:Ag ratios were 
approximately 3 fold higher at T  ^compared to T0, in the VWD patients, and around 2 
fold higher in Haem A, P < 0.001 (Table 5.3). No difference was found in the 
VWFppA/WF:Ag ratio at Ti between the VWD patients and control groups, P = 0.8.
Table 5.2 Molar concentrations of VWF:Ag and VWFpp in patients with type 1 
VWD and haemophilia A controls prior to administration of DDAVP.
In addition, circulating plasma levels are given for normal controls.
VWF.Ag 
(nmol L‘1) 
2 5 -7 5
VWFpp 
(nmol L-1)
VWFpp/ 
VWFAg ratio
Type 1 VWD 
(n = 26)
23.5*
(5.5 -  42)
2.9*
(1 .4-10.9)
0.13 n s 
(0.06 -  0.52)
Haemophilia A 
(n = 10)
47
(22.5 -  96.5)
8.2
(3.3 -  22.0)
0.17ns 
(0.06 -  0.70)
Normal controls 
(n = 20)
57.5
(33 -  97)
7.4
(4.5-17.4)
0.12
(0.07 -  0.30)
*P < 0.001; n.s. not significant; data is presented as medians (range)
Normal ranges: VWFpp 4.5 -  17.4 nmol L'1(as shown); VWF.Ag 25 -  75 nmol L’1.
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Table 5.3 1 h DDAVP response of VWF:Ag and VWFpp in patients with type 1 
VWD and haemophilia A controls.
VWF:Ag 
(nmol L-1)
VWFpp 
(nmol L’1)
VWFpp/VWF:Ag 
ratio at Ti
Type 1 VWD 
(n=26)
56.5 ** 
(14-117)
28.4*
(9.7-46.7)
0.42
(0.16-0.77)
Haemophilia A 
(n=10
61.0# 
(15-101)
40.0
(0 -  52.7)
0.37
(0.07 - 0.57)
Response is defined as the difference between molar concentration of VWF at 
baseline (T0) and 1 h following DDAVP (Ti);
* no significant difference between 1 h increase in VWF:Ag or VWFpp between 
study and control groups, P > 0.2 ;
# the 1 h increase in VWF:Ag from was significantly higher than the propeptide 
increase in both study and control groups, P < 0.005; data is presented as medians 
(range)
Figure 5.1. Molar concentrations of VWFpp (A) and VWF:Ag (B) and 
VWFpp/VWF:Ag ratios (C) at baseline in type 1 VWD patients (n = 26), 
haemophilia A controls (n = 10), and normal controls (n = 20). Median values 
are given in Table 5.2. Normal ranges: VWFpp 4.5 -  17.4 nmol L‘1 (as shown); 
VWF:Ag 25 -  75 nmol L*1. VWF:Ag and VWFpp levels were shown to be reduced in 
the type 1 VWD patients compared to both control groups, P < 0.001. No difference 
in VWFppA/WF:Ag ratios was found between the groups, P = 0.4
A
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Figure 5.2. Relationship between baseline VWF:Ag molar concentration and 
ratio of VWFpp to VWF:Ag. VWF.Ag concentration and the ratio of VWFpp to 
VWF:Ag prior to the administrations of DDAVP are shown for patients with type 1 
VWD ( ^  ,n = 26) and haemophilia A controls ^  ,n = 10). Significant inverse 
correlation was found between VWF:Ag and VWFppA/WF:Ag ratio in the study and 
control groups (r = -0.38, P < 0.02, n = 36) and VWD patients alone (r = -0.58, P < 
0.01, n = 26) but not in the haemophilia A controls (r = -0.45, P = 0.2, n = 10)
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Figure 5.3. Increase in molar concentration of VWF:Ag and VWF propeptide 30 
min after DDAVP administration in patients with type 1 VWD (n=26). The slope 
(r value) of 0.48 represents release of approximately two moles of VWF per mole 
VWFpp.
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5.4.4 Clearance of VWFpp and VWF:Ag
The molar concentrations of VWFpp and VWF:Ag over the time course T0 - T6are 
shown for the type 1 VWD patients and haemophilia A controls in Figs 5.4 and 5.5 
respectively. As was found for the type 1 VWD study cohort in Chapter 4, VWF:Ag 
t1/2 values were significantly shorter in this subgroup of type 1 VWD patients 
(median 3.8 h, P < 0.001, n = 26) than the haemophilia A controls (median 13.7 h, n 
= 10, Table 5.4, Fig. 5.6). In contrast, there was no difference in VWFpp t1/2 values 
between the study and control groups, P -  0.8, with respective median values of 2.5 
and 2.3 h (Table 5.4, Fig.5.6).
5.4.5 Relationship between VWF half-life and ratio of VWFpp to VWF:Ag
No correlation was found between the circulating plasma VWFppA/WF:Ag ratio and 
VWF:Ag ti/2 either in the type 1 VWD study and haemophilia A control groups (r = -
0.16, P = 0.4, n = 36, Fig. 5.7), or the study patients (r = -0.32, P -  0.1, n = 26). 
Similarly, no correlation was found between the VWFppA/WF:Ag ratio at and 
VWF:Ag ti/2 > P — 0.2 (data not shown). However, shortened VWFiAg ti/2 values were 
observed in the five type 1 VWD patients with increased VWFppA/WF.Ag ratios (Fig. 
5.7).
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Table 5.4 Calculated half-life values of VWF:Ag and VWFpp in type 1 VWD 
patients and haemophilia A controls.
VWF:Ag t1/2 (h) VWFpp t1/2(h)
Type 1 VWD 3.8* 2.5ns
(n = 26) (1 .9 -9 .6 )
oCOIr^-
Haemophilia A 13.7 2.3
(n = 10) (4.1 ->30) (0.8 -  8.5)
*P < 0.001; n.s. not significant; data is presented as medians (range)
Figure 5.4. Molar concentrations of VWFpp (A) and VWF:Ag (B) prior to and 
over 6 h following DDAVP administration in type 1 VWD patients (n = 26).
Data is presented as 25th and 75th centiles with range. Normal ranges: VWFpp 4.5
17.4 nmol L"1; VWF:Ag 25 -  75 nmol L'1.
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Figure 5.5. Molar concentrations of VWFpp (A) and VWF:Ag (B) prior to and 
over 6 h following DDAVP administration in haemophilia A controls (n = 10).
Data is presented as 25th and 75th centiles with range. Normal ranges: VWFpp 4.5 -
17.4 nmol L'1; VWF:Ag 25 -  75 nmol L'1.
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Figure 5.6A. Calculated half-life values of VWF:Ag in type 1 VWD patients and 
haemophilia A controls. VWF:Ag t1/2 values were significantly shorter in type 1 
VWD patients (median 3.8 h, P < 0.001, n = 26) than the controls (13.7 h, n = 10).
20-
10-
■■
type 1 VWD haem A
Figure 5.6B. Calculated half-life values of VWFpp in patients with type 1 VWD 
and haemophilia A controls.:No difference in VWFpp t^  was found between the 
study (median 2.5 h, P -  0.8, n = 26) and control groups (2.3 h, n = 10)
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CM
type 1 VWD haem A
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Figure 5.7. Relationship between VWF:Ag half-life and ratio of VWFpp to 
VWF:Ag. VWF:Ag values and the ratio of VWFpp to VWF:Ag in circulating 
plasma are shown for patients with type 1 VWD ( ^ ,n  = 26) and haemophilia A 
controls ( ^  , n = 10). No correlation was found between the VWFppA/WF:Ag 
ratio and VWF:Ag h/2 , both in the study and control groups (r = -0.16, P = 0.4, n = 
36) and the VWD patients alone (r = -0.32, P = 0.1, n = 26).
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5.4.6 Relationship between ABO blood group and ratio of VWFpp to VWF:Ag
Analysis of the type 1 VWD study and haemophilia A control groups together 
showed the VWFppA/WF:Ag ratios to be significantly increased in blood group O 
subjects (median 0.16, 0.11 -  0.70, P < 0.01, n = 24, Fig. 5.8) compared to blood 
group A subjects (0.10, 0.06 -  0.39, n = 12). Within the VWD patients, no significant 
difference was found in VWFpp/VWF:Ag ratios between blood group O and A 
patients, P = 0.2.(data not shown).
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Figure 5.8. Ratio of VWFpp to VWF:Ag in study and control groups according 
to ABO blood group The VWFpp/VWF:Ag ratio was found to be significantly 
increased in blood group O subjects (median 0.16, P < 0.01, n = 24) compared to 
blood group A subjects (median 0.10, n = 12).
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5.5 DISCUSSION
In this study, having confirmed the previous finding of increased plasma clearance 
of VWF released following DDAVP in the type 1 VWD patient subgroup, steady- 
state levels of VWFpp and VWF were examined and the release and clearance of 
VWFpp investigated. In addition to demonstrating reduced VWF levels, the type 1 
VWD study group were also shown to have lower steady-state concentrations of 
VWFpp than both haemophilia and normal control groups, consistent with defective 
VWF synthesis or secretion. Data from previous studies indicate that the plasma 
clearance of VWFpp is independent of VWF clearance and its shorter plasma 
survival has been shown to account for the lower steady steady-state concentrations 
of VWFpp compared to mature VWF in normal individuals (VWFppA/WF:Ag molar 
ratio ~0.1). (Borchiellini, et al 1996) However, despite the increased VWF:Ag 
clearance and preservation of normal VWFpp survival in the type 1 VWD patients in 
this study, no difference was found in VWFppA/WF:Ag ratios between the study and 
control groups. Differences between the kinetics of VWFpp and VWF:Ag and their 
disappearance following DDAVP administration could underlie this unexpected 
finding. Pertinent to this is that, unlike in cultured endothelial cells(Wagner, et al 
1987) and previous DDAVP studies in healthy individuals(Borchiellini, et al 1996), 
equimolar release of VWFpp and VWF:Ag was not demonstrated, either in the 
control group or in the patients with type 1 VWD. This was reflected by restricted
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DDAVP-induced increases in VWFpp/VWF:Ag ratio compared to previous 
studies.(Borchiellini, et al 1996) and indicates that not all VWFpp secreted after 
DDAVP administration is directly released into the systemic circulation. It is likely 
that a proportion of newly secreted VWFpp is extracted by other compartments (e.g. 
the extra-cellular matrix of the endothelium, circulating blood cells). Therefore, the 
multi-compartment distribution of VWFpp (and possibly VWF) could complicate the 
interpretation of clearance kinetics. Thus, the findings in this study suggest that, as 
was shown for mature VWF in Chapter 4, measurement of the propeptide of VWF 
following administration of DDAVP may also not reflect its steady state plasma 
levels.
It has previously been hypothesised that measurement of plasma levels of VWFpp 
in conjunction with VWF.Ag may provide insight into the underlying mechanism 
resulting in VWD.(de Romeuf and Mazurier 1998) While it has been proposed that 
concordant reductions in VWF:Ag and VWFpp resulting in preservation of the 
VWFppA/WF:Ag ratio may reflect defects in VWF synthesis and intracellular 
transport prior to the cleavage of VWFpp, it has been suggested that alterations in 
VWF following its secretion (such as increased clearance) could result in an 
increase in the VWFppA/WF:Ag ratio. Indeed, increased VWFppA/WF:Ag ratios 
have recently been reported in association with increased VWF clearance in a 
homogeneous population of type 1 VWD patients with cysteine mutations in the 
VWF-D3 domain,(Schooten, et al 2005) as well as in affected type 1 VWD 
individuals within four families with mutations in the D3 and D4 
domains.(Haberichter, et al 2006a)
Although increased plasma clearance of VWF was not shown to be consistently 
associated with an increase in the ratio of VWFpp to VWF:Ag in this study, 
significantly increased VWF clearance was observed in the five type 1 VWD patients 
with increased ratios of VWFpp to VWF:Ag. Of these five patients, four displayed a 
more severe VWD phenotype as defined by steady-state VWF:Ag concentrations of 
less than 20 IUdL'1, which contributed significantly towards the overall finding of 
inverse correlation between VWFppA/WF:Ag ratio and VWF:Ag level. These 
findings suggest that while an increased VWFppA/WF:Ag ratio may be a useful 
surrogate marker for the increased plasma clearance of VWF, increased clearance 
of VWF released following DDAVP is frequently found in the context of a normal 
ratio. The apparent dissociation of VWF:Ag half-life from the VWFppA/WF:Ag ratio 
further supports the likelihood of co-existent pathogenic mechanisms in these type 1 
VWD patients, in particular those with milder phenotypes as discussed in Chapter 4.
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The findings in this study cast doubt on whether the VWFpp/VWF:Ag ratio can 
usefully predict increased clearance of VWF in heterogeneous patient populations 
and challenge the findings from limited studies published in a few families, 
(Haberichter, et al 2006b) highlighting the problem of generalising a study of small 
numbers of patients from selected type 1 VWD families. The subgroup of VWD 
patients of more severe phenotype and increased VWFpp/VWF:Ag ratios is further 
considered in relation to findings of molecular analysis of VWF in Chapter 8.
The final aim of this study was to examine for ABO-related differences in the ratio of 
VWFpp to VWF:Ag. The suggestion that VWF released following DDAVP may not 
necessarily be a good measure of clearance of VWF released following constitutive 
secretion in the steady-state is further supported by the finding of increased 
VWFppA/WF:Ag ratios in association with blood group O in this study. This is 
despite the lack of relationship previously demonstrated between ABO blood group 
and clearance of VWF following DDAVP (Chapter 4). In view of the lack of 
consistency shown between VWF:Ag clearance following DDAVP and 
VWFppA/WF:Ag ratio, such a discrepancy is not unexpected. The ratios of VWFpp 
to VWF:Ag in the blood group A subjects were similar to the normal controls, 
fluctuating around a median of 0.1. The finding that the ratio was increased in blood 
group O subjects is consistent with recent findings from other studies (Haberichter, 
et al 2006a, Nossent, et al 2006) and supports the hypothesis of an ABO blood 
group effect on the rate of VWF clearance.(Mohlke, et al 1999b, Vlot, et al 2000)
The VWFpp immunoassay is a robust, reproducible assay. However, monoclonal 
antibodies to VWFpp were not commercially available at the time of this study. In 
laboratories where antibodies have been raised to VWFpp, the measurement of 
VWFpp has been successfully used to support the diagnosis of some cases of 
VWD, including acquired VWD. It has also been suggested that VWFpp may be 
useful in distinguishing between cases of acute and chronic endothelial cell 
perturbation.(van Mourik, et al 1999) Although the VWFpp assay was not being 
performed routinely at the time of this study, its use is likely to be widened following 
the recent development of commercial assays. In this study, the overall reduction in 
VWFpp levels in type 1 VWD patients illustrates the potential utility of this assay in 
the diagnosis of type 1 VWD. However, its value in differentiating causative 
mechanisms of the type 1 phenotype appears to be limited, as shown in this 
heterogeneous type 1 VWD cohort. As the VWFpp assay is not currently 
standardised, studies are required to evaluate inherited and acquired defects of 
VWF and recruitment into an ISTH/SSC multicentre study is underway.
94
Chapter 6
ADAMTS-13, VWF:CB and 
CLEARANCE OF VWF
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6.1 INTRODUCTION
VWF multimer size is controlled by several mechanisms in the circulation including 
proteolysis at a single peptide bond Tyr 1605 -Met 1606 in the VWF-A2 domain. This 
cleavage is the function of the plasma metalloprotease ADAMTS-13, first identified 
in 1996,(Furlan, et al 1996, Tsai 1996) and further characterised in 2001 .(Levy, et al 
2001, Zheng, et al 2001) Defective ADAMTS-13 proteolysis results in the 
accumulation of uncleaved or partially cleaved unusually or ultra-large (UL) 
multimers of VWF, resulting in systemic thrombotic microangiopathies such as 
thrombotic thrombocytopenic purpura (TTP).(Moake, et al 1982) The possible 
effects of increased ADAMTS-13 proteolysis on circulating VWF levels are less 
clear. In-vitro studies have shown a variation in susceptibility of VWF to ADAMTS-13 
mediated proteolysis according to blood group,(Bowen 2003) although whether this 
relates to lowered VWF levels has yet to be determined. Furthermore, increased 
susceptibility of VWF to proteolysis by ADAMTS-13 has been shown to associate 
with the Y1584C mutation,(Bowen and Collins 2004) reported as a founder 
haplotype among patients with type 1 VWD.(0'Brien, et al 2003)
Circulating plasma VWF in patients with type 1 VWD demonstrates normal 
functional activity and multimeric pattern. At the time of this study, the clearance 
pathway of VWF was poorly understood and it had not been established whether 
removal of VWF multimers was size-dependent.
High molecular weight (HMW) multimers of VWF preferentially bind to 
collagen(Santoro 1983) and therefore their function can be measured using the 
VWF collagen-binding assay (VWF:CB)(Brown and Bosak 1986). An inverse 
relationship has been demonstrated between VWF-related parameters and 
ADAMTS-13 activity over a wide range of VWF concentrations including following 
DDAVP, suggestive of consumption of ADAMTS-13 following the release of HMW 
multimers of VWF.(Mannucci, et al 2004, Reiter, et al 2003)
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6.2 AIMS
The aim of this study was to examine the relationship between VWF multimer size 
and the release and clearance of VWF by comparison of VWF level and collagen 
binding activity prior to and following DDAVP infusion. ADAMTS-13 activity was 
measured to determine whether this related to VWF clearance and/or VWF levels in 
this group of patients with type 1 VWD. It is also possible that released VWF 
multimers are more susceptible to proteolysis by ADAMTS-13 and that this may 
account for the increased plasma clearance of VWF observed in some type 1 VWD 
patients. To investigate this, susceptibility of HMW multimers of VWF to ADAMTS- 
13 mediated proteolysis was determined in the type 1 VWD patients.
6.3 MATERIALS AND METHODS
6.3.1 Patients and controls
Subgroups of type 1 VWD patients (n = 26) and haemophilia A controls (n = 10) 
from the cohorts recruited to the VWF clearance study in Chapter 4 were 
investigated.(Appendix 3) Diagnostic phenotypic data for the patient and control 
groups is summarised in Table 5.1. For the proteolysis studies, plasmas from a 
homozygous Y1584Y individual and a heterozygous Y1584C individual were used 
as controls. Both individuals had haemostatic parameters within the normal range.
6.3.2 VWF collagen binding ELISA (VWF. CB)
Principle
Collagen binds to VWF with preferential binding for HMW multimers of VWF. The 
ELISA used to measure VWF:CB activity in this study is based on the originally 
described immunoassay. (Brown and Bosak 1986).
Chemicals, reagents, controls, equipment and method
Chemicals, reagents, controls, equipment and method were as described for the 
VWF:Ag ELISA (Chapter 3, Section 3.2.2) using the following modifications:
1. The standard curve consisted of doubling dilutions of pooled normal plasma 
from 1/160 to 1/3200.
2. Coating antibody: human type III collagen (Cambridge Bio Science, UK) 
diluted in CB coat buffer 3 pgmL'1 (w/v), pH 7.3. Overnight incubation was at 
room temperature.
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3. CB Coat buffer, pH 7.3 :
a. NaCI 8.0 g
b. Na2HP04.12H20 2.11 g
c. NaH2P04.H20 0.2 g
d. KCL 0.2 g
e. Distilled H20  5 L
4. Dilution buffer: PBS/Tw-20/1% BSA (Sigma-Aldrich, Dorset, UK)
5. Following incubation with coat buffer, free binding sites were blocked with 
dilution buffer for 1 h, 150 pl_ per well, room temperature. This was then 
washed x 5 before addition of plasma patient and reference samples.
6. Capture antibody (HRP-conjugated rabbit anti-human VWF) diluted 1/3000 in 
dilution buffer
7. CV for the assay was 7%.
6.3.3 Measurement of release and clearance of VWF:CB and VWF:Ag 
following DDAVP
Plasma samples were analysed prior to (T0) and over 6 h following DDAVP 
administration (Ti - T6). The method used to calculate VWF:CB t 1/2 and VWF:Ag t i/2 
is described in Chapter 3, Section 3.5.
6.3.4 Measurement of ADAMTS-13 activity
Analysis was performed by Dr Richard Starke, University College London 
ADAMTS-13 activity was measured using a method based on the preferential 
binding of HMW forms of VWF to collagen, as previously described.(Gerritsen, et al 
1999) The diluted plasma sample to be tested was added to normal human plasma 
in which protease activity had been abolished. The VWF present in the protease- 
depleted plasma was digested by the ADAMTS-13 in the test plasma. VWF:CB 
activity of the LMW multimers resulting from the proteolytic degradation of VWF was 
measured. ADAMTS-13 activity was quantitated using a calibration curve obtained 
from the incubation of VWF-substrate with serial dilutions of normal plasma.
CVs for the assay were 3.5% (intra-plate) and <5% (inter-plate). Plasma samples 
were analysed prior to (T0) and over 6 h following DDAVP administration (Ti - T6).
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6.3.5 Susceptibility of VWF to proteolysis
Analysis was performed by Dr Derrick Bowen, School of Medicine, Cardiff University 
Cryoprecipitate was prepared from plasma as previously described,(Bowen and 
Collins 2004) and dissolved in 50 pL of Tris-HCI (5 mmol L*1, pH 8.0). VWF:Ag of the 
dissolved cryoprecipitate was determined using ELISA. Proteolysis was performed 
using a minor modification of a previously described method(Gerritsen, et al 1999): 
dissolved cryoprecipitate was used as the source of VWF, and group O 
cryodepleted plasma was used as the source of ADAMTS-13. Both the quantity of 
VWF:Ag and the volume of group O cryodepleted plasma were identical for all 
proteolysis incubations. The same group O cryodepleted plasma was used for all 
experiments. Proteolysis reactions were incubated at 37°C for 3 hours and the 
extent of proteolysis was assessed using VWF multimer analysis (Chapter 3,
Section 3.3) applied to aliquots taken at the start and end of the proteolysis 
incubation. The susceptibility of VWF to proteolysis was measured in patient 
samples at T0 and T^
6.3.6 Genotypic analysis of the Y1584C mutation
Genomic DNA was extracted as described in Chapter 3, Section 3.4.1. A 682-bp 
fragment of exon 28 of VWF was amplified by PCR using primers K2A and K1B 
primers as described in Section 3.4.3. The Y1584C amino acid mutation in the A2 
domain of VWF results from the single nucleotide polymorphism (SNP) 4751 A>G in 
exon 28 of the VWF gene. This SNP affects a Kpnl restriction site (GGTACC, A = 
Kpn\+ and encodes tyrosine, G_= KpnV and encodes cysteine) Thus, the 682 bp 
K2A-K1B PCR product was genotyped at codon 1584 by incubating an aliquot (15 
pL) for 2 hs with 40 U of Kpnl restriction enzyme (Roche, East Sussex, UK). Kpnl+ 
yielded fragments of 276 and 406 bp, for Kpnl'the PCR product remained 
undigested at 682 bp. 1.5 % agarose gel was prepared (2.25 g agarose, 150 mL 
TBS, 8 pL ethidium bromide) and 8 pL of restricted product was run with 3 pL 
loading buffer. Marker XIV was used (2 pL MXIV, 15 pL H20, 4 pL loading buffer). 
Unrestricted PCR product was used as the negative control (blank).
6.3.7 Data and statistical analysis
Analyses of data were performed using GraphPad Prism (GraphPad Prism version 
4.0, GraphPad Software, San Diego, USA). Data was analysed using the Mann- 
Whitney-Wilcoxon test and correlation analysis was performed using Spearman’s 
rank. Data are presented as median values with range.
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6.4 RESULTS
6.4.1 Collagen binding activity and VWF release
VWF:CB activities, VWF:Ag levels and ratios of VWF:CB to VWF:Ag at T0 and Ti in 
type 1 VWD patients (n = 26) and haemophilia A controls (n = 10) are summarised 
in Table 6.1. As expected, VWF:CB activities were significantly lower in the VWD 
study patients than controls (P < 0.05) at both T0and Ti and no significant difference 
was found between VWF:CBA/WF:Ag ratios in the study (median 0.9, P > 0.1, n = 
26) and control groups (0.96, n = 10, Table 6.1).
In the type 1 VWD patients, the ratio of VWF:CB to VWF:Ag at Ti was significantly 
higher than atT0, P< 0.01 (Fig.6.1), with respective median values of 1.1 (0.5 -  1.5) 
and 0.9 (0.6 -  1.4). No significant difference was found between the median ratios at 
T0 and T6 (median 0.97, P = 0.2). VWF:CBA/WF:Ag ratios were also increased in the 
haemophilia A controls at Ti (median 1.1, 0.9 -  1.4, Fig.6.2) compared to T0 (0.95,
0.8 -  1.3) although this was not shown to be statistically significant (P = 0.08).
Within the VWD study group, 20 patients demonstrated an increase in 
VWF:CBA/WF:Ag ratio following DDAVP, reflecting the release of HMW multimers 
of VWF. Of the six VWD patients in whom the VWF:CBA/WF:Ag ratio was reduced 
at T! compared to T0, two patients (Patients 10 and 25) from one kindred (Kindred 
10) displayed significant reduction in T  ^VWF:CBA/WF:Ag ratios compared to the 
median, with respective T0 values of 0.9 and 0.9 falling to 0.6 and 0.5 at T|. In the 
control group, a reduction in VWF:CBA/WF:Ag ratio between T0and Ti was shown in 
three subjects, although the values at T, did not vary significantly from the median.
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Table 6.1. VWF:Ag, VWF:CB and VWF:CB/VWF:Ag ratios prior to and 1 h following administration of DDAVP in type 1 VWD patients and 
haemophilia A controls. ADAMTS-13 activity is also shown in the type 1 VWD patients.
*P < 0.005; ** P <  0.05; n.s. not significant; NT. not tested;
pre DDAVP (To) 1h post DDAVP (Ti)
VWF:Ag
(IUdL1)
50-150
VWF:CB
(IUdL1) 
50 -175
VWF:CB/ 
VWF:Ag ratio
ADAMTS-13 
activity (%) 
66 -126
VWF:Ag
(IUdL1)
VWF:CB
(IUdL1)
VWF:CB/ 
VWF:Ag ratio
ADAMTS-13 
activity (%)
Type 1 VWD 
(n=26)
47*
(11 -8 4 )
43*
(9-102)
_ _  . n.s.0.91
(0.60-1.37)
89
(51-127)
175**
(41 -271 )
178*
(41 -  265)
. . .  n.s.1.10
(0.50-1.50)
75
(42.7-111)
Haemophilia A 
(n=10)
94
(45 -193)
95
(49-186)
0.96
(0 .85- 1.35)
NT 216
(165-307)
246
(154-300)
1.12
(0.89-1.36)
NT
Figure 6.1. Ratio of VWF:CB to VWF:Ag pre- and post-DDAVP in patients with 
type 1 VWD (n = 26). VWF:CBA/WF:Ag ratios are shown at baseline (T0) and 1 h 
and 6 h following DDAVP (T1f T6). The VWF:CBA/WF:Ag ratio at Ti was found to be 
significantly increased (median 1.1, P<  0.01) as compared to T0 (0.9). Median ratios 
at T0 and T6were not found to differ significantly (median 0.97, P = 0.2).
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Figure 6.2. Ratio of VWF:CB to VWF:Ag pre- and post-DDAVP in haemophilia 
controls (n = 10). Increased ratios of VWF:CBA/WF:Ag were found at Ti (median 
1.1) compared to T0 (0.9), however this was not statistically significant, P -  0.08.
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6.4.2 Collagen binding activity and VWF clearance
Calculated VWF:CB t1/2 values for the type 1 VWD patients and haemophilia A 
controls are given in Appendix 3 and shown in Fig.6.3. As was shown for VWF:Ag 
h/2 , VWF:CB t1/2 values in the type 1 VWD study patients were significantly shorter 
(median 4.4 h, P < 0.005) than the controls (median 8.2 h, Table 6.2). Similarly, 
correlation was found between VWF.CB at T0and VWF:CB t1/2 in the combined 
study and controls groups (r = 0.43, P < 0.05, n = 36), but not in either group when 
analysed separately (r = 0.24, P = 0.2, n = 26; r = 0.13, P = 0.7, n = 10). In addition, 
VWF:CB ti/2 correlated significantly with VWF:Ag h/2 on analysis of both groups 
together (r = 0.77, P < 0.0001, n = 36, Fig.6.4) as well in each group alone (r = 0.66, 
P < 0.005, n = 26; r = 0.79, P < 0.005, n = 10).
Table 6.2. Calculated half-life values of VWF:Ag and VWF:CB in type 1 VWD 
patients and haemophilia A controls.
Data are presented as medians (range). *P < 0.005
VWF:Agt,„
<h)
VWF:CB t1/2 
(h)
Type 1 VWD 3.8* 4.4*
(n=26)
COo>Io> (1 .7-10.3)
Haemophilia A 13.7 8.2
(n=10) (4.1 ->30) (3.4-35.9)
Figure 6.3. Calculated VWF:CB half-life values in type 1 VWD patients and 
haemophilia A controls). Median VWF:CB ti/2 values in the VWD patients (4.4 h, P 
< 0.005, n = 26) were significantly shorter than the controls (8.2 h, n = 10).
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Figure 6.4. Relationship between half-life values of VWF:Ag and VWF:CB in 
type 1 VWD patients and haemophilia A controls. Values of VWF:Ag t1/2and 
VWF:CB tM2 are shown for patients with type 1 VWD (^  ,n = 26) and haemophilia A 
controls ( ^  , n = 10). Correlation between VWF:Ag t1/2 and VWF.CB ti/2 was 
found on analysis of the study and control groups together (r = 0.77, P < 0.0001, n 
= 36) and study patients (r = 0.66, P < 0.005, n = 26) and control groups alone (r = 
0.79, P< 0.005, n= 10).
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6.4.3 ADAMTS-13 activity and VWF clearance
ADAMTS-13 activities were measured pre- and post-DDAVP (T0 - T6) in type 1 VWD 
patients (n = 26). ADAMTS-13 levels at T0 were within normal limits in 22 of the type 
1 VWD patients; the remaining four had reductions in ADAMTS-13 of up to 15%
(Fig. 6.5). DDAVP infusion resulted in an overall decrease in ADAMTS-13 levels 
(Fig. 6.5, Table 6.1). The fall in ADAMTS-13 activity from T0 to T<\ correlated 
significantly with the increase in VWF:Ag and VWF:CB (r = -0.58, P < 0.005; r = -
0.32, P < 0.0005, data not shown). However, no inverse correlation was found 
between absolute ADAMTS-13 activity and either VWF:Ag level or VWF:CB activity 
prior to or over 6 h following DDAVP, T0-  T6 (P > 0.1, data not shown). In addition 
no correlation was found between baseline ADAMTS-13 activity (T0) and either 
VWF:Ag t1/2 (r = -0.03, P = 0.9) or VWF:CB t1/2 (r = 0.12, P = 0.6). ADAMTS-13 
activity was found to be higher in VWD patients of blood group A (median 99.7% 
(80.2 -  126.6), n = 8, P< 0.01) than blood group O (80.3% (50.8 -  95.8) n = 16, 
data not shown).
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Figure 6.5. ADAMTS-13 activity pre- and post-DDAVP in patients with type 1 
VWD (n = 26). ADAMTS-13 activities are shown at baseline (T0) and 1 h and 6 h 
following DDAVP (Ti, T6 respectively). ADAMTS-13 activity was reduced at both T, 
(median 75%, P < 0.05) and T6(76%, P < 0.05) as compared to T0(89%).
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6.4.4 Y1584C mutation and VWF clearance
Genotypic analysis for 4751 A>G was performed in type 1 VWD patients (n = 26) 
and haemophilia A controls (n = 10) Heterozygosity for the A and G alleles was 
demonstrated in one study patient (Patient 12) and one control (Control 11). 
(Fig.6.6) Respective VWF:Ag ti/2 values in these heterozygous subjects were 4.8 
and 16 h compared to median values of 3.8 and 11.4 h in the homozygous 4751A 
VWD patients (n = 25) and haemophilia A controls (n = 9).
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Figure 6.6. Genotypic analysis for 4751A>G performed as described in Materials 
and Methods. Kpnl+ yielded fragments of 276 and 406 bps, for KpnY; the PCR 
product remained undigested at 682 bps. Lane 16: positive control (Y1584C) 
showing undigested and digested fragments; Lane 17 Blank. Subjects in lanes 9 
(Patient 12) and 15 (Control 11) can be seen to be heterozygous for the A and G 
alleles (heterozygous Y1584C).
<-682bp’s
<-406bp’s
<-276bp’s
Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
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6.4.5 Susceptibility of VWF to proteolysis by ADAMTS-13; relation to VWF 
clearance.
The susceptibility of VWF to ADAMTS-13 mediated proteolysis was measured pre- 
and 1 h post DDAVP infusion (T0, Ti) in the type 1 VWD patients study group (n = 
26).
Multimer profiles of cryo-precipitated VWF at T0 and pre-proteolysis
All samples gave a multimer profile essentially comparable with normal. In addition, 
all samples showed a relative increase in a band, which had the fastest 
electrophoretic mobility on the blot (Fig.6.7).
Proteolysis of cryo-precipitated VWF, T0
The VWF of only one sample, Patient 12 (Y1584C as shown above), showed a 
significantly increased susceptibility to proteolysis compared with a homozygous 
Y1584Y control. Susceptibility was equivalent to that observed for a heterozygous 
Y1584C control (Fig 6.8).
Multimer profiles of cryo-precipitated VWF at 7\ and pre-proteolysis
1. Patient samples showed the full range of multimers from LMW to HMW 
(Fig. 6.8).
2. All ^  samples showed an increase in the low and intermediate weight 
multimers, suggesting an increased overall level of proteolysis (Fig. 6.7).
Comparison of multimer profiles of cryo-precipitated VWF at T0 and 7\ and 
pre-proteolysis
1. There was a greater representation of HMW multimers in Patients 18, 21 
and 26 at Ti compared with T0. This is not unexpected in view of the 
action of DDAVP.
2. The relative enrichment noted above for the fastest migrating band at T0
was apparent, but to a lesser extent, at Ti (Fig.6.7).
Comparison of proteolysis of cryo-precipitated VWF at T0 and 7t
1. Patient 12 (Y1584C), who showed an increased susceptibility to
proteolysis at T0 (Fig.6.8A), also showed increased susceptibility to
proteolysis at Ti (Fig. 6.8B), and the magnitude was similar for both.
2. All remaining patients showed an equivalent susceptibility to proteolysis
at Tt compared with T0.
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3. The fast migrating band that appeared increased prior to proteolysis in 
both pre- and post-DDAVP samples, was no longer enriched after 
proteolysis.
In summary, for a given patient, plasma VWF showed a similar extent of proteolysis 
at T0 and T1f irrespective of the Y1584C phenotype (Fig.6.8B)
Although the Ti multimer profiles indicate that there is an increased level of 
proteolysis of VWF in the circulation at T1t the proteolysis studies show that this is 
not associated with an increased susceptibility of VWF to proteolysis.
The significance of the fast migrating band is uncertain: although this increase has 
not been observed previously on screening of normal samples, because it immuno- 
stained with polyclonal anti-VWF, it must be related to VWF. The increase in this 
band was very evident at T0, less evident at Ti and, following proteolysis of each 
sample, the band was no longer enriched, possible because it was masked by a 
product of VWF proteolysis.
Figure 6.7 Multimeric analysis of VWF pre- and post- DDAVP, before and after 
VWF proteolysis. Respective pre- and post-DDAVP samples are placed side-by- 
side. The gel shows the fast-migrating band which is increased in all samples, the 
increase in the satellite bands of each triplet post-DDAVP and the equivalent 
proteolysis of each pre- and post-DDAVP pair.
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Figure 6.8 Assessment of the extent of proteolysis of plasma VWF using 
multimer analysis
A. Plasma VWF from 3 patients (a, b, c) with type 1 VWD was cryoprecipitated 
and incubated with group 0  cryodepleted plasma as a source of ADAMTS- 
13. Comparison of the multimer profiles immediately before proteolysis (I = 
Oh) and at the end of the proteolysis incubation (I = 3h) reveals a loss of 
HMW forms and an increase in LMW forms, together with a relative increase 
in the satellite bands. Proteolysis was considerably greater in the case of 
patient ‘b\ who is heterozygous for Y1584C (Patient 12)
B. The analysis is as described for panel A, however it includes both pre- and 
post-DDAVP plasma VWF (T0 and Ti)
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6.5 DISCUSSION
In this study, the relationship between the release and clearance of VWF and its 
multimer size was examined by measuring the level and collagen binding activity of 
VWF released following stimulation by DDAVP in patients with type 1 VWD and 
haemophilia A controls. The finding of an increase in the ratio of VWF:CB to 
VWF:Ag following DDAVP infusion in the majority of subjects is consistent with an 
increase in circulating HMW multimers of VWF.(Ruggeri, et al 1982) This illustrates 
a structural difference between VWF released following DDAVP and circulating 
VWF, which may affect the clearance kinetics of VWF as discussed in Chapter 4. 
The ratio of VWF:CB to VWF:Ag was found to decrease significantly following 
DDAVP in two type 1 VWD patients from one kindred. Although this is suggestive of 
removal of HMW multimers from the circulation, the underlying mechanism is not 
clear and warrants further investigation. The ratio was also found to decrease to a 
less degree following DDAVP in four further type 1 VWD patients and three controls: 
the reason for this is not clear, although it is possible that this reflects normal 
variation.
The increased plasma clearance of VWF:Ag demonstrated in this subgroup of type 
1 VWD patients is consistent with the findings for the whole type 1 cohort previously 
investigated (Chapter 4). In this study the half-life values of VWF:CB following 
DDAVP were also shown to be significantly shorter in the type 1 VWD patients as 
compared to the controls. The observation that the half-lives of VWF:Ag and 
VWF:CB did not generally differ on an individual basis is suggestive of no 
preferential clearance of released HMW multimers. This contrasts with previously 
reported findings in similar studies of released VWF,(Casonato 2005, van Genderen 
P. J. J 1997) as well as some findings in animal studies of infused VWF.(Turecek, et 
al 1997) However, a recent animal model has shown clearance of infused VWF to 
be independent of multimer size,(Lenting, et al 2004) consistent with the findings of 
released VWF in this study.
In view of the normal multimeric pattern and apparently normal function of the 
residing circulating plasma VWF in type 1 VWD, it is not clear whether increased 
clearance of VWF arises subsequent to its increased proteolysis. Having 
demonstrated no relationship in this study between the plasma clearance of VWF 
and the size of its multimers by indirect measurement, VWF proteolysis was directly 
examined in the type 1 VWD patients. The absence of a relationship between 
ADAMTS-13 activity and the half-lives of both VWF:Ag and VWF:CB suggests that
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proteolysis by ADAMTS-13 does not directly relate to the plasma clearance of HMW 
multimers of VWF in patients with type 1 VWD. The question as to whether 
increased clearance of VWF could result from increased susceptibility to ADAMTS- 
13-mediated proteolysis has also been addressed. This does not appear to be the 
case. Prolonged in vitro incubation of purified patient VWF (containing HMW 
multimers) with ADAMTS-13 results in degradation of the VWF to its LMW multimers 
and ultimately to dimeric proteolytic fragments. Based on this principle, the 
susceptibility of VWF to proteolysis was measured in patient samples pre- and post- 
DDAVP thereby facilitating comparison between circulating and released VWF. 
Comparison of the multimer patterns before and 3 h after incubation of both pre- and 
post-DDAVP plasma with ADAMTS-13 revealed that there was no evidence of 
increased susceptibility of VWF to proteolysis in 25 out of 26 type 1 VWD patients 
studied. Only the plasma of one patient showed increased proteolysis. Thus the 
differences in VWF clearance rates of the type 1 VWD patients in this study are not 
reflected by differences in susceptibility to proteolysis by ADAMTS-13.
The one study patient who did demonstrate increased susceptibility to proteolysis 
was shown to be heterozygous for the Y1584C mutation. Although this mutation is 
known for its ability to influence susceptibility to ADAMTS-13 in vitro,(Bowen and 
Collins 2004) the relationship between Y1584C and the in vivo plasma clearance of 
VWF has not been examined previously. It is possible that the increased proteolysis 
associated with C1584 is due to the proximity of this residue to the ADAMTS-13 
cleavage site in the A2 domain of VWF. C1584 is fully solvent exposed and 
available for new inter- or intramolecular disulphide linkages that could alter the 
conformation of the A2 domain and enhance access to the cleavage site for 
ADAMTS-13.(0'Brien, et a /2003, Sutherland, eta! 2004) The VWF half-life in the 
type 1 VWD patient identified in this study as heterozygous for Y1584C was reduced 
at 4.8 h. However, the half-lives in the 25 ‘wild types’ were also reduced (median 3.8 
h) and therefore the increased clearance observed in these patients cannot be 
explained by Y1584C. Taken together with the normal plasma VWF:Ag clearance 
found in the Y1584C haemophilia A control (16 h), these results suggest that the 
plasma clearance of VWF is unlikely to be significantly affected by the presence of 
this mutation. The Y1584C mutation is further discussed in Chapter 9.
The absence of a relationship between ADAMTS-13 mediated proteolysis and VWF 
clearance supports indirect experimental data. Firstly, basal VWF levels have not 
been shown to be increased in ADAMTS-13 deficient mice when compared to 
normal mice of the same genetic background. (Motto, et al 2005) Secondly, no
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difference in VWF clearance rates has been demonstrated between wt-VWF and a 
variant containing a type 2A mutation (which increases VWF susceptibility to 
cleavage by ADAMTS-13) in a rat model.(Stoddart, et al 1996)
Having found no evidence of a relationship between VWF proteolysis and the rate of 
VWF clearance, the mechanism by which increased ADAMTS-13 proteolysis may 
affect circulating VWF levels remains unknown. In contrast to previous reports in 
normal individuals,(Mannucci, et al 2004) type 1 VWD patients of blood group O 
were not found to have higher activities of ADAMTS-13 than non-0 patients in this 
study. Recent in-vitro studies have shown a variation in the susceptibility of VWF to 
ADAMTS-13 mediated proteolysis according to blood group in the order O = B > A = 
AB.(Bowen 2003, O'Donnell, et al 2005) These observations suggest that the 
presence of ABH antigens on one or more of the glycosylation moieties that flank 
the VWF cleavage site for ADAMTS-13 may influence proteolysis and through this 
mechanism influence plasma VWF level. However this possibility remains to be 
shown. It is possible that VWF proteolysis and VWF level are not directly related 
although both may be influenced by ABO blood group.
It is also possible that rather than influencing VWF level, ADAMTS-13-mediated 
proteolysis affects the function of VWF and it is this that gives rise to symptoms of 
bleeding. It has been proposed that following proteolysis of the VWF-platelet string, 
the fragments of VWF that are released into the circulation are no longer subject to 
shear stress and the subsequent stages of clot formation at the cell surface result 
from the participation of the remaining portion of the VWF-platelet string.(Dong
2005) Increased rates of proteolysis of the VWF-platelet string could therefore result 
in defective haemostasis via a variety of mechanisms that are independent of 
circulating VWF levels. (Bowen and Collins 2006) As well as explaining some of the 
variability in bleeding phenotype between patients with similar VWF:Ag levels, this 
theory may account for the compromise in primary haemostasis observed in some 
individuals with normal standard functional assays of VWF.(Bowen and Collins
2006) It may also, at least partly account for the enrichment of blood group O in type 
1 VWD.(Gill, et al 1987)
The relationship between plasma levels of VWF-related parameters and ADAMTS- 
13 activity over a range of concentrations prior to and over 6 h following infusion of 
DDAVP was examined in this group of type 1 VWD patients. The decrease in 
ADAMTS-13 activity after infusion of DDAVP in the type 1 VWD patients is 
consistent with previously reported findings in normal subjects and type 1 VWD
112
patients.(Mannucci, et al 2004, Reiter, et al 2003) DDAVP as a direct cause of this 
reduction in ADAMTS-13 activity has been excluded by studies of both DDAVP and 
VWF-containing plasma concentrate in patients with type 3 VWD.(Mannucci, et al 
2004). Inverse correlation was shown between the decrease in ADAMTS-13 activity 
and simultaneous increase in VWF level and collagen binding activity following 
DDAVP. However, multimer analysis indicated an increase in the low and 
intermediate VWF multimers 1 h following DDAVP compared to baseline. Although 
these findings may appear to contradict the observed overall increase in the ratio of 
VWF:CB to VWF:Ag following DDAVP, it is possible that the VWF:CB reflects the 
presence of very HMW forms which are not in sufficient quantity to visualise on 
multimer analysis or which do not transfer efficiently from the multimer gel. In 
contrast to previously reported findings, no inverse correlation between absolute 
values of ADAMTS-13 and VWF:Ag or VWF:CB was found at any time point prior to 
or following DDAVP in this study. (Mannucci, et al 2004, Reiter RA 2003) Taken 
together, these findings suggest that the relationship between circulating VWF and 
ADAMTS-13 levels in patients with type 1 VWD is likely to be complex. Although 
ADAMTS-13 may localise onto UL-VWF released following DDAVP, resulting in an 
increase in proteolysis and reduction in detectable ADAMTS-13 activity, such a 
direct regulatory mechanism between ADAMTS-13 and its substrate has yet to be 
established. Further studies are warranted to elucidate both the mechanism and 
biological significance of these findings.
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Chapter 7
GLYCOSYLATION 
AND CLEARANCE OF VWF
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7.1 INTRODUCTION
VWF is a highly glycosylated and sialylated protein containing 10 sites for O-linked 
and 12 sites for N-linked glycosylation. The structures of the VWF oligosaccharide 
side chains are very diverse and although their functional role remains unclear, the 
nature and extent of glycosylation of plasma VWF may play a significant role in the 
genetic variation of VWF plasma levels and/or its clearance.
Exposed galactose (Gal) residues are required for the binding of VWF to the hepatic 
asialoglycoprotein receptor (ASGPR). Therefore, variability in exposure of Gal may 
influence plasma VWF clearance in vivo. A mutation which alters cell type-specific 
expression of the Galgt2 glycosyltransferase gene has been shown to result in 
increased clearance of VWF in a murine model giving rise to a partial quantitative 
deficiency of VWF.(Mohlke, et al 1999b) Another murine model has demonstrated 
increased clearance of endogenous VWF in the absence of the sialyltransferase 
ST3Gal-IV, (Ellies, et al 2002) and the finding of significant reduction in VWF half-life 
in rabbits following removal of sialyl-groups further supports the protective effect of 
sialylation.(Sodetz, et al 1977)
The lectin Ricinus communis agglutinin I (RCA I) has a high affinity for non-reducing 
terminal fc-linked Gal residues on VWF,(Matsui, et al 1991, Osawa and Tsuji 1987) 
and an increased RCA-I/VWF ratio, suggestive of increased Gal exposure, has been 
found in some patients with a partial quantitative deficiency of VWF.(Ellies, et al 
2002) Erythina crystagalli agglutinin (ECA) also has an affinity for exposed Gal on 
the N-linked structure N-acetyllactosamine (Gal(U1-4)GlcNAc) and O-linked 
GalNAc.(Debray, etal 1986, Iglesias, etal 1982)
The expression of A antigen on VWF released following DDAVP infusion has 
previously been shown to be increased when compared to plasma VWF.(Brown, et 
al 2002) This suggests that oligosaccharide structures may differ between pools of 
VWF, which may be relevant to the function and/or clearance of VWF.
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7.2 AIMS
The aim of this study was to investigate variability in the exposure of galactose 
residues as a possible mechanism for increased clearance of VWF resulting in a 
reduction in VWF levels. Binding of the lectins RCA-I and ECA was examined in a 
cohort of patients with type 1 VWD and the relationship with VWF levels and the 
plasma clearance of VWF released following DDAVP was investigated. To 
determine whether differences in glycosylation profiles between circulating and 
released VWF could account for the increased VWF clearance observed in some 
type 1 VWD patients, lectin binding was examined both prior to and following 
administration of DDAVP.
7.3 MATERIALS AND METHODS
Binding of the lectins RCA-I and ECA to VWF was measured using ELISA assays 
that were developed and optimised for the purposes of this study, based on a 
previously described method.(Ellies, et al 2002) VWF:Ag levels were measured in 
parallel and results were expressed as a ratio of RCA-I or ECA binding to VWF per 
unit of VWF:Ag.
Several technical difficulties were encountered during the development and work-up 
of these immunoassays: the problem of non-specific binding of the lectin to the 
coating antibody was largely eliminated by substantially reducing the concentration 
of the coating antibody and increasing the concentration of bovine serum albumin in 
the block. Although these measures were successful in the cases of RCA-I and 
ECA, the non-specific binding observed with Conconavalin A (Con A) was not 
overcome, and therefore studies using Con A were abandoned.
7.3.1 Patients and controls
A subgroup of type 1 VWD patients (n = 29) was investigated in whom VWF:Ag ti/2 
had been measured following administration of DDAVP (Chapter 4). Binding of 
RCA-I and ECA to VWF was analysed in plasma samples at T0. In addition, RCA-I 
binding to VWF was measured at Ti and T6 in the VWD study group. Reference 
ranges were derived from the plasma samples of 20 normal controls (n = 20).
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7.3.2 Measurement of Ricinus communis agglutinin-l binding to VWF. 
Principle
The assays were based on the ELISA for measurement of VWF:Ag (3.2.2), using 
polyclonal rabbit anti-human antibodies to capture VWF and biotinylated lectins as 
additional detector antibodies to bind to specific VWF oligosaccharide structures.
Chemicals, reagents, controls and equipment
Chemicals, reagents, controls and equipment were as described for the VWF:Ag 
ELISA (Chapter 3, Section 3.2.2) with the following modifications:
1. Dilution buffer: 150 mM TBS/ 0.1% Tw-20/ 3% BSA (Sigma-Aldrich, Dorset, 
UK), pH 8.0
2. Block: 3% BSA in 150 mM TBS, pH 8.0
TBS. 150mM, pH 8.0
3. Capture antibody: Biotinylated Ricinus Communis Agglutinin I (RCA-I)) 
(Vector Laboratories, Peterborough, UK)
4. HRP-conjugated streptavidin (Vector Laboratories, Peterborough, UK)
Method
Plates were coated as per VWF:Ag ELISA with the rabbit anti-human VWF antibody, 
diluted 1/6000. Following overnight incubation at 4°C the plate and washing, the 
plate was blocked with 3% (w/v) BSA/TBS, sealed and incubated on a plate shaker 
(400-500 oscillations per minute) at room temperature for 90 min before washing a 
further five times. The standard curve consisted of doubling dilutions of pooled 
normal plasma from 1/8 to 1/160. The patient plasma samples and reference 
samples were diluted 1:10 to 1:40 in 3% (w/v) BSA/TBS/0.1% (v/v) Tw-20. Each 
dilution was dispensed in triplicate, with 100 pL of sample per well. The plate was 
sealed and incubated on a plate shaker at room temperature for one hour, and then 
washed five times. RCA-I was diluted 1/5000 in 3% (w/v) BSA/TBS/0.1% (v/v) and 
100 pL aliquots were dispensed at a final concentration of 1 pg/ml (w/v) and the 
plate was incubated for a further hour at room temperature. Following further 
washing, 100 pL aliquots of HRP-conjugated streptavidin diluted 1/10000 in 3%
(w/v) BSA/TBS/0.1% (v/v) were added and the plate was incubated for 7 min. Prior 
to the end of incubation the substrate solution was prepared and the reaction was 
incubated and terminated as per the VWF:Ag ELISA method. The plate was read 
and standard curve derived as per VWF:Ag ELISA. The 1/80 dilution of the
a. NaCI
b. TRIZMA-Base
c. Distilled H2Q
11.68 g 
12.12 g 
2000 mL
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reference plasma was taken as 100%. The RCA-I binding of each dilution of the test 
samples were extrapolated from the standard curve and the mean values 
calculated.
Coefficient of variation
Intra-plate: The repeatability was determined by assaying three concentrations of 
three control samples on six replicates in one assay run. CVs were 7.4, 8.1 and 
8.8% respectively.
Inter-plate: The reproducibility was determined by testing three control samples at 
three dilutions on six replicates over 3 days: CV was consistently found to be less 
than 10% (8.3, 6.1 and 3.9% respectively).
Negative controls
The specificity for RCA-I was assessed with plasma from a type 3 VWD patient 
(FVIII:C 2 IU dL'1; VWF:Ag < 1 III dL'1) diluted ten fold less than normal plasma at 
serial dilutions (1/1, 1/2, and 1/4 ). For all dilutions, the response was never above 
that of buffer. This demonstrates an absence of non-specific binding, although the 
negative findings could result from the absence of VWF and/or FVIII. To investigate 
this further, RCA-I binding was measured in plasma from a patient with severe 
haemophilia A (FVIII:C < 1 IU dL'1, FVIILAg < 1 IU dL'1, VWF:Ag 105 IU dL'1): the 
RCA-I to VWF:Ag ratio was 1.03, indicating normal binding of RCA in the absence of 
FVIII. This was confirmed by demonstrating no significant alteration in RCA-I binding 
(P < 0.01) in three control samples following the elution of FVIII using CaCI2.
7.3.3 Measurement of Erythina crystagalli agglutinin binding to VWF. 
Principle, chemicals, reagents, controls and equipment.
As described for the measurement of RCA-I binding to VWF (7.3.2), substituting 
biotinylated Erythina Critically Agglutinin I (ECA) (Vector Laboratories,
Peterborough, UK) in place of RCA-I.
Method
As described for the measurement of RCA-I binding to VWF with the following 
amendments
1. ECA was diluted 1/500 in 3% (w/v) BSA/TBS/0.1% (v/v) and 100 pL aliquots 
were dispensed at a final concentration of 10 pg/ml and the plate was 
incubated for 75 min.
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2. HRP-conjugated streptavidin was diluted 1/2000 in 3% (w/v) BSA/TBS/0.1% 
(v/v) and following the addition of 100 pL into each well, the plate was 
incubated for 10 min.
Coefficient of variation (CV)
Intra-plate: The repeatability was determined by assaying three concentrations of 
three control samples on six replicates in one assay run. CVs were 6.7, 7.4 and 
7.8% respectively.
Inter-plate: The reproducibility was determined by testing three control samples at 
three dilutions on six replicates over 3 days: CV was consistently less than 10%.
Negative controls
As for RCA-I, the specificity for ECA-I was assessed with plasma from patients with 
type 3 VWD and severe haemophilia A. There was no binding to plasma from a type 
3 VWD control (above) and ECA binding to the FVIII-deficient plasma (above) and 
plasma eluted of FVIII in three controls (above) was normal.
7.3.4 Data and statistical analysis
Analyses of data were performed using GraphPad Prism (GraphPad Prism version 
4.0, GraphPad Software, San Diego, USA).Data was analysed using Spearman’s 
rank correlation and the Mann-Whitney-Wilcoxon and Kruskal-Wallis tests and 
paired t-test. Data are presented as median values with range.
7.4 RESULTS
7.4.1 Binding of Ricinus communis agglutinin-l to VWF
RCA-I binding to VWF was measured in 29 patients with type 1 VWD at T0
(Appendix 3) and 20 normal controls at basleine (Appendix 4). The median ratio of 
RCA-I binding to VWF per unit of VWF:Ag in the type 1 VWD patients was 1.25 at T0 
compared to 1.0 at baseline in the normal controls (Fig 7.1, Table 7.1). This 
represents a significant increase in RCA-I binding to VWF in the type 1 VWD 
patients (P < 0.01). Inverse correlation was found between the VWF binding of 
RCA-I and VWF:Ag level in the combined study and control groups (r = -0.43, P < 
0.005, n = 49, Fig.7.2). Correlation between RCA-I binding and baseline VWF:Ag 
was significant in the controls alone (r = -0.45, P < 0.05 , n = 20), but not in the VWD 
patients (r = -0.18, P = 0.4, n = 29 )
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7.4.2 Binding of Ricinus communis agglutinin-l to VWF released following 
DDAVP
RCA-I binding to VWF at was measured at Ti and T6 in the type 1 VWD patients. 
There was no significant difference found between RCA-I binding to VWF at Ti 
(median 1.19, P= 0.7, Fig. 7.3) and T6 (median 1.16, P -  0.6) when compared to T0 
(median 1.25) in the VWD patients (n = 29).
7.4.3 Binding of Erythina Cristagalli Agglutinin to VWF
ECA binding was measured in the same study and control groups. The ratio of ECA
binding to VWF per unit of VWF:Ag was significantly higher in the type 1 VWD 
patients at T0 (median 1.38, P < 0.01, n = 29) than controls at baseline (1.0, n = 20, 
Fig.7.4, Table 7.1). Inverse correlation was found between ECA binding to VWF and 
VWF.Ag level in the combined study and control groups (r = -0.53, P < 0.001, n =
49, Fig.7.5). This correlation was also found to be significant in the controls alone (r 
= -0.66, P < 0.005, n = 20), but not in the VWD patients (r = -0.16, P -  0.38, n =
29).
Table 7.1. Binding of the lectins RCA-I and ECA to VWF in type 1 VWD patients 
and normal controls.
Data is presented as median with range (#) and 95% confidence intervals (C.l.) 
where stated.
* P < 0.01; NT not tested
VWF:Ag
(IUdL*1)
VWF:Agt,„
(h) RCA-I binding to VWF ECA binding to VWF
Type 1 
VWD 
(n = 29)
46
(11-84*)
4.1
(1.9-9.6*)
1.25*
(0.78 -  2.05#)
95% C.l. 1.11-1.29
1.38*
(0.75 -  2.50*)
95% C.l. 1.34-1.67
Normal 
controls 
(n = 20)
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(66-194*) NT
1.0
(0.59-1 .4 #)
95% C.l. 0.92 -1.09
1.0
(0.49-1.87*)
95% C.l. 0.88-1.28
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Figure 7.1. Binding of Ricinus communis agglutinin I to VWF in type 1 VWD 
patients and control subjects. RCA-I binding to VWF in type 1 VWD patients was 
increased (median 1.25, P < 0.01, n = 29) compared to the controls (median 1.0).
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Figure 7.2. Relationship between binding of Ricinus communis agglutinin I to 
VWF in type 1 VWD patients (+,n = 29) and control subjects ( A » n = 20) and 
circulating VWF:Ag levels. Inverse correlation was found between RCA-I binding 
to VWF and baseline VWF:Ag in the combined study and control groups (r = -0.43, 
P < 0.005, n = 49) Correlation between RCA-I binding and baseline VWF:Ag was 
significant in the controls alone (r = -0.45, P < 0.05 , n = 20), but not in the VWD 
patients (r = -0.18, P = 0.4, n = 29).
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Figure 7.3. RCA-I binding to VWF prior to and 1 h and 6 h following DDAVP in 
type 1 VWD patients (n = 29). Plasma samples were analysed prior to (T0) and 1 h 
and 6 h following DDAVP infusion (T1f T6). Statistical analysis showed there to be no 
significant difference in the median ratio of RCA-I/VWF to VWF:Ag between 
circulating VWF (median 1.25, P = 0.8, n = 29) and released VWF at Ti (1.13) and 
T6 (1.19).
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Figure 7.4. Binding of Erythina crystagalli agglutinin to VWF in type 1 VWD 
patients and control subjects. ECA binding to VWF in type 1 VWD patients was 
increased (median 1.38, P < 0.01, n = 29) compared to the controls are shown 
(median 1.0).
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Figure 7.5. Relationship between binding of Erythina crystagalli agglutinin to 
VWF in type 1 VWD patients ( ^ ,n  = 29) and normal subjects ,n = 20) and 
circulating plasma VWF:Ag levels. Inverse correlation was found between ECA 
binding to VWF and baseline VWF:Ag in the combined study and controls groups (r 
= -0.52, P< 0.001, n = 49).Correlation between ECA binding and baseline VWF:Ag 
was significant in the controls alone (r = -0.64, P < 0.005 , n = 20), but not in the 
VWD patients (r = -0.16, P = 0.38, n = 29)
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7.4.4 RCA-I and ECA binding and clearance of VWF
There was no correlation between either RCA-I or ECA binding and VWF:Ag ti/2 in 
the type 1 VWD patients (r = 0.19, P = 0.3; r = -0.10, P = 0.6, n = 29, Fig.7.6).
To avoid the possibility of a masking effect when analysed as a group, VWF:Ag ti/2 
values were analysed according to RCA-I binding with increased binding defined as 
a ratio of RCA-IA/WF to VWF:Ag > 1.10. The median VWF:Ag ti/2 value was found 
to be longer in patients where binding was within the normal range (4.8 h, range 2.3 
-  8.7, n = 18, Fig.7.7) compared to patients with increased binding (3.5 h, 0.9 -  9.6, 
n = 11). However, this difference was not shown to be significant, P = 0.06.
7.4.5 Relationship between binding of RCA-I and ECA to VWF
Direct correlation was found between RCA-I and ECA binding in the study and 
control groups, (r = 0.4, P<  0.01, n = 49, data not shown).
123
Figure 7.6. Relationship between RCA-I (A) and ECA (B) binding to VWF and 
half-life of VWF in type 1 VWD patients. No correlation was demonstrated 
between RCA-I or ECA binding to VWF with VWF:Ag ti/2 (r = 0.19, P -  0.3; r = -0.10, 
P = 0.6, n = 29 respectively).
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Figure 7.7. Half-life values of VWF:Ag according to binding of RCA-I to VWF in 
patients with type 1 VWD. Increased RCA-I binding was defined as a ratio of RCA- 
IA/WF to VWF.Ag >1.10. Median VWF:Ag 11/2 in patients with increased binding is 
shown as 4.8 h (n = 18) compared to 3.5 h (n = 11) in the patients in whom RCA-I 
binding was not increased. No significant difference was demonstrated between the 
groups, P = 0.06.
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7.4.6 RCA-I and ECA binding and ABO blood group
No difference in RCA-I or ECA binding to VWF was found between subjects 
according to ABO blood group (P > 0.2, n = 50, data not shown).
7.5 DISCUSSION
The word lectin is derived from the Latin, legere, meaning to pick up or choose and 
was first used in the 1940s following the discovery that certain agglutinins were 
capable of ‘selecting’ types of cells based on their blood group activities. The term is 
now used in a broader sense to describe carbohydrate-binding and cell- 
agglutinating proteins of non-immune origin. Lectins are ubiquitous, being found in 
plants, viruses, animals and microorganisms, but in spite of this, their function in 
nature is not clear. Lectins often demonstrate a preference for oligosaccharides, 
which they bind with 2 -3 fold greater affinity than monosaccharides.(Sharon 1989) 
The oligosaccharide-binding specificities of various lectins have been determined 
using structurally defined glycoconjugates. Therefore lectins are useful tools for the
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fractionation and identification of carbohydrate structure of glycoproteins and have 
been utilised in the determination of oligosaccharide structures of VWF.(Matsui, et al 
1991, Osawa and Tsuji 1987)
RCA -I is one of two galactose (Gal) binding lectins isolated from Ricinus communis 
(castor bean) seeds and has a high affinity for non-reducing terminal ft Gal 
residues.(Osawa and Tsuji 1987) Erythina crystagalli agglutinin (ECA) is also a 
legume lectin and has been shown to bind strongly to exposed Gal within N- 
acetyllactosamine (Gal(ft1-4)GlcNAc) residues (Debray, etal 1986, Iglesias, etal 
1982) Therefore the predominant affinities of RCA-I and ECA towards VWF involve 
N-linked glycan structures (Chapter 1, Fig.1.5A): In addition, both lectins bind 
weakly to O-linked GalNAc,(Iglesias, et al 1982, Matsui, et al 1991) and RCA-I has 
also been shown to bind to O-linked exposed Gal residues (Fig. 1.5B).
In this study, the relationship between the clearance of released VWF and exposure 
of Gal residues on VWF has been investigated by developing immunoassays to 
detect RCA-I and ECA-I binding to VWF. The increased binding of RCA-I to VWF 
found in type 1 VWD patients, consistent with previously reported findings,(Ellies, et 
al 2002) was shown to relate to lowered circulating plasma concentration of 
VWF:Ag. Similar findings were obtained for ECA binding. The correlation between 
the binding of both lectins and VWF:Ag levels was weaker in the type 1 VWD 
patients than the controls, a finding that may reflect insufficient sample size or the 
heterogeneity of the pathogenesis of reduced VWF levels in the VWD group.
Increased binding of RCA-I and ECA to VWF were not shown to relate to increased 
VWF clearance of regulated released VWF in type 1 VWD patients. It is possible 
that increased Gal exposure results in reduced VWF levels via an alternative 
mechanism, or may indeed represent normal variability. The absence of a 
relationship between VWF clearance and exposed Gal may reflect the primary 
importance of clearance, by mechanisms unrelated to exposed Gal, for determining 
the steady-state distribution of glycosylation in VWF. Further analysis of the VWD 
group showed VWF half-life to differ between patients according to whether or not 
RCA-I binding was increased. Although this was not shown to be statistically 
significant, the increased RCA-I binding observed in patients with longer half-lives 
suggests there may be a direct relationship between RCA-I binding and VWF half- 
life. A possible explanation for this is the increased likelihood of desialylation the 
longer VWF resides in the circulation. If this were the case, a greater reduction in 
RCA-I binding between samples pre and 1 h post DDAVP may be expected in
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patients with longer VWF half-lives: this was not observed in this study (data not 
shown). Increased binding of peanut agglutinin, a lectin highly specific for the O- 
glycan structure Gal(pi-3)GalNAc, has recently been reported as relating to low 
VWF levels and enhanced VWF clearance.(van Schooten, et al 2007) As the 
detection of O-linked glycosylation in these patients required prior desialylation of 
VWF, these findings also suggest that the resultant increased VWF clearance was 
independent of exposed Gal residues.
As discussed in Chapter 4, structural differences in VWF released following DDAVP 
and plasma VWF may result in differences in the clearance kinetics between plasma 
and newly released VWF. Indeed the expression of A antigen on VWF released 
following DDAVP infusion has previously been shown to be increased when 
compared to plasma VWF.(Brown, et al 2002) This is suggestive of rapid VWF 
glycosylation in response to DDAVP and that VWF derived from endothelial cell 
storage pools may contain different oligosaccharide side chain structures than 
circulating VWF. However, no significant difference between RCA-I binding to 
circulating VWF and VWF released following DDAVP infusion was demonstrated in 
this study. This suggests that the increased clearance of VWF demonstrated within 
this cohort of type 1 VWD patients does not reflect VWF released following DDAVP 
as having a different Gal exposure from circulating VWF in the steady-state. The 
absence of variation of RCA-I and ECA binding toVWF observed between ABO 
blood groups is unexpected given the known variation in the terminal sugar 
structures of the ABH antigens. Inadequacies in the sample size could account for 
this finding.
Further analysis of the VWF oligosaccharide structures in individuals with type 1 
VWD is warranted. Although lectins may be useful to detect variability in the 
glycosylation profile, definitive analysis of the carbohydrate composition of VWF by 
mass spectrometry and other methods is more likely to elucidate any effect of 
glycosylation on VWF clearance.
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Chapter 8
MOLECULAR ANALYSIS OF VWF GENE
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8.1 INTRODUCTION
At the outset of this study, it had been proposed that a partial quantitative deficiency 
of VWF may represent a complex genetic trait.(Sadler 2002) While many molecular 
defects in the VWF gene (VWF) had been identified in cases of types 2 and 3 
VWD,(Baronciani, e ta l2000, Fressinaud, eta!2002, Mohlke, etal 1999a) molecular 
analysis of VWF in individuals with type 1 VWD had identified the causative 
mutation in only a minority of patients.(Mohlke, et al 1999a) Furthermore, non­
linkage between VWF and the type 1 phenotype had been described in some 
families.(Casana, etal 2001, Castaman, etal 1999) Fourteen VWF mutations 
reported to be associated with type 1 VWD were included on the ISTH VWF 
mutation database (http://www.vwf.aroup.shef.ac.uk/index.htmh at the time of this 
study. Of these, thirteen had been demonstrated in exons 28 (10) and 26 (3) with 
the remaining mutation in exon 19. Three large studies were underway to examine 
the molecular basis of type 1 VWD in relation to clinical phenotype.
It had been proposed that the A1-A3 and D’-D3 domains of VWF may contain 
receptor-recognition sites affecting in vivo VWF plasma clearance.(Lenting, et al 
2004) Several dominant VWD mutations within D’-D3 domain have subsequently 
been shown to result in or in associated with increased VWF 
clearance,(Haberichter, et al 2006a, Lenting, et al 2004, Schooten, et al 2005). 
These include the Vicenza variant, resulting from the mutation R1205H, and 
classified as VWD subtype 2M at the time of this study.(Sadler 1994) It is therefore 
possible that missense mutations in VWF may underlie the decreased half-lives 
observed in some of the type 1 VWD patients in this study.
VWF is bound, through specific regions within its A1 and A3 domains, to the 
different types of collagen that constitute the main component of extracellular 
matrices. VWF has been shown to bind to the fibrillar collagens types I and III via 
the A3 domain,(Cruz, et al 1995, Lankhof, et al 1996) and the non-fibrillar collagen 
type VI via the A1 domain.(Hoylaerts, et al 1997) Several mutations in the A3 
domain have been reported that result in defective binding of VWF to collagen in the 
presence of normal multimers.(Ribba, etal 2001, Schneppenheim 2001)
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8.2 AIMS
The overall aim of this study was to identify VWF mutations associated with 
increased VWF clearance or that may otherwise contribute towards the type 1 
phenotype in a cohort of patients in whom plasma clearance of VWF following 
DDAVP administration had been measured. In addition, patients who had been 
excluded from the type 1 VWD study cohort following the finding of discordant ratios 
of VWF:CB to VWF:Ag were further investigated.
8.3 MATERIALS AND METHODS
8.3.1 Patients
Genotypic analysis was performed in 28 of the type 1 VWD patients (25 kindred) in 
whom clearance of VWF released following DDAVP had been examined (Chapter 4, 
Appendix 3). Four of the type 1 VWD patients had steady-state VWF:Ag levels 
reduced to < 20 IUdL'1 The three patients excluded from the study following the 
finding of discordantly low VWF:CB activities (Patients 3, 20 and 42, Appendix 2) 
and their families were also investigated. Within the type 1 VWD group, two patients 
displayed low levels of FVIIkC (Patients 5 and 25). These patients and their families 
were further investigated.
8.3.2 Phenotypic analysis
FVIIkC, VWF.Ag, VWF:RCo, VWF:CB, VWFpp assays and analysis of VWF 
multimers were performed as described in Chapters 3, 5 and 6. Determination of 
VWF:Ag ti/2 values is described in Chapter 3.
8.3.3 Genotypic analysis
Regions of the VWF gene, encoding domains A1, A2, A3 and D’-D3 of the VWF 
protein were sequenced.
Amplification of Exons
Genomic DNA was extracted from peripheral blood lymphocytes using a standard 
phenol/chloroform method as described in Chapter 3, Section 3.4. The relevant 
exons (18-20,  24, 26 -  33) of VWF and flanking intronic regions were amplified as 
described in Chapter 3, Section 3.4.3 using the following gene specific primers and 
PCR conditions shown in Table 8.1. Amplicons were visualised on a 1.5% agarose 
gel with 0.1% Ethidium bromide as previously described.
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Primers
Exon 18:
Forward primer (F) 5’GTCCCCCTGAGTGGGCAACT3’ 
Reverse primer (R) 5’AACTGAAGGGCAGGCACCAG3’
Exon 19:
F 5’AGGAGGGCTTTAGATCAGTCACT3’
R 5’GTGCGGAAGGTCCTGTGG3’
Exon 20:
F 5TGTTCCTTCATTGCCTCCAT3’
R 5TAGGAGGGGTGGGAGCTGTG3’
Exon 24:
F 5’GGGGGTTGTGGGTGGTATGA3’
R 5’AAAAAGCCGAAGTGGTGTCT3’
Exon 26:
F 5’CAACATTATCTCCAGATGGC3’
R 5’GT CCTAT CT CT GACCTGCAA3’
Exon 27:
F 5’GTTAAAAATGAGGCTTCCTC3’
R 5’TTTACCCAAAACCTAGT CT CTA3’
Exon 28:
28A
F 5’CAGAAGTGTCCACAGGTTCT3’
R 5’T GT CCG AT CCTT CC AGG ACCT3’
28B (as described in Chapter 3, Section 3.4.3)
F 5’T GGTT CT GG AT GT GGCGTT C3’
R 5’TCTTGGCAGATGCATGTAGC3’
Exon 29:
F 5’GTAGGCCTGGTGGCCATTGT3’
Exon 30:
R 5’AGGAGCAAAGTGACTGCTCCG3’
Exon 31:
F S’ATCCACCGTTAAGACGGGGTGTCGS’
R 5’GGCTGGGGTTACTTTTGGATGTTGT3’
Exon 32:
F 5’T GAACAT CTT CCT CATAGGGCT G A3’
R 5’CCATGAACAGAAACTTAAAG3’
Exon 33:
F 5’CCT CAGCCT CAT GT CCCTAT3’
R 5’CCCCAAACACATTCTTAACC3’
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Table 8.1. Conditions for PCR amplification of VWF exons. Method is described 
in Chapter 3, Section 3.4.3. dNTPs and MgCI2 were used for ail exons except exon 
20 (in which KCI was used*), at respective concentrations of 1.25 mM and 50 mM. 
Temperatures for amplification (amp), replication (rep) and annealing (ann) are 
given. 40 cycles were performed for each exon.
Exon 18 19 20 24 26 27 28A 28B 29 30 31 32 33
n h 4
buffer (pi)
5 5 5 5 5 5 5 5 5 5 5 5
dNTPs
(pl)
5 5 5 5 5 5 5 5 5 5 5 5 5
MgCI2(pl) 1.5 1 5* 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
Amp (°C) 94 94 94 94 94 94 94 94 94 94 94 94 94
Rep (°C) 57 60 60 60 51 53 59 58 60 60 61 54 57
Ann (°C) 72 72 72 72 72 72 72 72 72 72 72 72 72
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Sequence analysis of VWF
Prior to sequence analysis, the products obtained from PCR amplification of the 
exons of VWF listed above were purified using a commercial kit (QIAquick PCR 
Purification kit, Qiagen Ltd., West Sussex, UK). This process removes excess 
oligonucleotide primers and remaining deoxyribonucleotide triphosphates and salts 
that were used in the PCR. Both the forward and reverse strands were directly 
sequenced by automated sequencing technology using a fluorescent detection 
system (Applied Biosystems 3100 Avant Sequencer). The cycle sequencing 
reactions were carried out using the recommended protocol. Each sequencing 
reaction consisted of 1 pL of Big Dye Terminators v1.1© (on ice), I pL of template 
DNA, 3.2 pmol of sequencing primer, 3.5 pL of Terminator Reaction Buffer©, and
13.5 pL of dH20  for a final reaction volume of 20 pL. This was then placed in a 
thermocycler (GeneAmp PCR system) on the following program:
25 Cycles
1:00 0:10
4:0'
0:05
END
Sequencing reactions were carried out in 96 well microtitre plates. Following 
amplification the products were purified using the following protocol: 50 pL of 95% 
ethanol and 2 pL of sodium acetate were added to each sample, mixed and left to 
stand for 15 min. The plate was then spun in a refrigerated centrifuge at 1650 rpm at 
4°C for 45 min. The supernatant was removed by inverting the plate, placing it on a 
layer of tissues and spun up to 185 rpm. 70 pL of 70% ethanol was then added to 
each sample, and the plate was again centifuged at 1650 rpm at 4°C for 15 minutes. 
The supernatant was removed as previously described and spun for 1 min. Finally, 
20 pL HiDi Formamide(C) was added to the samples to resuspend the DNA. 
Automated capillary sequencing was then performed (ABI 3100 Avant Genetic 
Analyser)
8.3.4 Investigation of FVIII binding
Microtitre plates (Dynatech, Immulon 4) were coated with 100 pL of 1:200 dilution of 
monoclonal antibody (Monoclonal anti VWF Ab lot RFF-VIII:R1) raised against the 
Gplba binding site of VWF. After leaving at 4°C overnight, the plates were washed
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five times with TBS, pH 8.0 (Chapter 7, Section 7.3.1). Serial dilutions of the 
standards (1:100 -  1:800) and the patients were performed by doubling dilutions 
and 100 pL dispensed into the wells. Following incubation at 4°C for 48 h, the plate 
was washed five times in TBS . Endogenous FVIII was removed by incubating with 
100 pL of 350 mM CaCI2 in TBS for 1 h at room temperature. The plate was washed 
3 times and further incubated with 100 pL 350 mM CaCI2 for 1 h.
1 U/mL recombinant FVIII (Helixate, Baxter, UK) was mixed with re-incubation buffer 
(50 mM Tris, 100 mM NaCI pH 8.0, 2% BSA, 1 mL of 1M CaCI2, 0.002% Tween) 
and added to the wells. This was incubated for a further 2 h at 37 °C. The plate was 
then washed a further three times. FVIII binding was then measured by 
chromogenic assay using the Coatest VIII:C/4 Chromogenic kit (Quadratech, UK). 
Optical densities were read at 405 nm using the Dynex MRX (Dynex Technologies, 
UK) microtitre plate reader.
Molecular analysis of VWF for type 2N mutations was performed by sequencing of 
exons 18, 19, 20, 24 and 26, as described in Section 8.3.2
8.4 RESULTS
All DNA base changes are heterozygous unless otherwise stated.
Analysis of regions of VWF encoding the A1-A3 and D’D3 domains of VWF 
identified a total of nine mutations in eight of the 28 type 1 VWD patients 
investigated (n = 8, Appendix 3). These mutations are discussed below and 
phenotypic and genotypic data are summarised in Table 8.2. Of the four patients 
with baseline VWF:Ag levels < 20 IUdL'1, mutations were identified in three (Patients 
7, 14, 34, Appendix 3).
8.4.1 Sequencing of exons 18 -  20
2303 A>G (R768Q)
2303 A>G (R768Q) was identified in exon 18 encoding the D’ domain in one patient 
(Patient 6), a 48 year old female who had presented with a postpartum 
haemorrhage. Other family members including her three offspring were 
subsequently shown to be affected.
2771 G>A (R924Q)
2771 G>A (R924Q) was identified in exon 21 of Patients 10 and 25 (kindred 10) and 
2561 G>A (R854Q) was identified in Patient 25. Both of these mutations are within 
the VWF-D’D3 domain. Kindred 10 is discussed in detail in Section 8.4.5.
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Table 8.2. Mutations identified by sequence analysis of exons 1 8 - 2 0  and 26 -  33 in 28 individuals with type 1 VWD.
Previously unreported mutations denoted by #;
Bleeding times performed at the time of diagnosis are shown.
NT: not tested
* range derived from 20 normal controls (Chapter 5)
Kindred Patient ABO
Blood
Group
Bleeding
Time
(min)
FVIII:C
(IUdL1)
VWF:Ag
(IUdL1)
VWF:RCo
(IUdL1)
VWF:CB
(IUdL1)
VWFpp/
VWF:Ag
ratio
VWFiAg
tl/2
(h)
Exon Mutation(s) Amino acid 
Substitution
<8 50-150 50-150 50-150 50-150 0.07 -  0.3*
5 5 O NT 18 25 26 26 0.15 1.9 27 3613A>C* R1205S
6 6 A 18 34 42 38 44 0.06 3.5 18 2303A>G* R768Q
10 25 A 7 13 30 23 34 0.13 5.6 2120
2771 G>A 
2561 G>A
R924Q
R854Q
10 10 A NT 66 27 23 50 0.10 3.2 21 2771 G>A R924Q
11 12 A 8 62 34 30 48 0.13 4.8 28 4751A>G Y1584C
12 14 O 25 20 13 17 10 0.45 3.3 27 3613C>T* R1205C
28 31 O NT 27 18 16 12 0.55 3.5 28 4247A>T* I1416N
40 43 A >20 22 14 11 9 0.49 3 28 4247A>T* I1416N
8.4.2 Sequencing of exons 26 and 27
Sequencing of exon 27 identified two nucleotide substitutions at 3613 resulting in 
arginine substitutions at 1206 in the VWF-D3 domain: 3613 C>T (R1205C) in 
Patient 14 and 3613 A>C (R1205S) in Patient 5. Neither mutation has been reported 
previously. VWF:Ag and VWF:CB levels prior to and over 6 h following DDAVP 
infusion are shown in Fig. 8.1. Respective VWF:Ag t1/2 values of 3.3 h and 1.9 h 
were calculated and the VWFppA/WF:Ag ratio was increased in Patient 14. 
3613C>T(R1205C)
Patient 14, a 41 year old male, presented aged 17 years with prolonged bleeding 
following dental treatment. He had a lifelong clinical history of bleeding symptoms.
He had no siblings and no other family members were known to have a bleeding 
disorder. VWF multimeric pattern was normal.
3613 A>C (R1205S)
The clinical history and results for Patient 5 and kindred are given in Section 8.4.5.
8.4.3 Sequencing of exon 28 
4247 T>A (I1416N)
At the time of the study, 4247 T>A (I1416N), identified in the VWF-A1 domain in 
Patients 31 and 43, had not been reported as a causative mutation in VWD. Patients 
31 and 43 were both male, aged 48 and 54 years respectively, with a moderate to 
severe clinical phenotype and dominant family history. I1416N was also identified in 
a type 2M VWD kindred investigated in Chapter 9: VWF levels and functional 
parameters pre- and post DDAVP for I1416N patients (n = 4) are shown in Table 
9.6. Patients demonstrated a functionally restricted release of VWF, with a 
predominant platelet-binding defect. VWF multimeric analysis was normal pre- and 
post DDAVP (data not shown). Both the ratio of VWFpp to VWF:Ag and clearance of 
VWF:Ag was increased in I1416N patients (Table 9.6), with concordance 
demonstrated between the half-lives of VWF:Ag and VWF:CB (Appendix 3). A 
detailed discussion of I1416N is presented in Chapter 9.
4751 A>G (Y1584C)
The VWF-A2 domain mutation 4751 A>G (Y1584C) was identified in Patient 12, 
confirming the findings by PCR restriction analysis reported in Chapter 6. Patient 12 
is a 52 year old female who presented with excessive bleeding following 
thyroidectomy 10 years previously. There was no significant family history of 
bleeding although her mother was also found to have reduced VWF levels. A 
detailed discussion of 4751 A>G (Y1584C) mutation is presented in Chapter 9.
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8.4.4 Sequencing of exons 29 -  33
No mutations were identified in exons 29, 30, 31, 32 or 33 encoding the VWF-A3 
domain.
Figure 8.1. VWF:Ag level and VWF:CB activity prior to and over 6 h following 
DDAVP in Patients 5 and 14 in whom A>C and C>T nucleotide substitutions at 
3613 were identified, resulting in R1205S and R1205C respectively. In addition, 
pre- and 1 h post VWF:RCo activities are shown for Patient 5.
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8.4.5 Investigation of patients with low VWF.CB activity: Patients 3, 40 and 42
Patients 3, 20 and 42 were excluded from the type 1 VWD study cohort due to the 
finding of discordantly low VWF:CB activities (Appendix 2). This section reports the 
results of further investigation of these patients and their families.
Patient 3
Patient 3 (11:1) is a male from a kindred with a dominant family history of VWD with a 
severe bleeding phenotype (Fig. 8.2). Many of the affected family members, 
including his mother (1:1) and more distant relatives are under the care of the Arthur 
Bloom Haemophilia Centre in Cardiff. Phenotypic data for Patient 3, his sibling (ll:2) 
and mother (1:1) are detailed in Table 8.3. Multimeric analysis was normal on 1.4% 
gel on plasma samples pre- and post DDAVP in Patient 3 (data not shown).
VWF:Ag and VWF:CB values pre- and over 6 h post DDAVP are shown in Fig. 8.3. 
Despite initial rises in both VWF:Ag and VWF:CB, the rate of clearance was 
markedly increased with calculated half-lives of 0.92 h and 1.20 h respectively. 
VWF:RCo activity increased to 25 IUdL*11 h following DDAVP. The molar 
concentration of VWFpp pre-DDAVP was 3.8 nM (NR 4.5 -  17.8) and the molar ratio 
of VWFpp to VWF:Ag was 1.5 (NR 0.07 -  0.3). Sequence analysis of VWF in 
Patient 3 demonstrated 3614 G>A in exon 27, encoding R1205H in the VWF-D3 
domain. Molecular analysis of the VWF gene was also performed in another 
affected branch of this family as part of the UKHCDO type 1 VWD molecular 
genetics study (Cumming, et al 2006): R1205H was confirmed in the maternal 
grandmother’s cousin and shown to segregate with disease phenotype in this 
branch of the family.
Figure 8.2. Family tree of Patient 3 (11:1)
ll:2
111:1 lll:2 lll:3
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Table 8.3. Phenotypic data for Patient 3 and affected family members.
Multimeric analysis was normal on repeated testing of all family members
Subject
FVIII:C
(IUdL1)
50-150
VWF:Ag
(IUdL1)
50-150
VWF:RCo
(IUdL1)
50-150
VWF:CB 
(IUdL1) 
50 -175
Patient 3 
(11:1)
7 4 <10 1
ll:2 30 17 <10 19
1:1 18 10 <10 15
Figure 8.3. VWF:Ag and VWF:CB values prior to and over 6 h following DDAVP 
in Patient 3. Half-life values of VWF:Ag and VWF:CB were calculated at 0.92 h and
1.2 h respectively.
VWF.Ag (IUdL-1) 
VWF:CB (IUdL-1)
Time (hours)
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Patient 20
Patient 20 (11:1, Fig. 8.4) is a male who was diagnosed with VWD at the age of 39 
years following investigation of his seven year old daughter for symptoms of easy 
bruising (proband 111:1). Other than mild bruising symptoms in Patient 20, there was 
no significant clinical history of bleeding in any other family members including 
following tonsilloadenoidectomy and circumcision. The remainder of the 
investigations performed at diagnosis in the proband (111:1), her two siblings (lll:2 
and lll:3) and father (Patient 20,11:1) are shown in Table 8.4. On the basis of the 
clinical and laboratory phenotype, including the finding of normal multimeric pattern, 
type 1 VWD was diagnosed in all the family members investigated
Figure 8.4. Family tree of Patient 20
□ — f— O
ihj-o o
11:1 ll:3 ll:2
i l l
111:1 lll:2 lll:3
Results of 6 h DDAVP study are shown in Fig. 8.5. Calculated half-lives of VWF:Ag 
and VWF:CB were 5.3 h and 5.1 h respectively. Although steady-state VWF:Ag level 
and VWF:RCo activity were within normal limits, VWF:CB was reduced with a 
VWF:CBA/WF:Ag ratio of 0.58, despite normal multimeric analysis (Table 8.5) 
Neither VWF:RCo nor VWF:CB activities had been measured at the time of 
diagnosis in any of the offspring of Patient 20, who were subsequently further 
investigated (Table 8.5). The VWF:Ag level and VWF:RCo activity were both found 
to be within normal limits in all family members except the proband (111:1). However, 
there was significant anxiety relating to venepuncture in subjects lll:2 and lll:3.
Unlike Patient 20, a discordant reduction in VWF:CB activity was not demonstrated 
in any of his offspring, including the proband. Targeted sequence analysis of VWF, 
as described in Section 8.3, identified 5191T>A in exon 30 encoding the VWF-A3 
domain mutation S1731T in Patient 20 and his three offspring.
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Table 8.4. Investigations performed at time of diagnosis in Patient 20 and 
offspring (1997). Multimeric analysis was normal in all subjects.
‘ Functional activity of VWF was measured using an in-house ELISA using 
monoclonal antibodies.(Murdock, et al 1997). Results are shown for tests performed 
on two separate occasions in subjects 11:1 and 111:1; in subjects lll:2 and lll:3, blood 
tests were performed on one occasion only.
Subject Age
FVIII:C 
(IUdL*1) 
50 -150
VWF:Ag 
(IUdL*1) 
50 -150
VWF: Ac* 
(IUdL*1) 
50 -150
VWF: Ac/ 
VWF:Ag
11:1
(Patient 20) 39 years 70, 90 46, 54 46, 51 1, 0.9
111:1 7 years 46, 87 77, 52 84, 47 1.6, 0.9
lll:2 5 years 98 72 39 0.5
III :3 12 months 58 54 33 0.6
Table 8.5. Investigations performed in 2005 in Patient 20 and offspring.
Multimeric analysis was normal in all subjects.
Subject Age
(years)
FVIII:C
(IUdL*1)
50-150
VWF:
Ag
(IUdL*1)
50-150
VWF:
RCo
(IUdL*1)
50-150
VWF:
CB
(IUdL*1)
50-175
VWF:CB/
VWF:Ag
ratio
Mutation
Analysis
11:1
(Patient 20) 44 72 59 56 34 0.58
5191 T>A 
(S1731T)
111:1 14 63 43 44 40 0.93 5191 T>A (S1731T)
lll:2 12 70 85 68 63 0.74 5191 T>A (S1731T)
lll:3 8 90 75 64 63 0.84 5191 T>A (S1731T)
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Figure 8.5. VWF:Ag and VWF:CB values in Patient 20 prior to and over 6 h 
following DDAVP. Calculated half-life values of VWF:Ag and VWF:CB were 5.3 h 
and 5.1 h respectively.
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time (h)
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Patient 42
Patient 42 (11:1, Fig. 8.6) is a 25 year old female with a history of VWD in her mother; 
both individuals displayed similar laboratory and bleeding phenotypes and there was 
no other known family history. Patient 42 was recruited into the type 1 VWD study 
and 6 h data are shown in Fig.8.7. Despite a ratio of VWF:RCo to VWF:Ag of 0.8 at 
baseline, there was a discordant reduction in VWF:CB activity (VWF:CB to VWF:Ag 
ratio 0.46 shown on repeated plasma samples) and Patient 42 was consequently 
excluded from the study. Calculated half-life values of VWF:Ag and VWF:CB were
1.5 h and 1.8 h respectively. The mother of Patient 42 was further investigated and 
a VWF:CBA/WF:Ag ratio of 0.7 was found. No mutations were demonstrated on 
sequence analysis of regions of VWF encoding the A1-A3 and D’D3 domains. 
Multimeric analysis was normal in both affected individuals.
Figure 8.6. Family tree of Patient 42
11:1
Figure 8.7. VWF:Ag, VWF:CB and FVIIliC values in Patient 42 prior to and over 
6 h following DDAVP. Pre- and 1h post VWF:RCo activities are also shown.
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8.4.6 Investigation of patients with reduced FVIII:C levels
Two of the type 1 VWD patients investigated in this study also displayed significantly 
lowered FVIII:C levels (Patients 5 and 25, Appendix 2). The clinical and laboratory 
phenotype and genotype for these kindred are described below.
Patient 5
Patient 5 (IV:2, Fig.8.8) was investigated in 1996 following the diagnosis of mild 
haemophilia A in her 18 month old son. There was a history of haemophilia A in a 
maternal uncle (ll:5) and male cousin (lll:4). Patient 5 had a history of menorrhagia 
but no other significant bleeding history and she had not received DDAVP treatment 
prior to the study. Phenotypic data for Patient 5 at the time of diagnosis, as well as 
that of her son (V:2), daughter (V:1) and mother (lll:2) are given in Table 8.6.
The 6 h DDAVP data for Patient 5 are shown in Fig.8.1. In addition VWF:RCo 
activities are shown at T0and TCalculated half-life values for VWF:Ag and 
VWF:CB were 1.9 h and 2.9 h respectively. Sequence analysis of regions of VWF 
encoding the A1-A3 and D’D3 domains identified 3613A>C (R1205S) in the VWF- 
D3 domain of Patient 5 (IV:2) and her son (V:2) Mutation sequence analysis of the 
FVIII gene demonstrated 2048A>C (Y664S) mutation in exon 13 of V:2. Mutations at 
this codon, but not involving this particular base, have previously been associated 
with haemophilia A. Both Patient 5 (IV:2) and her daughter (V:1) and mother (lll:2) 
were shown to be heterozygous for this mutation
Table 8.6. Investigations performed at time of diagnosis in Patient 5 and family 
(1996). Multimeric analysis was normal in all subjects. NT: not tested
Subject Age FVIIliC
(IUdL’1)
50-150
VWF:Ag
(IUdL*1)
50-150
VWF:RCo
(IUdL*1)
50-150
VWF:CB
(IUdL’1)
50-175
IV:2
(Patient 5)
34 years 18 25 26 26
V:1 9 years 79 82 83 86
V:2 18
months
4 24 21 25
III :2 61 33 31 45 NT
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Figure 8.8. Family tree of Patient 5 (IV:2). Symbols are as previously denoted 
although refer to mutation in FVIII gene. Carrier status of haemophilia A is 
indicated by dot: this was confirmed in 111:2, IV:2 and V:1; the remainder are deemed 
to be obligate carriers from the family pedigree.
1:1
©
l:2
11:1
— ©
ll:2 ll:3 l:4 ll:5 ll:6 ll:7
lll:2 lll:3
<3
IV:1 IV:2 IV:3 IV:4
©
V:1 V2
145
Patient 25 (kindred 10)
Patient 25 (11:1, Fig. 8.9) is a 45 year old male who presented aged 5 years with 
excessive bleeding following circumcision and dental extractions. There was no 
significant family history of bleeding. Subsequent testing resulted in the finding of 
reduced VWF levels in his father (1:1) and two of his children (lll:2 and lll:4, Fig.8.9, 
Table 8.8), none whom were clinically affected. Unlike Patient 25, reduction in FVIII 
levels was not found in other family members (Table 8.8). Ill:2 was also recruited in 
the type 1 VWD study (Patient 10, Appendix 2).
Figure 8.9. Family tree of Patient 25 (Kindred 10)
111:1 lll:2 lll:3 III4
At the outset of the study, Patient 25 (11:1) was known to have reduced FVIII binding 
activity (Fig.8.10). The mutation 2561 G>A (R854Q) had previously been 
demonstrated in Patient 25 although had not been shown to be transmitted to the 
affected offspring, lll:2 and lll:4.{Jenkins, 1999} The 6 h responses to DDAVP of 
FVIIkC, VWF:Ag and VWF:CB in Patient 25 are shown in Fig. 8.11. Calculated 
VWF:Ag t1/2 values for Patient 25 and Patient 10 were 5.6 and 3.2 h respectively. 
Notably, as discussed in Chapter 6 the ratio of VWF:CB to VWF:Ag was shown to 
decrease significantly following DDAVP in both patients.
Sequence analysis of the targeted regions of VWF in Patients 25 and 10 described 
in Section 8.3 identified 2771 G>A (R924Q) in exon 21 of both patients. This kindred 
was further investigated as part of the UKHCDO type 1 VWD molecular genetics 
study (Cumming, et al 2006): direct DNA sequencing of the essential regions of 
VWF (including exons, splice site boundaries, 5’- and 3’- untranslated regions) was 
initially performed in Patient 25. Based on these findings, targeted DNA sequencing 
of the VWF gene was subsequently carried out on the other recruited family 
members (1:1, l:2, ll:2,111:1, lll:2,111:3,111:4). In addition to Patients 25 and 10, 
heterozygosity for 2771 G>A (R924Q) was demonstrated in the other affected family
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members 1:1 and lll:4. The intron 34 candidate splice site mutation, 5843-8C>G was 
also identified and shown to segregate with reduced VWF levels. In addition, 2561 
G>A (R854Q) was demonstrated in the mother of Patient 25 (l:2), as well as his two 
unaffected offspring, 111:1 and lll:3. Segregation of the VWD phenotype with VWF 
was investigated by means of VWF haplotype studies. Type 1 VWD was shown to 
segregate with the haplotype inherited from individual 1:1 and the type 2N VWD 
R854Q allele was shown to be associated with the haplotype inherited from 
individual l:2.
Table 8.7. Phenotypic data for Kindred 10 (affected members).
Multimeric analysis was normal in all subjects.
Subject ABO blood 
group
FVIII:C
(IUdL1)
50 -150
VWF:Ag
(IUdL'1)
50-150
VWF:RCo
(IUdL'1)
50 -150
11:1
(Patient 25)
A 13 30 34
lll:2
(Patient 10)
A 60 41 30
1:1 O 85 45 41
lll:4 A 80 40 25
Figure 8.10. Graph showing the FVIII binding of Patient 25 and normal 
controls. The method is described in Section 8.3.4.
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Figure 8.11. FVIII:C, VWF:Ag and VWF:CB values prior to and over 6 h 
following DDAVP in Patient 25.
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8.5 DISCUSSION
In the ISTH-SSC revised classification of 1994, it was assumed that all VWD arose 
from mutations within the VWF gene.(Sadler 1994) However, the recently updated 
classification recognises that VWD may result from heterogeneous pathophysiologic 
mechanisms and no longer restricts the diagnosis of VWD to VWF 
mutations.(Sadler, et al 2006) This is pertinent to type 1 VWD, in which mutation 
analysis has rarely been reported until recently and was generally restricted to the 
more severe forms of the disease. At the outset of this study, a total of 14 mutations 
had been reported in association with type 1 VWD. The findings of one international 
and two national multicentre studies (EU, UKHCDO and Canadian) have recently 
been reported, providing new insights into the molecular pathogenesis of type 1 
VWD.(Cumming, et al 2006, Goodeve, et al 2007, James, et al 2007a) There are 
now 117 VWF mutations included on the ISTH VWF mutation database 
(www.vwf.group.shef.ac.uk) and the possibility of increased VWF clearance as a 
molecular mechanism in VWD has led to the proposal of a new and distinct variant 
of type 1 VWD: type 1C (Sadler, et al 2006)
In this study, regions of the VWF gene, encoding domains A1 ,A2,A3 and D’-D3 of 
the protein were sequenced for possible mutations. These regions have been 
associated with increased clearance and may contain receptor-recognition sites 
affecting in vivo clearance(Lenting, et al 2004) Of the 28 type 1 VWD patients
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studied, mutations were identified in eight patients from 25 kindred (~30%). 
Consistent with previous findings,(Eikenboomf et al 2006) a higher likelihood of 
VWF linkage was shown in cases with lower levels of VWF. However, despite a 
significant proportion of the type 1 VWD patient cohort demonstrating increased 
VWF clearance following DDAVP, none of the four mutations within the D’-D3 region 
of VWF reported in association with reduced VWF survival and VWF:Ag levels were 
identified: 3389G>T (C1130F), 3445T>C (C1149R)(Schooten, et al 2005), 3614 
G>A (R1205HXLenting, et al 2004) and W1144G.(Haberichter, et al 2006a) 
Significantly increased VWF clearance in association with reduced VWF levels was 
demonstrated in four of the type 1 VWD patients demonstrating three previously 
unreported mutations: 4247A>T (I1416N, Patients 31, 43), 3613 A>C (R1205S, 
Patient 5) and 3613 C>T (R1205C, Patient 14). Three of these patients (Patients 14, 
31, 43) demonstrated a more severe phenotype with VWF:Ag levels less than 
20IUdL-1 as well as increased ratios of VWFpp to VWF:Ag..
The Vicenza variant, R1205H, resulting from the nucleotide substitution 3614 G>A 
was the original mutation in which increased VWF clearance was described and 
subsequently confirmed in a murine model. (Casonato, et al 2002, Lenting, et al 
2004). R1205H was identified in one patient who had been excluded from the type 1 
VWD study cohort following the finding of a discordant reduction in VWF:CB activity 
(Patient 3). The significantly reduced VWF level and accelerated plasma VWF 
clearance observed in this patient together with a moderate to severe bleeding 
phenotype and dominant penetrance are characteristic of this variant.(Cumming, et 
al 2006, Lenting, et al 2004) Historically, the Vicenza subtype has been classified as 
variants of both types 1 and 2 VWD and due to the presence of circulating UL-VWF 
multimers in some patients, was categorised as type 2M VWD at the time of the 
study.(Sadler 1994) When the level of VWF is sufficiently high for its precise 
measurement, concordance with functional activity has been demonstrated, 
resulting in the re-classification of the Vicenza variant as type 1 VWD in the recent 
ISTH-SSC recommendations.(Sadler, et al 2006) UL-VWF multimers were not 
detectable in the R1205H patient in this study, either in circulating plasma or 
following DDAVP: this finding is consistent with other reports.(Casonato, et al 2006, 
Lester, et al 2006) The absence of UL-HMW multimers in Vicenza patients could be 
misleading if relied upon diagnostically, and the R1205H variant illustrates a case 
where genetic diagnosis may play an important role. Establishing the diagnosis is 
particularly relevant to inform the appropriate clinical management given the rapid 
clearance of VWD released following DDAVP.
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It has been suggested that the Increased HMW multimers in the Vicenza variant 
may correlate with the increased turnover of VWF, including increased VWF 
proteolysis by ADAMTS-13. However, given the rapid plasma clearance of the 
VWF/R1205H mutant, it is possible that increased proteolysis is not observed in the 
steady state, resulting in the persistence of circulating UL multimers. In contrast to 
type 2A VWD, in which the decreased survival mainly concerns the high and 
intermediate molecular weight multimers,(Dent, et al 1990, Gralnick, et al 1985) the 
increased VWF clearance has been shown to involve multimers of all sizes in 
Vicenza patients. The mechanism by which the R1205H mutation affects VWF 
clearance is not currently known.
Two further arginine substitutions at 1205 in the D3 domain were identified within 
the type 1 VWD cohort, R1205C and R1205S, both resulting from nucleotide 
substitutions at 3613. Increased VWF clearance was demonstrated in both patients. 
In addition, the R1205C patient (Patient 14) displayed an increase in the 
VWFppA/WF:Ag ratio, as well as a similar pattern of VWF release to that seen in the 
R1205H patient. The VWF response following DDAVP was greater in the R1205S 
patient (Patient 5) than both R1205H and R1205C patients, although as this patient 
had a coexistent diagnosis of Haemophilia A, the rise in FVIII was restricted. This 
co-pathology also leads to difficulties in defining a clear bleeding and laboratory 
phenotype of R1205S, although this did appear to be milder than for R1205H and 
R1205C. Functional studies are required to confirm the effect of these mutations on 
VWF clearance.
Two further patients were excluded from the type 1 VWD cohort due to isolated 
discrepancies in VWF:CB activity. It is possible that these findings result from the 
use of type III collagen in this study, which is relatively less sensitive to the presence 
of HMW multimers than type I collagen. (Penas, et al 2005). However, as well as 
being reduced in situations where there is a deficiency of VWF or its HMW 
multimers, a reduction in VWF:CB may also be observed in individuals with 
mutations in the VWF-A3 domain that interfere with the binding of VWF to 
collagen.(Goodeve, et al 2007, Ribba, et al 2001, Schneppenheim 2001) 
Heterozygosity for one of these mutations, 5191 T>A (S1731T) was identified in a 
patient with a previous diagnosis of type 1 VWD (Patient 20), although the finding of 
a discordantly low VWF:CB activity had excluded him from the type 1 VWD 
clearance study cohort. The laboratory phenotype in this patient is similar to that of 
the two previously reported S1731T cases: all demonstrated borderline low-normal 
VWF:Ag levels and VWF:RCo activities in the context of normal FVIII:C and
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multimeric patterns.(Ribba, et al 2001) No discordant reduction in VWF:CB activity 
was observed in the offspring of Patient 20, which included the propositus in this 
kindred, despite all being found to be heterozygous for S1731T. Patient 20 
demonstrated a satisfactory response in VWF levels to DDAVP. As expected, the 
discrepancy in VWF:CB activity persisted following DDAVP despite an increase in 
HMW multimers. No significant increase in the clearance of VWF:Ag or VWF:CB 
was found. Within this kindred, only the propositus demonstrated a clinical and 
laboratory phenotype consistent with type 1 VWD. The phenotypes in her siblings 
appear normal and the bleeding history in the father, Patient 20, is questionable. 
Limited molecular analysis of VWF was performed in this kindred and further 
pathogenic explanation(s), both genetic and non-genetic need to be considered.
In the two related patients previously reported as S1731T heterozygotes, the 
bleeding phenotype was shown to be mild.(Ribba, et al 2001) However, three other 
reported VWF-A3 mutations have not been shown to result in any bleeding 
problems.(Schneppenheim 2001) The relative abundance of VWF-A1 mutations in 
bleeding patients and lack of bleeding in carriers of VWF-A3 mutations questions 
the dogma that attributes VWF binding to fibrillar collagen exclusively via the A3 
domain.(Romijn, et al 2003) An interaction between the isolated VWF-A1 domain 
and collagen has recently been demonstrated during platelet recruitment,(Morales, 
et al 2006) and a reduction in the affinity of VWF for collagen has been found in a 
type 2B VWD family with a mutation in the A1 domain.(Baronciani, et al 2005) 
Furthermore, it has recently been shown that the A1 domain is capable of interacting 
with several types of collagen and is able to assume the function of the A3 domain 
to trigger platelet recruitment to human collagen fibres.(Bonnefoy, et al 2006) These 
findings may offer an explanation for the lack of bleeding observed in A3 defective 
mutants.
The recent inclusion of isolated collagen binding defects in the type 2M subgroup in 
the 2006 ISTH classification is somewhat controversial.(Sadler, et al 2006) Given 
the previous VWD classification was strictly focused on platelet-binding defects, at 
the time of this study, S1731T was unclassified. (Sadler 1994) As discussed above, 
patients heterozygous for these mutations appear to demonstrate minimal or no 
bleeding symptoms. The isolated collagen binding defect differs from the plasma 
VWF in type 1 individuals in whom the binding to collagen is normal,(Favaloro and 
Koutts 1997) and from 2A and 2B individuals in whom the collagen-binding defect 
appears to depend only upon the lack of HMW multimers.(Casonato, et al 1999) In 
type 2M VWD, the loss of binding capacity of VWF to platelet GPIba in the presence
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of a full range of VWF multimers retains normal collagen binding capacity.(Hillery, et 
al 1998) This kindred therefore illustrates the complexity of applying knowledge of 
VWF mutations to phenotypic data and the lack of clarity that molecular testing may 
contribute to VWD subtyping.
In contrast to the two patients in whom VWF mutations were identified, targeted 
sequencing of VWF did not identify any mutations in the third patient with 
discordantly low VWF:CB activity in whom accelerated VWF clearance was 
demonstrated (Patient 42). No discordance in VWF:CB activity was found in the 
patient's mother despite both individuals displaying near-identical concordant levels 
of VWF:Ag and VWF.RCo both pre and post DDAVP. These findings are consistent 
with a type 1 VWD phenotype, which is further supported by the findings of 
multimeric analysis. It is possible that the findings in this patient result from the use 
of type III collagen as discussed above.
At the outset of the study, Patient 25 (kindred 10) was known to be heterozygous for 
2561 G>A (R854Q), although this mutation not been demonstrated in his two 
affected offspring (including Patient 10). R854Q is the most common type 2N 
mutation and has been demonstrated in 73% of type 2N VWD patients in 
homozygous or compound heterozygous form.(Meyer, et al 1997) It has been 
suggested that R854Q is the only type 2N mutation responsive to DDAVP, as was 
shown in this patient.(Federici, et al 2004) Further investigation of this kindred in the 
UKHCDO type 1 VWD molecular genetics study also identified R854Q in the 
heterozygous state in the unaffected mother and two unaffected offspring of this 
patient, who are therefore carriers of this recessive type 2 VWD mutation.(Cumming, 
et al 2006)
2771 G>A (R924Q) is also included on the ISTH database as a causative type 2N 
mutation and in addition to the finding of heterozygosity for R924Q in Patients 25 
and 10 in this study, R924Q was identified in all other affected family members in 
the UKHCDO study.(Cumming, et al 2006) However, such segregation with type 1 
VWD phenotype was not found in all families identified with R924Q in the UKHCDO 
study. The intron 34 candidate splice site mutation, 5843-8C>G was also shown to 
track with the disease phenotype in this kindred and has been shown to be inherited 
in phase with R924Q in both family studies and haplotype analysis.(Cumming, et al 
2006) Although the frequent finding of R924Q and 5843-C>G in a control population 
has led to the suggestion that these are common polymorphisms, any possible 
contribution to the type 1 VWD phenotype is not clear at present. Therefore the
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molecular basis of type 1 VWD in this kindred remains uncertain, although it is likely 
that the low FVIII:C level in Patient 25 results from compound heterozygosity for 
R854Q and a type 1 VWD allele (carrying R924Q and 5843-8C>G). Notably,
Patients 10 and 25 both demonstrated significant reductions in VWF:CB/VWF:Ag 
ratio following DDAVP, the mechanism for which is not clear and further 
investigation is warranted.
The common aim of the three recent molecular studies was to examine the genetic 
basis of type 1 VWD by analysis of VWF in clinically affected patients and to relate 
the findings to the patient's clinical and laboratory phenotype and response to 
treatment.(Cumming, et al 2006, Goodeve, et al 2007, James, et al 2007a) Despite 
the finding of numerous novel mutations throughout VWF, functional studies are 
lacking in the majority of these VWF gene sequence variants. Therefore, at the 
present time it is not known whether these newly identified mutations are causative 
of VWD or if they are merely segregating with the mutant allele. These studies did 
not identify mutations in the VWF gene in up to 45% of patients with type 1 VWD. 
Taken together with the currently unexplained genetic basis for 40% of the variation 
in VWF levels,(Levy and Ginsburg 2001) this non-linkage to VWF supports a role for 
other genetic loci in the pathogenesis of type 1 VWD, especially in mild phenotypes. 
It is well established that Mvwfl on chromosome 11 results in an autosomal partial 
quantitative deficiency of VWF in a murine model due to the aberrant post- 
translational modification of VWF.(Mohlke, et al 1999b) Further candidate modifier 
genes have recently been reported in mouse models,(Lemmerhirt, et al 2007, 
Lemmerhirt, et al 2006, Shavit 2007) and studies of human orthologs are warranted.
In summary, the lower frequency of identified VWF mutations in this study (~30%) 
compared to recently published data can be attributed to the analysis of only 
selected regions of VWF. None of the four previously described mutations in the D'- 
D3 domain said to be associated with increased VWF clearance were found within 
this type 1 VWD cohort. This highlights the problem of generalising a study of small 
numbers of patients from selected type 1 VWD families and challenges the 
commonly held assumption of a clear link between VWF gene mutation and 
increased clearance of VWF: it is possible that these represent two separate but co­
incidental findings in a proportion of type 1 VWD patients. This study did not 
examine the D4 or CK domains, within which two further mutations have been 
shown to be associated with increased clearance.(Haberichter, et al 2006,
Schooten, et al 2005) Three of the five type 1 VWD patients shown to have 
increased ratios of VWFpp to VWF:Ag as well as significantly increased clearance of
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VWF following DDAVP, were found to have mutations within regions of VWF that 
may affect in vivo clearance: R1205C and I1416N. Functional studies are necessary 
to clarify whether these mutations are causative of increased VWF clearance. One 
of the D'-D3 mutations previously associated with increased VWF clearance, 
R1205H (Vicenza), was identified in a patient who had been excluded from the type 
1 cohort. This patient demonstrated a significant increase in both VWF clearance 
following DDAVP and the ratio of VWFpp to VWF:Ag in the context of markedly 
reduced VWF levels.
A clearer picture is now emerging of the clinical relevance of mutation analysis in 
type 1 VWD, including awareness of mutations associated with increased VWF 
clearance. However, the findings in this study suggest that the molecular basis for 
increased clearance and its classification as a distinct entity (type 1C) may be 
premature.(Sadler, et al 2006). Sequence analysis of VWF is labour-intensive and 
although it may provide important supplementary diagnostic information in some 
cases of type 1 VWD as discussed, the frequent finding of non-linkage in type 1 
VWD renders it unlikely that genotypic analysis will replace the current 
measurement of functional activity and multimeric analysis in the diagnostic 
laboratory setting. Finally, as this study illustrates, the application of knowledge of 
VWF mutations to phenotypic data is not straightforward.
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Chapter 9 
TYPE 2M VWD
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9.1 INTRODUCTION
Type 2M VWD is a variant of VWD in which the decreased binding of VWF to 
platelets occurs in the presence of normal VWF multimers. The proposed 
mechanism is a functional loss of binding of VWF to the platelet receptor, 
glycoprotein Iba (GPIba). This mechanism is supported by data from molecular 
studies, with 16 of the 18 reported causative mutations being located in the region of 
the A1 domain of VWF containing the GPIba binding site 
(http://www. vwf.aroup.shef.ac.uk/index.htmn.
The diagnosis of type 2M VWD is made on the basis of a personal and family history 
of bleeding, a reduction in VWF level with a discordant reduction in functional 
activity, and a normal multimeric pattern. Although VWF:CB is sensitive to 
functional variants associated with the loss of HMW multimers, i.e. type 2A and 2B 
in VWD, the assay has been shown not to reliably discriminate type 2M 
VWD.(Riddell, eta !2002)
Most type 2M VWD patients have not been shown to demonstrate a satisfactory 
response to DDAVP,(Federici, et al 2004, Mannucci, et al 1988) and it is 
recommended practice in the UK to perform a therapeutic trial of DDAVP in all type 
2M patients.(Pasi, et al 2004) The limitations of judging the effectiveness of DDAVP 
treatment based solely on the initial rise of VWF in patients with type 1 VWD have 
been discussed in Chapter 4. As a result, it is recommended practice to measure 
VWF levels at more than one time point following a test dose of DDAVP, including 
patients with type 2M patients.(Pasi, et al 2004)
Patients with the Vicenza variant were included in the type 2M subtype at the time of 
this study, as discussed in Chapter 8.(Sadler 1994) Increased VWF clearance had 
been reported in Vicenza patients, which had been proposed as the pathogenic 
mechanism of the Vicenza mutation, R1205H.(Casonato, et al 2002) The Y1584C 
mutation has been reported as being a founder haplotype in type 1 VWD,(O’Brien, 
et al 2003) and its prevalence in other bleeding disorders was not known at the time 
of this study.
In this study, a cohort of 25 patients (15 kindred) were investigated, of whom 14 
kindred had been previously investigated at the Royal Free hospital and shown to 
have phenotypic parameters consistent with type 2M VWD.(Nitu-Whalley IC 2000) 
Sequencing of a 936 bp fragment of the exon 28 gene had previously identified 
mutations in the VWF-A1 domain in five kindred, with a further kindred having Del
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642.(Nitu-Whalley 1C 2000) The phenotypic and genotypic data for this cohort at the 
outset of this study is summarised in Table 9.1.
9.2 AIMS
The objectives of this study were to determine the antigenic and functional response 
to DDAVP as well as the plasma clearance of released VWF within a cohort of 
patients in whom previous investigation at the Royal Free hospital had resulted in a 
probable or confirmed diagnosis of type 2M VWD.(Nitu-Whalley IC 2000) The 
possibility that the increased in vitro proteolysis of VWF by ADAMTS-13 
demonstrated in Y1584C heterozygotes may affect the plasma clearance of VWF 
was examined in these patients. Genotypic analysis of VWF was performed to 
identify likely causative mutations in exon 28. In addition, regions of the VWF gene 
encoding the D’D3 domains (which have been associated with increased clearance) 
were sequenced.
9.3 MATERIALS AND METHODS
9.3.1 Patients
A cohort of patients previously diagnosed with type 2M VWD was further 
investigated for possible causative mutations in targeted regions of the VWF gene (n 
= 25, Table 9.1). The diagnosis of type 2M VWD was based on previous clinical and 
laboratory findings, (Sadler 1994) with a qualitative defect of VWF defined by a ratio 
of VWF:RCo to VWF:Ag of less than 0.7. Genotypic analysis had demonstrated 
causative mutations in the VWF-A1 domain in a proportion of these patients (Table 
9.1). The patient cohort was invited to participate in a study investigating the 
response to DDAVP and clearance of released VWF over a 6 h time period and on 
this basis, seven patients from five kindred were recruited (3 males, 4 females). 
Exclusion criteria were as described for type 1 VWD patients and controls in 
Chapter 3, Section 3.5. Patients are numbered with the prefix ‘M’.
9.3.2 Coagulation investigations
VWF:Ag, VWF:RCo and FVIII:C assays were performed as previously described in 
Chapter 3, Section 3.2. The VWF:CB and VWFpp immunoassays are described in 
Chapter 6, Section 6.3.2 and Chapter 5, Section 5.3.2 respectively.
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9.3.3 Multimeric analysis
The method for the analysis of VWF multimers is described in Chapter 3, Section
3.3. Samples were electrophoresed on 1.4% agarose gels.
9.3.4 Genotypic Analysis
PCR amplification and sequencing of exons 18 -  20, 26, 27 and 28
Genomic DNA extraction is described in Chapter 3, section 3.4. PCR amplification of 
exons 18-20 ,  26, 27 and 28 and flanking intronic regions was performed as 
described in Chapter 3, Section 3.4.3 using the gene specific primers given in 8.3.3. 
The primers used for exon 28 differed from those used in the previous study of 
these patients. Sequencing of PCR products is described in Chapter 8, Section
8.3.3.
9.3.5 Measurement of clearance of VWF:Ag and VWF:CB following 
administration of DDAVP
VWF:Ag and VWF:CB were measured prior to (T0) and over 6 h following DDAVP 
(Ti -  T6). The method used to calculate VWF:Ag t1/2and VWF:CB t1/2 is described in 
Chapter 3, Section 3.5. Results were analysed and compared to the data obtained 
for type 1 VWD patients and haemophilia A controls in Chapters 4 and 6.
9.3.6 Data and Statistical Analysis
Analyses of data were performed using GraphPad Prism (GraphPad Prism version 
4.0, GraphPad Software, San Diego, USA). Data is presented as median values 
with range given in brackets. Statistical analyses were performed using the Mann- 
Whitney Wilcoxon, Kruskal-Wallis and paired t-tests and correlation analysis by 
Spearman’s rank.
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Table 9.1: Phenotypic and genotypic data in 15 kindred with previously diagnosed type 2M VWD.
Nl: not identified NT: not tested
I  HMW: multimeric analysis showed slight decrease in high molecular weight multimers (Fig.9.1)
ULHMW: unusually large HMW multimers (Fig.9.1)
*VWF:RCo based on one set of results 
# Novel candidate mutations.(Nitu-Whalley IC 2000)
Kindred Patient
Number
ABO Blood 
group
Bleeding 
Time (min)
FVIIkC
(IUdL1)
VWF:Ag
(IUdL1)
VWF:RCo
(IUdL1)
VWF:RCo/
VWF:Ag
VWF:CB
(IUdL1)
Multimers Mutation Amino-acid
substitution
<8 50 -150 50 - 150 50- 150 1 50-175
1 M/1 A 5.5 72 49 16* 0.33 NT Normal Nl
1 M/2 A 3.5 63 46 30* 0.65 66 Normal Nl
1 M/3 A 3.5 50 49 11* 0.22 61 Normal Nl
2 M/4 O 8 58 43 14* 0.32 50 Normal Nl
3 M/5 O 6 100 45 29 0.64 NT Normal Nl
4 M/6 A 9.5 68 17 <5 <0.29 NT Normal Nl
4 M/7 A 20 90 26 5 0.19 64 Normal Nl
5 M/8 O 13 34 17 12 0.7 NT Normal Nl
6 M/9 O 7.5 22 8 <5 <0.63 6 Normal Nl
6 M/10 O NT 20 9 <5 <0.56 6 Normal Nl
7 M/11 O >20 32 18 6 0.33 12 ULHMW Nl
8 M/12 A NT 29 33 <5 <0.15 55 Normal 4247 G>T I1416T*
8 M/13 O NT 50 40 <5 <0.13 54 Normal 4247 G>T I1416T*
9 M/14 A NT 73 38 25 0.66 NT Normal K1405del
9 M/15 A NT 52 50 30 0.6 NT Normal K1405del
10 M/16 O 20 30 19 <5 <0.26 5 I  HMW 3961 T>G Y1321D*
10 M/17 O 20 40 14 <5 <0.36 NT i  HMW 3961 T>G Y1321D*
11 M/18 O >20 38 23 <5 <0.22 19 Normal 4121 G>T R1374L
11 M/19 O NT 22 11 <5 <0.45 21 Normal 4121 G>T R1374L
11 M/20 O NT 25 13 <5 <0.38 24 Normal 4121 G>T R1374L
12 M/21 A 14 32 15 <5 <0.33 19 Normal Nl
13 M/22 A 20 165 76 20 0.26 55 Normal 3835 G>T V1279F*
14 M/23 B NT 48 19 <5 <0.26 14 ULHMW 3943 O T R1315C
12 M/24 A 20 58 16 <5 <0.31 13 Normal Nl
15 M/25 A NT 128 55 34 0.62 NT Normal Nl
Figure 9.1. Autoradiograph of VWF multimers. Multimers are shown for plasma 
samples from a normal individual (Lane 1), type 2A VWD control (Lane 2), Patient 
M/23 showing unusually large (UL) multimers (Lane 4), Patient M/16 showing a 
decrease of HMW multimers (Lane 5) and Patient M/11 showing UL multimers 
(Lane 6). Samples were electrophoresed on 1.4% agarose gels and the direction of 
electrophoresis is from top to bottom
9.4 RESULTS
9.4.1 Sequence analysis of VWF
All DNA base changes are heterozygous unless otherwise stated.
Sequence analysis of targeted regions of the VWF gene was performed in a cohort 
of patients previously diagnosed with type 2M VWD (n = 25) and the findings are 
shown in Table 9.2. Sequencing of exon 28A encoding the VWF-A1 domain 
identified 4120 C>T (R1374C) in Patients M/9 and M/10 (Kindred 6), 3943 C>T 
(R1315C) in Patient M/11 (Kindred 7) and 4247 T>A (I1416N) in Patients M/21 and 
M/24 (Kindred 12). The previously identified A1 mutations were also confirmed. 
Sequencing of exon 28B of VWF encoding the VWF-A2 domain identified 4751 A>G
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(Y1584C) in five patients from three kindred (20%; 95% C.l. 4.9 -  38.5%): patients 
M/1, M/2, M/3 (Kindred 1), M/8 (Kindred 5) and M/16 (Kindred 10). A novel 
candidate mutation had previously been identified in the A1 domain, 3961 T>G 
(Y1321D) in Kindred 10, both in the father (Patient M/16) and his daughter (Patient 
M/17, Table 9.1). Both affected individuals displayed similar bleeding and laboratory 
phenotypes, with a slight decrease in HMW multimers (Fig.9.1 ).The multimer 
patterns for Patients M/11 and M/23 showing the presence of both HMW and UL 
VWF multimers are also shown in Fig.9.1.
No mutations were identified in exons 18-20 ,  26 and 27 encoding the D-D3 
domain of VWF.
Table 9.2. Mutations identified in exon 28 of VWF in cohort of patients with 
VWD previously classified type 2M (n = 25). No mutation identified (Nl)
Kindred PatientNo.
ABO
Blood
group
Mutation
(heterozygous)
Amino-acid
substitution
1 M/1 A 4751 A>G Y1584C
1 M/2 A 4751 A>G Y1584C
1 M/3 A 4751 A>G Y1584C
2 M/4 O Nl -
3 M/5 O Nl -
4 M/6 A Nl -
4 M/7 A Nl -
5 M/8 O 4751 A>G Y1584C
6 M/9 O 4120 O T R1374C
6 M/10 O 4120 C>T R1374C
7 M/11 O 3943 C>T R1315C
8 M/12 A 4247 T>C I1416T
8 M/13 O 4247 T>C I1416T
9 M/14 A K1405del
9 M/15 A K1405del
10 M/16 O 3961 T>G 4751 A>G
Y1321D
Y1584C
10 M/17 O 3961 T>G Y1321D
11 M/18 O 4121 G>T R1374L
11 M/19 O 4121 G>T R1374L
11 M/20 O 4121 G>T R1374L
12 M/21 A 4247 T>A I1416N
13 M/22 A 3835 G>T V1279F
14 M/23 B 3943 O T R1315C
12 M/24 A 4247 T>A I1416N
15 M/25 A Nl -
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9.4.2 VWF parameters pre- and 1 h post DDAVP
A subgroup of patients was recruited into the DDAVP study (n = 7). VWF:Ag levels 
and ratios of VWF:RCo and VWF:CB to VWF:Ag at T0 and Ti are shown in Table
9.3. Notably, there was clear discordance between the reductions in VWF:RCo 
activities and VWF:Ag levels at T0 in only one patient (M/20). The ratio of VWF:RCo 
to VWF:Ag at T0 was found to be greater than 0.7 in three patients (M/2, M/3 and 
M/4) and was borderline in the remaining three patients from two kindred (M/21, 
M/24, M/25). It was found that while there was a concordant rise in VWF:Ag and 
VWF:RCo in Patients M/2, M/3, M/4 and M/25 to satisfactory levels at T^ the 1 h 
response, in particular the VWF:RCo activity was restricted in Patients M/20, M/21 
and M/24. The ratio of VWF:CB/VWF:Ag was shown to be higher at Ty than T0 in 
four patients (M/2, M/3, M/21, M/24), lower in one patient (M/4) and in two patients 
remained unchanged (M/20, M/25).
9.4.3 Plasma clearance of VWF:Ag and VWF:CB post DDA VP
VWF:Ag levels and VWF.CB activities were measured at T0 - T6and calculated 
VWF:Ag t1/2 and VWF.CB t1/2 values are shown in Table 9.4 (n = 7). No significant 
difference in VWF:Ag t1/2 was demonstrated between the type 2M patients (median
6.4 h, n = 7, Fig.9.2) and either type 1 VWD patients (4.2 h, P = 0.08, n = 40, 
Chapter 4) or haemophilia A controls, (10.1 h, P = 0.18, n = 17, Chapter 4). Overall, 
no difference was found between VWF:Ag t1/2 and VWF:CB 11/2 values (P = 0.2, n = 
6, Table 9.4. The notable exception to this is Patient M/3, who is discussed below. 
Within the two kindred in whom two affected members were studied (Patients M/2, 
M/3, Kindred 1 and Patients M/21, M/24, Kindred 12), baseline VWF related 
parameters, DDAVP response and half-life values were comparable (Tables 9.3 and
9.4).
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Table 9.3. VWF parameters pre (T°) and 1 h post DDAVP (T1) in patients previously diagnosed with type 2M VWD (n = 7).
Multimeric analysis was normal in all patients. *Based on minimum of 3 repeat samples.
Kindred Patient Number
VWF:Ag
To
(IUdL1)
VWF:RCo*/
VWF:Ag
To
VWF:CB/
VWF:Ag
To
VWF:Ag
Ti
(IUdL1)
VWF:RCo / 
VWF:Ag 
Ti
VWF:CB/
VWF:Ag
Ti
1 M/2 52 0.81 0.86 173 0.98 1.04
1 M/3 55 0.78 1.09 139 1.04 1.26
2 M/4 42 0.86 1.11 129 0.97 1.0
11 M/20 20 <0.5 0.7 51 <0.20 0.7
12 M/21 15 <0.67 1.00 48 0.56 1.25
12 M/24 16 0.68 0.81 52 0.36 1.25
15 M/25 65 0.66 1.12 126 0.88 1.11
Table 9.4. Half-life values of VWF:Ag and VWF:CB following DDAVP (n = 7). No
significant difference was found between VWF:Ag t1/2 and VWF:CB ti/2 values in 
each individual, P = 0.2. NT not tested
Patient
Number Kindred VWF:Ag t1/2 (h) VWF:CB t1/2 (h)
M/2 1 8.5 NT
M/3 1 11.9 6.2
M/4 2 5.4 6.6
M/20 11 3.7 3.2
M/21 12 4.3 3.5
M/24 12 3.5 3.3
M/25 15 27 11.1
Figure 9.2. Calculated VWF:Ag half-life values for patients previously 
diagnosed with type 2M VWD. Values are shown against VWF:Ag t1/2 values 
obtained in type 1 VWD patients and haemophilia A controls. No significant 
difference in median VWF:Ag Urz values was demonstrated between the type 2M 
patients (median 6.4 h, n = 7) and either the type 1 VWD patients (4.2 h, P = 0.08, n 
= 40) or haemophilia A controls (10.1 h, P -  0.18, n = 17).
30- A ▲
uL
10-
AA
A A A
type 2M type 1 VWD haem A
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9.4.4 Y1584C mutation and VWF clearance
Of the seven patients in whom VWF clearance was measured, 4751 A>G (Y1584C) 
was demonstrated in two (Patients M/2 and M3, Kindred 1) The VWF:Ag t1/2 values 
in these individuals were 8.5 h and 11.9 h respectively (Table 9.4). The third 
affected member in this kindred was over 60 years of age at the time of the study 
and was therefore not eligible. The median VWF:Ag Un in the five 4751A patients 
was 4.3 h (range 3.5 -  27 h).
9.4.5 Clinical and laboratory phenotype and genotype.
Quantitative defects of VWF
The laboratory phenotype in Patients M/2, M/3, M/4 and M/25 are consistent with a 
mild partial quantitative deficiency of VWF: in all cases the VWF:Ag is borderline 
normal/ reduced and the ratio of VWF:RCo to VWF:Ag = 0.66, with substantial 
release of functionally intact VWF following DDAVP administration (Table 9.3). 
Despite the previous finding of a discordant reduction in VWF:RCo activity in these 
patients (Table 9.1), a minimum of three repeated samples demonstrated 
concordance between VFW:RCo and VWF:Ag. Within Kindred 1, Patients M/2 and 
M/3 are brothers, who, along with their mother, Patient M/1, were diagnosed with 
VWD when Patient M/3 presented with bleeding complications following surgery at 
the age of 21 years. The clinical history in Patient M/1 at that time included 
postoperative bleeding and menorrhagia necessitating blood transfusion, however 
there was no significant clinical history in Patient M/2, including following 
tonsilloadenoidectomy. Patients M/2 and M/3 were also found to have reduced 
platelet ADP consistent with a platelet storage pool disorder. As reported above, 
Patients M/1, M/2 and M/3 (Kindred 1) were found to have the mutation 4751 A>G 
(Y1584C) in the VWF-A2 domain. Phenotypic data of all the patients in this study in 
whom Y1584C was identified (n = 5) together with the one the type 1 VWD patient 
(Patient 12, Appendix 3) and haemophilia A control (Control 11, Appendix 3) 
reported in Chapter 6, are shown in Table 9.5. All four Y1584C subjects in whom 
VWF release was examined (Patients M/2, M/3, Patient 12, Control 11) 
demonstrated an increase in the VWF:CB/VWF:Ag ratio following DDAVP (Table
9.5). All except one (Patient 12) demonstrated normal VWF:Ag values. Notably, 
VWF:CB ti/2 was shorter than VWF:Ag t1/2 in the three subjects in whom clearance 
of both parameters was measured (Patients M/3, 12, Control 11, Table 9.5).
Patient M/4 is a female who presented at the age of 30 years with haemoptysis and 
gum bleeding. She had previously undergone tonsilloadenoidectomy with no 
bleeding complications and there was no significant family history of bleeding.
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Patient M/25 is a female who presented aged 21 years with a syncopal episode 
secondary to severe anaemia requiring blood transfusion. Her clinical history 
included epistaxis, menorrhagia and easy bruising and there was no significant 
family history. Targeted molecular sequencing did not identify mutations in VWF in 
either of these patients.
Qualitative defects of VWF
In contrast to the patients described above, Patients M/20 (Kindred 11) and M/21 
and M/24 (Kindred 12) demonstrated a variety of qualitative defects of VWF with 
absent or restricted responses in VWF:RCo activity following DDAVP (Table 9.3). 
VWF:CB activity was shown to increase following DDAVP in Patients M/21 and 
M/24 was unchanged in Patient M/20 (Table 9.3). In addition, VWF:Ag t1/2 values 
were found to be shorter than the median iy2 in these patients (Table 9.4). The 
VWF-A1 domain mutation 4121 G>T (R1374L) had previously been identified in 
Kindred 11 (Patient M/20) and sequencing of exon 28 in this study identified 4247 
T>A (I1416N) in Kindred 12 (Patients M/21 and M/24). Patient M/21 presented at 
the age of 5 years with gastrointestinal haemorrhage. His mother, Patient M/24, 
reported a significant bleeding history necessitating blood transfusion. There was 
also a history of excessive bleeding in the maternal grandmother and a maternal 
cousin, who had been diagnosed with VWD in another centre. I1416N was also 
identified in two patients with type 1 VWD (Patients 31 and 43, Chapter 8, Appendix 
3) and phenotypic data for all I1416N patients is summarised in Table 9.6. I1416N 
has recently been reported in one patient with a loss of HMW multimers consistent 
with type 2A VWD phenotype.(Goodeve, et al 2007) Notably, as reflected by the 
VWF:CB functional activity (Table 9.6), multimeric analysis was normal both pre- 
and post-DDAVP in all patients identified with I1416N in this study (data not shown). 
Furthermore, the increase in VWF:CB/VWF:Ag ratio following DDAVP is consistent 
with release of HMW multimers of VWF (Table 9.6). Patients displayed a moderate 
to severe clinical and laboratory phenotype, (Table 9.6) with a variable platelet- 
binding defect in circulating VWF and a predominantly qualitative restrictive defect in 
VWF release (Patients M/21, M/24,Table 9.3). Both the ratio of VWFpp to VWF:Ag 
and clearance of VWF:Ag was increased in all I1416N patients (Table 9.6), with 
concordance between the half-lives of VWF:Ag and VWF:CB, as shown for M21 and 
M24 (Table 9.4).
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Table 9.5. Phenotypic data and half-life values in patients with VWD subtypes 1 and 2M and haemophilia A controls in whom heterozygosi 
ty for 4751 A>G (Y1584C) was identified (n = 7).
To: pre DDAVR Ti: 1 h post DDAVR Te: 6 h post DDAVP 
NT: not tested; NA: not applicable 
#3961 T>G (Y1321D) identified;
i  HMW: slight decrease in high molecular weight multimers
Subject Previous
diagnosis
Bleeding
Time
(min)
VWF:Ag
To
(IUdL1)
VWF:CB/
VWF-.Ag
To
VWF:Ag
Ti
(IUdL1)
VWF:CB/
VWF-.Ag
Ti
VWF:CB/
VWF-.Ag
To
FVIII/
VWF:Ag
ratio
Multimeric
analysis
VWF.Ag
tm
(h)
VWF:CB
tl/2
(h)
<8 50 -150
Patient 12 type 1 VWD 8 34 0.97 217 1.22 1.06 1.8 Normal 4.8 3.5
Control 11 Haem A NT 50 1.0 165 1.2 1.2 NA Normal 6.0 11
M/1 type 2M VWD 5.5 54 0.95 NT NT NT 1.3 Normal NT NT
M/2 type 2M VWD 3.5 50 0.86 173 1.04 NT 1.1 Normal 8.5 NT
M/3 type 2M VWD 3.5 47 1.09 139 1.26 1.12 1.2 Normal 11.9 6.2
M/8 type 2M VWD 13 17 NT NT NT NT 2.0 Normal NT NT
M/16# type 2M VWD 10 19 0.26 NT NT NT 1.6 i  HMW NT NT
Table 9.6. Phenotypic data and half-life values in patients with VWD subtypes 1 and 2M and in whom heterozygosity for 4247 T>C (11416N) 
was identified (n = 4). VWF multimeric analysis was normal in all subjects.
Patient Previous
diagnosis
Bleeding 
Time (min)
VWF: Ag To 
(IUdL1)
VWF:CB/ 
VWFrAg (To,
VWF: Ag Ti 
(IUdL1)
VWF:CB/ 
VWF.Ag (T i)
FVIII:C/VWF:Ag 
ratio (To)
VWFpp/Ag 
ratio (To)
VWF:Ag 
ti/2 (h)
31 type 1 VWD
NT 18 0.67 92 1.10 1.5 0.55 3.5
43 type 1 VWD
>20 11 0.81 53 1.19 2.7 0.49 3.0
M/21 type 2M 
VWD
14 15 1.0 48 1.25 2.1 0.56 3.5
M/24 type 2M 
VWD
20 16 0.81 52 1.25 3.6 0.57 3.3
9.5 DISCUSSION
The recently updated classification of VWD defines the type 2M subtype as 
including ‘qualitative variants with decreased VWF-dependent platelet adhesion 
without a selective deficiency of HMW VWF multimers. The assembly and secretion 
of large molecular weight multimers is approximately normal and the functional 
defect is caused by mutations that disrupt binding of VWF to platelets or 
subendothelium.’(Sadler, et al 2006)
In this study, targeted analysis of the VWF gene was performed in a cohort of 
patients with a historical diagnosis of type 2M VWD.(Nitu-Whalley 1C 2000) This 
included sequence analysis of the region of VWF that encodes the GPIba binding 
site within the A1 domain of VWF. Previous mutation analysis had identified six 
mutations in this region in 11 of the 25 patients examined (six of 15 kindred).(Nitu- 
Whalley IC 2000) In this study, three VWF-A1 mutations were identified in a further 
five patients (three kindred). It is possible that these mutations were not identified in 
the original study because of overlap between the primer used at that time and a 
polymorphic site and the primers used in this study had been redesigned to take 
account of this. One VWF-A2 domain mutation (Y1584C) was identified in five 
patients in this study (three kindred). One of these patients had previously been 
identified as having a VWF-A1 mutation. Combining the findings in both studies, a 
total of eight A1 domain mutations and one A2 domain mutation were identified in 20 
of these 25 patients (11 kindred).
The majority of patients registered with a diagnosis of type 2M VWD at the Royal 
Free Hospital had not received DDAVP at the outset of this study. One of the 
objectives of this study was to determine the antigenic and functional response to 
DDAVP as well as the plasma clearance of VWF released following DDAVP. Seven 
patients recruited from the cohort described above were investigated. In contrast to 
previous findings, concordance between circulating VWF levels and functional 
activity was demonstrated in four patients from three kindred in this study (Patients 
M/2 and M/3 (Kindred 1), Patient M/4, Patient M/25), consistent with a type 1 VWD 
phenotype. This was supported by the finding of a good functional VWF response 
following DDAVP in these patients as well as an absence of mutations in the VWF- 
A1 domain. As the VWF:CB assay is sensitive to loss of HMW multimers and not to 
platelet-binding defects, VWF function was determined by VWF:RCo activity in both 
studies. The cause of the discrepancy in VWF:RCo activities between studies found 
in some patients is not clear; it is known that the VWF:RCo inter- and intra-assay 
variation is considerable and coefficient of variation (CV) values up to 80% have
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been demonstrated in the most recent United Kingdom National External Quality 
Assessment Scheme (UKNEQAS). Furthermore, the EU type 1 VWD study has 
demonstrated considerable overlap in the ratio of VWF:RCo to VWF:Ag between 
subjects with normal and abnormal multimeric pattems.(Goodeve, et al 2007)
In the remaining patients investigated (Patient M/20 (Kindred 11) and Patients M/21 
and M/24 (Kindred 12)), the predominant functional defect related to VWF-platelet 
binding, consistent with the type 2M variant. Mutations in the VWF-A1 domain have 
been demonstrated in these patients. The finding of a restricted VWF response to 
DDAVP in this subgroup of patients, especially in VWF:RCo activity is consistent 
with the poor responses to DDAVP reported in the majority of patients with type 2M 
VWD.(Federici, et al 2004) These data reinforce the importance of laboratory 
monitoring of VWF:RCo activity following DDAVP in these patients.
Within both subgroups of patients studied (type 1 and type 2M phenotype), the ratio 
of VWF:CB to VWF:Ag was found to increase following DDAVP in the majority of 
patients, consistent with release of HMW multimers. This was similar to the findings 
in type 1 VWD patients and haemophilia A controls as discussed in Chapter 6. A 
wide range in the half-life values of VWF:Ag released following DDAVP was found, 
accounting for the lack of significant difference between the half-lives in this group of 
patients and both type 1 VWD and haemophilia A patients, in whom VWF clearance 
has previously been shown to be increased and normal respectively (Chapter 4). 
Although patient numbers in this study cohort are insufficient for formal analysis, the 
half-lives of VWF in the subgroup of patients with type 2M phenotype appeared to 
be shortened, the significance of which is not clear. In contrast, VWF clearance 
rates were within normal limits in the subgroup of patients with VWF parameters 
consistent with type 1 VWD. No mutations were identified on sequence analysis of 
regions of VWF encoding the D’-D3 domains of VWF, which have previously been 
reported in association with increased VWF clearance.(Haberichter, et al 2006a, 
Lenting, et al 2004, Schooten, et al 2005) Although this study provides only limited 
data on VWF clearance in type 2M VWD patients, further studies are warranted.
Genotypic analysis of the type 1 VWD subgroup demonstrated the VWF-A2 domain 
mutation 4751 A>G (Y1584C) in Patients M/2 and M/3 (Kindred 1). A detailed 
discussion of Y1584C is presented below. Investigation of the patients with type 2M 
phenotype had previously demonstrated 4121C>T (R1374L) in Kindred 11 (Patient 
M/20), and in this study 4247A>T (I1416N) was identified in Kindred 12 (Patients 
M/21 and M/24). I1416N was also identified in two patients with type 1 VWD
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(Chapter 8). The clinical and laboratory phenotype of all I1416N patients was shown 
to be similar: a dominant and penetrant pattern of inheritance was demonstrated, 
together with a poor functional response in VWF:RCo activity as compared to a 
much better (but still restricted) response in VWF:Ag and VWF:CB and normal 
multimeric pattern. In addition, all patients were shown to have a shortened VWF 
half-life as well as an increased ratio of FVIII to VWF:Ag. These findings suggest 
defective VWF synthesis/secretion, release of functionally deficient VWF 
(predominant platelet-binding defect) and increased VWF clearance as possible 
pathogenic mechanisms of 11416N. A further mutation affecting 11416 has 
previously been identified in a kindred in this study, 4247 T>C (I1416T, Kindred 8), 
and reported as a novel candidate VWD type 2M mutation.(Nitu-Whalley IC 2000)
The effect of R1374 mutations on VWF function is not clear, which has led to the 
classification of these mutations as both type 2A and type 2M VWD 
variants.(Casonato, et al 2001b, Goodeve, et a /2007, Hilbert, etal 1995) Multimeric 
analysis had previously been shown to be normal in the two kindred within this 
cohort in whom R1374 mutations were identified (Kindred 6 and 11). The laboratory 
phenotype in Kindred 6 (Patients M/9 and M/10) in whom 4120 C>T (R1374C) was 
demonstrated in this study is suggestive of a disproportionate reduction in VWF:RCo 
activity compared to both VWF:Ag and VWF.CB, although it is possible that the 
levels are too low to meaningfully differentiate. Discordance between functional 
activities of VWF:RCo and VWF:CB was more clearly defined in Kindred 11 in whom 
4121 G>T (R1374L) had previously been identified.(Nitu-Whalley IC 2000) 
Furthermore, the VWF:RCo/VWF:Ag ratio decreased following DDAVP in Patient 
M/20 (Kindred 11) with no change in the VWF:CB/VWF:Ag ratio. These findings are 
consistent with a predominant platelet-binding effect of R1374 mutations, with a 
relatively minor effect on VWF multimer size, consistent with the functional 
abnormality that defines type 2M VWD.
Controversy also surrounds the functional defect that results from the nucleotide 
substitution 3943 C>T (R1315C), identified in Patient M/11 in this study and 
previously identified in Patient M/23.(Nitu-Wha!ley IC 2000) Both patients 
demonstrated circulating UL-HMW multimers. As well as being reported as a type 
2M mutation(Casana, et al 1998) and a type 2A mutation,(Goodeve, et al 2007) 
R1315C has also been described in cases of type 1 VWD (James, et al 2007a)
While it is possible that these discrepancies may reflect variation in the sensitivity of 
multimeric analysis, this mutation illustrates the lack of clinically informative data that 
can result from the classification of VWD on a molecular basis.
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The prevalence of 4751 A>G (Y1584C) was determined in the cohort of patients 
with a historical diagnosis of type 2M VWD. Y1584C was demonstrated in five of the 
25 patients investigated (Kindred 1, 5,10). Sequence analysis of the A1, A2 and D’- 
D3 domains identified no other mutations in four of these patients. A candidate 
mutation in the A1 domain, 3961 T>G (Y1321D) had previously been identified in 
the kindred of the remaining Y1584C patient (Patient M/16, Kindred 10); both 
affected members of this kindred displayed a similar clinical and laboratory 
phenotype. As previously described, the phenotype in Kindred 1 was found to be 
consistent with type 1 VWD. Only targeted areas of the VWF gene were sequenced 
in these patients, and therefore the significance of Y1584C as causative or 
contributory towards the disease phenotype is not clear. Furthermore, although 
heterozygosity for Y1584C was demonstrated in one fifth of the patients and kindred 
in this study, the phenotypes of these patients were found to be heterogeneous: 
three of the five Y1584C and two Y1584Y patients demonstrated phenotypic 
parameters consistent with a partial quantitative deficiency of VWF and a lack of 
HMW multimers was found in the patient heterozygous for both Y1321D and 
Y1584C. This results in the demonstration of heterozygosity for Y1584C in only one 
of the 19 patients previously reported as having type 2M VWD.
Y1584C is the most frequently occurring VWF gene mutation in type 1 VWD with 
reported frequencies of 11% and 15% in type 1 VWD index cases in the EU and 
Canadian studies respectively,(Goodeve, et al 2007, James, et al 2007a) and 19% 
of affected kindred members in the UK study.(Cumming, et al 2006) These data 
contrast with reported frequencies in the normal population of 0% (O'Brien, et al
2003) and 1%.(Bowen, et al 2005) As reported in Chapter 6, Y1584C was 
demonstrated in one of the 27 patients (24 kindred) investigated with type 1 VWD 
(~4%). Taken together with the finding of Y1584C in Kindred 1 in this study results 
in an overall prevalence of Y1584C in type 1 VWD kindred of ~8 % in and ~15% in 
affected kindred members.
While Y1584C has been shown to be associated with a reduction in VWF 
levels,(Bowen, et al 2005) the mechanism is not known. When expressed in its 
homozygous form, C1584 has been shown to result in increased intracellular 
retention of VWF.(0'Brien, et al 2003) Analysis of the Y1584C patients in this cohort 
together with the Y1584C type 1 VWD patient and haemophilia A control (Chapter 6) 
showed the ratio of FVIII to VWF:Ag to be increased in some patients, suggestive of 
a defect in VWF synthesis or secretion. However, it is possible that this could be 
accounted for by confounding factors including other (as yet unidentified) VWF
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mutations. All Y1584C patients who had been stimulated with DDAVP were shown 
to demonstrate satisfactory responses in both the level and functional activity of 
VWF, with increased ratios of VWF:CB to VWF:Ag consistent with release of HMW 
multimers. The half-lives of VWF:Ag released following DDAVP were not found to be 
significantly shortened in these patients. This contrasts with the increased VWF 
clearance found in type 1 VWD patients, irrespective of the presence of the Y1584C 
mutation (Chapter 6). However, the VWF:CB half-life was found to be shorter than 
VWF:Ag half-life in the three Y1584C patients in whom both parameters were 
measured. This is consistent with in vitro finding of increased ADAMTS-13 mediated 
VWF proteolysis resulting from C1584. (Bowen and Collins 2004, Keeney, et al 
2007) Although the findings in this study do not define a clear mechanism of 
Y1584C, these data do suggest that increased in vitro ADAMTS-13 proteolysis does 
not significantly affect the plasma clearance of VWF.
The absence of consistent co-segregation of C1584 with either low VWF levels or 
bleeding phenotype in affected type 1 VWD kindred (Bowen, et al 2005, James, et al 
2006, Lanke, et al 2005) suggests that on its own, rather than being causative, 
C1584 may be a risk factor for type 1 VWD. Y1584C has been shown to be 
associated with blood group O in 95% of type 1 VWD patients,(Bowen, et al 2005, 
O'Brien, et al 2003) an even higher proportion than the reported prevalence of blood 
group O in type 1 VWD patients of 77%.(Gill, et al 1987) A recent study of a large 
population of blood donors has shown C1584 to exert a greater influence on VWF 
levels than blood group O. (Davies, et al 2006) Moreover, the combined effect of 
blood group O and C1584 was shown to be similar to their product, suggestive of a 
synergistic interaction between blood group O and Y1584C that results in reduction 
in VWF level.
An alternative explanation for the apparent enrichment of Y1584C in type 1 VWD 
has been proposed, which suggests that C1584 may be more prevalent in patients 
in whom primary haemostasis is defective, irrespective of where the defect lies in 
the platelet-VWF-vessell wall axis.(Bowen and Collins 2006) Therefore, rather than 
being causative of VWD, C1584 may increase the probability that an individual will 
present with bleeding symptoms of sufficient severity to warrant investigation.
This study highlights the lack of clear distinction between VWD types 1, 2M and 2A, 
with overlap demonstrated at both phenotypic and genotypic level. The findings in 
this study are consistent with previous data demonstrating the limited value of 
DDAVP in patients with type 2M VWD,(Federici, et al 2004) and thus re-enforce the
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clinical importance of distinguishing type 2M from type 1 VWD. It has recently been 
proposed that types 2A and 2M VWD should no longer be differentiated, thereby all 
variants with a decreased platelet-dependent function would be categorised 
together, regardless of the multimeric distribution.(Batlle 2007) Although this would 
simplify the classification and clinically important information would not be missed 
(such as the limited value of DDAVP in both subtypes), it does not address the main 
diagnostic difficulty in classifying VWD subtypes 1 and 2M.
Finally, this study illustrates the need for a better functional measurement of VWF 
activity. Some of the limitations of the VWF:RCo assay have been highlighted: this is 
currently the primary assay used to distinguish type 2M from type 1 VWD. Although 
a ratio of VWF.RCo to VWF:Ag of less than 0.7 is generally used to distinguish 
qualitative VWF defects,(Federici, et al 2002) a significantly higher likelihood of 
identifying A1 domain mutations has recently been shown in patients with 
VWF:RCoA/WF:Ag ratios of <0.4.(James, et al 2007b) The use of a ratio of 0.7 to 
differentiate qualitative from quantitative defects of VWF may account for the 
apparent previous over-diagnosis of type 2M VWD in some of the patients in this 
study. It has recently been proposed that the structural normality of plasma VWF 
could be assessed by the multimer pattern alone.(Goodeve, et al 2007) The 
findings in this study support the use of diagnostic genotypic analysis in the 
differentiation of VWD types 1 and 2M. Forthcoming recommendations from the 
ISTH/SSC working party on laboratory assays for VWD will hopefully address these 
issues.
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Chapter 10 
CONCLUSIONS
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Type 1 VWD is the most common variant of VWD and yet until recently was the 
least understood of the VWD subtypes. The work presented in this thesis coincided 
with the onset of three large studies of type 1 VWD, which have since provided new 
insights into this disorder and resulted in considerable improvement in the 
understanding of its molecular basis. (James et al, 2007, Goodeve et al 2007, 
Cumming et al 2006) Despite the finding of a large number of VWF mutations in 
these studies, functional data are largely lacking. It is now well established that 
lowered VWF levels do not appear to be linked to the VWF gene in a significant 
proportion of type 1 VWD patients, especially those with milder phenotypes. (James, 
et al 2006, Eikenboom et al, 2006)
In this thesis, the release and clearance of VWF released following DDAVP has 
been examined in a group of patients with a partial quantitative deficiency of VWF.
In keeping with previous reports, increased clearance of VWF has been 
demonstrated in a significant proportion of patients, supporting the view that 
decreased survival of VWF in plasma may be a mechanism underlying low VWF 
levels in some patients with type 1 VWD. (Brown, et al 2003, Michiels, et al 2002, 
van Genderen, et al 1997) A variety of parameters have been investigated in an 
attempt to identify VWF gene linked and non-linked variables that may affect VWF 
clearance. No single underlying common characteristic or variable was shown to 
predominate within the study group, despite the majority of these patients 
demonstrating increased rates of VWF clearance. Such absence of a common 
mechanism is however not surprising, given that type 1 VWD is a classification that 
can include patients with a ten-fold difference in absolute VWF levels.
The method used to calculate the half-life of VWF released following DDAVP in this 
thesis is well established and validated by the findings in the control group.(Brown, 
et al 2003, van Genderen P, 1997, Michiels et al, 2002). The demonstration of 
increased clearance of VWF released following DDAVP may be of therapeutic 
relevance in type 1 VWD patients. However, the findings in this thesis raise the 
possibility that this approach may provide limited information about the clearance of 
constitutively released VWF, which accounts for the majority of circulating VWF in 
plasma. This could account for the lack of consistency shown between the plasma 
clearance of VWF released following DDAVP and the relative circulating 
concentrations of VWFpp and VWF:Ag. It has been proposed that measurement of 
VWFpp may identify patients with shortened VWF:Ag half-lives.(Haberichter, et al 
2006) Although this thesis demonstrates increased VWF clearance following 
DDAVP in all patients with increased VWFppA/WF:Ag ratios (a suggested index of
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accelerated VWF clearance), increased VWF clearance was also commonly found 
in the context of normal VWFpp/VWF:Ag ratios. While the significance of these data 
is not clear, it can be concluded that the VWFpp/VWF:Ag ratio appears to be of 
limited value in predicting increased clearance of VWF released following DDAVP. 
This is particularly relevant given the current commercial development of the VWFpp 
assay.
Despite being the largest study of its kind to date, the patient and control numbers in 
this study may render it under-powered in its ability to demonstrate findings that are 
statistically significant. Pertinent to this is the study of ABO blood group effect on the 
clearance of VWF: while no significant difference in VWF clearance rates was 
observed between individuals of different ABO blood groups following DDAVP, 
ratios of VWFppA/WF:Ag ratio were shown to be significantly increased in 
individuals of blood group O compared to A. This discrepancy further illustrates the 
potential limitations of the approach used to assess VWF clearance in this thesis as 
discussed above. As well as being limited by patient numbers, heterogeneity of the 
pathogenic mechanisms within the VWD study group was also found to complicate 
the investigation of determinants of VWF clearance in this thesis. The study group 
included patients with VWF:Ag levels ranging from 5 - 5 0  IUdL'1. Consistent with 
previously reported findings, the likelihood of defining the underlying molecular 
mechanism in the VWF gene was found to be higher in patients of more severe 
phenotype, defined by a reduction in VWF:Ag levels to < 20 IUdL*1. (Eikenboom et 
al, 2006) Less clear-cut and more common was the finding of patients with 
circulating VWF:Ag values approaching normal levels who demonstrated increased 
rates of VWF clearance, yet normal ratios of VWFpp to VWF:Ag, and in whom no 
mutations were found within the regions of the VWF gene analysed. The genetic 
determinants of milder type 1 VWD phenotypes are known to be more complex and 
are more likely to involve contributions from other factors, including ABO blood 
group and increased VWF clearance, as the findings in this thesis suggest. Strict 
criteria in the selection of patients are necessary in future studies to overcome the 
problems encountered in association with patient heterogeneity in this thesis. 
However, the recruitment of patients with milder phenotypes is often difficult as 
these patients are likely to be less motivated than patients with more severe 
bleeding problems.
The VWF gene mutations identified in this thesis include the VWF-D3 mutation 
R1205H, (Vicenza) which has previously been demonstrated to be causative of 
increased VWF clearance (Lenting et al, 2004) and recently re-classified as a
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variant of type 1 VWD. (Sadler, 2006) Two novel candidate mutations were also 
identified that result from arginine substitutions at 1205, R1205C and R1205S, as 
well as a novel candidate mutation in the VWF-A1 domain, I1416N. These mutations 
were all associated with significantly accelerated VWF clearance and were in 
general identified in patients with steady-state VWF levels reduced to < 20 IUdL*1. 
Patients demonstrated both increased rates of clearance of released VWF and 
increased steady-state ratios VWFpp to VWF:Ag. In addition, all patients identified 
with the mutation I1416N demonstrated restricted functional release of VWF in the 
context of normal VWF multimeric analysis, consistent with a type 2M phenotype. 
Expression of these mutants is essential to confirm the significance of these 
findings.
The findings in this thesis suggest that increased plasma clearance of VWF does 
not consistently reflect steady-state VWF levels in type 1 VWD. Firstly, there was 
only a weak correlation between plasma VWF:Ag levels and the half-life values for 
VWF:Ag, and secondly, no difference was observed for the VWFppA/WF:Ag ratio 
between the type 1 VWD patients and controls. These findings suggest that reduced 
steady state VWF levels are either not, or only in part, due to increased clearance of 
VWF. A defect in intracellular transport and secretion by endothelial cells may also 
contribute towards the deficiency of VWF in these patients. It is also possible that 
because of structural differences between VWF released following DDAVP 
administration and plasma VWF, clearance kinetics of plasma and newly released 
VWF may differ. Indeed, VWF released following DDAVP infusion has previously 
been shown to differ from circulating VWF in terms of multimer composition and 
expression of A antigen. (Ruggeri, et al 1982, Brown, et al 2002) In this thesis, an 
increased HMW multimeric content of VWF, reflected by the relative increase in 
VWF:CB activity compared to VWF level, was observed following DDAVP in the 
majority of type 1 VWD patients and controls. While differential glycosylation of 
DDAVP-released VWF may be important in determining its half-life, this thesis did 
not demonstrate a significant difference in the exposure of galactose residues by the 
binding of the lectin RCA-I between circulating and released VWF. Furthermore, 
consistent with previously reported findings, inverse correlation was found between 
the binding of RCA-I to VWF and the steady-state VWF level. (Ellies et al, 2002) 
However, this relationship appeared to be independent of VWF clearance and 
together with recent reports, these findings suggest that VWF clearance is 
independent of the exposure of N- and O-linked galactose residues.(van Schooten 
et al, 2007)
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Although the ratio of VWF:CB to VWF:Ag was shown to increase following DDAVP 
in the majority of type 1 VWD patients and controls, two type 1 VWD patients from 
the same kindred demonstrated significant reductions in the ratio of VWF:CB to 
VWF:Ag. In both patients the VWF-D3 mutation R924Q mutation was identified, 
although the pathological significance of this mutation is not currently established. 
Neither patient was shown to demonstrate increased proteolysis of VWF by 
ADAMTS-13. While these findings are suggestive of the removal of HMW multimers, 
which may not be related to VWF proteolysis, the underlying mechanism is not clear 
and further studies are warranted.
It is not known how VWF proteolysis, plasma multimer distribution and VWF 
clearance are integrated in vivo. In this thesis, the size of VWF multimers in relation 
to the release and clearance following DDAVP has been examined. Clearance of 
VWF was not shown to be associated with either the absolute levels of ADAMTS-13 
or susceptibility of VWF to cleavage by ADAMTS-13. These findings are supported 
by recent indirect experimental data in which plasma VWF levels in wild-type and 
ADAMTS-13 deficient mice were not shown to differ.(Motto et at, 2005) After ABO 
blood group, C1584 has been shown to be the second most influential genetic 
modulator of VWF level in humans,(Davies et a/, 2006) and is known to influence 
the susceptibility of VWF to ADAMTS-13 mediated proteolysis.(Bowen and Collins,
2004) Despite the demonstration of increased rates of proteolysis in Y1584C 
heterozygotes, the findings in this thesis suggest that the Y1584C mutation does not 
have a major effect on VWF clearance.
Some of the complexities of VWD subtyping have been illustrated throughout this 
thesis and the relevance of developing a classification system that is both clinically 
and scientific informative has been discussed. The recently revised ISTH-SSC 
recommendations have attempted to address some of the limitations of the previous 
1994 VWD classification.(Sadler, et al 2006) These include the correlation of VWD 
phenotype with the likely response to DDAVP treatment. In addition, it has been 
proposed that that type 1 VWD patients demonstrating an increased VWF clearance 
phenotype should be classified as a distinct entity (type 1C). The findings in this 
thesis suggest that such a distinction may be premature at this stage and results of 
ongoing clinical studies comparing the biological response following DDAVP with 
clinical efficacy may provide a more clinically relevant basis for distinguishing 
patients with increased VWF clearance.
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To date, the asialoglycoprotein receptor is the only identified endocytic receptor that 
has been shown to mediate the removal of VWF from the circulation and its 
reactivity appears to be limited to hyposialylated VWF or VWF with an altered 
glycosylation profile.(Ellies, et al 2002, Mohlke, et al 1999) Preliminary data 
suggests that macrophage-like cells present in both the liver and the spleen may 
contribute towards the clearance of VWF (unpublished). An improved knowledge of 
the mechanisms of VWF clearance, including the identification of VWF clearance 
receptors, may help clarify the pathogenic role of altered VWF clearance in patients 
with type 1 VWD. As discussed, future studies of VWF clearance in type 1 VWD 
would benefit from the improved stratification of patients, with the focus being on 
patients with milder phenotypes. An approach of studying the clearance of VWF that 
has been constitutively released from the endothelial pool may provide a more 
accurate measurement of VWF clearance than the DDAVP-induced release studied 
in this thesis. Unlike regulated secretion, VWF secreted via the constitutive pathway 
is largely composed of dimers and small multimers. Methods such as plasma 
fractionation or chromatography could be used to separate VWF multimers by size 
and the plasma clearance of these multimers could be studied in a suitable murine 
model, notwithstanding the possible limitations of different receptor and proteolysis 
mechanisms.
In conclusion, the work presented in this thesis contributes novel observations on 
different aspects of VWF clearance. Although increased clearance of VWF released 
following DDAVP was a prevalent finding in the type 1 VWD cohort studied in this 
thesis, no unifying underlying mechanism, either VWF gene linked or non-linked, 
was shown to predominate in these patients. The findings in this thesis support the 
hypothesis that the phenotype of type 1 VWD is not due to a single causative effect 
but is likely to be due to a composite effect of a number of factors under separate 
genetic control.
180
References
Abildgaard, C.F., Suzuki, Z., Harrison, J., Jefcoat, K. & Zimmerman, T.S. (1980) 
Serial studies in von Willebrand's disease: variability versus "variants".
Blood, 56, 712-716.
Ain, K.B., Mori, Y. & Refetoff, S. (1987) Reduced clearance rate of thyroxine-binding 
globulin (TBG) with increased sialylation: a mechanism for estrogen-induced 
elevation of serum TBG concentration. Journal of Clinical Endocrinology and 
Metabolism, 65, 689-696.
Alexander, B.G., R (1953) Dual haemostatic defect in pseudo-hemophilia. J Clin 
Invest, 32, 551.
Allen, S., Abuzenadah, A.M., Hinks, J., Blagg, J.L., Gursel, T., Ingerslev, J.,
Goodeve, A.C., Peake, I.R. & Daly, M.E. (2000) A novel von Willebrand 
disease-causing mutation (Arg273Trp) in the von Willebrand factor 
propeptide that results in defective multimerization and secretion. Blood, 96, 
560-568.
Ashwell, G. & Harford, J. (1982) Carbohydrate-specific receptors of the liver. Annual 
Review of Biochemistry, 51, 531-554.
Baronciani, L., Cozzi, G., Canciani, M.T., Peyvandi, F., Srivastava, A., Federici, A.B. 
& Mannucci, P.M. (2000) Molecular characterization of a multiethnic group of 
21 patients with type 3 von Willebrand disease. Thromb Haemost, 84, 536- 
540.
Baronciani, L., Cozzi, G., Canciani, M.T., Peyvandi, F., Srivastava, A., Federici, A.B. 
& Mannucci, P.M. (2003) Molecular defects in type 3 von Willebrand disease: 
updated results from 40 multiethnic patients. Blood Cells Mol Dis, 30, 264- 
270.
Baronciani, L., Federici, A.B., Beretta, M., Cozzi, G., Canciani, M.T. & Mannucci, 
P.M. (2005) Expression studies on a novel type 2B variant of the von 
Willebrand factor gene (R1308L) characterized by defective collagen 
binding. J Thromb Haemost, 3, 2689-2694.
Batlle, J. (2007) Type 2M von Willebrand disease: a variant of type 2A? J Thromb 
Haemost, online prepublication.
Batlle, J., Lopez-Fernandez, M.F., Lopez-Borrasca, A., Lopez-Berges, C., Dent,
J.A., Berkowitz, S.D., Ruggeri, Z.M. & Zimmerman, T.S. (1987) Proteolytic 
degradation of von Willebrand factor after DDAVP administration in normal 
individuals. Blood, 70,173-176.
Beacham, D.A., Wise, R.J., Turci, S.M. & Handin, R.l. (1992) Selective inactivation 
of the Arg-Gly-Asp-Ser (RGDS) binding site in von Willebrand factor by site- 
directed mutagenesis. J Biol Chem, 267, 3409-3415.
Bennett, B. & Ratnoff, O.D. (1972) Changes in antihemophilic factor (AHF, factor 8) 
procoagulant activity and AHF-like antigen in normal pregnancy, and 
following exercise and pneumoencephalography. J Lab Clin Med, 80, 256- 
263.
181
Berkowitz, S.D. & Federici, A.B. (1988) Sialic acid prevents loss of large von
Willebrand factor multimers by protecting against amino-terminal proteolytic 
cleavage. Blood, 72,1790-1796.
Bernard, B.A., Yamada, K.M. & Olden, K. (1982) Carbohydrates selectively protect a 
specific domain of fibronectin against proteases. J Biol Chem, 257, 8549- 
8554.
Blomback, B., Blomback, M., Nilsson, I.M. & Svennerud, S. (1956) [Female
hemophilia and its management with human antihemophilic globulin.]. Nord 
Med, 56, 1654-1656.
Bloom, A.L. (1991) von Willebrand factor: clinical features of inherited and acquired 
disorders. Mayo Clin Proc, 66, 743-751.
Bloom, A.L., Peake, IR, Giddings, JCG. (1973) The presence and reactions of high 
and low molecular weight procoagulant factor VIII in the plasma of patients 
with von Willebrand's disease after treatment; significance for a structural 
hypothesis for factor VIII. Thrombosis Research, 3, 389-384-384.
Bodo, I., Katsumi, A., Tuley, E.A., Eikenboom, J.C., Dong, Z. & Sadler, J.E. (2001) 
Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular 
retention and degradation of heterodimers: a possible general mechanism 
for dominant mutations of oligomeric proteins. Blood, 98, 2973-2979.
Bonnefoy, A., Romijn, R.A., Vandervoort, P.A., I, V.A.N.R., Vermylen, J. &
Hoylaerts, M.F. (2006) von Willebrand factor A1 domain can adequately 
substitute for A3 domain in recruitment of flowing platelets to collagen. J 
Thromb Haemost, 4, 2151 -2161.
Bonthron, D., Orr, E.C., Mitsock, L.M., Ginsburg, D., Handin, R.l. & Orkin, S.H.
(1986) Nucleotide sequence of pre-pro-von Willebrand factor cDNA. Nucleic 
Acids Res, 14, 7125-7127.
Borchiellini, A., Fijnvandraat, K., ten Cate, J.W., Pajkrt, D., van Deventer, S.J.,
Pasterkamp, G., Meijer-Huizinga, F., Zwart-Huinink, L., Voorberg, J. & van 
Mourik, J.A. (1996) Quantitative analysis of von Willebrand factor propeptide 
release in vivo: effect of experimental endotoxemia and administration of 1- 
deamino-8-D-arginine vasopressin in humans. Blood, 88, 2951-2958.
Bouma, B.N., Wiegerinck, Y., Sixma, J.J., Van Mourik, J.A. & Mochtar, I.A. (1972) 
Immunological characterization of purified anti-haemophilic factor A (factor 
VIII) which corrects abnormal platelet retention in Von Willebrand's disease. 
Nat New Biol, 236, 104-106.
Bowen, D. J. (2003) An influence of ABO blood group on the rate of proteolysis of 
von Willebrand factor by ADAMTS13. Journal of Thrombosis and 
Haemostasis, 1, 33-40.
Bowen, D.J. (2004) Increased susceptibility of von Willebrand factor to proteolysis 
by ADAMTS13: should the multimer profile be normal or type 2A? Blood,
103, 3246.
Bowen, D.J. & Collins, P.W. (2004) An amino acid polymorphism in von Willebrand 
factor correlates with increased susceptibility to proteolysis by ADAMTS13. 
Blood, 103, 941-947.
182
Bowen, D.J. & Collins, P.W. (2006) Insights into von Willebrand factor proteolysis: 
clinical implications. Br J Haematol, 133, 457-467.
Bowen, D.J., Collins, P.W., Lester, W., Cumming, A.M., Keeney, S., Grundy, P., 
Enayat, S.M., Bolton-Maggs, P.H., Keeling, D.M., Khair, K., Campbell Tait,
R., Wilde, J.T., John Pasi, K. & Hill, F.G. (2005) The prevalence of the 
cysteine1584 variant of von Willebrand factor is increased in type 1 von 
Willebrand disease: co-segregation with increased susceptibility to 
ADAMTS13 proteolysis but not clinical phenotype. Br J Haematol, 128, 830- 
836.
Brock, T.A., Dvorak, H.F. & Senger, D.R. (1991) Tumor-secreted vascular
permeability factor increases cytosolic Ca2+ and von Willebrand factor 
release in human endothelial cells. Am J Pathol, 138, 213-221.
Brown, J.E. & Bosak, J.O. (1986) An ELISA test for the binding of von Willebrand 
antigen to collagen. Thromb Res, 43, 303-311.
Brown, S. (2003) von Willebrand factor and type 1 von Willebrand disease. Thesis 
submitted for Doctor of Medicine, University of Wales.
Brown, S.A., Collins, P.W. & Bowen, D.J. (2002) Heterogeneous detection of A-
antigen on von Willebrand factor derived from platelets, endothelial cells and 
plasma. Thrombosis and Haemostasis, 87, 990-996.
Brown, S.A., Eldridge, A., Collins, P.W. & Bowen, D.J. (2003) Increased clearance 
of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand 
disease: is it a potential pathogenic process? J Thromb Haemost, 1,1714- 
1717.
Cannon, W., Mendenhall, WL (1914) Factors affecting the coagulation time of blood 
IV: The hastening of coagulation in pain and emotional excitement. American 
Journal of Physiology, 34, 251.
Casana, P., Martinez, F., Espinos, C., Haya, S., Lorenzo, J.l. & Aznar, J.A. (1998) 
Search for mutations in a segment of the exon 28 of the human von 
Willebrand factor gene: new mutations, R1315C and R1341W, associated 
with type 2M and 2B variants. Am J Hematol, 59, 57-63.
Casana, P., Martinez, F., Haya, S., Espinos, C. & Aznar, J.A. (2001) Significant 
linkage and non-linkage of type 1 von Willebrand disease to the von 
Willebrand factor gene. Br J Haematol, 115, 692-700.
Cash, J.D., Gader, A.M. & da Costa, J. (1974) Proceedings: The release of 
plasminogen activator and factor VIII to lysine vasopressin, arginine 
vasopressin, l-desamino-8-d-arginine vasopressin, angiotensin and oxytocin 
in man. Br J Haematol, 27, 363-364.
Casonato, A., Pontara, E., Bertomoro, A., Sartorello, F., Cattini, M.G. & Girolami, A. 
(2001a) Von Willebrand factor collagen binding activity in the diagnosis of 
von Willebrand disease: an alternative to ristocetin co-factor activity? Br J 
Haematol, 112, 578-583.
Casonato, A., Pontara, E., Bertomoro, A., Sartorello, F. & Girolami, A. (1999) Which 
assay is the most suitable to investigate von Willebrand factor functional 
activity? Thromb Haemost, 81, 994-995.
183
Casonato, A., Pontara, E., Sartorello, F., Bertomoro, A., Durante, C. & Girolami, A. 
(2001b) Type 2M von Willebrand disease variant characterized by abnormal 
von willebrand factor multimerization. J Lab Clin Med, 137, 70-76.
Casonato, A., Pontara, E., Sartorello, F., Cattini, M.G., Gallinaro, L., Bertomoro, A., 
Rosato, A., Padrini, R. & Pagnan, A. (2006) Identifying type Vicenza von 
Willebrand disease. J Lab Clin Med, 147, 96-102.
Casonato, A., Pontara, E., Sartorello, F., Cattini, M.G., Sartori, M.T., Padrini, R. & 
Girolami, A. (2002) Reduced von Willebrand factor survival in type Vicenza 
von Willebrand disease. Blood, 99,180-184.
Casonato, A., Sartori, M.T., de Marco, L. & Girolami, A. (1990) 1-Desamino-8-D-
arginine vasopressin (DDAVP) infusion in type MB von Willebrand's disease: 
shortening of bleeding time and induction of a variable 
pseudothrombocytopenia. Thromb Haemost, 64,117-120.
Casonato, A.B., A; Cattini, MG; Gallinaro, L; Pontara, E; Sartorello, F; Soldera, C; 
Padrini, R; Pagnan, A. (2005) How von Willebrand Factor Survival 
Contributes to Determining von Willebrand Disease Phenotype. Journal of 
Thrombosis and Haemostasis, 3.
Castaman, G., Eikenboom, J.C., Bertina, R.M. & Rodeghiero, F. (1999)
Inconsistency of association between type 1 von Willebrand disease 
phenotype and genotype in families identified in an epidemiological 
investigation. Thromb Haemost, 82,1065-1070.
Cattaneo, M., Moia, M., Delle Valle, P., Castellana, P. & Mannucci, P.M. (1989) 
DDAVP shortens the prolonged bleeding times of patients with severe von 
Willebrand disease treated with cryoprecipitate. Evidence for a mechanism 
of action independent of released von Willebrand factor. Blood, 74, 1972- 
1975.
Celikel, R., Varughese, K.I., Madhusudan, Yoshioka, A., Ware, J. & Ruggeri, Z.M.
(1998) Crystal structure of the von Willebrand factor A1 domain in complex 
with the function blocking NMC-4 Fab. Nat Struct Biol, 5,189-194.
Collins, P.W., Macey, M.G., Cahill, M.R. & Newland, A.C. (1993) von Willebrand 
factor release and P-selectin expression is stimulated by thrombin and 
trypsin but not IL-1 in cultured human endothelial cells. Thromb Haemost,
70, 346-350.
Colvin, B., O'Callaghan, U, Thomas, N, Matthews, PBA, Kernoff, PBA, Tuddenham, 
EGD (1986) A survey of von Willebrand's disease in North London. La 
Ricerca in Cinica e Laboratorio, 236.
Counts, R.B., Paskell, S.L. & Elgee, S.K. (1978) Disulfide bonds and the quaternary 
structure of factor VII l/von Willebrand factor. J Clin Invest, 62, 702-709.
Cousin, P., Dechaud, H., Grenot, C., Lejeune, H., Hammond, G.L. & Pugeat, M.
(1999) Influence of glycosylation on the clearance of recombinant human sex 
hormone-binding globulin from rabbit blood. Journal of Steroid Biochemistry 
and Molecular Biology, 70, 115-121.
184
Cruz, M.A., Yuan, H., Lee, J.R., Wise, R.J. & Handin, R.I. (1995) Interaction of the 
von Willebrand factor (vWF) with collagen. Localization of the primary 
collagen-binding site by analysis of recombinant vWF A domain 
polypeptides. J Biol Chem, 270,19668.
Cumming, A., Grundy, P., Keeney, S., Lester, W., Enayat, S., Guilliatt, A., Bowen,
D., Pasi, J., Keeling, D., Hill, F., Bolton-Maggs, P.H., Hay, C. & Collins, P. 
(2006) An investigation of the von Willebrand factor genotype in UK patients 
diagnosed to have type 1 von Willebrand disease. Thromb Haemost, 96, 
630-641.
Datta, Y.H., Romano, M., Jacobson, B.C., Golan, D.E., Serhan, C.N. & Ewenstein, 
B.M. (1995) Peptido-leukotrienes are potent agonists of von Willebrand 
factor secretion and P-selectin surface expression in human umbilical vein 
endothelial cells. Circulation, 92, 3304-3311.
Davies, J.A., Collins, P.W., Hathaway, L.S. & Bowen, D.J. (2006) Effect of von 
Willebrand factor Y/C1584 on in vivo protein level and function, and 
interaction with ABO blood group. Blood, 109, 2840-2846
de la Fuente, B., Kasper, C.K., Rickies, F.R. & Hoyer, L.W. (1985) Response of
patients with mild and moderate hemophilia A and von Willebrand's disease 
to treatment with desmopressin. Ann Intern Med, 103, 6-14.
De Marco, L. & Shapiro, S.S. (1981) Properties of human asialo-factor VIII. A 
ristocetin-independent platelet-aggregating agent. Journal of Clinical 
Investigation, 68, 321-328.
De Meyer, S.F.e.a. (2007) Restoration of von Willebrand factor function in a murine 
model of severe von Willebrand disease after liver-specific gene transfer. J 
Thromb Haemost, 5, O-T-065.
de Romeuf, C. & Mazurier, C. (1998) Comparison between von Willebrand factor 
(VWF) and VWF antigen II in normal individuals and patients with von 
Willebrand disease. Thrombosis and Haemostasis, 80, 37-41.
Debeire, P., Montreuil, J., Samor, B., Mazurier, C., Goudemand, M., van Halbeek,
H. & Vliegenthart, J.F. (1983) Structure determination of the major 
asparagine-linked sugar chain of human factor VIII--von Willebrand factor. 
FEBS Lett, 151, 22-26.
Debray, H., Montreuil, J., Lis, H. & Sharon, N. (1986) Affinity of four immobilized 
Erythrina lectins toward various N-linked glycopeptides and related 
oligosaccharides. Carbohydr Res, 151, 359-370.
Dent, J.A., Berkowitz, S.D., Ware, J., Kasper, C.K. & Ruggeri, Z.M. (1990)
Identification of a cleavage site directing the immunochemical detection of 
molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci 
USA,  87, 6306-6310.
Dent, J.A., Galbusera, M. & Ruggeri, Z.M. (1991) Heterogeneity of plasma von 
Willebrand factor multimers resulting from proteolysis of the constituent 
subunit. J Clin Invest, 88, 774-782.
Dobrkovska A, K.U., Chediak JR (1998) Pharmacokinetics, efficacy and safety of 
Humate-P in von Willebrand disease. Haemophilia, 4, 33-39.
185
Dong, J.F. (2005) Cleavage of ultra-large von Willebrand factor by ADAMTS-13 
underflow conditions. J Thromb Haemost, 3,1710-1716.
Dong, J.F., Moake, J.L., Bernardo, A., Fujikawa, K., Ball, C., Nolasco, L., Lopez,
J.A. & Cruz, M.A. (2003) ADAMTS-13 metalloprotease interacts with the 
endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem, 278, 
29633-29639.
Durocher, J.R., Payne, R.C. & Conrad, M.E. (1975) Role of sialic acid in erythrocyte 
survival. Blood, 45,11-20.
Eikenboom, J., Van Marion, V., Putter, H., Goodeve, A., Rodeghiero, F., Castaman, 
G., Federici, A.B., Batlle, J., Meyer, D., Mazurier, C., Goudemand, J., 
Schneppenheim, R., Budde, U., Ingerslev, J., Vorlova, Z., Habart, D., 
Holmberg, L., Lethagen, S., Pasi, J., Hill, F. & Peake, I. (2006) Linkage 
analysis in families diagnosed with type 1 von Willebrand disease in the 
European study, molecular and clinical markers for the diagnosis and 
management of type 1 VWD. J Thromb Haemost, 4, 774-782.
Eikenboom, J.C., Castaman, G., Kamphuisen, P.W., Rosendaal, F.R. & Bertina,
R.M. (2002) The factor Vlll/von Willebrand factor ratio discriminates between 
reduced synthesis and increased clearance of von Willebrand factor. 
Thrombosis and Haemostasis, 87, 252-257.
Eikenboom, J.C., Matsushita, T., Reitsma, P.H., Tuley, E.A., Castaman, G., Briet, E. 
& Sadler, J.E. (1996) Dominant type 1 von Willebrand disease caused by 
mutated cysteine residues in the D3 domain of von Willebrand factor. Blood, 
88, 2433-2441.
Eikenboom, J.C., Reitsma, P.H., Peerlinck, K.M. & Briet, E. (1993) Recessive 
inheritance of von Willebrand's disease type I. Lancet, 341, 982-986.
Ellies, L.G., Ditto, D., Levy, G.G., Wahrenbrock, M., Ginsburg, D., Varki, A., Le, D.T. 
& Marth, J.D. (2002) Sialyltransferase ST3Gal-IV operates as a dominant 
modifier of hemostasis by concealing asialoglycoprotein receptor ligands. 
Proceedings of the National Academy of Sciences of the United States of 
America, 99,10042-10047.
Emsley, J., Cruz, M., Handin, R. & Liddington, R. (1998) Crystal structure of the von 
Willebrand Factor A1 domain and implications for the binding of platelet 
glycoprotein lb. J Biol Chem, 273,10396-10401.
Englender, T., Lattuada, A., Mannucci, P.M., Sadler, J.E. & Inbal, A. (1996) Analysis 
of Arg834Gln and Val902Glu type 2A von Willebrand disease mutations: 
studies with recombinant von Willebrand factor and correlation with patient 
characteristics. Blood, 87, 2788-2794.
Favaloro, E.J. & Koutts, J. (1997) Laboratory assays for von Willebrand factor:
relative contribution to the diagnosis of von Willebrand's disease. Pathology, 
29, 385-391.
Fay, P.J., Kawai, Y., Wagner, D.D., Ginsburg, D., Bonthron, D., Ohlsson-Wilhelm, 
B.M., Chavin, S.I., Abraham, G.N., Handin, R.I., Orkin, S.H. & et al. (1986) 
Propolypeptide of von Willebrand factor circulates in blood and is identical to 
von Willebrand antigen II. Science, 232, 995-998.
Federici, A.B. (1998) Diagnosis of von Willebrand disease. Haemophilia, 4, 654-660.
186
Federici, A.B. (2006) Management of inherited von Willebrand disease in 2006. 
Semin Thromb Hemost, 32, 616-620.
Federici, A.B., Castaman, G. & Mannucci, P.M. (2002) Guidelines for the diagnosis 
and management of von Willebrand disease in Italy. Haemophilia, 8, 607- 
621.
Federici, A.B., Elder, J.H., De Marco, L., Ruggeri, Z.M. & Zimmerman, T.S. (1984) 
Carbohydrate moiety of von Willebrand factor is not necessary for 
maintaining multimeric structure and ristocetin cofactor activity but protects 
from proteolytic degradation. Journal of Clinical Investigation, 74, 2049-2055.
Federici, A.B., Mazurier, C., Berntorp, E., Lee, C.A., Scharrer, I., Goudemand, J., 
Lethagen, S., Nitu, I., Ludwig, G., Hilbert, L. & Mannucci, P.M. (2004)
Biologic response to desmopressin in patients with severe type 1 and type 2 
von Willebrand disease: results of a multicenter European study. Blood, 103, 
2032-2038.
Fowler, W.E., Berkowitz, L.R. & Roberts, H.R. (1989) DDAVP for type MB von 
Willebrand disease. Blood, 74,1859-1860.
Fressinaud, E., Mazurier, C. & Meyer, D. (2002) Molecular genetics of type 2 von 
Willebrand disease. Int J Hematol, 75, 9-18.
Fujikawa, K., Suzuki, H., McMullen, B. & Chung, D. (2001) Purification of human von 
Willebrand factor-cleaving protease and its identification as a new member of 
the metalloproteinase family. Blood, 98,1662-1666.
Fukui, H., Mikami, S., Okuda, T., Murashima, N. & Takase, T. (1977) Studies of von 
Willebrand factor: effects of different kinds of carbohydrate oxidases, SH- 
inhibitors and some other chemical reagents. British Journal of Haematology, 
36, 259-270.
Furlan, M., Robles, R., Affolter, D., Meyer, D., Baillod, P. & Lammle, B. (1993)
Triplet structure of von Willebrand factor reflects proteolytic degradation of 
high molecular weight multimers. Proc Natl Acad Sci USA,  90, 7503-7507.
Furlan, M., Robles, R. & Lamie, B. (1996) Partial purification and characterization of 
a protease from human plasma cleaving von Willebrand factor to fragments 
produced by in vivo proteolysis. Blood, 87, 4223-4234.
Gaucher, C., Uno, H., Yamazaki, T., Mashiba, H. & Mazurier, C. (1998) A new 
candidate mutation (N528S) within the von Willebrand factor propeptide 
identified in a Japanese patient with phenotype IIC of von Willebrand 
disease. Eur J Haematol, 61,145-148.
Gerritsen, H.E., Robles, R., Lammle, B. & Furlan, M. (2001) Partial amino acid 
sequence of purified von Willebrand factor-cleaving protease. Blood, 98, 
1654-1661.
Gerritsen, H.E., Turecek, P.L., Schwarz, H.P., Lammle, B. & Furlan, M. (1999)
Assay of von Willebrand factor (vWF)-cleaving protease based on decreased 
collagen binding affinity of degraded vWF: a tool for the diagnosis of 
thrombotic thrombocytopenic purpura (TTP). Thromb Haemost, 82,1386- 
1389.
187
Giddings, J.C. & Shall, L. (1987) Enhanced release of von Willebrand factor by 
human endothelial cells in culture in the presence of phorbol myristate 
acetate and interleukin 1. Thromb Res, 47, 259-267.
Gill, J.C., Endres-Brooks, J., Bauer, P.J., Marks, W.J., Jr. & Montgomery, R.R.
(1987) The effect of ABO blood group on the diagnosis of von Willebrand 
disease. Blood, 69,1691-1695.
Ginsburg, D., Handin, R.I., Bonthron, D.T., Donlon, T.A., Bruns, G.A., Latt, S.A. & 
Orkin, S.H. (1985) Human von Willebrand factor (vWF): isolation of 
complementary DNA (cDNA) clones and chromosomal localization. Science, 
228, 1401-1406.
Goodeve, A., Eikenboom, J., Castaman, G., Rodeghiero, F., Federici, A.B., Batlle,
J., Meyer, D., Mazurier, C., Goudemand, J., Schneppenheim, R., Budde, U., 
Ingerslev, J., Habart, D., Vorlova, Z., Holmberg, L., Lethagen, S., Pasi, J.,
Hill, F., Hashemi Soteh, M., Baronciani, L., Hallden, C., Guilliatt, A., Lester, 
W. & Peake, I. (2007) Phenotype and genotype of a cohort of families 
historically diagnosed with type 1 von Willebrand disease in the European 
study, Molecular and Clinical Markers for the Diagnosis and Management of 
Type 1 von Willebrand Disease (MCMDM-1VWD). Blood, 109,112-121.
Goodeve, A. & Peake, I. (2001) A standard nomenclature for von Willebrand factor 
gene mutations and polymorphisms. Best Pract Res Clin Haematol, 14, 235- 
240.
Goudemand, J., Mazurier, C., Samor, B., Bouquelet, S., Montreuil, J. &
Goudemand, M. (1985) Effect of carbohydrate modifications of factor Vlll/von 
Willebrand factor on binding to platelets. Thrombosis and Haemostasis, 53, 
390-395.
Goudemand, J., Scharrer, I., Bemtorp, E., Lee, C.A., Borel-Derlon, A., Stieltjes, N., 
Caron, C., Scherrmann, J.M., Bridey, F., Tellier, Z., Federici, A.B. & 
Mannucci, P.M. (2005) Pharmacokinetic studies on Wilfactin, a von 
Willebrand factor concentrate with a low factor VIII content treated with three 
virus-inactivation/removal methods. J Thromb Haemost, 3, 2219-2227.
Gralnick, H.R. (1978) Factor Vlll/von Willebrand factor protein. Galactose a cryptic 
determinant of von Willebrand factor activity. Journal of Clinical Investigation, 
62, 496-499.
Gralnick, H.R., Coller, B.S. & Sultan, Y. (1976) Carbohydrate deficiency of the factor 
Vlll/von Willebrand factor Protein in von Willebrand's disease variants. 
Science, 192, 56-59.
Gralnick, H.R., Sultan, Y. & Coller, B.S. (1977) Von Willebrand's disease: combined 
qualitative and quantitative abnormalities. New England Journal of Medicine, 
296, 1024-1030.
Gralnick, H.R., Williams, S.B., McKeown, L.P., Maisonneuve, P., Jenneau, C.,
Sultan, Y. & Rick, M.E. (1985) In vitro correction of the abnormal multimeric 
structure of von Willebrand factor in type I la von Willebrand’s disease. Proc 
Natl Acad Sci USA,  82, 5968-5972.
Gralnick, H.R., Williams, S.B., McKeown, L.P., Rick, M.E., Maisonneuve, P.,
Jenneau, C. & Sultan, Y. (1986) DDAVP in type I la von Willebrand's disease. 
Blood, 67, 465-468.
188
Gralnick, H.R., Williams, S.B. & Rick, M.E. (1983) Role of carbohydrate in multimeric 
structure of factor Vlll/von Willebrand factor protein. Proceedings of the 
National Academy of Sciences of the United States of America, 80, 2771- 
2774.
Haberichter, S.L., Balistreri, M., Christopherson, P., Morateck, P., Gavazova, S.,
Bellissimo, D.B., Manco-Johnson, M.J., Gill, J.C. & Montgomery, R.R. (2006) 
Assay of the von Willebrand factor (VWF) propeptide to identify patients with 
type 1 von Willebrand disease with decreased VWF survival. Blood, 108, 
3344-3351.
Haberichter, S.L., Jacobi, P. & Montgomery, R.R. (2003) Critical independent
regions in the VWF propeptide and mature VWF that enable normal VWF 
storage. Blood, 101,1384-1391.
Haberichter, S.L., Jozwiak, M.A., Rosenberg, J.B., Christopherson, P.A. &
Montgomery, R.R. (2002) The von Willebrand factor propeptide (VWFpp) 
traffics an unrelated protein to storage. Arterioscler Thromb Vase Biol, 22, 
921-926.
Hamilton, K.K. & Sims, P.J. (1987) Changes in cytosolic Ca2+ associated with von 
Willebrand factor release in human endothelial cells exposed to histamine. 
Study of microcarrier cell monolayers using the fluorescent probe indo-1. J 
Clin Invest, 79, 600-608.
Hansen, J.B., Wilsgard, L., Olsen, J.O. & Osterud, B. (1990) Formation and
persistence of procoagulant and fibrinolytic activities in circulation after 
strenuous physical exercise. Thromb Haemost, 64, 385-389.
Harvey, P.J., Keightley, A.M., Lam, Y.M., Cameron, C. & Lillicrap, D. (2000) A single 
nucleotide polymorphism at nucleotide -1793 in the von Willebrand factor 
(VWF) regulatory region is associated with plasma VWF:Ag levels. Br J 
Haematol, 109, 349-353.
Hashemi, S., Palmer, D.S., Aye, M.T. & Ganz, P.R. (1993) Platelet-activating factor 
secreted by DDAVP-treated monocytes mediates von Willebrand factor 
release from endothelial cells. J Cell Physiol, 154, 496-505.
Hattori, R., Hamilton, K.K., McEver, R.P. & Sims, P.J. (1989) Complement proteins 
C5b-9 induce secretion of high molecular weight multimers of endothelial von 
Willebrand factor and translocation of granule membrane protein GMP-140 
to the cell surface. J Biol Chem, 264, 9053-9060.
Hegeman, R.J., van den Eijnden-Schrauwen, Y. & Emeis, J.J. (1998) Adenosine 
3':5'-cyclic monophosphate induces regulated secretion of tissue-type 
plasminogen activator and von Willebrand factor from cultured human 
endothelial cells. Thromb Haemost, 79, 853-858.
Hewson, W. (1846) An inquiry into the properties of the blood with remarks on some 
of its morbid appearances. In: Experimental inquiries. Part I. The Sydenham 
Society, London, UK.
Hilbert, L., Gaucher, C. & Mazurier, C. (1995) Identification of two mutations
(Arg611 Cys and Arg611 His) in the A1 loop of von Willebrand factor (vWF) 
responsible for type 2 von Willebrand disease with decreased platelet- 
dependent function of vWF. Blood, 86, 1010-1018.
189
Hillery, C.A., Mancuso, D.J., Evan Sadler, J., Ponder, J.W., Jozwiak, M.A.,
Christopherson, P.A., Cox Gill, J., Paul Scott, J. & Montgomery, R.R. (1998) 
Type 2M von Willebrand disease: F606I and I662F mutations in the 
glycoprotein lb binding domain selectively impair ristocetin- but not 
botrocetin-mediated binding of von Willebrand factor to platelets. Blood, 91, 
1572-1581.
Holmberg, L., Nilsson, I.M., Borge, L., Gunnarsson, M. & Sjorin, E. (1983) Platelet 
aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in 
Type MB von Willebrand's disease. N Engl J Med, 309, 816-821.
Howard, M.A. & Firkin, B.G. (1971) Ristocetin--a new tool in the investigation of 
platelet aggregation. Thromb Dlath Haemorrh, 26, 362-369.
Hoyer, L.W. & Shainoff, J.R. (1980) Factor VIIl-related protein circulates in normal 
human plasma as high molecular weight multimers. Blood, 55,1056-1059.
Hoylaerts, M.F., Yamamoto, H., Nuyts, K., Vreys, I., Deckmyn, H. & Vermylen, J.
(1997) von Willebrand factor binds to native collagen VI primarily via its A1 
domain. Biochem J, 324 ( Pt 1), 185-191.
Iglesias, J.L., Lis, H. & Sharon, N. (1982) Purification and properties of a D-
galactose/N-acetyl-D-galactosamine-specific lectin from Erythrina cristagalli. 
EurJ Biochem, 123, 247-252.
Ingram, G.l. (1961) Increase in antihaemophilic globulin activity following infusion of 
adrenaline. J Physiol, 156, 217-224.
Ishibashi, S., Hammer, R.E. & Herz, J. (1994) Asialoglycoprotein receptor deficiency 
in mice lacking the minor receptor subunit. J Biol Chem, 269, 27803-27806.
Jacquemin, M., Neyrinck, A., Hermanns, M.I., Lavend'homme, R., Rega, F., Saint- 
Remy, J.M., Peerlinck, K., Van Raemdonck, D. & Kirkpatrick, C.J. (2006) 
FVIII production by human lung microvascular endothelial cells. Blood, 108, 
515-517.
Jaffe, E.A., Hoyer, L.W. & Nachman, R.L. (1973) Synthesis of antihemophilic factor 
antigen by cultured human endothelial cells. Journal of Clinical Investigation, 
52, 2757-2764.
James, P.D., Notley, C., Hegadom, C., Leggo, J., Tuttle, A., Tinlin, S., Brown, C., 
Andrews, C., Labelle, A., Chirinian, Y., O'Brien, L., Othman, M., Rivard, G., 
Rapson, D., Hough, C. & Lillicrap, D. (2007a) The mutational spectrum of 
type 1 von Willebrand disease: Results from a Canadian cohort study. Blood, 
109, 145-154.
James, P.D., Notley, C., Hegadom, C., Poon, M.C., Walker, I., Rapson, D. &
Lillicrap, D. (2007b) Challenges in defining type 2M von Willebrand disease: 
results from a Canadian cohort study. J Thromb Haemost, 5, 1914-1922.
James, P.D., Paterson, A.D., Notley, C., Cameron, C., Hegadom, C., Tinlin, S., 
Brown, C., O'Brien, L., Leggo, J. & Lillicrap, D. (2006) Genetic linkage and 
association analysis in type 1 von Willebrand disease: results from the 
Canadian type 1 VWD study. J Thromb Haemost, 4, 783-792.
190
Jem, C., Eriksson, E., Tengborn, L., Risberg, B., Wadenvik, H. & Jern, S. (1989)
Changes of plasma coagulation and fibrinolysis in response to mental stress. 
Thromb Haemost, 62, 767-771.
Kadir, R.A., Economides, D.L., Sabin, C.A., Owens, D. & Lee, C.A. (1999)
Variations in coagulation factors in women: effects of age, ethnicity, 
menstrual cycle and combined oral contraceptive. Thromb Haemost, 82, 
1456-1461.
Kanwar, S., Woodman, R.C., Poon, M.C., Murohara, T., Lefer, A.M., Davenpeck, 
K.L. & Kubes, P. (1995) Desmopressin induces endothelial P-selectin 
expression and leukocyte rolling in postcapillary venules. Blood, 86, 2760- 
2766.
Kao, K.J., Pizzo, S.V. & McKee, P.A. (1980) Factor Vlll/von Willebrand protein.
Modification of its carbohydrate causes reduced binding to platelets. Journal 
of Biological Chemistry, 255,10134-10139.
Katsumi, A., Tuley, E.A., Bodo, I. & Sadler, J.E. (2000) Localization of disulfide 
bonds in the cystine knot domain of human von Willebrand factor. J Biol 
Chem, 275, 25585-25594.
Kaufmann, J.E., Oksche, A., Wollheim, C.B., Gunther, G., Rosenthal, W. & Vischer, 
U.M. (2000) Vasopressin-induced von Willebrand factor secretion from 
endothelial cells involves V2 receptors and cAMP. J Clin Invest, 106, 107- 
116.
Keeney, S., Grundy, P., Collins, P.W. & Bowen, D.J. (2007) C1584 in von
Willebrand factor is necessary for enhanced proteolysis by ADAMTS13 in 
vitro. Haemophilia, 13, 405-408.
Kessler, C.M., Floyd, C.M., Frantz, S.C. & Orthner, C. (1990) Critical role of the
carbohydrate moiety in human von Willebrand factor protein for interactions 
with type I collagen. Thromb Res, 57, 59-76.
Kolatkar, A.R., Leung, A.K., Isecke, R., Brossmer, R., Drickamer, K. & Weis, W.l.
(1998) Mechanism of N-acetylgalactosamine binding to a C-type animal 
lectin carbohydrate-recognition domain. J Biol Chem, 273,19502-19508.
Laffan, M., Brown, S.A., Collins, P.W., Cumming, A.M., Hill, F.G., Keeling, D.,
Peake, I.R. & Pasi, K.J. (2004) The diagnosis of von Willebrand disease: a 
guideline from the UK Haemophilia Centre Doctors' Organization. 
Haemophilia, 10,199-217.
Lamont, P.A. & Ragni, M.V. (2005) Lack of desmopressin (DDAVP) response in
men with hemophilia A following liver transplantation. J Thromb Haemost, 3, 
2259-2263.
Lanke, E., Johansson, A.M., Hallden, C. & Lethagen, S. (2005) Genetic analysis of 
31 Swedish type 1 von Willebrand disease families reveals incomplete 
linkage to the von Willebrand factor gene and a high frequency of a certain 
disease haplotype. J Thromb Haemost, 3, 2656-2663.
Lankhof, H., van Hoeij, M., Schiphorst, M.E., Bracke, M., Wu, Y.P., Ijsseldijk, M.J., 
Vink, T., de Groot, P.G. & Sixma, J.J. (1996) A3 domain is essential for 
interaction of von Willebrand factor with collagen type III. Thromb Haemost, 
75, 950-958.
191
Laurell, C.B. (1966) [Immunoelectrophoresis of serum as a diagnostic aid]. 
Lakartidningen, 63, 3168-3171.
Legaz, M.E., Schmer, G., Counts, R.B. & Davie, E.W. (1973) Isolation and
characterization of human Factor VIII (antihemophilic factor). Journal of 
Biological Chemistry, 248, 3946-3955.
Lemmerhirt, H.L., Broman, K.W., Shavit, J.A. & Ginsburg, D. (2007) Genetic 
regulation of plasma von Willebrand factor levels: quantitative trait loci 
analysis in a mouse model. J Thromb Haemost, 5, 329-335.
Lemmerhirt, H.L., Shavit, J.A., Levy, G.G., Cole, S.M., Long, J.C. & Ginsburg, D. 
(2006) Enhanced VWF biosynthesis and elevated plasma VWF due to a 
natural variant in the murine Vwf gene. Blood, 108, 3061-3067.
Lenting, P.J., Westein, E., Terraube, V., Ribba, A.S., Huizinga, E.G., Meyer, D., de 
Groot, P.G. & Denis, C.V. (2004) An experimental model to study the in vivo 
survival of von Willebrand factor. Basic aspects and application to the 
R1205H mutation. J Biol Chem, 279, 12102-12109.
Lester, W.A., Guilliatt, A.M., Surdhar, G.K., Enayat, S.M., Wilde, J.T., Willoughby,
S., Grundy, P., Cumming, A.M., Collins, P.W. & Hill, F.G. (2006) Inherited 
and de novo von Willebrand disease 'Vicenza' in UK families with the 
R1205H mutation: diagnostic pitfalls and new insights. Br J Haematol, 135, 
91-96.
Lethagen, S., Carlson, M. & Hillarp, A. (2004) A comparative in vitro evaluation of 
six von Willebrand factor concentrates. Haemophilia, 10, 243-249.
Levine, J.D., Harlan, J.M., Harker, L.A., Joseph, M.L. & Counts, R.B. (1982)
Thrombin-mediated release of factor VIII antigen from human umbilical vein 
endothelial cells in culture. Blood, 60, 531-534.
Levy, G. & Ginsburg, D. (2001) Getting at the variable expressivity of von Willebrand 
disease. Thrombosis and Haemostasis, 86,144-148.
Levy, G.G., Nichols, W.C., Lian, E.C., Foroud, T., McClintick, J.N., McGee, B.M., 
Yang, A.Y., Siemieniak, D.R., Stark, K.R., Gruppo, R., Sarode, R., Shurin, 
S.B., Chandrasekaran, V., Stabler, S.P., Sabio, H., Bouhassira, E.E., 
Upshaw, J.D., Jr., Ginsburg, D. & Tsai, H.M. (2001) Mutations in a member 
of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. 
Nature, 413, 488-494.
Levy-Toledano, S., Caen, J.P., Halmos, T. & Mester, L. (1973) Dissociation between 
human platelet agglomerating activity and factor VIII procoagulant activity of 
bovine plasma preparations by chemical treatment. I. Effect of 
neuraminidase. Pathol Biol (Paris), 21, Suppl:60-62.
Liu, L., Choi, H., Bernardo, A., Bergeron, A.L., Nolasco, L., Ruan, C., Moake, J.L. & 
Dong, J.F. (2005) Platelet-derived VWF-cleaving metalloprotease ADAMTS- 
13. J Thromb Haemost, 3, 2536-2544.
Lowe, J.B. (1993) The blood group-specific human glycosyltransferases. Baillieres 
Clin Haematol, 6, 465-492.
192
Lynch, D.C., Zimmerman, T.S., Collins, C.J., Brown, M., Morin, M.J., Ling, E.H. &
Livingston, D.M. (1985) Molecular cloning of cDNA for human von Willebrand 
factor: authentication by a new method. Cell, 41, 49-56.
Lyons, S.E., Bruck, M.E., Bowie, E.J. & Ginsburg, D. (1992) Impaired intracellular
transport produced by a subset of type IIA von Willebrand disease mutations. 
J Biol Chem, 267, 4424-4430.
Macfarlane, D.E., Stibbe, J., Kirby, E.P., Zucker, M.B., Grant, R.A. & McPherson, J. 
(1975) Letter: A method for assaying von Willebrand factor (ristocetin 
cofactor). Thromb Diath Haemorrh, 34, 306-308.
Mancuso, D.J., Tuley, E.A., Westfield, L.A., Lester-Mancuso, T.L., Le Beau, M.M., 
Sorace, J.M. & Sadler, J.E. (1991) Human von Willebrand factor gene and 
pseudogene: structural analysis and differentiation by polymerase chain 
reaction. Biochemistry, 30, 253-269.
Mannucci, P., Canciani, T., Rota, L., Donovan, B. (1982) Response of factor Vlll/von 
Willebrand factor to DDAVP in healthy subjects and patients with 
haemophilia A and von Willebrand's disease. British Journal of Haematology, 
47, 283-293.
Mannucci, P., Gagnatelli, G, D'Alonozo (1972) Stress and blood coagulation. 
Schattauer Verlag, Stuttgart.
Mannucci, P.M. (1997) Desmopressin (DDAVP) in the treatment of bleeding 
disorders: the first 20 years. Blood, 90, 2515-2521.
Mannucci, P.M. (2004) Treatment of von Willebrand's Disease. N Engl J Med, 351, 
683-694.
Mannucci, P.M., Bettega, D. & Cattaneo, M. (1992) Patterns of development of
tachyphylaxis in patients with haemophilia and von Willebrand disease after 
repeated doses of desmopressin (DDAVP). Br J Haematol, 82, 87-93.
Mannucci, P.M., Capoferri, C. & Canciani, M.T. (2004) Plasma levels of von
Willebrand factor regulate ADAMTS-13, its major cleaving protease. BrJ 
Haematol, 126, 213-218.
Mannucci, P.M. & Cattaneo, M. (1992) Desmopressin: a nontransfusional treatment 
of hemophilia and von Willebrand disease. Haemostasis, 22, 276-280.
Mannucci, P.M., Lombardi, R., Castaman, G., Dent, J.A., Lattuada, A., Rodeghiero, 
F. & Zimmerman, T.S. (1988) von Willebrand disease "Vicenza" with larger- 
than-normal (supranormal) von Willebrand factor multimers. Blood, 71, 65- 
70.
Mannucci, P.M., Pareti, F.I., Holmberg, L., Nilsson, I.M. & Ruggeri, Z.M. (1976) 
Studies on the prolonged bleeding time in von Willebrand's disease. J Lab 
Clin Med, 88, 662-671.
Mannucci, P.M., Ruggeri, Z.M., Pareti, F.l. & Capitanio, A. (1977) 1-Deamino-8-d- 
arginine vasopressin: a new pharmacological approach to the management 
of haemophilia and von Willebrands' diseases. Lancet, 1, 869-872.
Marcianiak, E. (1957) The influence of adrenaline in blood coagulation. Acta Physiol 
Pol, 8, 224.
193
Matsui, T., Kihara, C., Fujimura, Y., Mizuochi, T. &Titani, K. (1991) Carbohydrate 
analysis of human von Willebrand factor with horseradish peroxidase- 
conjugated lectins. Biochemical and Biophysical Research Communications, 
178, 1253-1259.
Matsui, T., Shimoyama, T., Matsumoto, M., Fujimura, Y., Takemoto, Y., Sako, M., 
Hamako, J. & Titani, K. (1999) ABO blood group antigens on human plasma 
von Willebrand factor after ABO-mismatched bone marrow transplantation. 
Blood, 94, 2895-2900.
Matsui, T., Titani, K. & Mizuochi, T. (1992) Structures of the asparagine-linked
oligosaccharide chains of human von Willebrand factor. Occurrence of blood 
group A, B, and H(O) structures. Journal of Biological Chemistry, 267, 8723- 
8731.
Mazurier, C. (1992) von Willebrand disease masquerading as haemophilia A. 
Thromb Haemost, 67, 391-396.
Mazurier, C., Gaucher, C., Jorieux, S. & Goudemand, M. (1994) Biological effect of 
desmopressin in eight patients with type 2N ('Normandy') von Willebrand 
disease. Collaborative Group. Br J Haematol, 88, 849-854.
Mazurier, C., Goudemand, J., Hilbert, L., Caron, C., Fressinaud, E. & Meyer, D. 
(2001) Type 2N von Willebrand disease: clinical manifestations, 
pathophysiology, laboratory diagnosis and molecular biology. Best Pract Res 
Clin Haematol, 14, 337-347.
Meriane, F., Zerhouni, L., Djeha, N., Goudemand, M. & Mazurier, C. (1993)
Biological effects of a S/D-treated, very high purity, von Willebrand factor 
concentrate in five patients with severe von Willebrand disease. Blood 
Coagu! Fibrinolysis, 4,1023-1029.
Meyer, D., Fressinaud, E., Gaucher, C., Lavergne, J.M., Hilbert, L., Ribba, A.S., 
Jorieux, S. & Mazurier, C. (1997) Gene defects in 150 unrelated French 
cases with type 2 von Willebrand disease: from the patient to the gene. 
INSERM Network on Molecular Abnormalities in von Willebrand Disease. 
Thromb Haemost, 78, 451-456.
Michiels, J.J., van de Velde, A., van Vliet, H.H., van der Planken, M., Schroyens, W. 
& Bememan, Z. (2002) Response of von Willebrand factor parameters to 
desmopressin in patients with type 1 and type 2 congenital von Willebrand 
disease: diagnostic and therapeutic implications. Seminars in Thrombosis 
and Hemostasis, 28,111 -132.
Miller, C.H., Dilley, A., Richardson, L., Hooper, W.C. & Evatt, B.L. (2001) Population 
differences in von Willebrand factor levels affect the diagnosis of von 
Willebrand disease in African-American women. Am J Hematol, 67, 125-129.
Miller, C.H., Graham, J.B., Goldin, L.R. & Elston, R.C. (1979a) Genetics of classic 
von Willebrand's disease. I. Phenotypic variation within families. Blood, 54, 
117-136.
Miller, C.H., Graham, J.B., Goldin, L.R. & Elston, R.C. (1979b) Genetics of classic 
von Willebrand's disease. II. Optimal assignment of the heterozygous 
genotype (diagnosis) by discriminant analysis. Blood, 54,137-145.
194
Moake, J.L., Rudy, C.K., Troll, J.H., Weinstein, M.J., Colannino, N.M., Azocar, J., 
Seder, R.H., Hong, S.L. & Deykin, D. (1982) Unusually large plasma factor 
Vllkvon Willebrand factor multimers in chronic relapsing thrombotic 
thrombocytopenic purpura. N Engl J Med, 307,1432-1435.
Moffat, E.H., Giddings, J.C. & Bloom, A.L. (1984) The effect of desamino-D-arginine 
vasopressin (DDAVP) and naloxone infusions on factor VIII and possible 
endothelial cell (EC) related activities. Br J Haematol, 57, 651-662.
Mohlke, K.L., Nichols, W.C. & Ginsburg, D. (1999a) The molecular basis of von 
Willebrand disease. Int J Clin Lab Res, 29,1-7.
Mohlke, K.L., Purkayastha, A.A., Westrick, R.J. & Ginsburg, D. (1998) Comparative 
mapping of distal murine chromosome 11 and human 17q21.3 in a region 
containing a modifying locus for murine plasma von Willebrand factor level. 
Genomics, 54,19-30.
Mohlke, K.L., Purkayastha, A.A., Westrick, R.J., Smith, P.L., Petryniak, B., Lowe,
J.B. & Ginsburg, D. (1999b) Mvwf, a dominant modifier of murine von 
Willebrand factor, results from altered lineage-specific expression of a 
glycosyltransferase. Cell, 96,111-120.
Montgomery, R.R. & Zimmerman, T.S. (1978) von Willebrand's disease antigen II. A 
new plasma and platelet antigen deficient in severe von Willebrand's 
disease. J Clin Invest, 61, 1498-1507.
Morales, L.D., Martin, C. & Cruz, M.A. (2006) The interaction of von Willebrand
factor-A1 domain with collagen: mutation G1324S (type 2M von Willebrand 
disease) impairs the conformational change in A1 domain induced by 
collagen. J Thromb Haemost, 4, 417-425.
Morell, A.G., Gregoriadis, G., Scheinberg, I.H., Hickman, J. & Ashwell, G. (1971)
The role of sialic acid in determining the survival of glycoproteins in the 
circulation. J Biol Chem, 246,1461-1467.
Morfini, M., Mannucci, P.M., Tenconi, P.M., Longo, G., Mazzucconi, M.G., 
Rodeghiero, F., Ciavarella, N., De Rosa, V. & Arter, A. (1993) 
Pharmacokinetics of monoclonally-purified and recombinant factor VIII in 
patients with severe von Willebrand disease. Thromb Haemost, 70, 270-272.
Morisato, D.K. & Gralnick, H.R. (1980) Selective binding of the factor Vlll/von 
Willebrand factor protein to human platelets. Blood, 55, 9-15.
Motto, D.G., Chauhan, A.K., Zhu, G., Homeister, J., Lamb, C.B., Desch, K.C.,
Zhang, W., Tsai, H.M., Wagner, D.D. & Ginsburg, D. (2005) Shigatoxin 
triggers thrombotic thrombocytopenic purpura in genetically susceptible 
ADAMTS 13-deficient mice. J Clin Invest, 115, 2752-2761.
Murdock, P.J., Woodhams, B.J., Matthews, K.B., Pasi, K.J. & Goodall, A.H. (1997) 
von Willebrand factor activity detected in a monoclonal antibody-based 
ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for 
diagnostic use. Thromb Haemost, 78,1272-1277.
Nachman, R., Levine, R. & Jaffe, E.A. (1977) Synthesis of factor VIII antigen by 
cultured guinea pig megakaryocytes. J Clin Invest, 60, 914-921.
195
Nelsestuen, G.L. & Suttie, J.W. (1971) Properties of asialo and aglycoprothrombin. 
Biochem Biophys Res Commun, 45,198-203.
Nichols, T.C., Samama, C.M., Bellinger, D.A., Roussi, J., Reddick, R.L., Bonneau, 
M., Read, M.S., Bailliart, O., Koch, G.G., Vaiman, M. & et al. (1995a)
Function of von Willebrand factor after crossed bone marrow transplantation 
between normal and von Willebrand disease pigs: effect on arterial 
thrombosis in chimeras. Proc Natl Acad Sci USA,  92, 2455-2459.
Nichols, W.C., Cooney, K.A., Mohlke, K.L., Ballew, J.D., Yang, A., Bruck, M.E., 
Reddington, M., Novak, E.K., Swank, R.T. & Ginsburg, D. (1995b) von 
Willebrand disease in the RIIIS/J mouse is caused by a defect outside of the 
von Willebrand factor gene. Blood, 86, 2461.
Nilsson, I.M., Blomback, M., Jorpes, E., Blomback, B. & Johansson, S.A. (1957a) 
Von Willebrand's disease and its correction with human plasma fraction 1-0. 
Acta Med Scand, 159,179-188.
Nilsson, I.M., Blomback, M. & Von Francken, I. (1957b) On an inherited autosomal 
hemorrhagic diathesis with antihemophilic globulin (AHG) deficiency and 
prolonged bleeding time. Acta Med Scand, 159, 35-57.
Nitu-Whalley, I.C., Lee, C.A., Griffioen, A., Jenkins, P.V. & Pasi, K.J. (2000) Type 1 
von Willebrand disease - a clinical retrospective study of the diagnosis, the 
influence of the ABO blood group and the role of the bleeding history. Br J 
Haematol, 108, 259-264.
Nitu-Whalley IC, R.A., Lee CA, Pasi KJ, Owens D, Enayat MS, Perkins SJ, Jenkins 
PV. (2000) Identification of type 2 von Willebrand disease in previously 
diagnosed type 1 patients: a reappraisal using phenotypes, genotypes and 
molecular modelling. Thrombosis and Haemostasis, 86, 998-1004.
Nolan, B., White, B., Smith, J., O'Reily, C., Fitzpatrick, B. & Smith, O.P. (2000)
Desmopressin: therapeutic limitations in children and adults with inherited 
coagulation disorders. Br J Haematol, 109, 865-869.
Nossent, A.Y., V, V.A.N.M., NH, V.A.N.T., Rosendaal, F.R., Bertina, R.M., JA, 
V.A.N.M. & Eikenboom, H.C. (2006) von Willebrand factor and its 
propeptide: the influence of secretion and clearance on protein levels and 
the risk of venous thrombosis. J Thromb Haemost, 4, 2556-2562.
O'Brien, L.A., James, P.D., Othman, M., Berber, E., Cameron, C., Notley, C.R.,
Hegadom, C.A., Sutherland, J.J., Hough, C., Rivard, G.E., O'Shaunessey, D. 
& Lillicrap, D. (2003) Founder von Willebrand factor haplotype associated 
with type 1 von Willebrand disease. Blood, 102, 549-557.
O'Donnell, J., Boulton, F.E., Manning, R.A. & Laffan, M.A. (2002a) Amount of H 
antigen expressed on circulating von Willebrand factor is modified by ABO 
blood group genotype and is a major determinant of plasma von Willebrand 
factor antigen levels. Arterioscler Thromb Vase Biol, 22, 335-341.
O'Donnell, J., Boulton, F.E., Manning, R.A. & Laffan, M.A. (2002b) Genotype at the 
secretor blood group locus is a determinant of plasma von Willebrand factor 
level. Br J Haematol, 116, 350-356.
196
O'Donnell, J. & Laffan, M.A. (2001) The relationship between ABO histo-blood
group, factor VIII and von Willebrand factor. Transfusion Medicine, 11, 343- 
351.
O'Donnell, J. & Laffan, M.A. (2003) Dissociation of ABH antigen expression from
von Willebrand factor synthesis in endothelial cell lines. Br J Haematoi, 121, 
928-931.
O'Donnell, J., Mille-Baker, B. & Laffan, M. (2000) Human umbilical vein endothelial 
cells differ from other endothelial cells in failing to express ABO blood group 
antigens. J Vase Res, 37, 540-547.
O'Donnell, J.S., McKinnon, T.A., Crawley, J.T., Lane, D.A. & Laffan, M.A. (2005) 
Bombay phenotype is associated with reduced plasma-VWF levels and an 
increased susceptibility to ADAMTS13 proteolysis. Blood, 106,1988-1991.
Orstavik, K.H., Magnus, P., Reisner, H., Berg, K., Graham, J.B. & Nance, W. (1985) 
Factor VIII and factor IX in a twin population. Evidence for a major effect of 
ABO locus on factor VIII level. Am J Hum Genet, 37, 89-101.
Osawa, T. & Tsuji, T. (1987) Fractionation and structural assessment of
oligosaccharides and glycopeptides by use of immobilized lectins. Annu Rev 
Biochem, 56, 21-42.
Over, J., Sixma, J.J., Bruine, M.H., Trieschnigg, M.C., Vlooswijk, R.A., Beeser-
Visser, N.H. & Bouma, B.N. (1978) Survival of 125iodine-labeled Factor VIII 
in normals and patients with classic hemophilia. Observations on the 
heterogeneity of human Factor VIII. J Clin Invest, 62, 223-234.
Pasi, K.J., Collins, P.W., Keeling, D.M., Brown, S.A., Cumming, A.M., Dolan, G.C., 
Hay, C.R., Hill, F.G., Laffan, M. & Peake, I.R. (2004) Management of von 
Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' 
Organization. Haemophilia, 10, 218-231.
Penas, N., Perez-Rodriguez, A., Torea, J.H., Loures, E., Noya, M.S., Lopez-
Fernandez, M.F. & Batlle, J. (2005) von Willebrand disease R1374C: type 2A 
or 2M? A challenge to the revised classification. High frequency in the 
northwest of Spain (Galicia). Am J Hematol, 80,188-196.
Pergolizzi, R.G., Jin, G., Chan, D., Pierre, L., Bussel, J., Ferris, B., Leopold, P.L. & 
Crystal, R.G. (2006) Correction of a murine model of von Willebrand disease 
by gene transfer. Blood, 108, 862-869.
Pierce-Cretel, A., Pamblanco, M., Strecker, G., Montreuil, J., Spik, G., Dorland, L., 
Van Halbeek, H. & Vliegenthart, J.F. (1982) Primary structure of the N- 
glycosidically linked sialoglycans of secretory immunoglobulins A from 
human milk. European Journal of Biochemistry, 125, 383-388.
Pimanda, J.E., Ganderton, T., Maekawa, A., Yap, C.L., Lawler, J., Kershaw, G.,
Chesterman, C.N. & Hogg, P.J. (2004) Role of thrombospondin-1 in control 
of von Willebrand factor multimer size in mice. J Biol Chem, 279, 21439- 
21448.
Plow, E.F., Pierschbacher, M.D., Ruoslahti, E., Marguerie, G.A. & Ginsberg, M.H. 
(1985) The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von 
Willebrand factor binding to platelets. Proc Natl Acad Sci USA,  82, 8057- 
8061.
197
Pruis, J. & Emeis, J.J. (1990) Endothelin-1 and -3 induce the release of tissue-type 
plasminogen activator and von Willebrand factor from endothelial cells. Eur J 
Pharmacol, 187,105-112.
Purvis, A.R. & Sadler, J.E. (2004) A covalent oxidoreductase intermediate in
propeptide-dependent von Willebrand factor multimerization. J Biol Chem, 
279, 49982-49988.
Rastegar-Lari, G., Villoutreix, B.O., Ribba, A.S., Legendre, P., Meyer, D. & Baruch,
D. (2002) Two clusters of charged residues located in the electropositive 
face of the von Willebrand factor A1 domain are essential for heparin 
binding. Biochemistry, 41, 6668-6678.
Reiter, R.A., Knobl, P., Varadi, K. & Turecek, P.L. (2003) Changes in von Willebrand 
factor-cleaving protease (ADAMTS13) activity after infusion of 
desmopressin. Blood, 101, 946-948.
Ribba, A.S., Loisel, I., Lavergne, J.M., Juhan-Vague, I., Obert, B., Cherel, G.,
Meyer, D. & Girma, J.P. (2001) Ser968Thr mutation within the A3 domain of 
von Willebrand factor (VWF) in two related patients leads to a defective 
binding of VWF to collagen. Thromb Haemost, 86, 848-854.
Ribes, J.A., Francis, C.W. & Wagner, D.D. (1987) Fibrin induces release of von 
Willebrand factor from endothelial cells. J Clin Invest, 79,117-123.
Riddell, A.F., Jenkins, P.V., Nitu-Whalley, I.C., McCraw, A.H., Lee, C.A. & Brown, 
S.A. (2002) Use of the collagen-binding assay for von Willebrand factor in 
the analysis of type 2M von Willebrand disease: a comparison with the 
ristocetin cofactor assay. Br J Haematol, 116,187-192.
Rodeghiero, F. & Castaman, G. (2001) Congenital von Willebrand disease type I: 
definition, phenotypes, clinical and laboratory assessment. Best Pract Res 
Clin Haematol, 14, 321-335.
Rodeghiero, F., Castaman, G., Di Bona, E. & Ruggeri, M. (1989) Consistency of 
responses to repeated DDAVP infusions in patients with von Willebrand's 
disease and hemophilia A. Blood, 74,1997-2000.
Rodeghiero, F., Castaman, G., Di Bona, E., Ruggeri, M., Lombardi, R. & Mannucci, 
P.M. (1988) Hyper-responsiveness to DDAVP for patients with type I von 
Willebrand's disease and normal intra-platelet von Willebrand factor. Eur J 
Haematol, 40,163-167.
Rodeghiero, F., Castaman, G. & Dini, E. (1987) Epidemiological investigation of the 
prevalence of von Willebrand's disease. Blood, 69, 454-459.
Rodeghiero, F., Castaman, G. & Mannucci, P.M. (1996) Prospective multicenter 
study on subcutaneous concentrated desmopressin for home treatment of 
patients with von Willebrand disease and mild or moderate hemophilia A. 
Thromb Haemost, 76, 692-696.
Rodeghiero, F., Castaman, G. & Tosetto, A. (1990) von Willebrand factor antigen is 
less sensitive than ristocetin cofactor for the diagnosis of type I von 
Willebrand disease-results based on an epidemiological investigation. 
Thromb Haemost, 64, 349-352.
198
Rodeghiero, F., Castaman, G., Tosetto, A., Batlle, J., Baudo, F., Cappelletti, A., 
Casana, P., De Bosch, N., Eikenboom, J.C., Federici, A.B., Lethagen, S., 
Linari, S. & Srivastava, A. (2005) The discriminant power of bleeding history 
for the diagnosis of type 1 von Willebrand disease: an international, 
multicenter study. J Thromb Haemost, 3, 2619-2626.
Romijn, R.A., Westein, E., Bouma, B., Schiphorst, M.E., Sixma, J.J., Lenting, P.J. & 
Huizinga, E.G. (2003) Mapping the collagen-binding site in the von 
Willebrand factor-A3 domain. J Biol Chem, 278,15035-15039.
Rosenberg, J.B., Haberichter, S.L., Jozwiak, M.A., Vokac, E.A., Kroner, P.A., Fahs, 
S.A., Kawai, Y. & Montgomery, R.R. (2002) The role of the D1 domain of the 
von Willebrand factor propeptide in multimerization of VWF. Blood, 100, 
1699-1706.
Rosenfeld, L. & Kirby, E.P. (1979) The effects of neuraminidase treatment on the 
biological activities of factor VIII. Thrombosis Research, 15, 255-261.
Roussi, J., Turecek, P.L., Andre, P., Bonneau, M., Pignaud, G., Bal dit Sollier, C.,
Schlokat, U., Dorner, F., Schwarz, H.P. & Drouet, L. (1998) Effects of human 
recombinant, plasma-derived and porcine von Willebrand factor in pigs with 
severe von Willebrand disease. Blood Coagul Fibrinolysis, 9, 361-372.
Ruggeri, Z.M. (1999) Structure and function of von Willebrand factor. Thromb 
Haemost, 82, 576-584.
Ruggeri, Z.M., Mannucci, P.M., Lombardi, R., Federici, A.B. & Zimmerman, T.S. 
(1982) Multimeric composition of factor Vlll/von Willebrand factor following 
administration of DDAVP: implications for pathophysiology and therapy of 
von Willebrand's disease subtypes. Blood, 59, 1272-1278.
Ruggeri, Z.M., Orje, J.N., Habermann, R., Federici, A.B. & Reininger, A.J. (2006) 
Activation-independent platelet adhesion and aggregation under elevated 
shear stress. Blood, 108,1903-1910.
Ruggeri, Z.M. & Zimmerman, T.S. (1981) Heterogeneity in von Willebrand's disease. 
Progress in Clinical and Biological Research, 72,139-148.
Ruggeri, Z.M. & Zimmerman, T.S. (1987) von Willebrand factor and von Willebrand 
disease. Blood, 70, 895-904.
Sadler, J.E. (1994) A revised classification of von Willebrand disease. For the
Subcommittee on von Willebrand Factor of the Scientific and Standardization 
Committee of the International Society on Thrombosis and Haemostasis. 
Thromb Haemost, 71, 520-525.
Sadler, J.E. (1998) Biochemistry and genetics of von Willebrand factor. Annual 
Review of Biochemistry, 67, 395-424.
Sadler, J.E. (2002) Von Willebrand disease type 1: a diagnosis in search of a 
disease. Blood.
Sadler, J.E. (2003) Von Willebrand disease type 1: a diagnosis in search of a 
disease. Blood, 101, 2089-2093.
Sadler, J.E. (2004) Slippery criteria for von Willebrand disease type 1. J Thromb 
Haemost, 2, 1720-1723.
199
Sadler, J.E. (2005) New concepts in von Willebrand disease. Annu Rev Med, 56, 
173-191.
Sadler, J.E., Budde, U., Eikenboom, J.C., Favaloro, E.J., Hill, F.G., Holmberg, L., 
Ingerslev, J., Lee, C.A., Lillicrap, D., Mannucci, P.M., Mazurier, C., Meyer,
D., Nichols, W.L., Nishino, M., Peake, I.R., Rodeghiero, F., Schneppenheim, 
R., Ruggeri, Z.M., Srivastava, A., Montgomery, R.R. & Federici, A.B. (2006) 
Update on the pathophysiology and classification of von Willebrand disease: 
a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost, 
4, 2103-2114.
Sadler, J.E., Shelton-lnloes, B.B., Sorace, J.M., Harlan, J.M., Titani, K. & Davie,
E.W. (1985) Cloning and characterization of two cDNAs coding for human 
von Willebrand factor. Proc Natl Acad Sci USA,  82, 6394-6398.
Salzman, E.W. (1963) Measurement of Platelet Adhesiveness. A Simple in Vitro 
Technique Demonstrating an Abnormality in Von Willebrand's Disease. J 
Lab Clin Med, 62, 724-735.
Samor, B., Mazurier, C., Goudemand, M., Debeire, P., Fournet, B. & Montreuil, J. 
(1982) Preliminary results on the carbohydrate moiety of factor Vlll/von 
Willebrand factor (FVIII/vWf). Thrombosis Research, 25, 81-89.
Samor, B., Michalski, J.C., Debray, H., Mazurier, C., Goudemand, M., Van Halbeek, 
H., Vliegenthart, J.F. & Montreuil, J. (1986) Primary structure of a new 
tetraantennary glycan of the N-acetyllactosaminic type isolated from human 
factor Vlll/von Willebrand factor. European Journal of Biochemistry, 158, 
295-298.
Samor, B., Michalski, J.C., Mazurier, C., Goudemand, M., De Waard, P.,
Vliegenthart, J.F., Strecker, G. & Montreuil, J. (1989) Primary structure of the 
major O-glycosidically linked carbohydrate unit of human von Willebrand 
factor. Glycoconjugate Journal, 6, 263-270.
Santoro, S.A. (1983) Preferential binding of high molecular weight forms of von 
Willebrand factor to fibrillar collagen. Biochim Biophys Acta, 756,123-126.
Schneppenheim, R., Budde, U. & Ruggeri, Z.M. (2001) A molecular approach to the 
classification of von Willebrand disease. Best Pract Res Clin Haematol, 14, 
281-298.
Schneppenheim, R., ObserT, Drewke E, Grosse-Wieltsch U, Oyen F, Sutor AH, 
Wermes C, Budde U (2001) Isolated molecular defects of von Willebrand 
factor binding to collagen do not correlate with bleeding symptoms. Blood, 
2001,41a.
Schneppenheim, R., Thomas, K.B., Krey, S., Budde, U., Jessat, U., Sutor, A.H. & 
Zieger, B. (1995) Identification of a candidate missense mutation in a family 
with von Willebrand disease type IIC. Hum Genet, 95, 681-686.
Schooten, C.J., Tjernberg, P., Westein, E., Terraube, V., Castaman, G., Mourik,
J.A., Hollestelle, M.J., Vos, H.L., Bertina, R.M., Berg, H.M., Eikenboom, J.C., 
Lenting, P.J. & Denis, C.V. (2005) Cysteine-mutations in von Willebrand 
factor associated with increased clearance. J Thromb Haemost, 3, 2228- 
2237.
200
Schorer, A.E., Moldow, C.F. & Rick, M.E. (1987) Interleukin 1 or endotoxin
increases the release of von Willebrand factor from human endothelial cells. 
Br J Haematol, 67, 193-197.
Scott, J.P., Montgomery, R.R. & Retzinger, G.S. (1991) Dimeric ristocetin
flocculates proteins, binds to platelets, and mediates von Willebrand factor- 
dependent agglutination of platelets. J Biol Chem, 266, 8149-8155.
Shapiro, G.A., Andersen, J.C., Pizzo, S.V. & McKee, P.A. (1973) The subunit
structure of normal and hemophilic factor VIII. J Clin Invest, 52, 2198-2210.
Sharon, N.L., H (1989) Lectins. Chapman and Hall Ltd, London.
Shavit, J.A., Lemmerhirt, D., Ginsburg, D. (2007) Regulation of plasma von 
Willebrand factor (VWF) by modifier genea. J Thromb Haemost.
Shima, M., Fujimura, Y., Nishiyama, T., Tsujiuchi, T., Narita, N., Matsui, T., Titani,
K., Katayama, M., Yamamoto, F. & Yoshioka, A. (1995) ABO blood group 
genotype and plasma von Willebrand factor in normal individuals. Vox 
Sanguinis, 68, 236-240.
Shinde, U., Fu, X. & Inouye, M. (1999) A pathway for conformational diversity in
proteins mediated by intramolecular chaperones. J Biol Chem, 274,15615- 
15621.
Short, P.E., Williams, C.E., Picken, A.M. & Hill, F.G. (1982) Factor VIII related 
antigen: an improved enzyme immunoassay. Med Lab Sci, 39, 351-355.
Simone, J.V., Vanderheiden, J. & Abildgaard, C.F. (1967) A semiautomatic one-
stage factor 8 assay with a commercially prepared standard. J Lab Clin Med, 
69, 706-712.
Sodetz, J.M., Paulson, J.C. & McKee, P.A. (1979) Carbohydrate composition and 
identification of blood group A, B, and H oligosaccharide structures on 
human Factor Vlll/von Willebrand factor. Journal of Biological Chemistry,
254, 10754-10760.
Sodetz, J.M., Paulson, J.C., Pizzo, S.V. & McKee, P.A. (1978) Carbohydrate on
human factor Vlll/von Willebrand factor. Impairment of function by removal of 
specific galactose residues. Journal of Biological Chemistry, 253, 7202-7206.
Sodetz, J.M., Pizzo, S.V. & McKee, P.A. (1977) Relationship of sialic acid to function 
and in vivo survival of human factor Vlll/von Willebrand factor protein.
Journal of Biological Chemistry, 252, 5538-5546.
Somosgyi, A. (1999) Clinical pharmacokinetics and dosing schedules. In: Human 
Pharmacology (ed. by J.L. TM Brody, KP Minnerman, HC Neu), pp. 47-65. 
Mosby, St Louis.
Souto, J.C., Almasy, L., Muniz-Diaz, E., Soria, J.M., Borrell, M., Bayen, L., Mateo,
J., Madoz, P., Stone, W., Blangero, J. & Fontcuberta, J. (2000) Functional 
effects of the ABO locus polymorphism on plasma levels of von Willebrand 
factor, factor VIII, and activated partial thromboplastin time. Arteriosclerosis, 
Thrombosis, and Vascular Biology, 20, 2024-2028.
201
Souto, J.C., Almasy, L., Soria, J.M., Buil, A., Stone, W., Lathrop, M., Blangero, J. & 
Fontcuberta, J. (2003) Genome-wide linkage analysis of von Willebrand 
factor plasma levels: results from the GAIT project. Thromb Haemost, 89, 
468-474.
Spik, G., Strecker, G., Foumet, B., Bouquelet, S., Montreuil, J., Doriand, L., van
Halbeek, H. & Vliegenthart, J.F. (1982) Primary structure of the glycans from 
human lactotransferrin. European Journal of Biochemistry, 121, 413-419.
Spivak, J.L. (1989) The in vivo metabolism of recombinant human erythropoietin. 
Contrib Nephrol, 76, 67-75; discussion 75-67.
Spom, L.A., Marder, V.J. & Wagner, D.D. (1986) Inducible secretion of large, 
biologically potent von Willebrand factor multimers. Cell, 46,185-190.
Spom, L.A., Marder, V.J. & Wagner, D.D. (1989) Differing polarity of the constitutive 
and regulated secretory pathways for von Willebrand factor in endothelial 
cells. J Cell Biol, 108, 1283-1289.
Stoddart, J.H., Jr., Andersen, J. & Lynch, D.C. (1996) Clearance of normal and type 
2A von Willebrand factor in the rat. Blood, 88,1692-1699.
Sultan, Y., Simeon, J., Maisonneuve, P. & Caen, J.P. (1976) Immunologic studies in 
von Willebrand's disease: alteration of factor Vlll/von Willebrand protein after 
transfusion with plasma concentrates in patients with von Willebrand's 
disease. Thromb Haemost, 35,110-119.
Sutherland, J.J., O'Brien, L.A., Lillicrap, D. & Weaver, D.F. (2004) Molecular 
modeling of the von Willebrand factor A2 Domain and the effects of 
associated type 2A von Willebrand disease mutations. J Mol Model (Online), 
10, 259-270.
Sweeney, J.D. & Hoemig, L.A. (1992) Intraplatelet von Willebrand factor and ABO 
blood group. Thromb Res, 68, 393-398.
Sweeney, J.D., Novak, E.K., Reddington, M., Takeuchi, K.H. & Swank, R.T. (1990) 
The RIIIS/J inbred mouse strain as a model for von Willebrand disease. 
Blood, 76, 2258-2265.
Takeuchi, M., Nagura, H. & Kaneda, T. (1988) DDAVP and epinephrine-induced 
changes in the localization of von Willebrand factor antigen in endothelial 
cells of human oral mucosa. Blood, 72, 850-854.
Titani, K., Kumar, S., Takio, K., Ericsson, L.H., Wade, R.D., Ashida, K., Walsh, K.A., 
Chopek, M.W., Sadler, J.E. & Fujikawa, K. (1986) Amino acid sequence of 
human von Willebrand factor. Biochemistry, 25, 3171-3184.
Tjemberg, P., Vos, H.L., Castaman, G., Bertina, R.M. & Eikenboom, J.C. (2004) 
Dimerization and multimerization defects of von Willebrand factor due to 
mutated cysteine residues. J Thromb Haemost, 2, 257-265.
Tranquille, N. & Emeis, J.J. (1991) On the role of calcium in the acute release of 
tissue-type plasminogen activator and von Willebrand factor from the rat 
perfused hindleg region. Thromb Haemost, 66, 479-483.
202
Tsai, H.M. (1996) Physiologic cleavage of von Willebrand factor by a plasma
protease is dependent on its conformation and requires calcium ion. Blood, 
87, 4235-4244.
Tsakiris, D.A., Haefeli, W.E., Linder, L., Steiner, B. & Marbet, G.A. (1995) Platelet
surface activation markers after DDAVP infusion in healthy subjects. Thromb 
Haemost, 74, 991-992.
Turecek, P.L., Gritsch, H., Pichler, L., Auer, W., Fischer, B., Mitterer, A., Mundt, W., 
Schlokat, U., Dorner, F., Brinkman, H.J., van Mourik, J.A. & Schwarz, H.P. 
(1997) In vivo characterization of recombinant von Willebrand factor in dogs 
with von Willebrand disease. Blood, 90, 3555-3567.
Turner, N., Nolasco, L., Tao, Z., Dong, J.F. & Moake, J. (2006) Human endothelial 
cells synthesize and release ADAMTS-13. J Thromb Haemost, 4,1396- 
1404.
van Genderen P. J. J, P.F.J., van de Moesdijk D., van Vliet H. H. D. M, van Strik J. 
J., Michiels J. J. (1997) Decreased half-life time of plasma von Willebrand 
factor collagen binding activity in essential thrombocythaemia; normalization 
after cytoreduction of the increased platelet count. Br J Haematol, 99, 832- 
836.
van Mourik, J.A., Boertjes, R., Huisveld, I.A., Fijnvandraat, K., Pajkrt, D., van
Genderen, P.J. & Fijnheer, R. (1999) von Willebrand factor propeptide in 
vascular disorders: A tool to distinguish between acute and chronic 
endothelial cell perturbation. Blood, 94,179-185.
van Mourik, J.A. & Romani de Wit, T. (2001) Von Willebrand factor propeptide in 
vascular disorders. Thromb Haemost, 86,164-171.
van Schooten, C.J., Denis, C.V., Lisman, T., Eikenboom, J.C., Leebeek, F.W., 
Goudemand, J., Fressinaud, E., van den Berg, H.M., de Groot, P.G. & 
Lenting, P.J. (2007) Variations in glycosylation of von Willebrand factor with 
O-linked sialylated T antigen are associated with its plasma levels. Blood, 
109, 2430-2437.
Vermylen, J., De Gaetano, G., Donati, M.B. & Verstraete, M. (1974) Platelet-
aggregating activity in neuraminidase-treated human cryoprecipitates: its 
correlation with factor-VIII-related antigen. British Journal of Haematology, 
26, 645-650.
Vermylen, J., Donati, M.B., De Gaetano, G. & Verstraete, M. (1973) Aggregation of 
human platelets by bovine or human factor VIII: role of carbohydrate side 
chains. Nature, 244, 167-168.
Verweij, C.L., Diergaarde, P.J., Hart, M. & Pannekoek, H. (1986) Full-length von 
Willebrand factor (vWF) cDNA encodes a highly repetitive protein 
considerably larger than the mature vWF subunit. Embo J, 5,1839-1847.
Vischer, U.M., Ingerslev, J., Wollheim, C.B., Mestries, J.C., Tsakiris, D.A., Haefeli, 
W.E. & Kruithof, E.K. (1997) Acute von Willebrand factor secretion from the 
endothelium in vivo: assessment through plasma propeptide (vWf:Agll) 
Levels. Thromb Haemost, 77, 387-393.
203
Vischer, U.M. & Wollheim, C.B. (1997) Epinephrine induces von Willebrand factor
release from cultured endothelial cells: involvement of cyclic AMP-dependent 
signalling in exocytosis. Thromb Haemost, 77, 1182-1188.
Vischer, U.M. & Wollheim, C.B. (1998) Purine nucleotides induce regulated
secretion of von Willebrand factor: involvement of cytosolic Ca2+ and cyclic 
adenosine monophosphate-dependent signaling in endothelial exocytosis. 
Blood, 91, 118-127.
Vlot, A.J., Koppelman, S.J., Bouma, B.N. & Sixma, J.J. (1998) Factor VIII and von 
Willebrand factor. Thrombosis and Haemostasis, 79, 456-465.
Vlot, A.J., Mauser-Bunschoten, E.P., Zarkova, A.G., Haan, E., Kruitwagen, C.L.,
Sixma, J.J. & van den Berg, H.M. (2000) The half-life of infused factor VIII is 
shorter in hemophiliac patients with blood group O than in those with blood 
group A. Thrombosis and Haemostasis, 83,65-69.
Von Willebrand, E.A. (1926) Hereditar pseudohemofili. Finska Lakaresallskapets 
Handlingar, 67, 7-112.
von Willebrand, E.A.J., R (1933) Uber eine neue Bluterkrangheit, die konstitutionelle 
Thrombopathie. Klin Wschr, 12, 414.
Voorberg, J., Fontijn, R., van Mourik, J.A. & Pannekoek, H. (1990) Domains 
involved in multimer assembly of von willebrand factor (vWF): 
multimerization is independent of dimerization. Embo J, 9, 797-803.
Wagner, D.D., Fay, P.J., Spom, L.A., Sinha, S., Lawrence, S.O. & Marder, V.J.
(1987) Divergent fates of von Willebrand factor and its propolypeptide (von 
Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad 
SciUSA,  84, 1955-1959.
Wagner, D.D. & Marder, V.J. (1984) Biosynthesis of von Willebrand protein by
human endothelial cells: processing steps and their intracellular localization. 
J Cell Biol, 99,2123-2130.
Wagner, D.D., Mayadas, T. & Marder, V.J. (1986) Initial glycosylation and acidic pH 
in the Golgi apparatus are required for multimerization of von Willebrand 
factor. J Cell Biol, 102, 1320-1324.
Weibel, E.P., GE (1964) New cytoplasmic components in arterial endothelia. J Cell 
Biol, 23,101-112.
Wemer, E.J., Broxson, E.H., Tucker, E.L., Giroux, D.S., Shults, J. & Abshire, T.C. 
(1993) Prevalence of von Willebrand disease in children: a multiethnic study. 
J Pediatr, 123, 893-898.
Wise, R.J., Pittman, D.D., Handin, R.I., Kaufman, R.J. & Orkin, S.H. (1988) The
propeptide of von Willebrand factor independently mediates the assembly of 
von Willebrand multimers. Cell, 52, 229-236.
Xie, L., Chesterman, C.N. & Hogg, P.J. (2001) Control of von Willebrand factor 
multimer size by thrombospondin-1. J Exp Med, 193, 1341-1349.
204
Zhang, Z.P., Falk, G., Blomback, M., Egberg, N. & Anvret, M. (1992a) A single 
cytosine deletion in exon 18 of the von Willebrand factor gene is the most 
common mutation in Swedish vWD type III patients. Hum Mol Genet, 1, 767- 
768.
Zhang, Z.P., Lindstedt, M., Falk, G., Blomback, M., Egberg, N. & Anvret, M. (1992b) 
Nonsense mutations of the von Willebrand factor gene in patients with von 
Willebrand disease type III and type I. Am J Hum Genet, 51, 850-858.
Zheng, X., Chung, D., Takayama, T.K., Majerus, E.M., Sadler, J.E. & Fujikawa, K. 
(2001) Structure of von Willebrand factor-cleaving protease (ADAMTS13), a 
metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol 
Chem, 276, 41059-41063.
Zimmerman, T.S., Ratnoff, O.D. & Powell, A.E. (1971) Immunologic differentiation of 
classic hemophilia (factor 8 deficiency) and von Willebrand's dissase, with 
observations on combined deficiencies of antihemophilic factor and 
proaccelerin (factor V) and on an acquired circulating anticoagulant against 
antihemophilic factor. J Clin Invest, 50, 244-254.
Zimmerman, T.S., Voss, R. & Edgington, T.S. (1979) Carbohydrate of the factor 
VIIl/von Willebrand factor in von Willebrand's disease. Journal of Clinical 
Investigation, 64, 1298-1302.
205
Appendices
206
Appendix 1
Nudeotide sequence of VWF cDNA and amino acid residues of pre-pro-VWF. The numbering of the 
nudeotides and amino acid residues are according to the ISTH subcommittee on VWF 
recommendations. (Goodeve and Peake, 2001) Numbering of the nucleotides commences with the 
initiator ATG and the numbering of the amino acid residues commences from the initiator methionine.
The nucleotide triplets (comprising A = adenine, T = thymine, G = guanine and C = cytosine) are in the 
upper line and the corresponding amino add residues (see end of sequence for abbreviations) are 
given below the nucleotide triplets. The numbering shows the number of the nucleotide and then the 
amino add residue at the start of each line, e.g. 73/25. The amino add residues to which the N-linked 
and O-linked oligosaccharide side chains are attached have been highlighted in red (N) and blue (S or 
T) respectively.
l / i
ATG ATT CCT GCC AGA TTT GCC GGG GTG CTG CTT GOT CTG GCC CTC ATT TTG CCA GGG ACC CTT TGT GCA GAA 
M I  P A  R F A  G V  L L  A L A  L I  L P G T L C A E
73/25
GGA ACT CGC GGC AGG TCA TCC ACG GCC CGA TGC AGC CTT TTC GGA AGT GAC TTC GTC AAC ACC TTT GAT GGG 
G T R G R S S  T A R  C S L F G  S D F V N T F D G
145/49
AGC ATG TAC AGC TTT GCG GGA TAC TGC AGT TAC CTC CTG GCA GGG GGC TGC CAG AAA CGC TCC TTC TCG ATT 
S M Y  S F A G Y C S Y  L L A G G C Q K R  S F  S I
217/73
ATT GGG GAC TTC CAG AAT GGC AAG AGA GTG AGC CTC TCC GTG TAT CTT GGG GAA TTT TTT GAC ATC CAT TTG 
I G D F Q N G K R V  S L S V Y L G E F F D I  H L
289/97
TTT GTC AAT GGT ACC GTG ACA CAG GGG GAC CAA AGA GTC TCC ATG CCC TAT GCC TCC AAA GGG CTG TAT CTA 
F V N G T V T Q G D Q  R V S M P Y A S K G L Y L
361/121
GAA ACT GAG GCT GGG TAC TAC AAG CTG TCC GGT GAG GCC TAT GGC TTT GTG GCC AGG ATC GAT GGC AGC GGC 
E T E A G Y Y K L S G E  A Y G F V  A R I D G S G
433/145
AAC TTT CAA GTC CTG CTG TCA GAC AGA TAC TTC AAC AAG ACC TGC GGG CTG TGT GGC AAC TTT AAC ATC TTT
N F Q V L L  S D R Y F N K T C G L C G N F N I F
505/169
GCT GAA GAT GAC TTT ATG ACC CAA GAA GGG ACC TTG ACC TCG GAC CCT TAT GAC TTT GCC AAC TCA TGG GCT 
A E  D D F M T Q E G T L  T S D P Y D F A N S W A
577/193
CTG AGC AGT GGA GAA CAG TGG TGT GAA CGG GCA TCT CCT CCC AGC AGC TCA TGC AAC ATC TCC TCT GGG GAA 
L S  S G  E Q W C E R A S P P S  S S C N I  S S G E
649/217
ATG CAG AAG GGC CTG TGG GAG CAG TGC CAG CTT CTG AAG AGC ACC TCG GTG TTT GCC CGC TGC CAC CCT CTG 
M Q K G L W E Q C Q L L K  S T S V F A R C H P L
721/241
GTG GAC CCC GAG CCT TTT GTG GCC CTG TGT GAG AAG ACT TTG TGT GAG TGT GCT GGG GGG CTG GAG TGC GCC 
V D P E P F V A L C E K T L C E C A G G L E C A
793/265
TGC CCT GCC CTC CTG GAG TAC GCC CGG ACC TGT GCC CAG GAG GGA ATG GTG CTG TAC GGC TGG ACC GAC CAC 
C P A L L E Y  A R T C A Q E G M V L Y  G W T D H
865/289
AGC GCG TGC AGC CCA GTG TGC CCT GCT GGT ATG GAG TAT AGG CAG TGT GTG TCC CCT TGC GCC AGG ACC TGC 
S A C S P V C P A G M E Y R Q C  V S P C A R T C
937/313
CAG AGC CTG CAC ATC AAT GAA ATG TGT CAG GAG CGA TGC GTG GAT GGC TGC AGC TGC CCT GAG GGA CAG CTC 
Q S  L H  I N E M C Q E R C V D  G C S C P E G Q L
1009/337
CTG GAT GAA GGC CTC TGC GTG GAG AGC ACC GAG TGT CCC TGC GTG CAT TCC GGA AAG CGC TAC CCT CCC GGC 
L D E G L C V E  S T E C P C V H S G K R Y  P P G
1081/361
ACC TCC CTC TCT CGA GAC TGC AAC ACC TGC ATT TGC CGA AAC AGC CAG TGG ATC TGC AGC AAT GAA GAA TGT 
T S L S R  D C N T C I C R N S Q W I C S N E E C
1153/385
CCA GGG GAG TGC CTT GTC ACA GGT CAA TCA CAC TTC AAG AGC TTT GAC AAC AGA TAC TTC ACC TTC AGT GGG 
P G E C L V T G Q S H F K S F D N R Y F T F S G
1225/409
ATC TGC CAG TAC CTG CTG GCC CGG GAT TGC CAG GAC CAC TCC TTC TCC ATT GTC ATT GAG ACT GTC CAG TGT 
I C Q Y L L A R D C Q D H S F S I V I  E T V Q C
1297/433
GCT GAT GAC CGC GAC GCT GTG TGC ACC CGC TCC GTC ACC GTC CGG CTG CCT GGC CTG CAC AAC AGC CTT GTG 
A D D  R D A V C T R S V T V R L P G L H N  S L V
1369/457
AAA CTG AAG CAT GGG GCA GGA GTT GCC ATG GAT GGC CAG GAC GTC CAG CTC CCC CTC CTG AAA GGT GAC CTC 
K L K H G A G V A M D G Q D V Q L P L L K G D L
1441/481
CGC ATC CAG CAT ACA GTG ACG GCC TCC GTG CGC CTC AGC TAC GGG GAG GAC CTG CAG ATG GAC TGG GAT GGC 
R I Q H T V T A S V R L S Y G E  D L Q M D W D G
1513/505
CGC GGG AGG CTG CTG GTG AAG CTG TCC CCC GTC TAT GCC GGG AAG ACC TGC GGC CTG TGT GGG AAT TAC AAT 
R G R L L V K L S P V Y A G K T C G L C G N Y N
1585/529
GGC AAC CAG GGC GAC GAC TTC CTT ACC CCC TCT GGG CTG GCG GAG CCC CGG GTG GAG GAC TTC GGG AAC GCC 
G N Q G D  D F L T P S G L A E P R V E  D F G N A
1657/553
TGG AAG CTG CAC GGG GAC TGC CAG GAC CTG CAG AAG CAG CAC AGC GAT CCC TGC GCC CTC AAC CCG CGC ATG 
W K L H G D C Q D L Q K Q H  S D P C A L N P R M
1729/577
ACC AGG TTC TCC GAG GAG GCG TGC GCG GTC CTG ACG TCC CCC ACA TTC GAG GCC TGC CAT CGT GCC GTC AGC 
T R F S E E A C  A V L T  S P T F E  A C H R A V S
1801/601
CCG CTG CCC TAC CTG CGG AAC TGC CGC TAC GAC GTG TGC TCC TGC TCG GAC GGC CGC GAG TGC CTG TGC GGC 
P L P Y L R N C R Y D V C S C S D G R E C L C G
1873/625
GCC CTG GCC AGC TAT GCC GCG GCC TGC GCG GGG AGA GGC GTG CGC GTC GCG TGG CGC GAG CCA GGC CGC TGT 
A L A S Y A A A C A G  R G V R V A W R E P G R C
1945/649
GAG CTG AAC TGC CCG AAA GGC CAG GTG TAC CTG CAG TGC GGG ACC CCC TGC AAC CTG ACC TGC CGC TCT CTC 
E L N C P K  G Q V Y L Q C G  T P C N L T C R S L
2017/673
TCT TAC CCG GAT GAG GAA TGC AAT GAG GCC TGC CTG GAG GGC TGC TTC TGC CCC CCA GGG CTC TAC ATG GAT 
S Y P D E  E C N E A C L E  G C F C P P G L Y M D
2089/697
GAG AGG GGG GAC TGC GTG CCC AAG GCC CAG TGC CCC TGT TAC TAT GAC GGT GAG ATC TTC CAG CCA GAA GAC 
E R G D C V P K A Q C P C Y Y D G E  I F Q P  E D
2161/721
ATC TTC TCA GAC CAT CAC ACC ATG TGC TAC TGT GAG GAT GGC TTC ATG CAC TGT ACC ATG AGT GGA GTC CCC 
I F S D H H  T M C Y C  E D G F  M H C T  M S  G V P
2233/745
GGA AGC TTG CTG CCT GAC GCT GTC CTC AGC AGT CCC CTG TCT CAT CGC AGC AAA AGG AGC CTA TCC TGT CGG 
G S L L P D A V L S  S P  L S H R  S K R Ser L S C R
2305/769
CCC CCC ATG GTC AAG CTG GTG TGT CCC GCT GAC AAC CTG CGG GCT GAA GGG CTC GAG TGT ACC AAA ACG TGC 
P P M V K L V C P A D N L R A E G L E  C T K T C
2377/793
CAG AAC TAT GAC CTG GAG TGC ATG AGC ATG GGC TGT GTC TCT GGC TGC CTC TGC CCC CCG GGC ATG GTC CGG 
Q N  Y  D L  E C M S  M G  C V S G  C L  C P P  G M V  R
2449/817
CAT GAG AAC AGA TGT GTG GCC CTG GAA AGG TGT CCC TGC TTC CAT CAG GGC AAG GAG TAT GCC CCT GGA GAA 
H E N R C V A L E R C P C F H Q G K  E Y A P G E
2521/841
ACA GTG AAG ATT GGC TGC AAC ACT TGT GTC TGT CGG GAC CGG AAG TGG AAC TGC ACA GAC CAT GTG TGT GAT 
T V  K I G C N T C V C R D R K W N C T  D H V C D
2593/865
GCC ACG TGC TCC ACG ATC GGC ATG GCC CAC TAC CTC ACC TTC GAC GGG CTC AAA TAC CTG TTC CCC GGG GAG 
A T C S T  I G M A H Y L T F D G L K Y  L F P G E
2665/889
TGC CAG TAC GTT CTG GTG CAG GAT TAC TGC GGC AGT AAC CCT GGG ACC TTT CGG ATC CTA GTG GGG AAT AAG 
C Q Y V L V  Q D Y  C G  S N P G T F R I  L V G N K
2737/913
GGA TGC AGC CAC CCC TCA GTG AAA TGC AAG AAA CGG GTC ACC ATC CTG GTG GAG GGA GGA GAG ATT GAG CTG 
G C  S H P S V K C K K R V  T I  L V E G G  E I E L
2809/937
TTT GAC GGG GAG GTG AAT GTG AAG AGG CCC ATG AAG GAT GAG ACT CAC TTT GAG GTG GTG GAG TCT GGC CGG 
F D G  E V N V K R P M K D E T H F E V V E S G R
2881/961
TAC ATC ATT CTG CTG CTG GGC AAA GCC CTC TCC GTG GTC TGG GAC CGC CAC CTG AGC ATC TCC GTG GTC CTG 
Y 1 I L L L G K A L S V V W D R H L S I S V V L
2953/985
AAG CAG ACA TAC CAG GAG AAA GTG TGT GGC CTG TGT GGG AAT TTT GAT GGC ATC CAG AAC AAT GAC CTC ACC 
K Q T Y Q E K V C G L C G N F D G I  Q N N D L T
3025/1009
AGC AGC AAC CTC CAA GTG GAG GAA GAC CCT GTG GAC TTT GGG AAC TCC TGG AAA GTG AGC TCG CAG TGT GCT 
S S N L Q V  E E D P V  D F G N  S W K V  S S Q C  A
3097/1033
GAC ACC AGA AAA GTG CCT CTG GAC TCA TCC CCT GCC ACC TGC CAT AAC AAC ATC ATG AAG CAG ACG ATG GTG 
D T R K V P L D S S P A T C H N N I M K Q T M V
3169/1057
GAT TCC TCC TGT AGA ATC CTT ACC AGT GAC GTC TTC CAG GAC TGC AAC AAG CTG GTG GAC CCC GAG CCA TAT 
D S S C R I L T S D V F Q  D C N K L V D P E P Y
3241/1081
CTG GAT GTC TGC ATT TAC GAC ACC TGC TCC TGT GAG TCC ATT GGG GAC TGC GCC TGC TTC TGC GAC ACC ATT 
L D V C  I Y D T  C S C  E S I G D C  A C F  C D T  I
3313/1105
GCT GCC TAT GCC CAC GTG TGT GCC CAG CAT GGC AAG GTG GTG ACC TGG AGG ACG GCC ACA TTG TGC CCC CAG 
A A Y A H  V C  A Q  H G K  V V  T W  R T  A T L C P Q
3385/1129
AGC TGC GAG GAG AGG AAT CTC CGG GAG AAC GGG TAT GAG TGT GAG TGG CGC TAT AAC AGC TGT GCA CCT GCC 
S C E E  R N L R E N G Y E C E W R Y N  S C A  P A
3457/1153
TGT CAA GTC ACG TGT CAG CAC CCT GAG CCA CTG GCC TGC CCT GTG CAG TGT GTG GAG GGC TGC CAT GCC CAC 
C Q V T C Q H P  E P L A C P V Q C V E G C H A H
3529/1177
TGC CCT CCA GGG AAA ATC CTG GAT GAG CTT TTG CAG ACC TGC GTT GAC CCT GAA GAC TGT CCA GTG TGT GAG 
C P P G K  I L D E L L Q T C V D P E D C P V  C E
3601/1201
GTG GCT GGC CGG CGT TTT GCC TCA GGA AAG AAA GTC ACC TTG AAT CCC AGT GAC CCT GAG CAC TGC CAG ATT 
V A G R R F A  S G K K  V T L N P  S D P E H C Q  I
3673/1225
TGC CAC TGT GAT GTT GTC AAC CTC ACC TGT GAA GCC TGC CAG GAG CCG GGA GGC CTG GTG GTG CCT CCC ACA 
C H C  D V V N L T C E A C Q E P G G L V V P  P T
3745/1249
GAT GCC CCG GTG AGC CCC ACC ACT CTG TAT GTG GAG GAC ATC TCG GAA CCG CCG TTG CAC GAT TTC TAC TGC 
D A P V S P T T L Y V E D I  S E  P P L H D F Y C
3817/1273
AGC AGG CTA CTG GAC CTG GTC TTC CTG CTG GAT GGC TCC TCC AGG CTG TCC GAG GCT GAG TTT GAA GTG CTG 
S R L L D L V F L L D G S  S R L  S E A E  F E V L
3889/1297
AAG GCC TTT GTG GTG GAC ATG ATG GAG CGG CTG CGC ATC TCC CAG AAG TGG GTC CGC GTG GCC GTG GTG GAG 
K A F V V  D M  M E  R L R  I S Q K W V R V  A V  V E
3961/1321
TAC CAC GAC GGC TCC CAC GCC TAC ATC GGG CTC AAG GAC CGG AAG CGA CCG TCA GAG CTG CGG CGC ATT GCC 
Y H D G S H A Y I G L K D R K R P  S E L R R I A
4033/1345
AGC CAG GTG AAG TAT GCG GGC AGC CAG GTG GCC TCC ACC AGC GAG GTC TTG AAA TAC ACA CTG TTC CAA ATC 
S Q V K Y A G  S Q V A S T S E V L K Y T L F Q I
4105/1369
TTC AGC AAG ATC GAC CGC CCT GAA GCC TCC CGC ATC GCC CTG CTC CTG ATG GCC AGC CAG GAG CCC CAA CGG 
F S  K I D R P E A S R I A L L L M A S Q E  P Q R
4177/1393
ATG TCC CGG AAC TTT GTC CGC TAC GTC CAG GGC CTG AAG AAG AAG AAG GTC ATT GTG ATC CCG GTG GGC ATT 
M S R N F V R Y V Q G L K K K K V  I V I  P V G I
4249/1417
GGG CCC CAT GCC AAC CTC AAG CAG ATC CGC CTC ATC GAG AAG CAG GCC CCT GAG AAC AAG GCC TTC GTG CTG 
G P H A N L K Q I  R L I E  K Q A P E N K A F V L
4321/1441
AGC AGT GTG GAT GAG CTG GAG CAG CAA AGG GAC GAG ATC GTT AGC TAC CTC TGT GAC CTT GCC CCT GAA GCC 
S S V D E  L E Q Q R D E  I V  S Y L C D L A P E A
4393/1465
CCT CCT CCT ACT CTG CCC CCC CAC ATG GCA CAA GTC ACT GTG GGC CCG GGG CTC TTG GGG GTT TCG ACC CTG 
P P  P T L P  P H M A Q  V  T V  G P G  L L G V S  T L
4465/1489
GGG CCC AAG AGG AAC TCC ATG GTT CTG GAT GTG GCG TTC GTC CTG GAA GGA TCG GAC AAA ATT GGT GAA GCC 
G P K R N S  M V L  D V A F V L E G S D K I  G E A
4537/1513
GAC TTC AAC AGG AGC AAG GAG TTC ATG GAG GAG GTG ATT CAG CGG ATG GAT GTG GGC CAG GAC AGC ATC CAC 
D F N  R S K E F M E E  V I  Q R M D V G Q D  S I H
4609/1537
GTC ACG GTG CTG CAG TAC TCC TAC ATG GTG ACC GTG GAG TAC CCC TTC AGC GAG GCA CAG TCC AAA GGG GAC 
V T V L Q Y S Y M V T V E Y  P F S E A Q S K G D
4681/1561
ATC CTG CAG CGG GTG CGA GAG ATC CGC TAC CAG GGC GGC AAC AGG ACC AAC ACT GGG CTG GCC CTG CGG TAC 
I L Q R  V R  E I R Y Q G G N R T N T G L A L R Y
4753/1585
CTC TCT GAC CAC AGC TTC TTG GTC AGC CAG GGT GAC CGG GAG CAG GCG CCC AAC CTG GTC TAC ATG GTC ACC 
L S D H  S F L V  S Q G D R E Q A P N L V Y M V T
4825/1609
GGA AAT CCT GCC TCT GAT GAG ATC AAG AGG CTG CCT GGA GAC ATC CAG GTG GTG CCC ATT GGA GTG GGC CCT 
G N  P A S D E  I K R L P G D I  Q V V P I G V G P
4897/1633
AAT GCC AAC GTG CAG GAG CTG GAG AGG ATT GGC TGG CCC AAT GCC CCT ATC CTC ATC CAG GAC TTT GAG ACG 
N A N V Q E L E  R I G W P N A P I  L I Q D F E T
4969/1657
CTC CCC CGA GAG GCT CCT GAC CTG GTG CTG CAG AGG TGC TGC TCC GGA GAG GGG CTG CAG ATC CCC ACC CTC 
L P  R E A P D L V L Q R C C S G E G L Q I P T L
5041/1681
TCC CCT GCA CCT GAC TGC AGC CAG CCC CTG GAC GTG ATC CTT CTC CTG GAT GGC TCC TCC AGT TTC CCA GCT 
S P A  P D C S Q  P L D V I  L L L D G S S S F P A
5113/1705
TCT TAT TTT GAT GAA ATG AAG AGT TTC GCC AAG GCT TTC ATT TCA AAA GCC AAT ATA GGG CCT CGT CTC ACT 
S Y F D E M K S F A K A F I S K A N I G  P R L T
5185/1729
CAG GTG TCA GTG CTG CAG TAT GGA AGC ATC ACC ACC ATT GAC GTG CCA TGG AAC GTG GTC CCG GAG AAA GCC 
Q V S V L Q Y  G S I T T I  D V P W N V V P E K A
5257/1753
CAT TTG CTG AGC CTT GTG GAC GTC ATG CAG CGG GAG GGA GGC CCC AGC CAA ATC GGG GAT GCC TTG GGC TTT 
H L L S L V D V M Q R E G G  P S Q I  G D A L  G F
5329/1777
GCT GTG CGA TAC TTG ACT TCA GAA ATG CAT GGT GCC AGG CCG GGA GCC TCA AAG GCG GTG GTC ATC CTG GTC 
A V R Y L T S  E M H G A R P G  A S K A V V I  L V
5401/1801
ACG GAC GTC TCT GTG GAT TCA GTG GAT GCA GCA GCT GAT GCC GCC AGG TCC AAC AGA GTG ACA GTG TTC CCT 
T D V S V D S V D A A  A D A A R S N R V T V F P
5473/1825
ATT GGA ATT GGA GAT CGC TAC GAT GCA GCC CAG CTA CGG ATC TTG GCA GGC CCA GCA GGC GAC TCC AAC GTG 
I G I G D  R Y D A A Q L R I L A G P A G D S N V
5545/1849
GTG AAG CTC CAG CGA ATC GAA GAC CTC CCT ACC ATG GTC ACC TTG GGC AAT TCC TTC CTC CAC AAA CTG TGC 
V K L Q  R I E D L P T M V T L G N S F L H K  L C
5617/1873
TCT GGA TTT GTT AGG ATT TGC ATG GAT GAG GAT GGG AAT GAG AAG AGG CCC GGG GAC GTC TGG ACC TTG CCA 
S G F V R I C M D E D G N E K R P G  D V W T L P
5689/1897
GAC CAG TGC CAC ACC GTG ACT TGC CAG CCA GAT GGC CAG ACC TTG CTG AAG AGT CAT CGG GTC AAC TGT GAC 
D Q C H T V T  C Q P D G Q T L L K S H  R V N C D
5761/1921
CGG GGG CTG AGG CCT TCG TGC CCT AAC AGC CAG TCC CCT GTT AAA GTG GAA GAG ACC TGT GGC TGC CGC TGG 
R G L R P S C P N  S Q S P V K V E  E T C G C R W
5833/1945
ACC TGC CCC TGC GTG TGC ACA GGC AGC TCC ACT CGG CAC ATC GTG ACC TTT GAT GGG CAG AAT TTC AAG CTG 
T C P C V C T G S  S T R H  I V T F D G Q N F K L
5905/1969
ACT GGC AGC TGT TCT TAT GTC CTA TTT CAA AAC AAG GAG CAG GAC CTG GAG GTG ATT CTC CAT AAT GGT GCC 
T G  S C S Y V L F Q N K E Q D L E  V I L H N G A
5977/1993
TGC AGC CCT GGA GCA AGG CAG GGC TGC ATG AAA TCC ATC GAG GTG AAG CAC AGT GCC CTC TCC GTC GAG CTG 
C S P G  A R Q G C M K S  I E V K H S A L S V E L
6049/2017
CAC AGT GAC ATG GAG GTG ACG GTG AAT GGG AGA CTG GTC TCT GTT CCT TAC GTG GGT GGG AAC ATG GAA GTC 
H S D M E V  T V N G R L V S  V P Y V G G N M E V
6121/2041
AAC GTT TAT GGT GCC ATC ATG CAT GAG GTC AGA TTC AAT CAC CTT GGT CAC ATC TTC ACA TTC ACT CCA CAA 
N V Y G  A I M H  E V  R F N H  L G  H I  F T F T P Q
6193/2065
AAC AAT GAG TTC CAA CTG CAG CTC AGC CCC AAG ACT TTT GCT TCA AAG ACG TAT GGT CTG TGT GGG ATC TGT 
N N E F Q L Q L S  P K T F A S K T Y  G L C G I  C
6265/2089
GAT GAG AAC GGA GCC AAT GAC TTC ATG CTG AGG GAT GGC ACA GTC ACC ACA GAC TGG AAA ACA CTT GTT CAG 
D E  N G A N D F M L  R D G T  V T T D W K T  L V Q
6337/2113
GAA TGG ACT GTG CAG CGG CCA GGG CAG ACG TGC CAG CCC ATC CTG GAG GAG CAG TGT CTT GTC CCC GAC AGC 
E W T V Q  R P  G Q T C Q  P I L E E  Q C L V P D S
6409/2137
TCC CAC TGC CAG GTC CTC CTC TTA CCA CTG TTT GCT GAA TGC CAC AAG GTC CTG GCT CCA GCC ACA TTC TAT 
S H C Q V L L L P  L F A E C H K V L A P A T F Y
6481/2161
GCC ATC TGC CAG CAG GAC AGT TGC CAC CAG GAG CAA GTG TGT GAG GTG ATC GCC TCT TAT GCC CAC CTC TGT 
A I C Q Q D S C H Q E Q V C E V I  A S Y A H L C
6553/2185
CGG ACC AAC GGG GTC TGC GTT GAC TGG AGG ACA CCT GAT TTC TGT GCT ATG TCA TGC CCA CCA TCT CTG GTC 
R T  N G V  C V D W R  T P D F  C A M  S C P  P S L V
6625/2209
TAC AAC CAC TGT GAG CAT GGC TGT CCC CGG CAC TGT GAT GGC AAC GTG AGC TCC TGT GGG GAC CAT CCC TCC 
Y N H C E H  G C P  R H  C D  G N  V  S S C  G D  H P  S
6697/2233
GAA GGC TGT TTC TGC CCT CCA GAT AAA GTC ATG TTG GAA GGC AGC TGT GTC CCT GAA GAG GCC TGC ACT CAG 
E G C F C P P D K V M L E G S C V P E E  A C T Q
6769/2257
TGC ATT GGT GAG GAT GGA GTC CAG CAC CAG TTC CTG GAA GCC TGG GTC CCG GAC CAC CAG CCC TGT CAG ATC 
C I G E  D G V Q H Q F L E  A W V P D H  Q P C Q I
6841/2281
TGC ACA TGC CTC AGC GGG CGG AAG GTC AAC TGC ACA ACG CAG CCC TGC CCC ACG GCC AAA GCT CCC ACG TGT 
C T C L S G  R K V N C T  T Q P C P T  A K A P T C
6913/2305
GGC CTG TGT GAA GTA GCC CGC CTC CGC CAG AAT GCA GAC CAG TGC TGC CCC GAG TAT GAG TGT GTG TGT GAC 
G L C E V  A R L R Q N A D Q C C P E Y E C V C D
6985/2329
CCA GTG AGC TGT GAC CTG CCC CCA GTG CCT CAC TGT GAA CGT GGC CTC CAG CCC ACA CTG ACC AAC CCT GGC 
P V S C D L  P P V P H C E R G L Q P T  L T N P G
7057/2353
GAG TGC AGA CCC AAC TTC ACC TGC GCC TGC AGG AAG GAG GAG TGC AAA AGA GTG TCC CCA CCC TCC TGC CCC 
E C R P  N F T C  A C R K E E C K R V  S P P  S C P
7129/2377
CCG CAC CGT TTG CCC ACC CTT CGG AAG ACC CAG TGC TGT GAT GAG TAT GAG TGT GCC TGC AAC TGT GTC AAC 
P H R L P T L R K T Q C C D E Y E C A C N C V N
7201/2401
TCC ACA GTG AGC TGT CCC CTT GGG TAC TTG GCC TCA ACC GCC ACC AAT GAC TGT GGC TGT ACC ACA ACC ACC 
S T V S  C P L G Y L A S T A T N D C G C T T T T
7273/2425
TGC CTT CCC GAC AAG GTG TGT GTC CAC CGA AGC ACC ATC TAC CCT GTG GGC CAG TTC TGG GAG GAG GGC TGC 
C L P D  K V C V H R S T I Y P V G Q F W E E G C
7345/2449
GAT GTG TGC ACC TGC ACC GAC ATG GAG GAT GCC GTG ATG GGC CTC CGC GTG GCC CAG TGC TCC CAG AAG CCC 
D V C T C T D M E  D A V M G L R V A Q C S Q K P
7417/2473
TGT GAG GAC AGC TGT CGG TCG GGC TTC ACT TAC GTT CTG CAT GAA GGC GAG TGC TGT GGA AGG TGC CTG CCA 
C E D  S C R S G F T Y V L H E  G E C C G R C L P
7489/2497
TCT GCC TGT GAG GTG GTG ACT GGC TCA CCG CGG GGG GAC TCC CAG TCT TCC TGG AAG AGT GTC GGC TCC CAG 
S A C E V V T G S P R G D S Q S S W K S V G S Q
7561/2521
TGG GCC TCC CCG GAG AAC CCC TGC CTC ATC AAT GAG TGT GTC CGA GTG AAG GAG GAG GTC TTT ATA CAA CAA 
W A S P E N P C L I N E C V R V K  E E V F I Q Q
7633/2545
AGG AAC GTC TCC TGC CCC CAG CTG GAG GTC CCT GTC TGC CCC TCG GGC TTT CAG CTG AGC TGT AAG ACC TCA 
R N V S C P Q L E V P V C P S G F Q L S C K T S
7705/2569
GCG TGC TGC CCA ACG TGT CGC TGT GAG CGC ATG GAG GCC TGC ATG CTC AAT GGC ACT GTC ATT GGG CCC GGG 
A C C  P T  C R C  E R M E  A C M L  N G T V  I G P G
7777/2593
AAG ACT GTG ATG ATC GAT GTG TGC ACG ACC TGC CGC TGC ATG GTG CAG GTG GGG GTC ATC TCT GGA TTC AAG 
K T V M I D V C T T C R C M V Q V G V I  S G F K
7849/5617
CTG GAG TGC AGG AAG ACC ACC TGC AAC CCC TGC CCC CTG GGT TAC AAG GAA GAA AAT AAC ACA GGT GAA TGT 
L E C R K T T C N P C P L G Y K E E N N T G E C
7921/2641
TGT GGG AGA TGT TTG CCT ACG GCT TGC ACC ATT CAG CTA AGA GGA GGA CAG ATC ATG ACA CTG AAG CGT GAT 
C G  R C L P T  A C T I  Q L  R G G Q  I M T L K R D
7993/2665
GAG ACG CTC CAG GAT GGC TGT GAT ACT CAC TTC TGC AAG GTC AAT GAG AGA GGA GAG TAC TTC TGG GAG AAG 
E T L Q D G C D T H F C K V N E R G E Y F W E K
8065/2689
AGG GTC ACA GGC TGC CCA CCC TTT GAT GAA CAC AAG TGT CTG GCT GAG GGA GGT AAA ATT ATG AAA ATT CCA 
R V T G C P  P F D E H K C L A E G G K I M K I  P
8137/2713
GGC ACC TGC TGT GAC ACA TGT GAG GAG CCT GAG TGC AAC GAC ATC ACT GCC AGG CTG CAG TAT GTC AAG GTG 
G T C C D T C E E  P E C N D I T A R L Q Y V K V
8209/2737
GGA AGC TGT AAG TCT GAA GTA GAG GTG GAT ATC CAC TAC TGC CAG GGC AAA TGT GCC AGC AAA GCC ATG TAC 
G S C K S E V  E V D I H Y  C Q G K C A S K A M Y
8281/2761
TCC ATT GAC ATC AAC GAT GTG CAG GAC CAG TGC TCC TGC TGC TCT CCG ACA CGG ACG GAG CCC ATG CAG GTG 
S I D  I N D V Q D Q C S C C S P T  R T E P M Q V
8353/2785
GCC CTG CAC TGC ACC AAT GGC TCT GTT GTG TAC CAT GAG GTT CTC AAT GCC ATG GAG TGC AAA TGC TCC CCC 
A L H C  T N G S V V Y  H E  V  L N A  M E C  K C S  P
8425/2809
AGG AAG TGC AGC AAG TGAGGCTGCTGCAGCTGCATGGGTGCCTGCT 
R K C S K
8471
GCTGCCTGCCTTGGCCTGATGGCCAGGCCAGAGTGCTGCCAGTCCTCTGCATGTTCTGCTCTTGTGCCCT
8541
TCTGAGCCCACAATAAAGGCTGAGCTCTTATCTTGCAAAAA
Abbreviations for amino acid residues.
A Ala Alanine K Lys Lysine
R Arg Arginine M Met Methionine
N Asn Asparagine F Phe Phenylalanine
D Asp Aspartic acid P Pro Proline
C Cys Cysteine S Ser Serine
Q Gin Glutamine T Thr Threonine
E Glu Glutamic acid W Trp Tryptophan
G Gly Glycine Y Tyr Tyrosine
H His Histidine V Val Valine
I lie Isoleucine
L Leu Leucine
1. Goodeve A, Peake I. A  standard nomenclature for von Willebrand factor gene mutations and polymorphisms. 
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Appendix 2, Table 1. Phenotypic data for type 1 VWD patients at time of
diagnosis
Patient
Number
Kindred sex ABO
Blood
group
age
(years)
FVIII:C
(IUdL1)
VWF:Ag
(IUdL1)
VWF:RCo
(IUdL1)
1 1 M O 35 56 45 44
2 2 M A 52 60 34 46
3 3 M O 46 7 4 5
4 4 F O 47 52 36 35
5 5 F O 40 18* 25 26
6 6 F A 48 34 42 38
7 7 M A 27 36 14 11
8 8 M O 36 62 29 34
9 9 F O 27 80 35 35
10 10 F A 21 66 27 23
11 8 F O 60 67 36 41
12 11 F A 52 62 34 30
13 8 M O 31 68 36 41
14 12 M O 41 20 13 17
15 13 M O 34 64 50 52
16 14 M O 25 52 36 36
17 15 M O 32 60 50 36
18 16 M O 22 70 38 37
19 17 F O 43 57 39 46
20 18 M A 44 70 46 56
21 19 F O 57 52 42 38
22 20 F A 40 69 22 17
23 21 M O 32 58 37 30
24 22 F O 32 64 37 37
25 10 M A 45 13** 30 23
26 23 F A 28 68 44 52
27 24 M A 57 28 10 9
28 25 M O 31 35 17 14
29 26 M O 39 70 47 46
30 27 M A 38 48 30 23
31 28 M O 48 27 18 16
32 29 F NT 21 21 9 10
33 30 F NT 30 70 43 39
34 31 M NT 45 131 45 47
35 32 M A 35 76 33 43
36 33 F A 51 104 40 42
37 34 F A 44 95 49 41
38 35 F O 33 27 13 10
39 36 F O 19 78 45 36
40 37 M A 52 18 14 32
41 38 F O 49 61 44 41
42 39 F A 25 28 25 24
43 40 M A 54 22 14 11
VWF multimeric analysis was normal in all patients.
Patients 3, 20 and 42 were subsequently found to have discordant ratios of VWF:CB to 
VWF:Ag and excluded from the study 
NT-not tested
* Patient 5 known haemophilia A carrier ** Patient 25 known to have factor VIII binding defect
Appendix 2, Table 2. Phenotypic data for haemophilia A controls
Patient
Number
Kindred sex ABO
Blood
group
age
(years)
FVIIhC
(IUdL1)
VWF:Ag
(IUdL1)
VWF:RCo
(IUdL1)
1 1 M A 57 19 238 240
2 2 M O 31 33 93 99
3 3 M B 35 38 168 300
4 4 M B 54 10 192 178
5 5 M 0 56 4 61 48
6 6 M 0 44 5 131 196
7 7 M 0 26 17 82 82
8 8 M O 19 17 65 NT
9 9 M O 36 6 45 50
10 10 M 0 44 20 63 84
11 11 M 0 47 5 50 67
12 12 M A 58 26 193 124
13 13 M O 41 7 162 128
14 14 M O 40 26 83 100
15 15 M O 41 30 159 112
16 16 M A 41 8 105 92
17 17 M A 25 38 126 118
NT - not tested
Appendix 3, Table 1. Type 1 VWD patient data (n = 40)
Patient
Number
Kindred sex ABO
Blood
group
VWF:Ag
T«
(IUdL1)
VWFpp 
To (nM)
VWF:CB
To
(IUdL1)
ADAMTS-13
To (%)
VWFpp/
VWF:Ag
ratio
Increase
in
VWF:Ag 
from To
to Ti 
(IUdL1)
VWF:Ag
Ti
(IUdL1)
VWF:Ag
tin
(h)
VWFpp
tl/2
(h)
VWF:CB
tm
(h)
Y1584C Amino
acid
Sub­
stitution
RCA-I /
VWF:Ag
To
ECA/
VWF:Ag
To
1 1 M 0 46 2.847 47 61.792592 0.12 94 140 7 2.9 5.53 NT NT 1.31 1.99
2 2 M A 84 2.9 102 82.9 0.06 109 193 7.7 2.6 10.28 tyr/tyr Nl 1.25 1.04
4 4 F 0 27 1.9 37 60.74448 0.14 70 97 4 2.1 4.93 tyr/tyr Nl 2.05 2.24
5 5 F 0 43 3.324 26 76.799224 0.15 101 144 1.9 2.5 2.97 tyr/tyr R1205S 1.02 1.32
6 6 F A 51 1.594 44 126.63004 0.06 92 143 3.5 8 9.88 tyr/tyr R768Q 1.05 0.75
7 7 M A 17 2.864 14 92.625214 0.34 100 117 2.3 2.6 1.72 tyr/tyr Nl 1.26 1.57
8 8 M 0 50 4.372 44 71.7 0.17 136 186 3 2.3 3.06 tyr/tyr Nl 0.92 1.06
9 9 F 0 49 2.671 49 50.852605 0.11 89 138 8.7 2.6 4.22 NT NT 1.25 1.34
10 10 F A 57 2.8 50 99.906122 0.1 115 172 3.2 2.5 7.85 tyr/tyr R924Q 1.28 1.31
11 8 F 0 51 3.355 60 89.281019 0.13 105 156 6.8 3.5 6.76 tyr/tyr Nl 1.27 1.87
12 11 F A 58 3.809 56 116.13377 0.13 159 217 4.8 2.4 3.49 cys/tyr Y1584C 1.12 1.37
13 8 M 0 56 10.891 50 83.836846 0.39 154 210 3.2 1.7 3.76 tyr/tyr Nl 1.18 1.5
14 12 M 0 13 2.944 10 59.305591 0.45 28 41 3.3 3.1 4.65 tyr/tyr R1205C 1.1 1.56
15 13 M 0 52 3.5 43 94.54418 0.13 128 180 4.3 2.9 4.62 tyr/tyr Nl 1.25 1.44
16 14 M 0 46 3.724 43 75.940924 0.16 153 199 3.8 2.6 3.13 tyr/tyr Nl 1.26 0.76
17 15 M 0 56 3.6 56 88.533646 0.13 177 233 1.9 2.8 3.31 NT NT 0.79 1.16
18 16 M 0 38 3.3 30 95.856564 0.17 127 165 5.6 1.8 4.98 tyr/tyr Nl 1.14 1.32
19 17 F 0 43 2.497 43 93.643472 0.12 181 224 4.1 2.5 4.21 tyr/tyr Nl 1.05 1.54
21 19 F 0 42 2.4 38 73.124677 0.11 137 179 3.3 2.1 3.43 tyr/tyr Nl 1.29 1.72
22 20 F A 18 1.4 16 80.166905 0.16 36 54 6.2 2.3 6.51 NT Nl 1.38 1.38
23 21 M 0 51 3 49 95.594954 0.12 111 162 3.8 2.1 3.13 tyr/tyr Nl 1.05 1.38
Nl: not identified NT: not tested CONTINUED..
CONTINUED..
Appendix 3, Table 1. Type 1 VWD patient data (n = 40)
Patient
Number
Kindred sex ABO
Blood
group
VWF.Ag
To
(IUdL1)
VWFpp 
T. (nM)
VWF-.CB
To
(IUdL1)
ADAMTS-13
To (%)
VWFpp/
VWF:Ag
ratio
Increase
in
VWF:Ag 
from To 
to Ti 
(IUdL1)
VWF:Ag
Ti
(IUdL1)
VWF'.Ag
tl/2
(h)
VWFpp
tl/2
(h)
VWF:CB
tm
(h)
Y1584C Amino
acid
Sub­
stitution
RCA-I /
VWF:Ag
To
ECA/
VWF:Ag
To
25 22 F O 50 2.7 42 90.6515 0.11 161 211 4.8 2.9 6.31 tyr/tyr Nl 1.46 1.97
25 10 M A 37 2.4 34 98.537787 0.13 234 271 5.6 1.9 5.68 tyr/tyr R854Q;R924Q 1.34 1.19
26 23 F A 74 4.1 74 100.7 0.11 141 215 2.8 2.4 3.37 tyr/tyr Nl 1.07 2.04
27 24 M A 10 NT NT NT NT 14 24 2.6 NT NT tyr/tyr Nl NT NT
28 25 M O 17 NT NT NT NT 29 46 2.9 NT NT tyr/tyr Nl NT NT
29 26 M O 47 NT NT NT NT 188 235 5 NT NT tyr/tyr Nl 1.32 2.38
30 27 M A 30 NT NT NT NT 157 187 6.3 NT NT tyr/tyr Nl 1.53 2.54
31 28 M O 18 4.7 NT NT 0.52 75 93 3.5 2.6 NT tyr/tyr I1416N 0.82 1.26
32 29 F NT 9 NT NT NT NT 104 113 1.5 NT NT NT NT NT NT
33 30 F NT 43 NT NT NT NT 102 145 4.6 NT NT NT NT NT NT
34 31 M NT 45 NT NT NT NT 65 110 8.6 NT NT NT NT NT NT
35 32 M A 33 NT NT NT NT 57 90 5.2 NT NT NT NT NT NT
36 33 F A 40 NT NT NT NT 101 141 11.4 NT NT NT NT NT NT
37 34 F A 49 NT NT NT NT 65 114 4.9 NT NT NT NT NT NT
38 35 F O 13 NT NT NT NT 35 48 3.6 NT NT NT NT NT NT
39 36 F O 45 NT NT NT NT 127 172 4.5 NT NT NT NT NT NT
40 37 M A 14 NT NT NT NT 71 85 1.3 NT NT NT NT NT NT
41 38 F O 44 3.7 52 NT 0.17 83 127 9.6 2.2 5 tyr/tyr Nl 1.01 1.46
43 40 M A 14 2.7 9 NT 0.39 42 56 3 2 2.4 tyr/tyr I1416N 1.11 1.21
Nl: not identified NT: not tested
Appendix 3, Table 2. Haemophilia A controls data (n = 17)
Control
Number
sex ABO
Bloodgroup
VWF:Ag 
To (IUdL1)
VWFpp 
To (nM)
VWF:CB 
To (IUdL1)
ADAMTS-
13
To (%)
VWFpp/
VWF:Ag
ratio
Increase
in
VWF:Ag 
from To
to Ti
(lU/dL)
VWF:Ag 
Ti (IUdL1)
VWF:Ag
tm
(h)
VWFpp
tm
(h)
VWF:CB
tm
(h)
Y1584C
1 M A 238 NT NT NT NT 166 404 26.1 NT NT NT
2 M 0 93 NT NT NT NT 122 215 10.1 NT NT NT
3 M B 168 NT NT NT NT 135 303 10.1 NT NT NT
4 M B 192 NT NT NT NT 192 384 9.5 NT NT NT
5 M 0 61 NT NT NT NT 138 199 9.1 NT NT NT
6 M 0 131 NT NT NT NT 200 331 6.9 NT NT NT
7 M 0 82 NT NT NT NT 162 244 4.2 NT NT NT
8 M 0 65 8.9 55 NT 0.27 144 209 4.3 1.4 3.4 tyr/tyr
9 M 0 45 4.3 49 NT 0.19 154 199 11.4 2.3 16 tyr/tyr
10 M 0 63 22 70 NT 0.7 121 184 5.4 0.8 5.1 tyr/tyr
11 M 0 50 4.2 50 NT 0.17 115 165 16 2.3 11.5 cys/tyr
12 M A 193 8.4 186 NT 0.09 30 223 >30* 6 35.9 tyr/tyr
13 M O 162 11 150 NT 0.14 102 264 20 6.1 7.9 tyr/tyr
14 M 0 83 8 112 NT 0.19 185 268 7 2 8.6 tyr/tyr
15 M O 159 14 92 NT 0.18 43 202 >30* 1.1 26.5 tyr/tyr
16 M A 105 3.3 98 NT 0.06 202 307 4.1 3.3 4.4 tyr/tyr
17 M A 126 4.8 145 NT 0.08 123 249 16.8 8.5 5.3 tyr/tyr
Nl: not identified 
NT: not tested
* In two of the control subjects, the 1 h rise in VWF:Ag concentration was sustained over the 6 h time course and a k value was not obtainable. The VWF:Ag tm 
values for these subjects is shown as being greater than 30 h.
Appendix 4, Normal control group (n = 20)
Control ABO blood 
group
VWF:Ag
(IUdL1)
VWFpp/ 
VWF:Ag ratio
RCA-I / 
VWF:Ag
ECA/ 
VWF:Ag
1 0 68 0.22 1.05 1.45
2 AB 145 0.1 1.01 0.75
3 B 129 0.11 0.19 0.78
4 0 128 0.11 0.79 1.55
5 0 100 0.12 0.71 1.09
6 AB 147 0.16 1.21 1
7 0 89 0.11 1.12 1.29
8 0 131 0.17 1.03 1.12
9 AB 152 0.12 0.86 0.56
10 AB 116 0.09 0.75 0.86
11 0 103 0.1 0.98 1.77
12 AB 194 0.11 0.59 0.49
13 0 66 0.07 1.16 1.87
14 AB 90 0.14 1.14 0.83
15 AB 115 0.14 1.03 0.63
16 AB 131 0.13 0.87 0.61
17 AB 109 0.08 1.07 1.42
18 AB 115 0.14 1.4 0.75
19 AB 97 0.3 1.21 0.69
20 0 84 0.09 1.12 1.74
